EU Local Number,Report Type,EV Gateway Receipt Date,Primary Source Qualification,Primary Source Country for Regulatory Purposes,Literature Reference,Patient Age Group,Patient Age Group (as per reporter),Parent Child Report,Patient Sex,Reaction List PT (Duration – Outcome - Seriousness Criteria),Suspect/interacting Drug List (Drug Char - Indication PT - Action taken - [Duration - Dose - Route]),Concomitant/Not Administered Drug List (Drug Char - Indication PT - Action taken - [Duration - Dose - Route]),ICSR Form
EU-EC-10016546378,Spontaneous,2023-12-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Haematuria (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016546378&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016546579,Spontaneous,2023-12-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Night sweats (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Heart rate increased - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016546579&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016547526,Spontaneous,2023-12-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Haematuria (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016547526&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016550015,Spontaneous,2023-12-29 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Memory impairment (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016550015&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016550339,Spontaneous,2023-12-29 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Atrial flutter - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016550339&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016538613,Spontaneous,2023-12-28 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Aplasia pure red cell (n/a - Unknown - Other Medically Important Condition),<BR><BR>Aplastic anaemia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016538613&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016541073,Spontaneous,2023-12-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Haematuria (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 prophylaxis - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Unknown - [1d - 1{DF} - n/a]),<BR><BR>COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - COVID-19 immunisation - Unknown - [1d - 1{DF} - n/a]),<BR><BR>SPIKEVAX [ELASOMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a - More in ICSR])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016541073&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016541444,Spontaneous,2023-12-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Rash (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016541444&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016542149,Spontaneous,2023-12-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Cough (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dysgeusia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Limb discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Middle insomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Paraesthesia oral (n/a - Unknown - Other Medically Important Condition),<BR><BR>Skin warm (n/a - Unknown - Other Medically Important Condition),<BR><BR>Sleep disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","AVAMYS [FLUTICASONE FUROATE] (C - Allergy test - n/a - [n/a - n/a - n/a]),<BR><BR>[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE, BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE] (C - Asthma late onset - n/a - [n/a - n/a - n/a]),<BR><BR>[CHLORPHENAMINE MALEATE] (C - Food allergy - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - Asthma late onset - n/a - [n/a - n/a - n/a]),<BR><BR>[TIOTROPIUM, TIOTROPIUM BROMIDE, TIOTROPIUM BROMIDE MONOHYDRATE] (C - Asthma - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016542149&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016531533,Spontaneous,2023-12-27 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Guillain-Barre syndrome (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Hypoaesthesia (n/a - Recovering/Resolving - ),<BR><BR>Muscular weakness (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016531533&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016531741,Spontaneous,2023-12-27 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Blood pressure increased (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chills (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Feeling cold (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [1d - n/a - n/a])","[ACITRETIN] (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[LOVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016531741&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016524445,Spontaneous,2023-12-26 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a - More in ICSR])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016524445&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016527773,Spontaneous,2023-12-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Amyloidosis (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016527773&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016522640,Spontaneous,2023-12-25 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Atrial flutter (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Condition aggravated (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - n/a])","[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Atrial flutter - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016522640&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016523109,Spontaneous,2023-12-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Circulatory collapse (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Depressed level of consciousness (2d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Dysstasia (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Gait inability (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Incontinence (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Pneumonia (45d - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016523109&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016523129,Spontaneous,2023-12-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Agitation (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Herpes zoster disseminated (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016523129&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016523252,Spontaneous,2023-12-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Accelerated hypertension (39d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016523252&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016519360,Spontaneous,2023-12-23 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Pericarditis (4mo - Recovered/Resolved - Caused/Prolonged Hospitalisation),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016519360&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016516572,Spontaneous,2023-12-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Myalgia (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016516572&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016504985,Spontaneous,2023-12-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Rash (3d - Recovered/Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016504985&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016505523,Spontaneous,2023-12-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Hyperhidrosis (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016505523&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016505911,Spontaneous,2023-12-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Blister (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),<BR><BR>Gait disturbance (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),<BR><BR>Oedema (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),<BR><BR>Peripheral swelling (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),<BR><BR>Rash erythematous (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a])",[ALLOPURINOL] (C - n/a - n/a - ),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016505911&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016506381,Spontaneous,2023-12-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Rash macular (7d - Recovered/Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016506381&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016493389,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Gait disturbance (n/a - Recovering/Resolving - ),<BR><BR>Muscular weakness (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Pain (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016493389&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016494456,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26)] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016494456&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016494485,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (3d - Recovered/Resolved - ),<BR><BR>Chills (2d - Recovered/Resolved - ),<BR><BR>Diarrhoea (2d - Recovered/Resolved - ),<BR><BR>Fatigue (4d - Recovered/Resolved - ),<BR><BR>Headache (3d - Recovered/Resolved - ),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (2d - Recovered/Resolved - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (2d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016494485&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016495891,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Hypertension (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),<BR><BR>Myocardial infarction (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),<BR><BR>Respiratory distress (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016495891&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016499295,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chest pain (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Heart rate abnormal (435min - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Malaise (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Pallor (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Paraesthesia (n/a - Unknown - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","LINACLOTIDE [LINACLOTIDE] (C - n/a - n/a - [n/a - 290ug - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[ESCITALOPRAM, ESCITALOPRAM OXALATE] (C - n/a - n/a - [n/a - 5mg - n/a]),<BR><BR>[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - n/a - n/a - [n/a - 2{DF} - n/a]),<BR><BR>[EZETIMIBE] (C - n/a - n/a - [n/a - 10mg - n/a]),<BR><BR>[OMEPRAZOLE] (C - Hyperchlorhydria - n/a - [n/a - 40mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016499295&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016485327,Spontaneous,2023-12-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Syncope (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),<BR><BR>SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.1 [ELASOMERAN, IMELASOMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>SPIKEVAX XBB.1.5 [ANDUSOMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - 1{DF} - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016485327&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016485453,Spontaneous,2023-12-19 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Arthralgia (n/a - Unknown - ),<BR><BR>Muscular weakness (n/a - Unknown - ),<BR><BR>Pain (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016485453&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016485691,Spontaneous,2023-12-19 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Death (n/a - Fatal - Results in Death, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])","RANEXA 375 MG [RANOLAZINE] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>TRULICITY [DULAGLUTIDE] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>ZONEGRAN 100 MG [ZONISAMIDE] (C - n/a - n/a - [n/a - 2{DF} - n/a]),<BR><BR>[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[ALLOPURINOL] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016485691&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016486234,Spontaneous,2023-12-19 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Gait disturbance (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - .35mL - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016486234&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016486565,Spontaneous,2023-12-19 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Arthritis (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016486565&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016487450,Spontaneous,2023-12-19 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Arthralgia (n/a - Recovered/Resolved With Sequelae - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016487450&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016488903,Spontaneous,2023-12-19 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Polyarthritis (5wk - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016488903&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016489680,Spontaneous,2023-12-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (5d - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Drug ineffective (5d - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Neck pain (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Polymyalgia rheumatica (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016489680&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016477581,Spontaneous,2023-12-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Arthralgia (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016477581&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016479398,Spontaneous,2023-12-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Swelling (2d - Recovered/Resolved - ),<BR><BR>Vaccination site erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site pruritus (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016479398&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016480074,Spontaneous,2023-12-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dysgeusia (n/a - Unknown - ),<BR><BR>Headache (n/a - Unknown - ),<BR><BR>Pain (n/a - Unknown - ),<BR><BR>Toothache (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016480074&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016480512,Spontaneous,2023-12-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Dysmenorrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Menstruation delayed (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Presyncope (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vertigo (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016480512&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016480919,Spontaneous,2023-12-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Amenorrhoea (n/a - Unknown - ),<BR><BR>Menstruation delayed (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016480919&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016481006,Spontaneous,2023-12-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Menstruation delayed (n/a - Recovered/Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016481006&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016481229,Spontaneous,2023-12-18 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Contusion (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a])","MØLLERS PHARMA TRAN [DOKONEKSENT, IKOSAPENTETYL, OMEGA-3, TOKOFEROL, TRAN, VITAMIN A, VITAMIN D] (C - n/a - n/a - ),<BR><BR>OLANZAPINE TEVA [OLANZAPINE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016481229&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016481236,Spontaneous,2023-12-18 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Brief resolved unexplained event (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Disorientation (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Renal failure (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>ELIQUIS [APIXABAN] (S - Thrombosis prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Immunisation - n/a - [n/a - n/a - n/a])","[ATORVASTATIN] (C - Blood cholesterol increased - n/a - [n/a - n/a - n/a]),<BR><BR>[CANDESARTAN, CANDESARTAN CILEXETIL] (C - Blood pressure increased - n/a - [n/a - n/a - n/a]),<BR><BR>[METOPROLOL, METOPROLOL SUCCINATE, METOPROLOL TARTRATE] (C - Blood pressure increased - n/a - [n/a - n/a - n/a]),<BR><BR>[PHENAZONE, CAFFEINE] (C - Pain - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016481236&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016481624,Spontaneous,2023-12-18 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Bone pain (3d - Recovered/Resolved - ),<BR><BR>Burning sensation (n/a - Recovered/Resolved - ),<BR><BR>Headache (n/a - Unknown - ),<BR><BR>Influenza like illness (n/a - Unknown - ),<BR><BR>Myalgia (n/a - Unknown - ),<BR><BR>Pain in jaw (3d - Recovered/Resolved - ),<BR><BR>Pruritus (n/a - Recovered/Resolved - ),<BR><BR>Toothache (3d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016481624&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016465378,Spontaneous,2023-12-15 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>SPIKEVAX [ELASOMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016465378&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016466229,Spontaneous,2023-12-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016466229&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016466256,Spontaneous,2023-12-15 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Cough (n/a - Recovered/Resolved - ),<BR><BR>Deep vein thrombosis (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Dyspnoea (n/a - Recovered/Resolved - ),<BR><BR>Pneumonia (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pulmonary embolism (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 4{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016466256&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016467728,Spontaneous,2023-12-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Condition aggravated (n/a - Not Recovered/Not Resolved - ),<BR><BR>Eye pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vitreous detachment (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016467728&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016468023,Spontaneous,2023-12-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Product administration error (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - Prophylaxis - n/a - [n/a - n/a - Intramuscular use]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Prophylaxis - n/a - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016468023&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016468721,Spontaneous,2023-12-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Endometriosis (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - Depression - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016468721&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016468748,Spontaneous,2023-12-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Amenorrhoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Menstruation irregular (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016468748&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016469744,Spontaneous,2023-12-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Heavy menstrual bleeding (n/a - Unknown - ),<BR><BR>Menstrual disorder (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])","[DRIED FERROUS SULFATE, FERROUS SULFATE] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016469744&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016470232,Spontaneous,2023-12-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Brain fog (n/a - Unknown - Other Medically Important Condition),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Disturbance in attention (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Memory impairment (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pharyngeal erythema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE, BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE] (C - n/a - n/a - [n/a - 200mg - n/a]),<BR><BR>[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - Hormone replacement therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[MONTELUKAST, MONTELUKAST SODIUM] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[PROGESTERONE] (C - Hormone replacement therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - Depressed mood - n/a - [n/a - 50mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016470232&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016471559,Spontaneous,2023-12-15 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest discomfort (0d - Recovered/Resolved - ),<BR><BR>Oropharyngeal discomfort (0d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",METHOTREXATE [METHOTREXATE] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016471559&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016457532,Spontaneous,2023-12-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthma (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Disease recurrence (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lower respiratory tract infection (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nasopharyngitis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [1d - n/a - n/a])","[SALBUTAMOL, SALBUTAMOL SULFATE] (C - n/a - Dose not changed - [n/a - n/a - Inhalation use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016457532&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016457797,Spontaneous,2023-12-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Menstrual disorder (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016457797&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016458709,Spontaneous,2023-12-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Tachycardia (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016458709&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016459049,Spontaneous,2023-12-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","ELIQUIS 5 MG FILM-COATED TABLETS [APIXABAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>PANTOPRAZOLE 20 MG - GASTRO-RESISTANT TABLET  (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BECLOMETASONE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FORMOTEROL, FORMOTEROL FUMARATE, FORMOTEROL FUMARATE DIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[GLYCOPYRRONIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016459049&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016459150,Spontaneous,2023-12-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Diarrhoea (n/a - Recovering/Resolving - ),<BR><BR>Muscle twitching (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016459150&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016459997,Spontaneous,2023-12-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (1d - Recovered/Resolved - ),<BR><BR>Diarrhoea (1d - Recovered/Resolved - ),<BR><BR>Fatigue (2d - Recovered/Resolved - ),<BR><BR>Headache (3d - Recovered/Resolved - ),<BR><BR>Migraine (3d - Recovered/Resolved - ),<BR><BR>Myalgia (2d - Recovered/Resolved - ),<BR><BR>Nausea (1d - Recovered/Resolved - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016459997&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016460085,Spontaneous,2023-12-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Blister (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dry skin (n/a - Not Recovered/Not Resolved - ),<BR><BR>Rash (n/a - Not Recovered/Not Resolved - ),<BR><BR>Skin burning sensation (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016460085&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016460266,Spontaneous,2023-12-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (1d - Recovered/Resolved - ),<BR><BR>Fatigue (1d - Not Recovered/Not Resolved - ),<BR><BR>Headache (1d - Recovered/Resolved - ),<BR><BR>Lymphadenopathy (1d - Recovered/Resolved - ),<BR><BR>Nausea (1d - Recovered/Resolved - ),<BR><BR>Oral fungal infection (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site pain (3d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016460266&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016460513,Spontaneous,2023-12-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016460513&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016460664,Spontaneous,2023-12-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Facial pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Insomnia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain in jaw (n/a - Not Recovered/Not Resolved - ),<BR><BR>Rhinalgia (n/a - Unknown - ),<BR><BR>Sinusitis (n/a - Not Recovered/Not Resolved - ),<BR><BR>Toothache (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])","INSULATARD [INSULIN HUMAN, INSULIN HUMAN (RDNA), INSULIN HUMAN ISOPHANE (RDNA)] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>OZEMPIC [SEMAGLUTIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016460664&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016461309,Spontaneous,2023-12-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Anosmia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hypogeusia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016461309&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016461612,Spontaneous,2023-12-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Arthralgia (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016461612&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016461681,Spontaneous,2023-12-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Cough (n/a - Recovering/Resolving - ),<BR><BR>Diarrhoea (4d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hypogeusia (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - ),<BR><BR>Rhinorrhoea (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016461681&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016461730,Spontaneous,2023-12-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016461730&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016464040,Spontaneous,2023-12-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"COVID-19 (8d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (8d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016464040&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016452286,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,Eczema (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016452286&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016453142,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Chronic myeloid leukaemia (n/a - Not Recovered/Not Resolved - Life Threatening),<BR><BR>Post-acute COVID-19 syndrome (n/a - Unknown - Life Threatening)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016453142&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016454140,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Herpes zoster oticus (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","METHOTREXATE [METHOTREXATE] (C - Rheumatoid arthritis - Dose not changed - [n/a - 1{DF} - n/a]),<BR><BR>[ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM TRIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016454140&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016454728,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016454728&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016443649,Spontaneous,2023-12-12 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Vaccination site pruritus (n/a - Unknown - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016443649&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016443787,Spontaneous,2023-12-12 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Dizziness (1d - Recovered/Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016443787&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016443933,Spontaneous,2023-12-12 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Lymph node pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])","[AMLODIPINE, AMLODIPINE BESILATE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[CANDESARTAN CILEXETIL] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016443933&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016447082,Spontaneous,2023-12-12 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - ),<BR><BR>Blood pressure increased (n/a - Not Recovered/Not Resolved - ),<BR><BR>COVID-19 (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Heart rate increased (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])","[LATANOPROST] (C - Glaucoma - n/a - [n/a - n/a - Intraocular use]),<BR><BR>[OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, OMEPRAZOLE SODIUM] (C - Dyspepsia - n/a - [n/a - 20mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016447082&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016432453,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Atrial fibrillation (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>COVID-19 (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Cerebrovascular accident (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Transient ischaemic attack (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (S - Immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016432453&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016434689,Spontaneous,2023-12-11 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Amenorrhoea (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016434689&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016435052,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Headache (n/a - Recovered/Resolved With Sequelae - ),<BR><BR>Lacrimation increased (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016435052&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016435811,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016435811&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016437153,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (6d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (6d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.1 [ELASOMERAN, IMELASOMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","IBUPROFEN [IBUPROFEN, IBUPROFEN SODIUM] (C - Sinus headache - n/a - [n/a - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID] (C - Pyrexia - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRADIOL, NORETHISTERONE, NORETHISTERONE ACETATE, ESTRADIOL, NORETHISTERONE ACETATE, ESTRADIOL HEMIHYDRATE] (C - Hormone replacement therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRADIOL] (C - Hormone replacement therapy - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016437153&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016437645,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Balance disorder (18h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dizziness (18h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Gait inability (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Somnolence (12h - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016437645&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016437859,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Unknown - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Pain (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016437859&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016438249,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Atrial fibrillation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Atrial flutter (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea exertional (n/a - Unknown - Other Medically Important Condition),<BR><BR>Ear pain (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Emotional distress (n/a - Unknown - Other Medically Important Condition),<BR><BR>Extrasystoles (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Heart rate decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Heart rate increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (3d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","EDOXABAN [EDOXABAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Atrial fibrillation - n/a - [n/a - 2.5mg - n/a]),<BR><BR>[CALCIUM CARBONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FLECAINIDE, FLECAINIDE ACETATE] (C - n/a - n/a - [n/a - 100mg - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016438249&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016424212,Spontaneous,2023-12-08 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Blindness (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Migraine (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Vertigo (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[BECLOMETASONE DIPROPIONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BENZALKONIUM CHLORIDE, CHLORHEXIDINE DIHYDROCHLORIDE, ISOPROPYL MYRISTATE, LIQUID PARAFFIN, BENZALKONIUM CHLORIDE, ISOPROPYL MYRISTATE, LIQUID PARAFFIN, NEOMYCIN SULFATE, PREDNISOLONE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LACIDIPINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SALMETEROL, SALMETEROL XINAFOATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016424212&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016424646,Spontaneous,2023-12-08 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Feeling abnormal (n/a - Recovered/Resolved - ),<BR><BR>Headache (n/a - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016424646&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016425653,Spontaneous,2023-12-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Cluster headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016425653&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016427196,Spontaneous,2023-12-08 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Cardiac arrest (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Chest pain (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Dyspnoea (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Fatigue (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Interchange of vaccine products (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Lower respiratory tract infection (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Myopericarditis (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Palpitations (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Tachycardia (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016427196&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016415458,Spontaneous,2023-12-07 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Herpes zoster (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interstitial lung disease (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016415458&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016415575,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Lymphadenopathy (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016415575&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016415711,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Lymphadenopathy (3d - Recovered/Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016415711&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016415823,Spontaneous,2023-12-07 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,Epilepsy (n/a - Unknown - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016415823&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016416341,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (2d - Recovered/Resolved - ),<BR><BR>Lymphadenopathy (3d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016416341&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016416383,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Pruritus (n/a - Recovering/Resolving - ),<BR><BR>Rash erythematous (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016416383&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016417836,Spontaneous,2023-12-07 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,Cerebrovascular accident (n/a - Recovered/Resolved - Disabling),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016417836&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016418134,Spontaneous,2023-12-07 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Sudden death (0d - Fatal - Results in Death, Life Threatening, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - n/a]),<BR><BR>[INFLUENZA QUADRIVALENT VACCINE (RDNA)] (S - Influenza immunisation - Not applicable - [n/a - n/a - n/a])","ROTIGOTINE [ROTIGOTINE] (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>SITAGLIPTIN [SITAGLIPTIN] (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[BENSERAZIDE HYDROCHLORIDE, LEVODOPA] (C - n/a - Dose not changed - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016418134&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016418301,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Contusion (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Hypokinesia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016418301&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016418366,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Blister (n/a - Recovering/Resolving - ),<BR><BR>Chills (1d - Recovered/Resolved - ),<BR><BR>Oropharyngeal pain (5d - Recovered/Resolved - ),<BR><BR>Pyrexia (3d - Recovered/Resolved - ),<BR><BR>Rash (12d - Recovered/Resolved - ),<BR><BR>Skin exfoliation (n/a - Recovering/Resolving - ),<BR><BR>Tonsillar disorder (5d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])","[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BUDESONIDE, BUDESONIDE, MICRONISED] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ENALAPRIL, ENALAPRIL MALEATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FELODIPINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FORMOTEROL FUMARATE, FORMOTEROL FUMARATE DIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[HYDROCHLOROTHIAZIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INSULIN, INSULIN HUMAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MAGNESIUM, MAGNESIUM HYDROXIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MIRTAZAPINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SULFASALAZINE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016418366&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016419216,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Hypertension (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016419216&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016419227,Spontaneous,2023-12-07 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Breast pain (n/a - Unknown - Disabling),<BR><BR>Chest pain (n/a - Unknown - Disabling),<BR><BR>Epicondylitis (n/a - Unknown - Disabling),<BR><BR>Joint range of motion decreased (n/a - Unknown - Disabling),<BR><BR>Pain in extremity (n/a - Unknown - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","PREGABALIN [PREGABALIN] (C - n/a - n/a - [n/a - 300mg - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - 20mg - n/a]),<BR><BR>[NAPROXEN, NAPROXEN SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL, CODEINE PHOSPHATE HEMIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016419227&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016419643,Spontaneous,2023-12-07 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Herpes zoster (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (S - Influenza immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016419643&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016408095,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Pericarditis (n/a - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016408095&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016408242,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Disease recurrence (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016408242&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016408693,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Disturbance in sexual arousal (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])","[PHENTOLAMINE MESILATE, AVIPTADIL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016408693&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016409683,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Muscle spasms (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016409683&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016410165,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenia (n/a - Unknown - ),<BR><BR>Back pain (n/a - Unknown - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Neck pain (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016410165&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016411234,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Facial pain (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - ),<BR><BR>Mastication disorder (n/a - Recovering/Resolving - ),<BR><BR>Swelling (n/a - Recovering/Resolving - ),<BR><BR>Trismus (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site pain (2d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])","[HYDROXYZINE DIHYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE] (C - n/a - n/a - [1d - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016411234&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016411502,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Pain in extremity (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])","[METFORMIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[VENLAFAXINE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[ZIPRASIDONE] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016411502&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016412648,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Illness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Immune system disorder (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Dose not changed - [n/a - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Influenza immunisation - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - Influenza immunisation - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[ENALAPRIL MALEATE, HYDROCHLOROTHIAZIDE, ENALAPRIL, HYDROCHLOROTHIAZIDE] (C - Hypertension - n/a - [n/a - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016412648&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016399540,Spontaneous,2023-12-05 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chills (4d - Recovered/Resolved - ),<BR><BR>Paraesthesia (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016399540&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016399569,Spontaneous,2023-12-05 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Axillary pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016399569&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016399576,Spontaneous,2023-12-05 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (2d - Recovered/Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Vomiting (1d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016399576&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016399593,Spontaneous,2023-12-05 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Limb discomfort (n/a - Recovered/Resolved - ),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",[ESCITALOPRAM OXALATE] (C - n/a - n/a - [n/a - n/a - Oral use]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016399593&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016399985,Spontaneous,2023-12-05 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Polymyalgia rheumatica (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Urticaria (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - Product used for unknown indication - Unknown - [n/a - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - Product used for unknown indication - Unknown - [n/a - 1{DF} - n/a]),<BR><BR>COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - Product used for unknown indication - Unknown - [n/a - 1{DF} - n/a]),<BR><BR>SPIKEVAX [ELASOMERAN] (S - COVID-19 prophylaxis - Not applicable - [n/a - 1{DF} - n/a])","APIXABAN [APIXABAN] (C - Product used for unknown indication - n/a - [n/a - 10mg - n/a]),<BR><BR>MICARDIS [TELMISARTAN] (C - Product used for unknown indication - n/a - [n/a - 80mg - n/a]),<BR><BR>[BUDESONIDE, FORMOTEROL FUMARATE DIHYDRATE, FORMOTEROL FUMARATE, BUDESONIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL, COLECALCIFEROL, CALCIUM CARBONATE, ERGOCALCIFEROL] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a]),<BR><BR>[FOLIC ACID] (C - Product used for unknown indication - n/a - [n/a - .5mg - n/a]),<BR><BR>[MAGNESIUM ASPARTATE DIHYDRATE] (C - Product used for unknown indication - n/a - [n/a - 1000mg - n/a]),<BR><BR>[MOMETASONE FUROATE, MOMETASONE FUROATE MONOHYDRATE] (C - Product used for unknown indication - n/a - [n/a - 50ug - Nasal use]),<BR><BR>[NICORANDIL] (C - Product used for unknown indication - n/a - [n/a - 20mg - n/a]),<BR><BR>[OLOPATADINE HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - 4[drp] - Ocular use]),<BR><BR>[PREDNISONE] (C - Product used for unknown indication - n/a - [n/a - 1mg - n/a - More in ICSR]),<BR><BR>[SOTALOL, SOTALOL HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - 160mg - n/a]),<BR><BR>[VALACICLOVIR, VALACICLOVIR HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - 500mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016399985&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016400141,Spontaneous,2023-12-05 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (1d - Recovered/Resolved - ),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - ),<BR><BR>Vomiting (0d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016400141&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016400184,Spontaneous,2023-12-05 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Arthritis (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Sick leave (n/a - Not Recovered/Not Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])","[BETAMETHASONE, BETAMETHASONE VALERATE] (C - n/a - n/a - [n/a - n/a - Cutaneous use]),<BR><BR>[HYDROXYZINE DIHYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - 25mg - Oral use]),<BR><BR>[LISDEXAMFETAMINE DIMESYLATE] (C - n/a - n/a - [n/a - 40mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016400184&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016400236,Spontaneous,2023-12-05 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])","[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[SERTRALINE] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016400236&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016400243,Spontaneous,2023-12-05 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Eye irritation (6d - Recovered/Resolved - ),<BR><BR>Eye pain (6d - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Unknown - ),<BR><BR>Ocular discomfort (n/a - Unknown - ),<BR><BR>Oropharyngeal pain (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016400243&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016402000,Spontaneous,2023-12-05 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Arthralgia (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Eye pain (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Eye swelling (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Infection (3d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Joint swelling (3d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Joint swelling (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Nasal congestion (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016402000&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016402316,Spontaneous,2023-12-05 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dizziness (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Retching (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",[TOLTERODINE] (C - Hypertonic bladder - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016402316&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016403329,Spontaneous,2023-12-05 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016403329&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016403406,Spontaneous,2023-12-05 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Muscular weakness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016403406&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016391303,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Lymphadenopathy (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016391303&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016391323,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 4, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6B, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9V, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 14, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 18C, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 33F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 22F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 20, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19A, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 17F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 15B, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 12F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 11A, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9N, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 7F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 5, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 3, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 2, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 1, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 10A, PNEUMOCOCCAL POLYSACCHARIDE VACCINE (23 VALENT)] (S - n/a - n/a - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016391323&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016391333,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016391333&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016391339,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Nausea (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",[LEVONORGESTREL] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016391339&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016391669,Spontaneous,2023-12-04 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,Alcohol poisoning (n/a - Unknown - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016391669&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016395228,Spontaneous,2023-12-04 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Acute stress disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Agitation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Poor quality sleep (n/a - Unknown - Other Medically Important Condition),<BR><BR>Radiculitis brachial (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016395228&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016395256,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Cardiac flutter (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness postural (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Feeling cold (n/a - Unknown - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vertigo (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ESTRADIOL, NORETHISTERONE, NORETHISTERONE ACETATE, ESTRADIOL, NORETHISTERONE ACETATE, ESTRADIOL HEMIHYDRATE] (C - Menopause - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[PROGESTERONE, PROGESTERONE, MICRONISED] (C - Menopause - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016395256&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016395377,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Limb mass (n/a - Unknown - Disabling),<BR><BR>Shoulder injury related to vaccine administration (n/a - Unknown - Disabling),<BR><BR>Vaccination site pain (n/a - Unknown - Disabling),<BR><BR>Wound (n/a - Unknown - Disabling),<BR><BR>Wound secretion (n/a - Unknown - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016395377&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016395409,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016395409&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016395417,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Unknown - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - ),<BR><BR>Vaccination site swelling (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016395417&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016395509,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Blood glucose decreased (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Heart rate irregular (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Loss of consciousness (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pericarditis (1d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","SPIKEVAX [ELASOMERAN] (C - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[INSULIN, INSULIN HUMAN] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016395509&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016395532,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (2d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016395532&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016395652,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Periorbital swelling (1d - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016395652&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016383418,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Sleep disorder (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site pruritus (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016383418&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016383563,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (0d - Recovered/Resolved - ),<BR><BR>Dizziness (0d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (1d - Recovered/Resolved - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - ),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - ),<BR><BR>Vomiting (0d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016383563&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016383564,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Abdominal pain (n/a - Unknown - ),<BR><BR>Diarrhoea (6d - Recovered/Resolved - ),<BR><BR>Headache (5d - Recovered/Resolved - ),<BR><BR>Nausea (5d - Recovered/Resolved - ),<BR><BR>Palpitations (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016383564&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016383589,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Contusion (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hypoaesthesia (n/a - Unknown - ),<BR><BR>Paraesthesia (n/a - Unknown - ),<BR><BR>Rash (n/a - Not Recovered/Not Resolved - ),<BR><BR>Thrombosis (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016383589&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016383730,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Vision blurred (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>SPIKEVAX [ELASOMERAN] (S - n/a - n/a - [n/a - n/a - n/a])","[PARACETAMOL, CODEINE PHOSPHATE HEMIHYDRATE] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016383730&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016385267,Spontaneous,2023-12-01 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Confusional state (69d - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),<BR><BR>Epilepsy (69d - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),<BR><BR>Epilepsy (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Haemorrhage (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Seizure (69d - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [1d - n/a - n/a])","[CANDESARTAN, CANDESARTAN CILEXETIL] (C - n/a - n/a - [n/a - 8mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016385267&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016386034,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (2d - Unknown - ),<BR><BR>Chills (2d - Recovered/Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Nausea (2d - Recovered/Resolved - ),<BR><BR>Pyrexia (2d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016386034&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016386124,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Headache (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016386124&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016386444,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Diarrhoea (4d - Recovered/Resolved - ),<BR><BR>Disturbance in attention (4d - Unknown - ),<BR><BR>Dizziness (4d - Unknown - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Pruritus (n/a - Recovering/Resolving - ),<BR><BR>Rash erythematous (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016386444&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016386688,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Lymphadenopathy (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016386688&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016386963,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Dizziness (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016386963&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016387948,Spontaneous,2023-12-01 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Hypoacusis (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Tinnitus (n/a - Unknown - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016387948&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016373432,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chills (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Decreased appetite (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hyperhidrosis (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Myalgia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016373432&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016374498,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Condition aggravated (n/a - Not Recovered/Not Resolved - ),<BR><BR>Rhinorrhoea (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])","[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016374498&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016374591,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Sjogren's syndrome (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ESTROGEN NOS] (C - Menopause - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVONORGESTREL, LEVONORGESTREL MICRONISED] (C - Menopause - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ZOPICLONE] (C - Sleep disorder due to general medical condition, insomnia type - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016374591&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016374748,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Headache (0d - Recovered/Resolved - ),<BR><BR>Ophthalmic migraine (0d - Recovered/Resolved - ),<BR><BR>Photopsia (0d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016374748&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016375104,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Maternal exposure during pregnancy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[FOLIC ACID] (C - Vitamin supplementation - n/a - [n/a - 400ug - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016375104&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016375383,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016375383&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016375674,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Parosmia (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016375674&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016375734,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site erythema (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site swelling (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016375734&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016375751,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,Lower respiratory tract infection (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016375751&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016375796,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016375796&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016376080,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Malaise (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016376080&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016376163,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Lymph node pain (n/a - Recovering/Resolving - ),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Pain (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])","[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - n/a - n/a - [n/a - n/a - Cutaneous use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016376163&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016376514,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (8d - Recovered/Resolved - ),<BR><BR>Headache (8d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016376514&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016378424,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Chest pain (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Chills (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Diaphragmalgia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Extra dose administered (0d - Unknown - ),<BR><BR>Hallucination (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [1d - n/a - n/a])","[ACETYLSALICYLIC ACID, ACETYLSALICYLIC ACID PH. EUR., ASPIRIN BP] (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[PRIMIDONE] (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[TAMSULOSIN, TAMSULOSIN HYDROCHLORIDE] (C - n/a - Dose not changed - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016378424&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016379232,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Adrenal disorder (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Aortic valve incompetence (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Cushingoid (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Gait disturbance (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Post-acute COVID-19 syndrome (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[FEXOFENADINE, FEXOFENADINE HYDROCHLORIDE] (C - Hypersensitivity - n/a - [n/a - n/a - n/a]),<BR><BR>[FLUTICASONE PROPIONATE, SALMETEROL, FLUTICASONE PROPIONATE, SALMETEROL XINAFOATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[MOMETASONE] (C - Upper-airway cough syndrome - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - Asthma - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016379232&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016366558,Spontaneous,2023-11-29 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Urticaria (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",[PARACETAMOL] (C - n/a - n/a - [1d - n/a - Oral use]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016366558&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016366926,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Pyrexia (n/a - Recovered/Resolved - ),<BR><BR>Vomiting (n/a - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016366926&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016367332,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Condition aggravated (n/a - Not Recovered/Not Resolved - ),<BR><BR>Sensory disturbance (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016367332&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016367511,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (5d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (3d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016367511&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016367575,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Type 1 diabetes mellitus (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016367575&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016367696,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Arthritis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016367696&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016367746,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Asthma (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016367746&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016367950,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Drug ineffective (8d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (8d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[FOLIC ACID] (C - Vitamin supplementation - n/a - [n/a - 400ug - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016367950&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016367996,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dermatomyositis (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016367996&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016368072,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Infant,Yes,Female,"Maternal exposure during pregnancy (n/a - Unknown - Congenital Anomaly),<BR><BR>Sebaceous naevus (n/a - Unknown - Congenital Anomaly)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Transplacental])","[FOLIC ACID] (C - Vitamin supplementation - n/a - [n/a - 400ug - Transplacental]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - Transplacental])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016368072&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016368326,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Fatigue (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Myalgia (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016368326&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016368327,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arrhythmia supraventricular (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Atrial fibrillation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hypotension (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","RIVAROXABAN [RIVAROXABAN] (C - Arrhythmia supraventricular - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PERINDOPRIL, PERINDOPRIL TERT-BUTYLAMINE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016368327&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016368674,Spontaneous,2023-11-29 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Immune thrombocytopenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Thrombocytopenia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016368674&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016368962,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Anxiety (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Cardiac flutter (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Heart rate abnormal (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016368962&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016369007,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Clumsiness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016369007&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016369168,Spontaneous,2023-11-29 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Hypertensive crisis (n/a - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016369168&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016369360,Spontaneous,2023-11-29 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Cardiac failure (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Dyspnoea (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Gait disturbance (n/a - Unknown - Other Medically Important Condition),<BR><BR>Heart rate increased (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Heart rate irregular (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Insomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Mobility decreased (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Myocarditis (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Weight decreased (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016369360&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016370247,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>SPIKEVAX XBB.1.5 [ANDUSOMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","METHOTREXATE [METHOTREXATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>SAXENDA [LIRAGLUTIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CODEINE PHOSPHATE BP, PARACETAMOL PH. EUR., PARACETAMOL BP, CODEINE PHOSPHATE BP, PARACETAMOL DC, PARACETAMOL PH. EUR., CODEINE PHOSPHATE PH.EUR., PARACETAMOL PH. EUR., CODEINE PHOSPHATE PH.EUR., PARACETAMOL, CODEINE PHOSPHATE, PARACETAMOL, CODEINE PHOSPHATE BP, PARACETAMOL, CODEINE PHOSPHATE HEMIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CODEINE PHOSPHATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FLECAINIDE, FLECAINIDE ACETATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FOLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[TRAMADOL, TRAMADOL HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016370247&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016370371,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Herpes zoster (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[CODEINE] (C - Spondylitis - n/a - [n/a - n/a - n/a]),<BR><BR>[GABAPENTIN] (C - Sciatica - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016370371&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016370485,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Atrial flutter (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","APIXABAN [APIXABAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[PREDNISOLONE] (C - Polymyalgia rheumatica - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016370485&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016371434,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016371434&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016357265,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Urticaria (2d - Recovered/Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016357265&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016357389,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (2d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016357389&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016357835,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Myalgia (4d - Recovered/Resolved - ),<BR><BR>Vaccination site pain (4d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016357835&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016357875,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (1d - Recovered/Resolved - ),<BR><BR>Malaise (1d - Recovered/Resolved - ),<BR><BR>Vaccination site pain (1d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - Oral use]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016357875&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016358068,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Pain (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016358068&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016358113,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Headache (n/a - Unknown - ),<BR><BR>Heart rate increased (n/a - Unknown - ),<BR><BR>Malaise (n/a - Unknown - ),<BR><BR>Palpitations (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016358113&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016359188,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (n/a - Unknown - ),<BR><BR>Feeling hot (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])","[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016359188&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016359288,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Bursitis (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016359288&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016359932,Spontaneous,2023-11-28 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Tachycardia (3mo - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016359932&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016361082,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dizziness (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016361082&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016361105,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016361105&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016363113,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016363113&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016349069,Spontaneous,2023-11-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Urticaria (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PHENOXYMETHYLPENICILLIN, PHENOXYMETHYLPENICILLIN POTASSIUM] (S - Dental implantation, Prophylaxis - Dose not changed - [6d - n/a - Oral use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016349069&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016349528,Spontaneous,2023-11-27 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Cerebrovascular accident (63d - Recovered/Resolved With Sequelae - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016349528&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016350172,Spontaneous,2023-11-27 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Aphasia (n/a - Unknown - Disabling),<BR><BR>Cerebral infarction (n/a - Fatal - Results in Death, Disabling),<BR><BR>Dizziness (n/a - Unknown - Disabling),<BR><BR>Fall (n/a - Unknown - Disabling),<BR><BR>Interchange of vaccine products (n/a - Fatal - Results in Death),<BR><BR>Seizure (n/a - Unknown - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (C - COVID-19 immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016350172&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016353210,Spontaneous,2023-11-27 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Blood glucose increased (n/a - Recovered/Resolved - ),<BR><BR>Lipase increased (n/a - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])","GALVUS [VILDAGLIPTIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>REPAGLINIDE [REPAGLINIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016353210&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016339450,Spontaneous,2023-11-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Not Specified,"Back pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Muscle strain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Musculoskeletal stiffness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - n/a - Not applicable - [n/a - n/a - n/a])","CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>EDOXABAN [EDOXABAN] (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[LISINOPRIL, LISINOPRIL DIHYDRATE] (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[SOTALOL, SOTALOL HYDROCHLORIDE] (C - n/a - Dose not changed - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016339450&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016340321,Spontaneous,2023-11-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Hyperhidrosis (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nasopharyngitis (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination site erythema (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pruritus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site rash (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site warmth (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016340321&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016342768,Spontaneous,2023-11-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Heart rate increased (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Hypertension (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016342768&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016344834,Spontaneous,2023-11-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Dizziness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016344834&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016334291,Spontaneous,2023-11-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Epistaxis (1d - Recovered/Resolved - Caused/Prolonged Hospitalisation),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","PREGABALIN [PREGABALIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ASCORBIC ACID, CALCIUM GLUBIONATE, CALCIUM CARBONATE, CALCIUM, CALCIUM GLUBIONATE, CALCIUM CARBONATE, COLECALCIFEROL, CALCIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BUTYLSCOPOLAMINE, HYOSCINE BUTYLBROMIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[VITAMIN D] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016334291&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016336884,Spontaneous,2023-11-23 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016336884&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016324408,Spontaneous,2023-11-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Pericarditis (6d - Recovered/Resolved - Caused/Prolonged Hospitalisation),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[FINASTERIDE] (C - Benign prostatic hyperplasia - n/a - [n/a - n/a - n/a]),<BR><BR>[FLUTICASONE, SALMETEROL] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[TAMSULOSIN, TAMSULOSIN HYDROCHLORIDE] (C - Benign prostatic hyperplasia - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016324408&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016325246,Spontaneous,2023-11-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Cardiac disorder (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Hypotension (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Sinus node dysfunction (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016325246&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016325756,Spontaneous,2023-11-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination site hypoaesthesia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016325756&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016326976,Spontaneous,2023-11-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"COVID-19 (7d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (7d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016326976&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016326981,Spontaneous,2023-11-22 00:00:00,Healthcare Professional,Non European Economic Area,"Ando, Y.. A case of chronic inflammatory polyneuritis that developed after COVID-19 vaccination. The 74th Meeting of Northern Japan Pediatric Society. 2023;74th:53",12-17 Years,Not Specified,No,Female,Chronic inflammatory demyelinating polyradiculoneuropathy (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016326981&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016312542,Spontaneous,2023-11-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Drug ineffective (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016312542&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016313493,Spontaneous,2023-11-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Dizziness exertional (n/a - Recovering/Resolving - ),<BR><BR>Extrasystoles (n/a - Recovering/Resolving - ),<BR><BR>Presyncope (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a])","[ESCITALOPRAM, ESCITALOPRAM OXALATE] (C - n/a - n/a - )","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016313493&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016315780,Spontaneous,2023-11-21 00:00:00,Healthcare Professional,European Economic Area,Not available,12-17 Years,Adolescent,No,Female,Heavy menstrual bleeding (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016315780&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016315870,Spontaneous,2023-11-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Deafness (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Pharyngitis (n/a - Not Recovered/Not Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016315870&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016316841,Spontaneous,2023-11-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Atelectasis (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Atrial flutter (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Inferior vena cava dilatation (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Lung consolidation (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pericardial effusion (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pleural effusion (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Respiratory disorder (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Right atrial enlargement (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Right ventricular diastolic collapse (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016316841&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016318660,Spontaneous,2023-11-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016318660&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016303877,Spontaneous,2023-11-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"COVID-19 (n/a - Recovering/Resolving - Life Threatening, Disabling, Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovering/Resolving - Life Threatening, Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[LANSOPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016303877&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016305615,Spontaneous,2023-11-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Muscle fatigue (2d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016305615&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016306536,Spontaneous,2023-11-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Bone pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Ear pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Facial pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Gingival pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hyperaesthesia teeth (n/a - Unknown - Other Medically Important Condition),<BR><BR>Neuralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in jaw (n/a - Unknown - Other Medically Important Condition),<BR><BR>Toothache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224)] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016306536&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016307700,Spontaneous,2023-11-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hypoaesthesia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Migraine (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Photophobia (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","BIMATOPROST [BIMATOPROST] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - Hormone replacement therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016307700&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016308081,Spontaneous,2023-11-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Axillary pain (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016308081&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016308391,Spontaneous,2023-11-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Dysarthria (13d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016308391&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016308398,Spontaneous,2023-11-20 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Subileus (1wk - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016308398&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016311184,Spontaneous,2023-11-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Migraine (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016311184&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016293201,Spontaneous,2023-11-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Haemophagocytic lymphohistiocytosis (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Interstitial lung disease (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pancytopenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pneumothorax (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016293201&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016298687,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Asthenia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Sinusitis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016298687&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016299108,Spontaneous,2023-11-17 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>SPIKEVAX [ELASOMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016299108&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016285939,Spontaneous,2023-11-16 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chest pain (468d - Recovered/Resolved - Life Threatening, Disabling),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Life Threatening, Disabling),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Life Threatening, Disabling),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Life Threatening, Disabling),<BR><BR>Insomnia (n/a - Not Recovered/Not Resolved - Life Threatening, Disabling),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Life Threatening, Disabling),<BR><BR>Palpitations (468d - Recovering/Resolving - Life Threatening)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])","CIRCADIN [MELATONIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ALIMEMAZINE, ALIMEMAZINE TARTRATE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[CITALOPRAM, CITALOPRAM HYDROBROMIDE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[MACROGOL 400, OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[RISPERIDONE] (C - n/a - n/a - [n/a - n/a - Intramuscular use]),<BR><BR>[ZOPICLONE] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016285939&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016288075,Spontaneous,2023-11-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Joint swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016288075&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016288520,Spontaneous,2023-11-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Pharyngeal swelling (n/a - Unknown - ),<BR><BR>Tongue blistering (n/a - Unknown - ),<BR><BR>Tongue discomfort (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016288520&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016289072,Spontaneous,2023-11-16 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Death (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016289072&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016289129,Spontaneous,2023-11-16 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Atelectasis (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Back pain (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling),<BR><BR>COVID-19 (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Malaise (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Pleural effusion (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Pleuritic pain (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Pulmonary embolism (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Pulmonary infarction (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Spinal osteoarthritis (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[LANSOPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016289129&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016276620,Spontaneous,2023-11-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Dizziness (n/a - Recovered/Resolved With Sequelae - Disabling),<BR><BR>Nausea (n/a - Recovered/Resolved With Sequelae - Disabling),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Type 2 diabetes mellitus (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Vomiting (n/a - Recovered/Resolved With Sequelae - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016276620&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016277136,Spontaneous,2023-11-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016277136&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016277156,Spontaneous,2023-11-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Migraine (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016277156&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016277439,Spontaneous,2023-11-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myocarditis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pericarditis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Sensory loss (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[COVID-19 VACCINE] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016277439&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016279297,Spontaneous,2023-11-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Pruritus (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016279297&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016279328,Spontaneous,2023-11-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Burning sensation (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Formication (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016279328&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016279430,Spontaneous,2023-11-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Nightmare (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])","[BUDESONIDE, FORMOTEROL FUMARATE DIHYDRATE, FORMOTEROL FUMARATE, BUDESONIDE] (C - n/a - n/a - [n/a - n/a - Inhalation use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016279430&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016268805,Spontaneous,2023-11-14 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Chills (1d - Recovered/Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016268805&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016268820,Spontaneous,2023-11-14 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Dysgeusia (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016268820&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016269052,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vertigo (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - n/a - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016269052&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016269186,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Influenza (n/a - Recovered/Resolved With Sequelae - Disabling),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - n/a - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016269186&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016270584,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Cardiac fibrillation (2d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a])",[ATORVASTATIN] (C - Hypercholesterolaemia - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016270584&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016272855,Spontaneous,2023-11-14 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Blood cholesterol increased (n/a - Unknown - ),<BR><BR>Blood creatine phosphokinase increased (8d - Recovered/Resolved - ),<BR><BR>Blood glucose increased (n/a - Unknown - ),<BR><BR>Blood triglycerides increased (n/a - Unknown - ),<BR><BR>C-reactive protein increased (8d - Recovered/Resolved - ),<BR><BR>Cardiac failure (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - ),<BR><BR>Dilated cardiomyopathy (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Ejection fraction decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - ),<BR><BR>Feeling of despair (n/a - Unknown - ),<BR><BR>General physical health deterioration (n/a - Unknown - ),<BR><BR>Interchange of vaccine products (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Left ventricular dysfunction (n/a - Unknown - Other Medically Important Condition),<BR><BR>Movement disorder (n/a - Unknown - ),<BR><BR>Myocarditis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pulmonary arterial hypertension (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pulmonary embolism (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016272855&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016272934,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Appendicitis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016272934&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016273703,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"Arthralgia (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Soft tissue injury (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016273703&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016259969,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chest pain (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Gait inability (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Loss of consciousness (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Myocardial infarction (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain in jaw (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016259969&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016261164,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nervousness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tremor (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","IMRALDI [ADALIMUMAB] (C - Crohn's disease - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016261164&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016261185,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Cardiac flutter (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Heart rate increased (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016261185&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016266508,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Interchange of vaccine products (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Neuropathy peripheral (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",IRBESARTAN [IRBESARTAN] (C - Hypertension - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016266508&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016259361,Spontaneous,2023-11-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Swelling (1d - Recovered/Resolved - Other Medically Important Condition),"PEMBROLIZUMAB [PEMBROLIZUMAB] (S - n/a - Unknown - [1d - n/a - n/a]),<BR><BR>TOZINAMERAN, RILTOZINAMERAN [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016259361&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016252603,Spontaneous,2023-11-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dysphagia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Musculoskeletal stiffness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Torticollis (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",AERIUS [DESLORATADINE] (C - n/a - n/a - [n/a - n/a - Oral use]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016252603&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016252816,Spontaneous,2023-11-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Pyrexia (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016252816&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016252917,Spontaneous,2023-11-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Abdominal pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Abdominal tenderness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016252917&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016254530,Spontaneous,2023-11-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Polymyalgia rheumatica (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016254530&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016257102,Spontaneous,2023-11-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Amnesia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Depression (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016257102&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016257637,Spontaneous,2023-11-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016257637&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016242868,Spontaneous,2023-11-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Back pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Mood altered (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaginal haemorrhage (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE, BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MEDROXYPROGESTERONE ACETATE] (C - Endometrial hyperplasia - n/a - [n/a - n/a - n/a]),<BR><BR>[MONTELUKAST, MONTELUKAST SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016242868&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016243191,Spontaneous,2023-11-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Disease recurrence (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Herpes zoster (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016243191&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016243693,Spontaneous,2023-11-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>SPIKEVAX [ELASOMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[TOZINAMERAN MULTIVALENT NOS] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016243693&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016243883,Spontaneous,2023-11-09 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,Seizure (1d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016243883&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016244151,Spontaneous,2023-11-09 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Lymphadenopathy (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",[NABUMETONE] (C - n/a - n/a - [813d - n/a - Oral use]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016244151&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016236816,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Atrial fibrillation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - ),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016236816&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016237294,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Chest pain (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tachycardia (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016237294&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016237616,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Asthenia (7d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dizziness (7d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (6d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (7d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (4d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[INFLUENZA VIRUS] (C - Antiviral prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - Hypercholesterolaemia - n/a - [n/a - 10mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016237616&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016238609,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Dizziness (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016238609&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016239412,Spontaneous,2023-11-08 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Acute cardiac event (n/a - Fatal - Results in Death),<BR><BR>Myocarditis (n/a - Fatal - Results in Death)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])","LEVETIRACETAM [LEVETIRACETAM] (C - n/a - n/a - ),<BR><BR>VIMPAT [LACOSAMIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016239412&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016225831,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Anal haemorrhage (5d - Recovered/Resolved With Sequelae - Disabling, Other Medically Important Condition),<BR><BR>Diarrhoea (4d - Recovered/Resolved With Sequelae - Disabling, Other Medically Important Condition),<BR><BR>Drug hypersensitivity (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Hyperhidrosis (4d - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Paraesthesia (6d - Recovered/Resolved With Sequelae - Disabling, Other Medically Important Condition),<BR><BR>Rash (9d - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Vomiting (4d - Recovered/Resolved With Sequelae - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016225831&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016226648,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Chills (1d - Recovered/Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016226648&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016227568,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Bone pain (6d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dizziness (6d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Eye pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (7d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (6d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Sweating fever (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[INFLUENZA VIRUS] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LIDOCAINE, LIDOCAINE HYDROCHLORIDE] (C - Spinal anaesthesia - n/a - [n/a - n/a - n/a]),<BR><BR>[TETRACAINE, TETRACAINE HYDROCHLORIDE] (C - Spinal anaesthesia - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016227568&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016227740,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Restlessness (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016227740&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016227742,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Costochondritis (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016227742&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016228176,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Diarrhoea (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])","[LOSARTAN, LOSARTAN POTASSIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016228176&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016228897,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (1d - Recovered/Resolved - ),<BR><BR>Dizziness (2d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - ),<BR><BR>Nasal congestion (n/a - Unknown - ),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])","[PROPRANOLOL, PROPRANOLOL HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016228897&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016229320,Spontaneous,2023-11-07 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Fatigue (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016229320&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016229363,Spontaneous,2023-11-07 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Lymphadenopathy (7d - Recovered/Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016229363&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016229927,Spontaneous,2023-11-07 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (n/a - Recovering/Resolving - Disabling),<BR><BR>Asthenia (n/a - Recovering/Resolving - Disabling),<BR><BR>Balance disorder (n/a - Recovering/Resolving - Disabling),<BR><BR>Myalgia (n/a - Recovering/Resolving - Disabling),<BR><BR>Nervous system disorder (n/a - Recovering/Resolving - Disabling),<BR><BR>Oedema peripheral (n/a - Recovering/Resolving - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016229927&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016231326,Spontaneous,2023-11-07 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Herpes zoster (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016231326&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016231407,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Ear pain (n/a - Recovering/Resolving - ),<BR><BR>Herpes zoster (n/a - Recovering/Resolving - ),<BR><BR>Neck pain (n/a - Recovering/Resolving - ),<BR><BR>Pain (n/a - Recovering/Resolving - ),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016231407&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016232039,Spontaneous,2023-11-07 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Ageusia (n/a - Recovering/Resolving - ),<BR><BR>Brain fog (n/a - Not Recovered/Not Resolved - ),<BR><BR>Facial paralysis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Magnetic resonance imaging abnormal (n/a - Unknown - ),<BR><BR>Muscle spasms (n/a - Not Recovered/Not Resolved - ),<BR><BR>Tremor (n/a - Not Recovered/Not Resolved - ),<BR><BR>Visual impairment (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - Product used for unknown indication - Unknown - [n/a - 1{DF} - Intramuscular use]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - Product used for unknown indication - Unknown - [n/a - 1{DF} - Intramuscular use]),<BR><BR>[ELASOMERAN NOS] (S - COVID-19 prophylaxis - Not applicable - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016232039&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016218953,Spontaneous,2023-11-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dizziness (0d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])","[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[CANDESARTAN CILEXETIL] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016218953&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016218986,Spontaneous,2023-11-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Asthenia (n/a - Recovered/Resolved With Sequelae - ),<BR><BR>Blood pressure increased (n/a - Recovered/Resolved With Sequelae - ),<BR><BR>Disturbance in attention (n/a - Unknown - ),<BR><BR>Dizziness (n/a - Recovered/Resolved With Sequelae - ),<BR><BR>Dyspnoea (n/a - Recovered/Resolved With Sequelae - ),<BR><BR>Fatigue (n/a - Recovered/Resolved With Sequelae - ),<BR><BR>Headache (n/a - Recovered/Resolved With Sequelae - ),<BR><BR>Hypotonia (n/a - Recovered/Resolved With Sequelae - ),<BR><BR>Palpitations (n/a - Recovering/Resolving - ),<BR><BR>Sleep disorder (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 4{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016218986&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016220994,Spontaneous,2023-11-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Diarrhoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Vomiting (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016220994&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016222407,Spontaneous,2023-11-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016222407&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016222444,Spontaneous,2023-11-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Feeling abnormal (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Glossodynia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Paraesthesia oral (1d - Unknown - Other Medically Important Condition),<BR><BR>Vomiting (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[LISINOPRIL, LISINOPRIL DIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016222444&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016222554,Spontaneous,2023-11-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016222554&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016222968,Spontaneous,2023-11-06 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Eyelid ptosis (n/a - Unknown - Disabling),<BR><BR>Facial paralysis (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Multiple sclerosis (n/a - Unknown - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016222968&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016223914,Spontaneous,2023-11-06 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Headache (1d - Recovered/Resolved - ),<BR><BR>Pain in extremity (1d - Recovered/Resolved - ),<BR><BR>Palpitations (1d - Recovered/Resolved - ),<BR><BR>Paraesthesia (1d - Recovered/Resolved - ),<BR><BR>Peripheral swelling (1d - Recovered/Resolved - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016223914&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016224077,Spontaneous,2023-11-06 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Herpes zoster (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016224077&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016209820,Spontaneous,2023-11-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Dizziness postural (1d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016209820&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016210816,Spontaneous,2023-11-03 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dyspnoea (n/a - Unknown - ),<BR><BR>Head discomfort (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hypogeusia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nasal congestion (n/a - Unknown - ),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - ),<BR><BR>Parosmia (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a])","[ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM TRIHYDRATE] (C - Hiatus hernia - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016210816&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016201469,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Fall (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Hypotension (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - n/a - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016201469&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016201559,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"Dyspnoea (2d - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),<BR><BR>Headache (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Oxygen saturation decreased (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Pain in extremity (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (n/a - Unknown - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016201559&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016202366,Spontaneous,2023-11-02 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Abdominal pain (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Cholelithiasis (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Constipation (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Malaise (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Mesenteric vein thrombosis (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pancreatitis necrotising (n/a - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Portal vein thrombosis (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Presyncope (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Splenic vein thrombosis (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Vomiting (n/a - Unknown - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016202366&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016203364,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (1d - Recovered/Resolved - ),<BR><BR>Chest pain (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Confusional state (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Delirium (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Dysarthria (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (2d - Recovered/Resolved - ),<BR><BR>Influenza like illness (n/a - Unknown - ),<BR><BR>Muscular weakness (n/a - Recovering/Resolving - ),<BR><BR>Myocarditis (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Neck pain (1d - Recovered/Resolved - ),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (1d - Recovered/Resolved - ),<BR><BR>Syncope (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Tachycardia (n/a - Unknown - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016203364&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016203378,Spontaneous,2023-11-02 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,Hypertensive crisis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016203378&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016203938,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Decreased appetite (n/a - Unknown - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016203938&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016203974,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016203974&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016204644,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Hyperpyrexia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016204644&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016205026,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016205026&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016205500,Spontaneous,2023-11-02 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,Cardiac death (n/a - Fatal - Results in Death),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016205500&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016205873,Spontaneous,2023-11-02 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Angioedema (30min - Recovered/Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[IPRATROPIUM BROMIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVONORGESTREL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PANTOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016205873&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016196158,Spontaneous,2023-11-01 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Injection site urticaria (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pruritus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site warmth (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016196158&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016196750,Spontaneous,2023-11-01 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016196750&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016197310,Spontaneous,2023-11-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Injection site pain (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Peripheral swelling (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Rheumatoid arthritis (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Weight decreased (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 4{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016197310&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016199696,Spontaneous,2023-11-01 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Discomfort (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Mobility decreased (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - n/a - n/a])","ESOMEPRAZOLE [ESOMEPRAZOLE] (C - Barrett's oesophagus, Gastritis - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[VALACICLOVIR] (C - Prophylaxis - Dose not changed - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016199696&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016187431,Spontaneous,2023-10-31 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Mobility decreased (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Polymyalgia rheumatica (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016187431&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016189526,Spontaneous,2023-10-31 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Optic ischaemic neuropathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[GLICLAZIDE] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - Gastric ulcer - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016189526&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016189800,Spontaneous,2023-10-31 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Arthralgia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chills (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Myalgia (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ATENOLOL, ATENOLOL BP] (C - Blood pressure abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[BENDROFLUAZIDE] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016189800&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016191762,Spontaneous,2023-10-31 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Atrial fibrillation (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Disease recurrence (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016191762&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016179849,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Hyperhidrosis (n/a - Recovered/Resolved - ),<BR><BR>Loss of consciousness (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016179849&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016180691,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Confusional state (1d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016180691&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016181344,Spontaneous,2023-10-30 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,Cardiac failure acute (n/a - Not Recovered/Not Resolved - Life Threatening),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])","XARELTO [RIVAROXABAN] (C - Atrial fibrillation - n/a - [n/a - 2{DF} - Oral use]),<BR><BR>[ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM TRIHYDRATE, ESOMEPRAZOLE SODIUM] (C - Peptic ulcer - n/a - [n/a - 1{DF} - Oral use]),<BR><BR>[TAMSULOSIN HYDROCHLORIDE] (C - Benign prostatic hyperplasia - n/a - [n/a - 1{DF} - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016181344&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016173747,Spontaneous,2023-10-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Muscle spasms (n/a - Not Recovered/Not Resolved - ),<BR><BR>Tic (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016173747&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016173893,Spontaneous,2023-10-28 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Interchange of vaccine products (n/a - Unknown - ),<BR><BR>SARS-CoV-2 test positive (n/a - Unknown - ),<BR><BR>Vaccination failure (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - Product used for unknown indication - Unknown - [n/a - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - Product used for unknown indication - Unknown - [n/a - 1{DF} - n/a]),<BR><BR>SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5 [ELASOMERAN, DAVESOMERAN] (S - COVID-19 prophylaxis - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016173893&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016163793,Spontaneous,2023-10-27 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Cardiac ventricular thrombosis (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016163793&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016168204,Spontaneous,2023-10-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Syncope (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Thrombosis (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016168204&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016168334,Spontaneous,2023-10-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Hyperhidrosis (n/a - Recovered/Resolved With Sequelae - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 3{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016168334&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016154328,Spontaneous,2023-10-26 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Hallucination (1d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","RIVAROXABAN [RIVAROXABAN] (C - Thrombosis - n/a - [n/a - n/a - n/a]),<BR><BR>SPIRONOLACTONE [SPIRONOLACTONE] (C - Cardiac failure - n/a - [n/a - n/a - n/a]),<BR><BR>[DIGOXIN] (C - Cardiac failure - n/a - [n/a - n/a - n/a]),<BR><BR>[DILTIAZEM HYDROCHLORIDE PH. EUR.] (C - Cardiac failure - n/a - [n/a - n/a - n/a]),<BR><BR>[FUROSEMIDE] (C - Atrial fibrillation - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - Blood pressure measurement - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016154328&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016154490,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arrhythmia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hypertension (n/a - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[CODEINE] (C - Analgesic therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - Blood pressure increased - n/a - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - Blood cholesterol increased - n/a - [n/a - n/a - n/a]),<BR><BR>[TRIMIPRAMINE, TRIMIPRAMINE MALEATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016154490&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016155410,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Asthenia (36h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chills (36h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug interaction (36h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (36h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Influenza like illness (36h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Night sweats (36h - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (I - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[INTERFERON ALFA-2A] (I - Polycythaemia - Unknown - [n/a - n/a - n/a])","[ACETYLSALICYLIC ACID] (C - Polycythaemia - n/a - [n/a - n/a - n/a]),<BR><BR>[HYDROXYCARBAMIDE] (C - Polycythaemia vera - n/a - [n/a - n/a - n/a]),<BR><BR>[LISINOPRIL, LISINOPRIL DIHYDRATE] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016155410&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016155608,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Chills (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Immunisation - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016155608&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016155743,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Capillaritis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016155743&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016155845,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Drug hypersensitivity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Illness (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Syncope (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016155845&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016156418,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Mobility decreased (n/a - Unknown - ),<BR><BR>Musculoskeletal stiffness (1mo - Recovered/Resolved With Sequelae - ),<BR><BR>Pain (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016156418&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016156942,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Interchange of vaccine products (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Rash (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - n/a - [1d - n/a - n/a]),<BR><BR>VIDPREVTYN BETA [POLYSORBATE 80, SARS-COV-2, B.1.351 VARIANT, PREFUSION SPIKE DELTA TM PROTEIN, RECOMBINANT, SQUALENE, DL-ALPHA-TOCOPHEROL] (C - COVID-19 immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016156942&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016157150,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016157150&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016158440,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Feeling hot (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Off label use (n/a - Unknown - ),<BR><BR>Product use issue (n/a - Unknown - ),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rash (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rash macular (n/a - Unknown - Other Medically Important Condition),<BR><BR>Skin warm (n/a - Unknown - Other Medically Important Condition),<BR><BR>Urticaria (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016158440&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016161313,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Rheumatoid arthritis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016161313&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016145273,Spontaneous,2023-10-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Chronic gastritis (n/a - Not Recovered/Not Resolved - Disabling),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","INFLIXIMAB [INFLIXIMAB] (C - Behcet's syndrome - n/a - [n/a - n/a - n/a]),<BR><BR>MYCOPHENOLATE MOFETIL [MYCOPHENOLATE MOFETIL] (C - Behcet's syndrome - n/a - [n/a - 2g - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[LISDEXAMFETAMINE] (C - Attention deficit hyperactivity disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[MELOXICAM] (C - Arthralgia, Behcet's syndrome - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL, CODEINE PHOSPHATE, PARACETAMOL, CODEINE PHOSPHATE HEMIHYDRATE] (C - Behcet's syndrome - n/a - [n/a - n/a - n/a]),<BR><BR>[PREDNISOLONE] (C - Behcet's syndrome - n/a - [n/a - 5mg - n/a]),<BR><BR>[PROPRANOLOL, PROPRANOLOL HYDROCHLORIDE] (C - Sinus tachycardia - n/a - [n/a - n/a - n/a]),<BR><BR>[VENLAFAXINE, VENLAFAXINE HYDROCHLORIDE] (C - Depression - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016145273&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016145835,Spontaneous,2023-10-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Diarrhoea (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Feeding disorder (n/a - Unknown - ),<BR><BR>Headache (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Injection related reaction (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",SILDENAFIL CITRATE [SILDENAFIL CITRATE] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016145835&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016147404,Spontaneous,2023-10-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Cold sweat (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Diarrhoea (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hyperhidrosis (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Movement disorder (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Musculoskeletal stiffness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (S - Immunisation - Not applicable - [n/a - n/a - n/a])","[CHLORPHENAMINE MALEATE] (C - Seasonal allergy - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Back pain - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016147404&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016147889,Spontaneous,2023-10-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Asthenia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Formication (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Musculoskeletal stiffness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pruritus (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ATORVASTATIN] (C - Blood cholesterol abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016147889&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016149140,Spontaneous,2023-10-25 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Cerebral infarction (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Visual impairment (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016149140&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016149968,Spontaneous,2023-10-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Cardiac flutter (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Feeling hot (n/a - Unknown - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016149968&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016150234,Spontaneous,2023-10-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Injection related reaction (5d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - ),<BR><BR>Parosmia (n/a - Unknown - ),<BR><BR>Taste disorder (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016150234&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016151026,Spontaneous,2023-10-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug interaction (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Night sweats (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tinnitus (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (I - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>PEGINTERFERON ALFA-2A [PEGINTERFERON ALFA-2A] (I - Polycythaemia vera - Unknown - [n/a - n/a - n/a])","[ACETYLSALICYLIC ACID] (C - Polycythaemia - n/a - [n/a - n/a - n/a]),<BR><BR>[HYDROXYCARBAMIDE] (C - Polycythaemia vera - n/a - [n/a - n/a - n/a]),<BR><BR>[LISINOPRIL, LISINOPRIL DIHYDRATE] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016151026&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016151533,Spontaneous,2023-10-25 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Acute myocardial infarction (n/a - Unknown - Life Threatening, Other Medically Important Condition),<BR><BR>Angina pectoris (n/a - Recovering/Resolving - Life Threatening, Other Medically Important Condition),<BR><BR>Angina unstable (n/a - Unknown - Life Threatening, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>RANOLAZINE [RANOLAZINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>SAXAGLIPTIN [SAXAGLIPTIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CANDESARTAN, CANDESARTAN CILEXETIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ISOSORBIDE 5 MONONITRATE, ISOSORBIDE MONONITRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016151533&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016152925,Spontaneous,2023-10-25 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Acute kidney injury (11d - Fatal - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Hepatitis (11d - Fatal - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Necrotising myositis (11d - Fatal - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Respiratory failure (11d - Fatal - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Rhabdomyolysis (11d - Fatal - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use]),<BR><BR>[INFLUENZA QUADRIVALENT VACCINE (RDNA)] (S - Influenza immunisation - Not applicable - [n/a - n/a - n/a])","[ACETYLSALICYLIC ACID, ACETYLSALICYLIC ACID PH. EUR., ASPIRIN BP] (C - n/a - Dose not changed - [n/a - 75mg - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - Dose not changed - [n/a - 80mg - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - Dose not changed - [n/a - 2.5mg - n/a]),<BR><BR>[LANSOPRAZOLE] (C - Prophylaxis - Dose not changed - [n/a - 15mg - n/a]),<BR><BR>[LETROZOLE] (C - n/a - Dose not changed - [n/a - 2.5mg - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - Dose not changed - [n/a - 5mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016152925&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016139746,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Vertigo (n/a - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016139746&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016140017,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016140017&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016140119,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Urticaria (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016140119&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016140187,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Injection site swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymph node pain (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Musculoskeletal stiffness (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016140187&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016140806,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Abdominal pain upper (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Disorientation (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Feeling cold (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Mobility decreased (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pallor (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Syncope (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tinnitus (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016140806&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016140914,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Hypersensitivity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Off label use (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Urticaria (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","TOZINAMERAN, RILTOZINAMERAN [TOZINAMERAN, RILTOZINAMERAN] (S - Multiple sclerosis - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016140914&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016141108,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Illness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vision blurred (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016141108&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016141172,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Muscular weakness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Musculoskeletal stiffness (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","TOZINAMERAN, RILTOZINAMERAN [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (S - Influenza immunisation - Not applicable - [1d - n/a - n/a])","ESOMEPRAZOLE [ESOMEPRAZOLE] (C - Barrett's oesophagus, Gastritis - n/a - [n/a - n/a - n/a]),<BR><BR>[VALACICLOVIR] (C - Prophylaxis - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016141172&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016141220,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Night sweats (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016141220&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016141245,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Peripheral swelling (5d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016141245&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016142823,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Brain fog (n/a - Recovered/Resolved With Sequelae - ),<BR><BR>Disturbance in attention (n/a - Not Recovered/Not Resolved - ),<BR><BR>Emotional distress (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Feeling cold (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>SPIKEVAX [ELASOMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016142823&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016143330,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","TOZINAMERAN, RILTOZINAMERAN [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016143330&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016143434,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Postmenopausal haemorrhage (n/a - Unknown - Other Medically Important Condition),<BR><BR>Postmenopause (n/a - Not Recovered/Not Resolved - )","TOZINAMERAN, RILTOZINAMERAN [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (C - COVID-19 immunisation - n/a - [1d - n/a - n/a]),<BR><BR>SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.1 [ELASOMERAN, IMELASOMERAN] (C - COVID-19 immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - n/a - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016143434&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016131240,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Ageusia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Anosmia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chills (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Disturbance in attention (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Somnolence (3d - Recovered/Resolved - Other Medically Important Condition)","TOZINAMERAN, RILTOZINAMERAN [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016131240&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016131278,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Not Specified,Paraesthesia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[AMLODIPINE, AMLODIPINE BESILATE] (C - Blood pH increased - n/a - [n/a - n/a - n/a]),<BR><BR>[FINASTERIDE] (C - Benign prostatic hyperplasia - n/a - [n/a - n/a - n/a]),<BR><BR>[HYDROCHLOROTHIAZIDE, RAMIPRIL, RAMIPRIL] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016131278&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016131300,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Unknown - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Somnolence (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Unknown - Other Medically Important Condition)","TOZINAMERAN, RILTOZINAMERAN [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Diabetes mellitus - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016131300&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016132230,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chest pain (n/a - Unknown - ),<BR><BR>Dyspnoea (n/a - Unknown - ),<BR><BR>Fatigue (n/a - Unknown - ),<BR><BR>Pericarditis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016132230&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016132582,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Headache (14d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016132582&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016133505,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Adult,No,Not Specified,"Anxiety (n/a - Unknown - Other Medically Important Condition),<BR><BR>Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Cognitive disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Conduction disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Depression (n/a - Unknown - Other Medically Important Condition),<BR><BR>Disturbance in attention (n/a - Unknown - Other Medically Important Condition),<BR><BR>Emotional distress (n/a - Unknown - Other Medically Important Condition),<BR><BR>Executive dysfunction (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Foot deformity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Gait disturbance (n/a - Unknown - Other Medically Important Condition),<BR><BR>Increased tendency to bruise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Knee deformity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Limb discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lipoedema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lipoma (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphoedema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Memory impairment (n/a - Unknown - Other Medically Important Condition),<BR><BR>Movement disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Multiple sclerosis pseudo relapse (n/a - Unknown - Other Medically Important Condition),<BR><BR>Multiple sclerosis relapse (n/a - Unknown - Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Sensory loss (n/a - Unknown - Other Medically Important Condition),<BR><BR>Speech disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Visuospatial deficit (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016133505&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016134711,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Multiple sclerosis (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016134711&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016138437,Spontaneous,2023-10-23 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Immune thrombocytopenia (n/a - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016138437&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016121142,Spontaneous,2023-10-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal discomfort (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Abdominal pain upper (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Asthenia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Depression (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - Cerebrovascular accident - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016121142&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016124840,Spontaneous,2023-10-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Myelitis transverse (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016124840&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016126529,Spontaneous,2023-10-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dizziness (1d - Recovered/Resolved - ),<BR><BR>Electrocardiogram ST segment depression (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pallor (n/a - Unknown - ),<BR><BR>Pollakiuria (n/a - Unknown - ),<BR><BR>Presyncope (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - Not applicable - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA QUADRIVALENT VACCINE (RDNA)] (S - n/a - Not applicable - [n/a - n/a - n/a])","SPIRONOLACTONE [SPIRONOLACTONE] (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Atrial fibrillation - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[DIGOXIN] (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[FUROSEMIDE] (C - Cardiac failure congestive - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[WARFARIN, WARFARIN SODIUM] (C - n/a - Dose not changed - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016126529&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016113268,Spontaneous,2023-10-19 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Atrial fibrillation (148d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hypotension (148d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Rash (148d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","APIXABAN [APIXABAN] (C - n/a - n/a - [n/a - 2{DF} - n/a]),<BR><BR>EDOXABAN [EDOXABAN] (C - n/a - n/a - [1d - 1{DF} - n/a]),<BR><BR>IBUPROFEN [IBUPROFEN, IBUPROFEN SODIUM] (C - n/a - n/a - [n/a - n/a - Topical]),<BR><BR>[BETAMETHASONE DIPROPIONATE, CLOTRIMAZOLE, BETAMETHASONE, CLOTRIMAZOLE, CLOTRIMAZOLE PH. EUR., BETAMETHASONE DIPROPIONATE (PH. EUR.)] (C - n/a - n/a - [14d - n/a - Topical]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[CEFALEXIN] (C - n/a - n/a - [7d - 3{DF} - n/a]),<BR><BR>[DOXAZOSIN, DOXAZOSIN MESILATE] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - n/a - n/a - [2wk - 1{DF} - n/a]),<BR><BR>[FERROUS FUMARATE] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[SIMVASTATIN] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[SODIUM HYALURONATE] (C - n/a - n/a - [n/a - 2[drp] - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016113268&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016113520,Spontaneous,2023-10-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016113520&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016113559,Spontaneous,2023-10-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Asthma (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE, BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE] (C - Asthma late onset - n/a - [n/a - n/a - n/a]),<BR><BR>[MONTELUKAST, MONTELUKAST SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016113559&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016115160,Spontaneous,2023-10-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Brain neoplasm (n/a - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016115160&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016115193,Spontaneous,2023-10-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (1d - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (1d - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","BUMETANIDE [BUMETANIDE] (C - Fluid retention - n/a - [n/a - 2mg - n/a]),<BR><BR>ESOMEPRAZOLE [ESOMEPRAZOLE] (C - n/a - n/a - [n/a - 20mg - n/a]),<BR><BR>VALSARTAN, SACUBITRIL [VALSARTAN, SACUBITRIL] (C - n/a - n/a - [n/a - 2{DF} - n/a]),<BR><BR>[ALFACALCIDOL] (C - n/a - n/a - [n/a - 250ng - n/a]),<BR><BR>[ALLOPURINOL] (C - Gout - n/a - [n/a - 100mg - n/a]),<BR><BR>[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - 10mg - n/a]),<BR><BR>[ATORVASTATIN] (C - Hypercholesterolaemia - n/a - [n/a - 20mg - n/a]),<BR><BR>[BECLOMETASONE DIPROPIONATE] (C - n/a - n/a - [n/a - 4{DF} - n/a]),<BR><BR>[BUPRENORPHINE] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[CARVEDILOL] (C - n/a - n/a - [n/a - 12.5mg - n/a - More in ICSR]),<BR><BR>[CETIRIZINE, CETIRIZINE DIHYDROCHLORIDE] (C - Hypersensitivity - n/a - [n/a - 5mg - n/a]),<BR><BR>[DIHYDROCODEINE, DIHYDROCODEINE TARTRATE BP] (C - n/a - n/a - [n/a - 30mg - n/a]),<BR><BR>[DOCUSATE] (C - n/a - n/a - [n/a - 100mg - n/a]),<BR><BR>[DYDROGESTERONE, ESTRADIOL, DYDROGESTERONE, ESTRADIOL HEMIHYDRATE] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[GLICLAZIDE] (C - n/a - n/a - [n/a - 320mg - n/a]),<BR><BR>[PROCHLORPERAZINE] (C - n/a - n/a - [n/a - 5mg - n/a]),<BR><BR>[QUININE SULFATE] (C - n/a - n/a - [n/a - 300mg - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - n/a - n/a - [n/a - 2{DF} - n/a]),<BR><BR>[SPIRONOLACTONE] (C - n/a - n/a - [n/a - 12.5mg - n/a]),<BR><BR>[WARFARIN, WARFARIN SODIUM] (C - n/a - n/a - [n/a - 1mg - n/a - More in ICSR])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016115193&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016115966,Spontaneous,2023-10-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Chest pain (n/a - Unknown - Disabling),<BR><BR>Dyspnoea (n/a - Unknown - Disabling),<BR><BR>Fatigue (n/a - Unknown - Disabling),<BR><BR>Movement disorder (n/a - Unknown - Disabling),<BR><BR>Myocarditis (n/a - Recovered/Resolved With Sequelae - Disabling),<BR><BR>Palpitations (n/a - Unknown - Disabling),<BR><BR>Pericarditis (n/a - Recovered/Resolved With Sequelae - Disabling),<BR><BR>Pyrexia (n/a - Unknown - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[TRAMADOL, TRAMADOL HYDROCHLORIDE] (C - Arthritis - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016115966&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016117220,Spontaneous,2023-10-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Abdominal pain upper (n/a - Unknown - ),<BR><BR>Dizziness (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Visual impairment (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016117220&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016117427,Spontaneous,2023-10-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fall (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypotension (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - ),<BR><BR>Paralysis (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CYANOCOBALAMIN, VITAMIN B12] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016117427&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016118294,Spontaneous,2023-10-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Influenza (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - n/a - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016118294&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016104475,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nasopharyngitis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Sneezing (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[INDAPAMIDE, INDAPAMIDE HEMIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016104475&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016104955,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Dizziness (n/a - Recovered/Resolved - ),<BR><BR>Pain in extremity (n/a - Recovered/Resolved - ),<BR><BR>Syncope (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016104955&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016105189,Spontaneous,2023-10-18 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Acute coronary syndrome (1d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Angina pectoris (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL, CALCIUM CARBONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FERROUS SULFATE] (C - Blood iron decreased - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016105189&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016105231,Spontaneous,2023-10-18 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Cardiac flutter (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Heart rate increased (n/a - Recovered/Resolved - ),<BR><BR>Palpitations (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[DOXYCYCLINE, DOXYCYCLINE HYCLATE, DOXYCYCLINE MONOHYDRATE] (C - Acne - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016105231&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016105258,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Disturbance in attention (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea exertional (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Erythema (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Muscular weakness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ASCORBIC ACID, BETACAROTENE, BIOTIN, ERGOCALCIFEROL, CYANOCOBALAMIN, FOLIC ACID, NICOTINAMIDE, PYRIDOXINE, RIBOFLAVIN, THIAMINE, ZINC, CALCIUM, CHROMIUM, COPPER, IODINE, IRON, MAGNESIUM, MANGANESE, PANTOTHENIC ACID, PHOSPHORUS, POTASSIUM, SELENIUM, TOCOPHERYL ACETATE, MOLYBDENUM, ASCORBIC ACID, BETACAROTENE, ERGOCALCIFEROL, CYANOCOBALAMIN, FOLIC ACID, NICOTINAMIDE, PYRIDOXINE, RIBOFLAVIN, THIAMINE, ZINC, CALCIUM, CHROMIUM, COPPER, IODINE, IRON, MAGNESIUM, MANGANESE, PANTOTHENIC ACID, PHOSPHORUS, POTASSIUM, SELENIUM, MOLYBDENUM, DL-ALPHA TOCOPHEROL ACETATE, D-BIOTIN, ERGOCALCIFEROL, RETINOL] (C - Metabolic surgery - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - Anxiety - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016105258&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016105390,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chest pain (n/a - Unknown - ),<BR><BR>Dyspnoea (n/a - Unknown - ),<BR><BR>Hypertension (n/a - Unknown - ),<BR><BR>Palpitations (n/a - Unknown - ),<BR><BR>Pericarditis (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Syncope (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016105390&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016106100,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Feeling of body temperature change (n/a - Unknown - Other Medically Important Condition),<BR><BR>Loss of consciousness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vomiting (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016106100&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016106395,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Cough (n/a - Recovered/Resolved With Sequelae - Disabling, Other Medically Important Condition),<BR><BR>Laryngitis (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Sciatica (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CANDESARTAN, CANDESARTAN CILEXETIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CODEINE PHOSPHATE BP, PARACETAMOL PH. EUR., PARACETAMOL BP, CODEINE PHOSPHATE BP, PARACETAMOL DC, PARACETAMOL PH. EUR., CODEINE PHOSPHATE PH.EUR., PARACETAMOL PH. EUR., CODEINE PHOSPHATE PH.EUR., PARACETAMOL, CODEINE PHOSPHATE, PARACETAMOL, CODEINE PHOSPHATE BP, PARACETAMOL, CODEINE PHOSPHATE HEMIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FLUOXETINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[QUININE SULFATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016106395&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016106547,Spontaneous,2023-10-18 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Haemorrhagic diathesis (n/a - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Leukocytosis (n/a - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Lymphocytic infiltration (n/a - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Night sweats (n/a - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Pancytopenia (n/a - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (n/a - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Thrombocytopenia (n/a - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 15ug - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016106547&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016106652,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Cardiac operation (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Cerebrovascular accident (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016106652&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016106662,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Interchange of vaccine products (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Sciatica (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[LOSARTAN, LOSARTAN POTASSIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[TAMSULOSIN, TAMSULOSIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016106662&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016107948,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Fatigue (n/a - Not Recovered/Not Resolved - Disabling),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[ESTRIOL] (C - Menopausal symptoms - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016107948&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016108249,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"COVID-19 (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Decreased appetite (n/a - Unknown - Disabling),<BR><BR>Diarrhoea (n/a - Unknown - Disabling),<BR><BR>Headache (n/a - Unknown - Disabling),<BR><BR>Malaise (n/a - Unknown - Disabling),<BR><BR>Myalgia (n/a - Unknown - Disabling),<BR><BR>Nausea (n/a - Unknown - Disabling),<BR><BR>Secretion discharge (n/a - Unknown - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016108249&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016109524,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016109524&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016110062,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Polymyalgia rheumatica (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016110062&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016111380,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chest discomfort (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dysphagia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - Product used for unknown indication - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - Product used for unknown indication - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - Product used for unknown indication - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.1 [ELASOMERAN, IMELASOMERAN] (S - COVID-19 prophylaxis - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>SPIKEVAX [ELASOMERAN] (S - COVID-19 prophylaxis - Not applicable - [n/a - 1{DF} - n/a])",[BENDROFLUAZIDE] (C - Blood pressure measurement - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016111380&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016096687,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Chills (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Cough (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Sinus pain (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - Blood pressure abnormal - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016096687&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016096700,Spontaneous,2023-10-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Ischaemic stroke (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016096700&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016096756,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Somnolence (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016096756&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016096910,Spontaneous,2023-10-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Deafness (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Nasopharyngitis (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016096910&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016096969,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Chills (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dizziness (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Ear pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lethargy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016096969&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016096974,Spontaneous,2023-10-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Urticaria (n/a - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Blood pressure increased - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[ATORVASTATIN] (C - Blood cholesterol increased - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[KETOPROFEN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - Dyspepsia - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016096974&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016096977,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Cardiac disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - ),<BR><BR>Dyspnoea (n/a - Unknown - ),<BR><BR>Fatigue (n/a - Unknown - ),<BR><BR>Malaise (n/a - Unknown - ),<BR><BR>Myocarditis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pericarditis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pulmonary embolism (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016096977&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016097025,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Abnormal dreams (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - ),<BR><BR>Insomnia (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[BENDROFLUAZIDE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[NIFEDIPINE] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016097025&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016097174,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Eye pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016097174&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016097418,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Not Specified,"Fatigue (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Myalgia (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","VIDPREVTYN BETA [POLYSORBATE 80, SARS-COV-2, B.1.351 VARIANT, PREFUSION SPIKE DELTA TM PROTEIN, RECOMBINANT, SQUALENE, DL-ALPHA-TOCOPHEROL] (C - COVID-19 immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016097418&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016097432,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Influenza (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[INFLUENZA QUADRIVALENT VACCINE (RDNA)] (S - Immunisation - Not applicable - [1d - n/a - n/a])","EDOXABAN [EDOXABAN] (C - Atrial fibrillation - n/a - [n/a - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (C - COVID-19 immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016097432&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016098048,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Body temperature decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypotension (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Syncope (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","AVASTIN [BEVACIZUMAB] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[VITAMIN D] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016098048&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016098657,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Deafness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016098657&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016098933,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Atrial fibrillation (6d - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),<BR><BR>Dyspnoea (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Fatigue (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Palpitations (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Pulmonary oedema (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Syncope (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Tachycardia (n/a - Unknown - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016098933&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016099027,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Condition aggravated (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Muscle spasms (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Neuralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Radiculopathy (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[BECLOMETASONE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[DIHYDROCODEINE TARTRATE, PARACETAMOL, PARACETAMOL BP, DIHYDROCODEINE TARTRATE BP, PARACETAMOL, DIHYDROCODEINE TARTRATE BP] (C - Pain in extremity - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRIOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016099027&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016099313,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Dehydration (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Ear pain (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Feeling cold (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Fluid intake reduced (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Gait disturbance (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Hypophagia (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Illness (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Nasopharyngitis (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Pharyngeal inflammation (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Pharyngitis (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Productive cough (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Pyrexia (7d - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Sensation of foreign body (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID] (C - Heart rate abnormal - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016099313&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016099379,Spontaneous,2023-10-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Pulmonary embolism (n/a - Not Recovered/Not Resolved - Life Threatening, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016099379&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016101172,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Ageusia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Tremor (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016101172&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016102241,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Back pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Immunisation - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016102241&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016102776,Spontaneous,2023-10-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Seizure (1d - Recovering/Resolving - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - Product used for unknown indication - Unknown - [1d - 1{DF} - n/a]),<BR><BR>SPIKEVAX XBB.1.5 [ANDUSOMERAN] (S - COVID-19 prophylaxis - Unknown - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016102776&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016103024,Spontaneous,2023-10-17 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Infection (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Stress (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[ANHYDROUS FUSIDIC ACID, FUSIDIC ACID, FUSIDIC ACID PH. EUR., SODIUM FUSIDATE, SODIUM FUSIDATE PH. EUR.] (C - Skin infection - n/a - [n/a - n/a - Cutaneous use]),<BR><BR>[ASCORBIC ACID, FERROUS FUMARATE] (C - Mineral supplementation - n/a - [n/a - 1{DF} - Oral use]),<BR><BR>[CETIRIZINE, CETIRIZINE DIHYDROCHLORIDE] (C - Urticaria - n/a - [n/a - 10mg - Oral use]),<BR><BR>[LEVONORGESTREL, LEVONORGESTREL MICRONISED] (C - Product used for unknown indication - n/a - [n/a - n/a - Intrauterine use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016103024&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016103733,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Condition aggravated (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Radiculopathy (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[BECLOMETASONE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[DIHYDROCODEINE TARTRATE, PARACETAMOL, PARACETAMOL BP, DIHYDROCODEINE TARTRATE BP, PARACETAMOL, DIHYDROCODEINE TARTRATE BP] (C - Pain in extremity - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRIOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016103733&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016089839,Spontaneous,2023-10-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Angina pectoris (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Blood pressure increased (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Dysphonia (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Productive cough (n/a - Unknown - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - Intravenous use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016089839&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016090117,Spontaneous,2023-10-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Deafness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Excessive cerumen production (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Musculoskeletal stiffness (n/a - Unknown - ),<BR><BR>Poor quality sleep (n/a - Recovering/Resolving - ),<BR><BR>Rhinitis (1d - Recovered/Resolved - ),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016090117&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016090310,Spontaneous,2023-10-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Genital herpes (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016090310&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016090457,Spontaneous,2023-10-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Herpes zoster (n/a - Recovering/Resolving - Disabling),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","EDOXABAN [EDOXABAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FLUOXETINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FUROSEMIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016090457&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016090514,Spontaneous,2023-10-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vertigo (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016090514&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016093285,Spontaneous,2023-10-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chills (8d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Productive cough (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[SIMVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016093285&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016093287,Spontaneous,2023-10-16 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Musculoskeletal discomfort (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Swelling (n/a - Recovering/Resolving - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016093287&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016093757,Spontaneous,2023-10-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dementia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Sudden death (n/a - Fatal - Results in Death)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016093757&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016093759,Spontaneous,2023-10-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Deafness unilateral (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[CYANOCOBALAMIN] (C - Pernicious anaemia - n/a - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016093759&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016095085,Spontaneous,2023-10-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Cold sweat (1d - Recovered/Resolved - ),<BR><BR>Nausea (1d - Recovered/Resolved - ),<BR><BR>Syncope (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016095085&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016077919,Spontaneous,2023-10-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Decreased appetite (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Feeling cold (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Night sweats (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Taste disorder (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [n/a - n/a - n/a])",[INFLUENZA VIRUS] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016077919&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016078237,Spontaneous,2023-10-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dysarthria (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Jaw clicking (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [n/a - n/a - n/a])","IBUPROFEN [IBUPROFEN, IBUPROFEN SODIUM] (C - Bone pain - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016078237&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016080173,Spontaneous,2023-10-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Pulmonary embolism (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016080173&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016080846,Spontaneous,2023-10-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Depressed mood (n/a - Unknown - Disabling),<BR><BR>Feeling abnormal (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Feeling cold (n/a - Unknown - Disabling),<BR><BR>Intellectual disability (n/a - Recovered/Resolved With Sequelae - Disabling, Other Medically Important Condition),<BR><BR>Nervousness (n/a - Unknown - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[DIMETICONE, LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE, SIMETICONE] (C - Diarrhoea - n/a - [2d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016080846&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016081101,Spontaneous,2023-10-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Back pain (n/a - Recovered/Resolved With Sequelae - ),<BR><BR>Chronic fatigue syndrome (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),<BR><BR>Depression (n/a - Recovered/Resolved With Sequelae - ),<BR><BR>Disturbance in attention (n/a - Recovered/Resolved With Sequelae - ),<BR><BR>Fatigue (n/a - Recovered/Resolved With Sequelae - ),<BR><BR>Headache (n/a - Recovered/Resolved With Sequelae - ),<BR><BR>Language disorder (n/a - Recovered/Resolved With Sequelae - ),<BR><BR>Memory impairment (n/a - Recovered/Resolved With Sequelae - ),<BR><BR>Pelvic pain (n/a - Recovered/Resolved With Sequelae - ),<BR><BR>Somnolence (n/a - Recovered/Resolved With Sequelae - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016081101&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016081507,Spontaneous,2023-10-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lethargy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (1d - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016081507&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016083052,Spontaneous,2023-10-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Arthritis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Decreased appetite (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Diarrhoea (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dizziness postural (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fibromyalgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","CLOPIDOGREL ZENTIVA [CLOPIDOGREL, CLOPIDOGREL HYDROGEN SULFATE] (C - Blood cholesterol increased - n/a - [n/a - n/a - n/a]),<BR><BR>PREGABALIN [PREGABALIN] (C - Fibromyalgia - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - Blood cholesterol increased - n/a - [n/a - n/a - n/a]),<BR><BR>[SOLIFENACIN] (C - Bladder irritation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016083052&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016083120,Spontaneous,2023-10-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Rash (n/a - Not Recovered/Not Resolved - ),<BR><BR>Rash erythematous (n/a - Not Recovered/Not Resolved - ),<BR><BR>Rash pruritic (n/a - Not Recovered/Not Resolved - ),<BR><BR>Suspected COVID-19 (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016083120&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016083795,Spontaneous,2023-10-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Transient ischaemic attack (1d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016083795&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016068682,Spontaneous,2023-10-12 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (3d - Recovered/Resolved - Disabling),<BR><BR>Chills (1d - Recovered/Resolved - Disabling),<BR><BR>Delirium (2d - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Diarrhoea (2d - Recovered/Resolved - Disabling),<BR><BR>Eye pain (1d - Recovered/Resolved - Disabling),<BR><BR>Loss of personal independence in daily activities (n/a - Unknown - ),<BR><BR>Migraine (n/a - Recovering/Resolving - Disabling),<BR><BR>Pyrexia (1d - Recovered/Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","DULOXETINE [DULOXETINE, DULOXETINE HYDROCHLORIDE] (C - Migraine - n/a - [n/a - n/a - n/a]),<BR><BR>[HYPROMELLOSE] (C - Dry eye - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL, CODEINE PHOSPHATE] (C - Fibromyalgia - n/a - [n/a - n/a - n/a]),<BR><BR>[PERINDOPRIL, PERINDOPRIL TERT-BUTYLAMINE] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016068682&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016068977,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Asthenia (n/a - Recovering/Resolving - Disabling),<BR><BR>Balance disorder (n/a - Recovering/Resolving - Disabling),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - Disabling),<BR><BR>Gait disturbance (n/a - Recovering/Resolving - Disabling),<BR><BR>Gastritis (n/a - Recovering/Resolving - Disabling),<BR><BR>Gastrointestinal pain (n/a - Recovering/Resolving - Disabling),<BR><BR>Hypersomnia (n/a - Recovering/Resolving - Disabling),<BR><BR>Loss of consciousness (n/a - Recovering/Resolving - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ALLOPURINOL] (C - Gout - n/a - [n/a - n/a - n/a]),<BR><BR>[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - Pain - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[DOXAZOSIN, DOXAZOSIN MESILATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[INDAPAMIDE, INDAPAMIDE HEMIHYDRATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Antiviral prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a]),<BR><BR>[PERINDOPRIL, PERINDOPRIL TERT-BUTYLAMINE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[PRAVASTATIN, PRAVASTATIN SODIUM] (C - Blood cholesterol abnormal - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016068977&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016069985,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Deafness neurosensory (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Hypoacusis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Sudden hearing loss (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016069985&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016070263,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Myalgia (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016070263&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016070848,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Pyrexia (2d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[ALLOPURINOL] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016070848&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016071119,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Loss of consciousness (n/a - Recovered/Resolved With Sequelae - Life Threatening, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016071119&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016071299,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Breast pain (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016071299&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016071476,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tremor (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016071476&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016072337,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Infusion related reaction (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Weight decreased (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - n/a - [1d - n/a - n/a]),<BR><BR>SPIKEVAX [ELASOMERAN] (C - COVID-19 immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016072337&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016073832,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Hallucination (n/a - Unknown - Disabling),<BR><BR>Headache (n/a - Unknown - Disabling),<BR><BR>Malaise (n/a - Unknown - Disabling),<BR><BR>Pyrexia (1d - Recovered/Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016073832&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016073947,Spontaneous,2023-10-12 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Rash (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","MIRABEGRON [MIRABEGRON] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[BENDROFLUMETHIAZIDE] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[FEXOFENADINE, FEXOFENADINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[METRONIDAZOLE, METRONIDAZOLE PH. EUR., METRONIDAZOLE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016073947&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016074600,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vomiting (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016074600&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016074876,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Rash (7d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Urticaria (8d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Blood pressure management - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016074876&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016075096,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,Taste disorder (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016075096&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016075332,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Erythema (n/a - Unknown - ),<BR><BR>Pain (n/a - Unknown - ),<BR><BR>Periorbital swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016075332&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016060606,Spontaneous,2023-10-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016060606&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016060642,Spontaneous,2023-10-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",[INFLUENZA VIRUS] (C - Immunisation - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016060642&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016061021,Spontaneous,2023-10-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"Drug ineffective (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016061021&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016061024,Spontaneous,2023-10-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Chills (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hyperhidrosis (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Immunodeficiency (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vomiting (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vomiting projectile (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","POSACONAZOLE [POSACONAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FOLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[TRANEXAMIC ACID] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016061024&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016061870,Spontaneous,2023-10-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dysphagia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Eating disorder (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Glossodynia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Swollen tongue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[INDAPAMIDE, INDAPAMIDE HEMIHYDRATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[MESALAZINE] (C - Colitis ulcerative - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016061870&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016061945,Spontaneous,2023-10-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Chills (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Feeling cold (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tremor (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BENDROFLUAZIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016061945&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016062409,Spontaneous,2023-10-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dizziness (n/a - Recovering/Resolving - ),<BR><BR>Vertigo (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016062409&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016062468,Spontaneous,2023-10-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Migraine (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Musculoskeletal stiffness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Speech disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Syncope (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016062468&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016062656,Spontaneous,2023-10-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Bone disorder (n/a - Unknown - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination site erythema (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pruritus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016062656&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016062863,Spontaneous,2023-10-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[BENDROFLUMETHIAZIDE] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016062863&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016063547,Spontaneous,2023-10-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.1 [ELASOMERAN, IMELASOMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016063547&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016064208,Spontaneous,2023-10-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016064208&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016065127,Spontaneous,2023-10-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016065127&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016065287,Spontaneous,2023-10-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (3d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016065287&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016065765,Spontaneous,2023-10-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Eye pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Eyelid oedema (5d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Face oedema (5d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","IBUPROFEN [IBUPROFEN, IBUPROFEN SODIUM] (C - Headache - n/a - [2d - n/a - n/a]),<BR><BR>[CHLORPHENAMINE MALEATE] (C - Adverse drug reaction - n/a - [2d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[PARACETAMOL, CODEINE PHOSPHATE] (C - Headache - n/a - [1d - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Prophylaxis - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016065765&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016066343,Spontaneous,2023-10-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - n/a - n/a - [n/a - 5mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016066343&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016066348,Spontaneous,2023-10-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - n/a - n/a - [n/a - 5mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016066348&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016067075,Spontaneous,2023-10-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Joint swelling (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016067075&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016067090,Spontaneous,2023-10-11 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Tinnitus (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])","[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - Influenza immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016067090&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016052686,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Breath sounds abnormal (n/a - Unknown - ),<BR><BR>Dyspnoea (n/a - Unknown - ),<BR><BR>Hypopnoea (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016052686&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016052815,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Periarthritis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016052815&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016053091,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Influenza like illness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","APIXABAN [APIXABAN] (C - Atrial fibrillation - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - Hypercholesterolaemia - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Atrial fibrillation - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016053091&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016055300,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Eye swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Face oedema (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Swelling face (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016055300&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016055321,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","IBUPROFEN [IBUPROFEN, IBUPROFEN SODIUM] (C - Headache - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016055321&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016055649,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Angioedema (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Feeling cold (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Musculoskeletal stiffness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016055649&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016055673,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Interchange of vaccine products (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Syncope (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016055673&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016055748,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016055748&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016056052,Spontaneous,2023-10-10 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Angioedema (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Stridor (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Wheezing (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [1d - n/a - n/a])","[BECLOMETASONE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[FORMOTEROL FUMARATE, BUDESONIDE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - Asthma - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016056052&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016056081,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Somnolence (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016056081&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016056105,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Eye pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Eye swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016056105&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016056131,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Blister (n/a - Unknown - Other Medically Important Condition),<BR><BR>Eyelid pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Ophthalmic herpes zoster (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016056131&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016056225,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Dysgeusia (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Feeling cold (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Hypersomnia (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Mobility decreased (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Myalgia (4d - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[GABAPENTIN] (C - Analgesic therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[MEBEVERINE] (C - Irritable bowel syndrome - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016056225&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016056226,Spontaneous,2023-10-10 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Face oedema (n/a - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016056226&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016056302,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Mobility decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Sleep disorder due to a general medical condition (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016056302&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016056303,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hot flush (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Influenza (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Productive cough (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016056303&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016056304,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Fatigue (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination site pain (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vertigo (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","EDOXABAN [EDOXABAN] (C - Atrial fibrillation - n/a - [n/a - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Atrial fibrillation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016056304&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016056342,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Chills (18h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (16h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (37h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (16h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Night sweats (40h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (16h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (3d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CANDESARTAN, CANDESARTAN CILEXETIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016056342&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016056469,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Pharyngeal swelling (2d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016056469&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016057631,Spontaneous,2023-10-10 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Pulmonary embolism (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - n/a - Not applicable - [1d - n/a - n/a])","[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[TRAZODONE, TRAZODONE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016057631&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016057747,Spontaneous,2023-10-10 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Confusional state (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hallucination (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016057747&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016058106,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Asthma (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Brain fog (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Cough variant asthma (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Herpes zoster (n/a - Unknown - Other Medically Important Condition),<BR><BR>Influenza (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Limb discomfort (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Paraesthesia (2d - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Syncope (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE, BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[PREDNISOLONE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016058106&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016058256,Spontaneous,2023-10-10 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Cerebrovascular accident (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016058256&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016059376,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Ear pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Eye pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Gingival pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Trigeminal neuralgia (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016059376&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016059801,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Diarrhoea (n/a - Unknown - ),<BR><BR>Visual impairment (1h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016059801&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016042329,Spontaneous,2023-10-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dizziness (n/a - Unknown - ),<BR><BR>Headache (n/a - Unknown - ),<BR><BR>Nausea (n/a - Unknown - ),<BR><BR>Pericarditis (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Syncope (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016042329&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016043142,Spontaneous,2023-10-09 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Alanine aminotransferase increased (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Gamma-glutamyltransferase increased (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hepatic function abnormal (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016043142&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016043153,Spontaneous,2023-10-09 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Enterocolitis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])","[BIFIDOBACTERIUM SPP.] (C - Diarrhoea - n/a - [n/a - n/a - n/a]),<BR><BR>[BUTYLSCOPOLAMINE, HYOSCINE BUTYLBROMIDE] (C - Abdominal pain lower - n/a - [n/a - n/a - n/a]),<BR><BR>[FAMOTIDINE] (C - Diarrhoea - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016043153&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016043241,Spontaneous,2023-10-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Atrial fibrillation (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Contusion (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016043241&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016043523,Spontaneous,2023-10-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension - n/a - [n/a - 5mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016043523&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016045393,Spontaneous,2023-10-09 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dizziness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hypersomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site erythema (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","ARIPIPRAZOLE [ARIPIPRAZOLE] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>OLANZAPINE [OLANZAPINE] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>PREGABALIN [PREGABALIN] (C - n/a - n/a - [n/a - 3{DF} - n/a]),<BR><BR>[ACAMPROSATE CALCIUM] (C - n/a - n/a - [29d - 6{DF} - n/a]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - n/a - n/a - [2d - 5{DF} - n/a]),<BR><BR>[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE] (C - n/a - n/a - [n/a - 4{DF} - Inhalation use]),<BR><BR>[BENZOYL PEROXIDE] (C - n/a - n/a - [2d - 1{DF} - Topical]),<BR><BR>[BETAMETHASONE SODIUM PHOSPHATE] (C - n/a - n/a - [n/a - 500ug - n/a]),<BR><BR>[BUDESONIDE, FORMOTEROL FUMARATE DIHYDRATE] (C - n/a - n/a - [n/a - 4{DF} - Inhalation use]),<BR><BR>[CODEINE PHOSPHATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[DIAZEPAM] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[LISDEXAMFETAMINE DIMESYLATE] (C - n/a - n/a - [n/a - 70mg - n/a]),<BR><BR>[LISDEXAMFETAMINE] (C - n/a - n/a - [n/a - 70mg - n/a]),<BR><BR>[LOPERAMIDE, LOPERAMIDE HYDROCHLORIDE] (C - n/a - n/a - [n/a - 16mg - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - 2{DF} - n/a]),<BR><BR>[PROCHLORPERAZINE] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[SALBUTAMOL SULFATE] (C - n/a - n/a - [n/a - 2{DF} - Inhalation use]),<BR><BR>[VENLAFAXINE HYDROCHLORIDE] (C - n/a - n/a - [99d - 1{DF} - n/a]),<BR><BR>[VENLAFAXINE, VENLAFAXINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016045393&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016045730,Spontaneous,2023-10-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Pyrexia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Seizure (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016045730&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016045957,Spontaneous,2023-10-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Atrial fibrillation (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Heart rate decreased (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lethargy (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Oxygen saturation decreased (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tremor (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - n/a])","APIXABAN [APIXABAN] (C - Anticoagulant therapy - n/a - [n/a - n/a - n/a]),<BR><BR>BUMETANIDE [BUMETANIDE] (C - Diuretic therapy, Incontinence - n/a - [n/a - n/a - n/a]),<BR><BR>[ALFUZOSIN] (C - Benign prostatic hyperplasia - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - Blood cholesterol abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Heart rate irregular - n/a - [n/a - n/a - n/a]),<BR><BR>[DONEPEZIL] (C - Dementia Alzheimer's type - n/a - [n/a - n/a - n/a]),<BR><BR>[FINASTERIDE] (C - Benign prostatic hyperplasia - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - Hyperchlorhydria - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016045957&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016046368,Spontaneous,2023-10-09 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Dizziness (n/a - Unknown - ),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Oedema peripheral (n/a - Not Recovered/Not Resolved - ),<BR><BR>Syncope (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016046368&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016046476,Spontaneous,2023-10-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Urticaria (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Blood pressure abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[CIMETIDINE] (C - Urticaria - n/a - [n/a - n/a - n/a]),<BR><BR>[TRAMADOL, TRAMADOL HYDROCHLORIDE] (C - Arthritis - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016046476&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016048682,Spontaneous,2023-10-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Decreased appetite (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hyperhidrosis (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Myalgia (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016048682&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016048755,Spontaneous,2023-10-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Herpes ophthalmic (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Oral herpes (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016048755&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016049571,Spontaneous,2023-10-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arrhythmia supraventricular (1d - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - Product used for unknown indication - Unknown - [n/a - 1{DF} - n/a]),<BR><BR>SPIKEVAX [ELASOMERAN] (S - COVID-19 prophylaxis - Unknown - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016049571&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016049874,Spontaneous,2023-10-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fibromyalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Herpes zoster (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016049874&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016032453,Spontaneous,2023-10-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Blister (n/a - Unknown - ),<BR><BR>Erythema (n/a - Unknown - ),<BR><BR>Herpes zoster (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain of skin (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016032453&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016033396,Spontaneous,2023-10-06 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Chronic obstructive pulmonary disease (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, IVR-186), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021 HAEMAGGLUTININ ANTIGEN, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (S - Immunisation - n/a - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016033396&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016034680,Spontaneous,2023-10-06 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Dyspnoea (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Eye swelling (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Face oedema (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016034680&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016035277,Spontaneous,2023-10-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Decreased appetite (114d - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Gait disturbance (n/a - Unknown - Other Medically Important Condition),<BR><BR>Listless (n/a - Unknown - Other Medically Important Condition),<BR><BR>Loss of control of legs (n/a - Unknown - Other Medically Important Condition),<BR><BR>Movement disorder (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016035277&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016035826,Spontaneous,2023-10-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fear (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nervousness (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Sleep disorder due to a general medical condition (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tremor (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016035826&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016037939,Spontaneous,2023-10-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal pain upper (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dysstasia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Gait disturbance (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Chronic obstructive pulmonary disease - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016037939&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016037969,Spontaneous,2023-10-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Cerebrovascular accident (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Vertigo (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016037969&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016023347,Spontaneous,2023-10-05 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Blood pressure increased (n/a - Unknown - ),<BR><BR>Diaphragmatic paralysis (92d - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016023347&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016025067,Spontaneous,2023-10-05 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Asthenia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug interaction (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Night sweats (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tinnitus (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (I - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[INTERFERON ALFA] (I - Polycythaemia - Unknown - [n/a - n/a - n/a])","HYDROXYCARBAMIDE [HYDROXYCARBAMIDE] (C - Polycythaemia vera - n/a - [n/a - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID] (C - Polycythaemia - n/a - [n/a - n/a - n/a]),<BR><BR>[HYDROXYCARBAMIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LISINOPRIL, LISINOPRIL DIHYDRATE] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016025067&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016027564,Spontaneous,2023-10-05 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (1d - Recovered/Resolved - ),<BR><BR>Fatigue (3d - Recovered/Resolved - ),<BR><BR>Heavy menstrual bleeding (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (2d - Recovered/Resolved - ),<BR><BR>Menstruation delayed (n/a - Not Recovered/Not Resolved - ),<BR><BR>Polymenorrhoea (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016027564&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016029516,Spontaneous,2023-10-05 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Condition aggravated (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Fall (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Hemiplegia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)","TOZINAMERAN, RILTOZINAMERAN [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - n/a - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016029516&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016015803,Spontaneous,2023-10-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Loss of bladder sensation (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Urinary incontinence (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","RITUXIMAB [RITUXIMAB] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LETROZOLE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016015803&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016016143,Spontaneous,2023-10-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Loss of consciousness (1d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016016143&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016016379,Spontaneous,2023-10-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Feeling hot (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Urticaria (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>LEVETIRACETAM [LEVETIRACETAM] (C - Epilepsy - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016016379&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016016380,Spontaneous,2023-10-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (3d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016016380&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016016559,Spontaneous,2023-10-04 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Heavy menstrual bleeding (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Iron deficiency (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016016559&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016017581,Spontaneous,2023-10-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Back pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Illness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Muscle fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016017581&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016017757,Spontaneous,2023-10-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",METHOTREXATE [METHOTREXATE] (C - Rheumatoid arthritis - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016017757&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016018250,Spontaneous,2023-10-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Recovering/Resolving - Disabling),<BR><BR>Decreased appetite (n/a - Recovering/Resolving - Disabling),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - Disabling),<BR><BR>Feeling hot (n/a - Unknown - Disabling),<BR><BR>Feeling of body temperature change (n/a - Unknown - Disabling),<BR><BR>Headache (4d - Recovered/Resolved - Disabling),<BR><BR>Hyperhidrosis (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Myalgia (n/a - Recovering/Resolving - Disabling),<BR><BR>Nausea (n/a - Recovering/Resolving - Disabling),<BR><BR>Pain (n/a - Unknown - Disabling),<BR><BR>Parosmia (5d - Recovered/Resolved - Disabling),<BR><BR>Pruritus (n/a - Unknown - Disabling),<BR><BR>Urticaria (3d - Recovered/Resolved - Disabling),<BR><BR>Vomiting (4d - Recovered/Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>PREGABALIN [PREGABALIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CODEINE PHOSPHATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[LANSOPRAZOLE, LANSOPRAZOLE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL, PARACETAMOL DC] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[VENLAFAXINE, VENLAFAXINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016018250&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016018941,Spontaneous,2023-10-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Intention tremor (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Tremor (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","SPIRONOLACTONE [SPIRONOLACTONE] (C - Hepatic failure - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - Portal hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[CARVEDILOL] (C - Portal hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016018941&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016019201,Spontaneous,2023-10-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Neuropathy peripheral (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[GABAPENTIN] (C - Neuralgia - n/a - [n/a - n/a - n/a]),<BR><BR>[MORPHINE SULFATE, MORPHINE SULPHATE BP] (C - Pain - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016019201&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016019248,Spontaneous,2023-10-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chest pain (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Dyspnoea (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Fatigue (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Malaise (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Myocarditis (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Pain (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Pericarditis (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Rash (n/a - Unknown - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (S - Influenza immunisation - Not applicable - [1d - n/a - n/a])","[ATORVASTATIN] (C - Blood cholesterol increased - n/a - [n/a - n/a - n/a]),<BR><BR>[BECLOMETASONE DIPROPIONATE] (C - Prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[FLUTICASONE PROPIONATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016019248&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016019507,Spontaneous,2023-10-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dizziness (1d - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dry mouth (1d - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Loss of consciousness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Malaise (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016019507&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016019583,Spontaneous,2023-10-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Bell's palsy (32d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016019583&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016020041,Spontaneous,2023-10-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016020041&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016021441,Spontaneous,2023-10-04 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Epilepsy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Generalised tonic-clonic seizure (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Nasopharyngitis (n/a - Recovering/Resolving - ),<BR><BR>Syncope (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016021441&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016008882,Spontaneous,2023-10-03 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Autoimmune hepatitis (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016008882&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016009899,Spontaneous,2023-10-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","BEMPEDOIC ACID [BEMPEDOIC ACID] (C - Blood cholesterol abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[EZETIMIBE] (C - Blood cholesterol abnormal - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016009899&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016009911,Spontaneous,2023-10-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Cerebrovascular accident (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Vertigo (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[BACLOFEN] (C - Spinal pain - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016009911&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016010358,Spontaneous,2023-10-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling hot (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Skin lesion (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016010358&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016011104,Spontaneous,2023-10-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Neuropathy peripheral (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/BRISBANE/59/2007 (H1N1)-LIKE STRAIN, A/BRISBANE/10/2007 (H3N2)-LIKE STRAIN, B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1) V REASS. X - 179 A, A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/NANCHANG 933/95 (H3N2), A/BAYERN/7/95 (H1N1) - LIKE STRAIN (A/JOHANNESBURG/82/96), B/BEIJING/184/93-LIKE STRAIN (B/HARBIN/7/94), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN (A/NEW CALEDONIA/20/99 REASS. IVR-116), A/CALIFORNIA/7/2004 (H3N2) - LIKE STRAIN (A/NEW YORK/55/2004 REASS. NYMC X-157), B/SHANGHAI/361/2002 - LIKE STRAIN (B/JIANGSU/10/2003), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN (A/NEW CALEDONIA/20/99 REASS. IVR-116), A/MOSCOW/10/99 (H3N2) - LIKE STRAIN (A/PANAMA/2007/99 REASS. RESVIR-17), B/SICHUAN/379/99-LIKE STRAIN (B/JOHANNESBURG/5/99), A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), A/CALIFORNIA/7/2009 (H1N1)-DERIVED STRAIN USED NYMC X-181, B/BRISBANE/60/2008, A/SWITZERLAND/9715293/2013 (H3N2)-LIKE STRAIN (A/SWITZERLAND/9715293/2013, NIB-88), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN B, A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1), A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1)V-LIKE VIRUS, A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/MASSACHUSETTS/2/2012 -DERIVED STRAIN USED (NYMC BX-51B), A/TEXAS/50/2012 (H3N2) – DERIVED STRAIN USED (NYMC X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/MASSACHUSETTS/2/2012 -DERIVED STRAIN USED (NYMC BX-51B), A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN A (H1N1), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN A (H3N2), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN B] (C - Immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016011104&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016011194,Spontaneous,2023-10-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Insomnia (n/a - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016011194&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016011952,Spontaneous,2023-10-03 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Angioedema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Urticaria (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016011952&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016003481,Spontaneous,2023-10-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Autoimmune haemolytic anaemia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",NOT AVAILABLE (C - Stenosis - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016003481&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016004518,Spontaneous,2023-10-02 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Chronic obstructive pulmonary disease (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - Intramuscular use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, IVR-186), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021 HAEMAGGLUTININ ANTIGEN, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (S - Immunisation - n/a - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016004518&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016005031,Spontaneous,2023-10-02 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Pain in extremity (n/a - Unknown - Disabling),<BR><BR>Paralysis (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016005031&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015991364,Spontaneous,2023-09-29 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),<BR><BR>COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ASCORBIC ACID, CALCIUM GLUBIONATE, CALCIUM CARBONATE, CALCIUM, CALCIUM GLUBIONATE, CALCIUM CARBONATE, COLECALCIFEROL, CALCIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FLUTICASONE] (C - Asthma - n/a - [n/a - 200ug - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - 15mg - n/a]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - Hypertension - n/a - [n/a - 50mg - Oral use]),<BR><BR>[PREDNISOLONE] (C - Myalgia - n/a - [n/a - 15mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015991364&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015993480,Spontaneous,2023-09-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Abdominal pain upper (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[CANDESARTAN, CANDESARTAN CILEXETIL] (C - Migraine - n/a - [n/a - n/a - n/a]),<BR><BR>[MESALAZINE] (C - Colitis ulcerative - n/a - [n/a - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015993480&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015994140,Spontaneous,2023-09-29 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Acute aseptic arthritis (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Rheumatoid factor positive (n/a - Not Recovered/Not Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015994140&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015995557,Spontaneous,2023-09-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Facial paralysis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015995557&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015995742,Spontaneous,2023-09-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal discomfort (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Dyspnoea (n/a - Unknown - Disabling),<BR><BR>Fatigue (n/a - Unknown - Disabling),<BR><BR>Feeling of body temperature change (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Heart rate increased (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Hyperhidrosis (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Palpitations (n/a - Unknown - Disabling),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Tachycardia (n/a - Unknown - Disabling),<BR><BR>Vertigo (n/a - Not Recovered/Not Resolved - Disabling)","TOZINAMERAN, RILTOZINAMERAN [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015995742&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015995959,Spontaneous,2023-09-29 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Elderly,No,Female,"Malaise (n/a - Not Recovered/Not Resolved - Life Threatening, Other Medically Important Condition),<BR><BR>Swollen tongue (n/a - Not Recovered/Not Resolved - Life Threatening, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015995959&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015996099,Spontaneous,2023-09-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Tachycardia (2d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015996099&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015996127,Spontaneous,2023-09-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Electric shock sensation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Mobility decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nerve injury (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[ALENDRONATE SODIUM, ALENDRONIC ACID] (C - Osteopenia - n/a - [n/a - n/a - n/a]),<BR><BR>[LETROZOLE] (C - Breast cancer female - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015996127&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015997703,Spontaneous,2023-09-29 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Diarrhoea (n/a - Unknown - ),<BR><BR>Gastrointestinal disorder (6wk - Unknown - ),<BR><BR>Vaccination site irritation (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])","[BISOPROLOL FUMARATE] (C - Supraventricular extrasystoles - n/a - [n/a - n/a - Oral use]),<BR><BR>[VITAMIN D] (C - Osteoporosis prophylaxis - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015997703&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015997707,Spontaneous,2023-09-29 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015997707&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015983481,Spontaneous,2023-09-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Chills (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015983481&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015986421,Spontaneous,2023-09-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Migraine (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015986421&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015986448,Spontaneous,2023-09-28 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abnormal menstrual clots (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dysmenorrhoea (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Intermenstrual bleeding (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use])",[DESOGESTREL] (C - Endometriosis - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015986448&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015987380,Spontaneous,2023-09-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Swelling (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015987380&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015987462,Spontaneous,2023-09-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Influenza like illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site erythema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site rash (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination site warmth (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015987462&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015987720,Spontaneous,2023-09-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Influenza (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015987720&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015987841,Spontaneous,2023-09-28 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Fall (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Muscular weakness (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015987841&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015988018,Spontaneous,2023-09-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Joint stiffness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Syncope (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ATORVASTATIN] (C - n/a - n/a - [n/a - 10mg - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015988018&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015989426,Spontaneous,2023-09-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Atrial fibrillation (3mo - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Blood pressure increased (n/a - Unknown - ),<BR><BR>Disease recurrence (3mo - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Feeling hot (n/a - Unknown - ),<BR><BR>Headache (n/a - Unknown - ),<BR><BR>Interchange of vaccine products (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","IRBESARTAN [IRBESARTAN] (C - Hypertension - n/a - [4841d - n/a - Oral use]),<BR><BR>MIRABEGRON [MIRABEGRON] (C - Prostatism - n/a - [n/a - n/a - Oral use]),<BR><BR>SILDENAFIL [SILDENAFIL] (C - Erectile dysfunction - n/a - [2258d - n/a - Oral use]),<BR><BR>[ACETYLSALICYLIC ACID] (C - Hypertension - n/a - [4841d - n/a - Oral use]),<BR><BR>[SIMVASTATIN] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015989426&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015976801,Spontaneous,2023-09-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Abdominal discomfort (n/a - Unknown - ),<BR><BR>Abdominal pain (n/a - Unknown - ),<BR><BR>Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Asthenia (n/a - Unknown - ),<BR><BR>Chills (n/a - Unknown - ),<BR><BR>Head discomfort (n/a - Unknown - ),<BR><BR>Headache (n/a - Unknown - ),<BR><BR>Herpes virus infection (n/a - Unknown - ),<BR><BR>Hypersomnia (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015976801&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015977137,Spontaneous,2023-09-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Dysphagia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Guillain-Barre syndrome (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Medical induction of coma (n/a - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Muscle atrophy (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Paraesthesia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Paralysis (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Quadriparesis (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015977137&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015978220,Spontaneous,2023-09-27 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Anaphylactic reaction (n/a - Recovering/Resolving - Life Threatening),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015978220&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015979381,Spontaneous,2023-09-27 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenia (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Cerebrovascular accident (n/a - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Dysarthria (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Facial paralysis (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015979381&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015980155,Spontaneous,2023-09-27 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Cough (n/a - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Rash (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - n/a])","AVAMYS [FLUTICASONE FUROATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BUDESONIDE, FORMOTEROL FUMARATE DIHYDRATE, FORMOTEROL FUMARATE, BUDESONIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRADIOL] (C - Adverse drug reaction - n/a - [n/a - n/a - n/a]),<BR><BR>[FEXOFENADINE, FEXOFENADINE HYDROCHLORIDE] (C - Multiple allergies - n/a - [n/a - n/a - n/a]),<BR><BR>[FINASTERIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PROGESTERONE, PROGESTERONE, MICRONISED] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015980155&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015967892,Spontaneous,2023-09-26 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Axillary pain (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Dysstasia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Feeling abnormal (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Groin pain (n/a - Recovered/Resolved With Sequelae - Disabling),<BR><BR>Muscular weakness (n/a - Recovered/Resolved With Sequelae - Disabling),<BR><BR>Musculoskeletal pain (n/a - Recovered/Resolved With Sequelae - Disabling),<BR><BR>Myalgia (n/a - Recovered/Resolved With Sequelae - Disabling),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Polymyalgia rheumatica (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation, Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015967892&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015969652,Spontaneous,2023-09-26 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Electrocardiogram abnormal (n/a - Unknown - ),<BR><BR>Pericarditis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pleuritic pain (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - Not applicable - [n/a - n/a - n/a]),<BR><BR>[B/PHUKET/3073/2013 – LIKE STRAIN (B/UTAH/9/2014, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/BRISBANE/60/2008] (S - n/a - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015969652&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015970039,Spontaneous,2023-09-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal distension (n/a - Unknown - Other Medically Important Condition),<BR><BR>Abdominal pain upper (n/a - Unknown - Other Medically Important Condition),<BR><BR>Diverticulitis (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Diverticulum (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[LETROZOLE] (C - Prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - Hiatus hernia - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015970039&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015973539,Spontaneous,2023-09-26 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Dyspnoea exertional (n/a - Recovered/Resolved With Sequelae - ),<BR><BR>Lymphadenopathy (n/a - Recovered/Resolved With Sequelae - ),<BR><BR>Pain in extremity (n/a - Recovered/Resolved With Sequelae - ),<BR><BR>Peripheral swelling (n/a - Recovered/Resolved With Sequelae - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015973539&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015960474,Spontaneous,2023-09-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015960474&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015962357,Spontaneous,2023-09-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Erythema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Musculoskeletal disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Musculoskeletal stiffness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015962357&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015962612,Spontaneous,2023-09-25 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Blood pressure increased (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Tremor (1d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015962612&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015962685,Spontaneous,2023-09-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Neuralgia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[FLUOXETINE] (C - Anxiety - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015962685&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015962819,Spontaneous,2023-09-25 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Cerebral haemorrhage (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Diplopia (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Dizziness postural (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Gait disturbance (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Headache (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[ATORVASTATIN] (C - Blood cholesterol abnormal - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015962819&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015962919,Spontaneous,2023-09-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"Angina pectoris (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Cough (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015962919&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015964712,Spontaneous,2023-09-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Herpes zoster (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Ophthalmic herpes zoster (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","IRBESARTAN [IRBESARTAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LERCANIDIPINE, LERCANIDIPINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015964712&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015948834,Spontaneous,2023-09-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Demyelination (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Gait disturbance (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015948834&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015950559,Spontaneous,2023-09-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Cardiac arrest (n/a - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Cardiomegaly (n/a - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Left ventricular failure (n/a - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Pain in extremity (n/a - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Pneumonia (n/a - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","ARIPIPRAZOLE [ARIPIPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CARBAMAZEPINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CARBOCISTEINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MIRTAZAPINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PROPRANOLOL, PROPRANOLOL HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015950559&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015952778,Spontaneous,2023-09-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Back pain (n/a - Recovering/Resolving - Disabling),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Disabling),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015952778&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015952992,Spontaneous,2023-09-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Muscle spasms (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMYLASE, LIPASE, PROTEASE, PANCREALIPASE, PANCREAS POWDER, PANCREAS POWDER FROM PORCINE, PANCREATIN, PANCREATIN BP, PANCRELIPASE AMYLASE, PANCRELIPASE PROTEASE, LIPASE] (C - Pancreatic failure - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015952992&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015953065,Spontaneous,2023-09-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Cardio-respiratory arrest (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Cardiovascular disorder (n/a - Unknown - ),<BR><BR>Interchange of vaccine products (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Pneumonia (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Fatal - Results in Death),<BR><BR>Respiratory arrest (n/a - Fatal - Results in Death, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[AZOSEMIDE] (C - Cardiac failure congestive - n/a - [n/a - n/a - Oral use]),<BR><BR>[DEXCHLORPHENIRAMINE, DEXCHLORPHENIRAMINE MALEATE] (C - Pruritus - n/a - [n/a - n/a - Oral use]),<BR><BR>[IMIDAFENACIN] (C - Hypertonic bladder - n/a - [n/a - n/a - Oral use]),<BR><BR>[SODIUM FERROUS CITRATE] (C - Iron deficiency anaemia - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015953065&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015955257,Spontaneous,2023-09-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Eye pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia intercostal (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Sleep disorder due to a general medical condition (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015955257&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015943945,Spontaneous,2023-09-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Asthenia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Feeling cold (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain (n/a - Recovered/Resolved - ),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - ),<BR><BR>Restlessness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Rhinorrhoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Seizure (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>VAXZEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - n/a - Unknown - [n/a - n/a - Intramuscular use])","[GABAPENTIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL, CODEINE PHOSPHATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ZOPICLONE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015943945&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015944217,Spontaneous,2023-09-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Epilepsy (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Loss of consciousness (10min - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015944217&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015945382,Spontaneous,2023-09-21 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Hypoxia (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Somnolence (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","ELIQUIS 5 MG FILM-COATED TABLETS [APIXABAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[DIGOXIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FUROSEMIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN POTASSIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METOPROLOL TARTRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PANTOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015945382&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015947544,Spontaneous,2023-09-21 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,Respiratory tract infection (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B)] (S - Influenza immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015947544&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015933881,Spontaneous,2023-09-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Ear congestion (n/a - Unknown - Other Medically Important Condition),<BR><BR>Excessive cerumen production (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lacrimation increased (10d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Middle ear effusion (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nasopharyngitis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Sudden hearing loss (30d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tinnitus (n/a - Unknown - Other Medically Important Condition),<BR><BR>Upper-airway cough syndrome (n/a - Unknown - Other Medically Important Condition),<BR><BR>Wheezing (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[MESTEROLONE] (C - Vulvovaginal dryness - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015933881&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015935998,Spontaneous,2023-09-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Asthenia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015935998&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015937611,Spontaneous,2023-09-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Adult,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015937611&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015927075,Spontaneous,2023-09-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (21d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (21d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",[MESTEROLONE] (C - Vulvovaginal dryness - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015927075&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015918847,Spontaneous,2023-09-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthritis (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Chest pain (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Dermatitis allergic (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Dyspnoea (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Eczema (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Fatigue (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Myocardial infarction (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Tachycardia (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015918847&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015920650,Spontaneous,2023-09-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Mobility decreased (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Musculoskeletal discomfort (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Sleep disorder (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypotension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015920650&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015908319,Spontaneous,2023-09-15 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Diplopia (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Dose not changed - [n/a - .3mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015908319&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015908927,Spontaneous,2023-09-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ROSUVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015908927&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015910814,Spontaneous,2023-09-15 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Graves' disease (n/a - Unknown - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015910814&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015910818,Spontaneous,2023-09-15 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Anaphylactic reaction (n/a - Unknown - Other Medically Important Condition),<BR><BR>Anxiety (n/a - Unknown - ),<BR><BR>Blood pressure decreased (n/a - Unknown - ),<BR><BR>Headache (n/a - Unknown - ),<BR><BR>Vomiting (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015910818&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015911374,Spontaneous,2023-09-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Gait inability (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Immunosuppression (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Lower respiratory tract infection (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Pneumonia (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015911374&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015911597,Spontaneous,2023-09-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Nasal congestion (n/a - Unknown - Other Medically Important Condition),<BR><BR>Sinonasal obstruction (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015911597&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015911905,Spontaneous,2023-09-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dizziness postural (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015911905&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015903399,Spontaneous,2023-09-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chills (11h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (11h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (11h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (11h - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[BECLOMETASONE DIPROPIONATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[CANDESARTAN, CANDESARTAN CILEXETIL] (C - Migraine - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL, CALCIUM CARBONATE] (C - Hypovitaminosis - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - Asthma - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015903399&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015893901,Spontaneous,2023-09-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015893901&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015895816,Spontaneous,2023-09-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Polymyalgia rheumatica (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015895816&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015898853,Spontaneous,2023-09-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Drug ineffective (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5 [ELASOMERAN, DAVESOMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>SPIKEVAX [ELASOMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015898853&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015885448,Spontaneous,2023-09-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Ocular discomfort (n/a - Unknown - ),<BR><BR>Oculogyric crisis (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015885448&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015887945,Spontaneous,2023-09-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Cardiac arrest (3d - Recovered/Resolved With Sequelae - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Fatigue (6d - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Malaise (6d - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015887945&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015888444,Spontaneous,2023-09-12 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Facial paresis (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Ischaemic stroke (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Vaccination site reaction (n/a - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015888444&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015881372,Spontaneous,2023-09-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Breath sounds abnormal (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Productive cough (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Sensation of foreign body (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Sputum discoloured (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015881372&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015882854,Spontaneous,2023-09-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Bursitis (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Condition aggravated (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Cyst (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Discomfort (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Disease recurrence (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Erythema nodosum (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Furuncle (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Headache (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Limb immobilisation (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Mobility decreased (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Neck pain (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Poor quality sleep (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Psoriasis (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Pulmonary sarcoidosis (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Rash erythematous (21d - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Synovial cyst (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Tendonitis (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use])","[LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM, HYDRATE] (C - Hypothyroidism - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015882854&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015882896,Spontaneous,2023-09-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Cough (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Productive cough (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Sensation of foreign body (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Sputum discoloured (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015882896&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015872037,Spontaneous,2023-09-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Paralysis (30min - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[MESALAZINE] (C - Colitis ulcerative - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015872037&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015872337,Spontaneous,2023-09-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Seizure (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015872337&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015872623,Spontaneous,2023-09-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Anti-neutrophil cytoplasmic antibody positive vasculitis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Facial pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain in jaw (n/a - Not Recovered/Not Resolved - ),<BR><BR>Swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Swelling face (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015872623&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015864253,Spontaneous,2023-09-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Body temperature increased (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash (n/a - Unknown - Other Medically Important Condition),<BR><BR>Swelling (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015864253&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015864465,Spontaneous,2023-09-07 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Cutaneous vasculitis (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015864465&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015866173,Spontaneous,2023-09-07 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Adult,No,Female,Facial paralysis (n/a - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015866173&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015854584,Spontaneous,2023-09-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthropathy (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Balance disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Blood potassium decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Blood pressure decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Coordination abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness postural (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Gait disturbance (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lethargy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Muscular weakness (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Blood pressure measurement - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015854584&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015855271,Spontaneous,2023-09-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Drug ineffective (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - n/a - Not applicable - [n/a - n/a - n/a])","[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Blood pressure measurement - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015855271&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015856613,Spontaneous,2023-09-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Fatigue (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Feeling hot (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Hypoaesthesia (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Kyphosis (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Mental fatigue (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Neuropathy peripheral (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Sciatica (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Sleep disorder due to a general medical condition (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Spinal pain (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Torticollis (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015856613&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015856928,Spontaneous,2023-09-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lethargy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Musculoskeletal stiffness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myofascial pain syndrome (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015856928&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015857113,Spontaneous,2023-09-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Diarrhoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypophagia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Illness (14d - Recovered/Resolved With Sequelae - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015857113&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015857169,Spontaneous,2023-09-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Groin pain (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Malaise (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015857169&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015859257,Spontaneous,2023-09-06 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Asthenia (n/a - Recovering/Resolving - ),<BR><BR>Feeling abnormal (n/a - Unknown - ),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site scar (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015859257&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015860193,Spontaneous,2023-09-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Facial paralysis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypoaesthesia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lower respiratory tract infection (n/a - Unknown - Other Medically Important Condition),<BR><BR>Sinusitis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tonsillitis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Transient ischaemic attack (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015860193&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015848053,Spontaneous,2023-09-05 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site injury (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site joint movement impairment (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015848053&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015848864,Spontaneous,2023-09-05 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Asthenia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Cardiovascular disorder (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Gait disturbance (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Gastrointestinal disorder (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Pain (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Syncope (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015848864&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015850293,Spontaneous,2023-09-05 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Psoriasis (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015850293&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015840284,Spontaneous,2023-09-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Balance disorder (n/a - Recovered/Resolved With Sequelae - Disabling, Other Medically Important Condition),<BR><BR>Balance disorder (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Deafness unilateral (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Vertigo (2mo - Recovered/Resolved With Sequelae - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use])","CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - Thrombocytosis - n/a - [n/a - 75mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015840284&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015840568,Spontaneous,2023-09-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Psoriatic arthropathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015840568&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015840586,Spontaneous,2023-09-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Headache (14d - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015840586&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015841287,Spontaneous,2023-09-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Balance disorder (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rotavirus infection (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vertigo (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015841287&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015842429,Spontaneous,2023-09-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015842429&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015843879,Spontaneous,2023-09-04 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Death (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Epilepsy (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","OLANZAPINE [OLANZAPINE] (C - Psychotic disorder - n/a - [n/a - n/a - n/a]),<BR><BR>RISPERIDONE [RISPERIDONE] (C - Psychotic disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[ACAMPROSATE] (C - Alcohol use - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL] (C - Vitamin D decreased - n/a - [n/a - n/a - n/a]),<BR><BR>[ETHOSUXIMIDE] (C - Epilepsy - n/a - [n/a - n/a - n/a]),<BR><BR>[FOLIC ACID] (C - Blood folate decreased - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[LYMECYCLINE] (C - Rosacea - n/a - [n/a - n/a - n/a]),<BR><BR>[PROCYCLIDINE] (C - Extrapyramidal disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[QUETIAPINE, QUETIAPINE FUMARATE] (C - Psychotic disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[SODIUM VALPROATE, VALPROIC ACID, SODIUM VALPROATE] (C - Epilepsy - n/a - [n/a - n/a - n/a]),<BR><BR>[VENLAFAXINE, VENLAFAXINE HYDROCHLORIDE] (C - Depression - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015843879&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015836631,Spontaneous,2023-09-01 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Cognitive disorder (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Memory impairment (n/a - Not Recovered/Not Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015836631&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015824324,Spontaneous,2023-08-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Chronic obstructive pulmonary disease (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[CICLESONIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FORMOTEROL FUMARATE, GLYCOPYRRONIUM BROMIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015824324&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015829682,Spontaneous,2023-08-31 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Anxiety (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dysphonia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - ),<BR><BR>Medial tibial stress syndrome (n/a - Unknown - ),<BR><BR>Palpitations (10d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Syncope (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015829682&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015829684,Spontaneous,2023-08-31 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Organ failure (n/a - Fatal - Results in Death, Life Threatening, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (C - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>SPIKEVAX [ELASOMERAN] (C - COVID-19 immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015829684&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015819210,Spontaneous,2023-08-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hypoaesthesia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Muscular weakness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Sensory level abnormal (n/a - Not Recovered/Not Resolved - ),<BR><BR>Swelling face (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015819210&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015820224,Spontaneous,2023-08-30 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,Ischaemic stroke (n/a - Unknown - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - Not applicable - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VACCINE] (S - n/a - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015820224&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015820230,Spontaneous,2023-08-30 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,Myocardial infarction (n/a - Unknown - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - Not applicable - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VACCINE] (S - n/a - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015820230&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015808600,Spontaneous,2023-08-29 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Dysarthria (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Loss of consciousness (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Syncope (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015808600&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015808618,Spontaneous,2023-08-29 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Loss of consciousness (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Syncope (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015808618&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015809390,Spontaneous,2023-08-29 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Asthenia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Cerebrovascular accident (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Decreased appetite (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Hypotonia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Infection (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Language disorder (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015809390&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015803990,Spontaneous,2023-08-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Anaphylactic reaction (n/a - Recovered/Resolved - ),<BR><BR>Cough (n/a - Recovered/Resolved - ),<BR><BR>Dyspnoea (n/a - Recovered/Resolved - ),<BR><BR>Pharyngeal swelling (n/a - Recovered/Resolved - ),<BR><BR>Rash pruritic (n/a - Recovered/Resolved - ),<BR><BR>Swollen tongue (n/a - Recovered/Resolved - ),<BR><BR>Tachycardia (n/a - Recovered/Resolved - ),<BR><BR>Wheezing (n/a - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015803990&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015806010,Spontaneous,2023-08-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Myalgia (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015806010&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015786559,Spontaneous,2023-08-24 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Circulatory collapse (n/a - Fatal - Results in Death),<BR><BR>Sudden death (n/a - Fatal - Results in Death)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015786559&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015787940,Spontaneous,2023-08-24 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Asthenia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015787940&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015788320,Spontaneous,2023-08-24 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Dyspnoea (2h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hypoxia (5min - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Loss of consciousness (10min - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - .3mL - Intramuscular use])","PLAVIX 75 MG FILM-COATED TABLETS [CLOPIDOGREL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE, FORMOTEROL FUMARATE DIHYDRATE, BECLOMETASONE DIPROPIONATE ANHYDROUS] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[THEOPHYLLINE, THEOPHYLLINE MONOHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[TIOTROPIUM BROMIDE MONOHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015788320&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015790289,Spontaneous,2023-08-24 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Herpes zoster (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Immune system disorder (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - n/a])",[CILOSTAZOL] (C - Blood pressure abnormal - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015790289&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015790828,Spontaneous,2023-08-24 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arrhythmia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Tachyarrhythmia (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015790828&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015775329,Spontaneous,2023-08-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Interchange of vaccine products (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Limb injury (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015775329&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015767923,Spontaneous,2023-08-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - ),<BR><BR>Cholelithiasis (n/a - Unknown - ),<BR><BR>Deep vein thrombosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Neuroleptic malignant syndrome (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pulmonary embolism (n/a - Unknown - Other Medically Important Condition),<BR><BR>Thrombosis with thrombocytopenia syndrome (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","ALOGLIPTIN [ALOGLIPTIN] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>CARBIDOPA, LEVODOPA [CARBIDOPA, LEVODOPA] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>ICOSAPENT ETHYL [ICOSAPENT ETHYL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>RIVASTIGMINE [RIVASTIGMINE, RIVASTIGMINE HYDROGEN TARTRATE] (C - n/a - n/a - [n/a - 18mg - n/a]),<BR><BR>ZONISAMIDE [ZONISAMIDE] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[ACONITE] (C - n/a - n/a - [n/a - 5g - n/a]),<BR><BR>[ANGELICA ROOT, GLYCYRRHIZA GLABRA, YOKUKANSAN] (C - n/a - n/a - [n/a - 2.5g - n/a]),<BR><BR>[FEXOFENADINE, FEXOFENADINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - 4{DF} - n/a]),<BR><BR>[LUBIPROSTONE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[MOMETASONE] (C - n/a - n/a - [n/a - 50ug - n/a]),<BR><BR>[PRANLUKAST] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[RHUBARB] (C - n/a - n/a - [n/a - 7.5g - n/a]),<BR><BR>[SENNOSIDE A] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[SODIUM PICOSULFATE] (C - Constipation - n/a - [n/a - 1mL - n/a]),<BR><BR>[TORASEMIDE] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[VIBEGRON] (C - n/a - n/a - [n/a - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015767923&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015768210,Spontaneous,2023-08-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Bundle branch block right (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Face oedema (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Menopausal symptoms (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])","[ALISMATIS RHIZOMA] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[ANGELICA ACUTILOBA ROOT] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[ATRACTYLODES LANCEA ROOT] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[CNIDIUM OFFICINALE ROOT] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[PAEONIA LACTIFLORA ROOT] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[PORIAE COCOS SCLEROTIUM] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015768210&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015772364,Spontaneous,2023-08-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Blood pressure increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Coma (n/a - Unknown - Life Threatening, Other Medically Important Condition),<BR><BR>Haematuria (n/a - Unknown - Life Threatening),<BR><BR>Haemorrhage intracranial (2d - Fatal - Results in Death, Life Threatening, Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Life Threatening),<BR><BR>Loss of consciousness (n/a - Unknown - Life Threatening, Other Medically Important Condition),<BR><BR>Vomiting (n/a - Unknown - Life Threatening)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [1d - n/a - n/a])","LEVETIRACETAM [LEVETIRACETAM] (C - n/a - n/a - [n/a - 250mg - n/a]),<BR><BR>[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE, BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE] (C - n/a - n/a - [n/a - 1{DF} - Inhalation use]),<BR><BR>[MACROGOL, SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - Dose not changed - [n/a - 2{DF} - n/a]),<BR><BR>[TEMAZEPAM] (C - n/a - n/a - [n/a - 10mg - n/a]),<BR><BR>[VITAMIN D] (C - n/a - n/a - [n/a - 800[iU] - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015772364&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015773651,Spontaneous,2023-08-22 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Urticaria chronic (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015773651&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015761276,Spontaneous,2023-08-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Coma (n/a - Unknown - Life Threatening),<BR><BR>Haematuria (n/a - Unknown - Life Threatening),<BR><BR>Haemorrhage intracranial (n/a - Fatal - Results in Death, Life Threatening),<BR><BR>Headache (n/a - Unknown - Life Threatening),<BR><BR>Hypertension (n/a - Unknown - Life Threatening),<BR><BR>Loss of consciousness (n/a - Unknown - Life Threatening),<BR><BR>Vomiting (n/a - Unknown - Life Threatening)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (S - Influenza immunisation - Unknown - [1d - n/a - n/a])","LEVETIRACETAM [LEVETIRACETAM] (C - n/a - n/a - [n/a - 500mg - n/a]),<BR><BR>[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE, BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE] (C - n/a - n/a - [n/a - 2{DF} - Inhalation use]),<BR><BR>[MACROGOL, SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (C - n/a - n/a - [n/a - 2{DF} - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - 6{DF} - n/a]),<BR><BR>[TEMAZEPAM] (C - n/a - n/a - [n/a - 10mg - n/a]),<BR><BR>[VITAMIN D] (C - n/a - n/a - [n/a - 800[iU] - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015761276&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015763015,Spontaneous,2023-08-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Eye inflammation (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),<BR><BR>Malaise (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),<BR><BR>Microscopic polyangiitis (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),<BR><BR>Otosalpingitis (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),<BR><BR>Pain (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),<BR><BR>Pain in extremity (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),<BR><BR>Red blood cell sedimentation rate increased (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),<BR><BR>Renal failure (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015763015&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015763922,Spontaneous,2023-08-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Cellulitis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Eczema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash erythematous (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rash macular (n/a - Unknown - Other Medically Important Condition),<BR><BR>Skin discolouration (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015763922&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015765515,Spontaneous,2023-08-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Glomerulonephritis minimal lesion (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Oedema peripheral (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pemphigoid (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 prophylaxis - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 prophylaxis - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.1 [ELASOMERAN, IMELASOMERAN] (S - COVID-19 prophylaxis - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>SPIKEVAX [ELASOMERAN] (S - COVID-19 prophylaxis - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>VIDPREVTYN BETA [POLYSORBATE 80, SARS-COV-2, B.1.351 VARIANT, PREFUSION SPIKE DELTA TM PROTEIN, RECOMBINANT, SQUALENE, DL-ALPHA-TOCOPHEROL] (S - COVID-19 prophylaxis - Not applicable - [n/a - 1{DF} - n/a])","BUMETANIDE [BUMETANIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL, CALCIUM CARBONATE] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a]),<BR><BR>[FAMOTIDINE] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a]),<BR><BR>[PANTOPRAZOLE SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015765515&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015756512,Spontaneous,2023-08-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Depression (n/a - Recovering/Resolving - ),<BR><BR>Hyperglycaemia (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Hypoglycaemia (n/a - Unknown - ),<BR><BR>Malaise (n/a - Unknown - ),<BR><BR>Memory impairment (n/a - Unknown - ),<BR><BR>Type 1 diabetes mellitus (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Type 2 diabetes mellitus (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015756512&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015744515,Spontaneous,2023-08-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Cognitive disorder (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Confusional state (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Gait disturbance (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Herpes zoster meningoencephalitis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Rash vesicular (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015744515&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015749805,Spontaneous,2023-08-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthma (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Brain neoplasm (n/a - Unknown - Other Medically Important Condition),<BR><BR>Epilepsy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Unknown - ),<BR><BR>Seizure (595min - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])",VIMPAT [LACOSAMIDE] (C - n/a - n/a - [n/a - n/a - Oral use]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015749805&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015738131,Spontaneous,2023-08-16 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (n/a - Unknown - Disabling),<BR><BR>Fatigue (n/a - Unknown - Disabling),<BR><BR>Mobility decreased (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Paraesthesia (n/a - Unknown - Disabling),<BR><BR>Pruritus (n/a - Unknown - Disabling),<BR><BR>Rash (n/a - Unknown - Disabling),<BR><BR>Vaccination site pain (n/a - Unknown - Disabling),<BR><BR>Vaccination site swelling (n/a - Unknown - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015738131&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015740128,Spontaneous,2023-08-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Brain fog (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Chest pain (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Chronic fatigue syndrome (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Condition aggravated (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Dizziness postural (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Dysstasia (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Gait disturbance (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Immune system disorder (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Memory impairment (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Myalgia (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Myocarditis (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Neurological symptom (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Oxygen saturation abnormal (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Post lumbar puncture syndrome (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Postural orthostatic tachycardia syndrome (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovered/Resolved With Sequelae - Disabling, Other Medically Important Condition),<BR><BR>Supraventricular tachycardia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Ventricular tachycardia (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015740128&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015732964,Spontaneous,2023-08-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Blindness unilateral (n/a - Recovered/Resolved With Sequelae - Disabling),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [1d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015732964&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015726096,Spontaneous,2023-08-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,"Arrhythmia (n/a - Recovering/Resolving - ),<BR><BR>Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Chills (n/a - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovered/Resolved - ),<BR><BR>Headache (n/a - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Recovered/Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015726096&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015715916,Spontaneous,2023-08-11 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Cerebrovascular accident (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Cough (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Disorientation (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Hemiasomatognosia (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Neurologic neglect syndrome (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Reversible cerebral vasoconstriction syndrome (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Thrombosis with thrombocytopenia syndrome (n/a - Unknown - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015715916&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015716571,Spontaneous,2023-08-11 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chest pain (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Myocarditis (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Troponin increased (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015716571&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015717402,Spontaneous,2023-08-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Influenza like illness (n/a - Unknown - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])","XARELTO [RIVAROXABAN] (C - n/a - Dose not changed - [n/a - 20mg - Oral use]),<BR><BR>[ALLOPURINOL, METHENAMINE] (C - n/a - Dose not changed - [n/a - 300mg - n/a]),<BR><BR>[AMLODIPINE] (C - n/a - Dose not changed - [n/a - 100mg - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - Dose not changed - [n/a - 90mg - n/a]),<BR><BR>[BETAXOLOL HYDROCHLORIDE] (C - n/a - Dose not changed - [n/a - 20mg - n/a]),<BR><BR>[BIOFLAVONOIDS, DIOSMIN, HESPERIDIN, MICRONISED PURIFIED FLAVONOIC FRACTION] (C - n/a - Dose not changed - [n/a - 500mg - Oral use]),<BR><BR>[FUROSEMIDE] (C - n/a - Dose not changed - [n/a - 40mg - n/a]),<BR><BR>[GLICLAZIDE] (C - n/a - Dose not changed - [n/a - 60mg - Oral use]),<BR><BR>[MAGNESIUM LACTATE DIHYDRATE] (C - n/a - Dose not changed - [n/a - 500mg - Oral use]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE] (C - n/a - Dose not changed - [n/a - 1000mg - Oral use]),<BR><BR>[MOXONIDINE] (C - n/a - Dose not changed - [n/a - 400ug - n/a]),<BR><BR>[POTASSIUM CHLORIDE] (C - n/a - Dose not changed - [n/a - 499mg - Oral use]),<BR><BR>[SULODEXIDE] (C - n/a - Dose not changed - [n/a - 60mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015717402&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015718801,Spontaneous,2023-08-11 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Cerebellar ataxia (n/a - Unknown - ),<BR><BR>Herpes zoster (45d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Orthostatic hypotension (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","BEVESPI AEROSPHERE [GLYCOPYRRONIUM BROMIDE, FORMOTEROL FUMARATE DIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MAGNESIUM OXIDE] (C - n/a - n/a - [n/a - 3{DF} - n/a]),<BR><BR>[MIDODRINE, MIDODRINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - 4{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015718801&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015721775,Spontaneous,2023-08-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Arrhythmia (n/a - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Chills (n/a - Unknown - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Erysipelas (n/a - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Malaise (n/a - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Pneumonia (n/a - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (n/a - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Respiratory distress (n/a - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (C - Influenza immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015721775&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015721780,Spontaneous,2023-08-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Erysipelas (n/a - Unknown - Other Medically Important Condition),<BR><BR>Gait inability (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pneumonia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (C - Influenza immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015721780&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015721784,Spontaneous,2023-08-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Cerebral thrombosis (7d - Recovered/Resolved - Caused/Prolonged Hospitalisation),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - Influenza immunisation - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[METOPROLOL, METOPROLOL TARTRATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[PANCREALIPASE, PANCREAS POWDER, PANCREATIN] (C - Pancreatic disorder - n/a - [n/a - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015721784&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015722894,Spontaneous,2023-08-11 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Interchange of vaccine products (n/a - Recovering/Resolving - Disabling),<BR><BR>Polymyalgia rheumatica (n/a - Recovering/Resolving - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [1d - n/a - n/a])","[FLUTICASONE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - Hypertension - n/a - [n/a - 50mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015722894&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015708671,Spontaneous,2023-08-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Sneezing (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015708671&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015709259,Spontaneous,2023-08-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Neonate (Preterm and Term newborns),Yes,Not Specified,"Cerebral palsy (n/a - Not Recovered/Not Resolved - Disabling, Congenital Anomaly, Other Medically Important Condition),<BR><BR>Maternal exposure during pregnancy (n/a - Not Recovered/Not Resolved - Disabling, Congenital Anomaly, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Transplacental])",[FOLIC ACID] (C - Vitamin supplementation - n/a - [n/a - 400ug - Transplacental]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015709259&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015711625,Spontaneous,2023-08-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015711625&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015711816,Spontaneous,2023-08-10 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Disease recurrence (n/a - Unknown - Other Medically Important Condition),<BR><BR>Seizure (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tonic convulsion (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015711816&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015712377,Spontaneous,2023-08-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Malaise (n/a - Recovering/Resolving - ),<BR><BR>Papule (n/a - Recovering/Resolving - ),<BR><BR>Pruritus (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[ENALAPRIL MALEATE] (S - Blood pressure management - Drug withdrawn - [n/a - n/a - n/a]),<BR><BR>[NOT AVAILABLE] (S - Blood cholesterol - Drug withdrawn - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015712377&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015713115,Spontaneous,2023-08-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Blood pressure increased (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),<BR><BR>Condition aggravated (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),<BR><BR>Heart rate increased (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),<BR><BR>Neuralgia (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015713115&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015713622,Spontaneous,2023-08-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Diarrhoea (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Malaise (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Vomiting (n/a - Fatal - Results in Death, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","DEXAMETHASONE [DEXAMETHASONE] (C - Noninfective encephalitis - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - Blood pressure measurement - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015713622&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015701217,Spontaneous,2023-08-09 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Fall (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Formication (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[DIENOGEST] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[QUETIAPINE, QUETIAPINE FUMARATE] (C - n/a - Unknown - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015701217&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015691619,Spontaneous,2023-08-08 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Back pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Recovered/Resolved - ),<BR><BR>Depression (n/a - Not Recovered/Not Resolved - ),<BR><BR>Gait disturbance (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site joint pain (n/a - Recovered/Resolved - ),<BR><BR>Migraine (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - Unknown - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015691619&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015696672,Spontaneous,2023-08-08 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,COVID-19 (n/a - Unknown - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015696672&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015686071,Spontaneous,2023-08-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015686071&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015688389,Spontaneous,2023-08-07 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Retinal vascular disorder (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Visual impairment (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015688389&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015689792,Spontaneous,2023-08-07 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Anxiety (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Brain fog (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Incorrect dose administered (n/a - Unknown - ),<BR><BR>Post-acute COVID-19 syndrome (n/a - Not Recovered/Not Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015689792&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015677473,Spontaneous,2023-08-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal pain (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015677473&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015677839,Spontaneous,2023-08-04 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Deafness (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Fatigue (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Lymphadenopathy (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Lymphoedema (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Pain (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Subcutaneous abscess (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015677839&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015679128,Spontaneous,2023-08-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015679128&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015679140,Spontaneous,2023-08-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[TOZINAMERAN MULTIVALENT NOS] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[PREDNISOLONE] (C - Polymyalgia rheumatica - n/a - [n/a - 2mg - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015679140&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015680551,Spontaneous,2023-08-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Dyspnoea (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Hypersensitivity (n/a - Unknown - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015680551&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015667298,Spontaneous,2023-08-03 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Interchange of vaccine products (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Interstitial lung disease (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",METHOTREXATE [METHOTREXATE] (C - Rheumatoid arthritis - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015667298&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015669278,Spontaneous,2023-08-03 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Discomfort (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Herpes zoster (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Neuralgia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015669278&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015669487,Spontaneous,2023-08-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chest pain (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Dyspnoea (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Fatigue (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Mental disorder (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Myocardial infarction (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Palpitations (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Tachycardia (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015669487&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015671010,Spontaneous,2023-08-03 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dermatitis allergic (n/a - Unknown - ),<BR><BR>Eyelid oedema (n/a - Unknown - ),<BR><BR>Face oedema (n/a - Unknown - ),<BR><BR>Localised oedema (n/a - Unknown - ),<BR><BR>Lymph node pain (n/a - Unknown - ),<BR><BR>Lymphadenopathy (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015671010&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015671779,Spontaneous,2023-08-03 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Erythema (n/a - Unknown - ),<BR><BR>Feeling hot (n/a - Unknown - ),<BR><BR>Headache (n/a - Unknown - ),<BR><BR>Urticaria (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - .3mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015671779&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015661559,Spontaneous,2023-08-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Osteoarthritis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Urticaria papular (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015661559&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015661599,Spontaneous,2023-08-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,Rheumatoid arthritis (n/a - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","ADALIMUMAB [ADALIMUMAB] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>METHOTREXATE [METHOTREXATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ASCORBIC ACID, CALCIUM GLUBIONATE, CALCIUM CARBONATE, CALCIUM, CALCIUM GLUBIONATE, CALCIUM CARBONATE, COLECALCIFEROL, CALCIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FOLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015661599&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015661690,Spontaneous,2023-08-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Gait disturbance (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Muscular weakness (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Tremor (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Visual impairment (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015661690&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015653042,Spontaneous,2023-08-01 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dizziness (n/a - Recovered/Resolved - ),<BR><BR>Headache (n/a - Recovered/Resolved - ),<BR><BR>Loss of consciousness (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>OZEMPIC [SEMAGLUTIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>TRIMBOW [BECLOMETASONE DIPROPIONATE, GLYCOPYRRONIUM BROMIDE, FORMOTEROL FUMARATE DIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL, CALCIUM CARBONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[NIFEDIPINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PREDNISONE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015653042&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015654184,Spontaneous,2023-08-01 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Altered state of consciousness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Unknown - ),<BR><BR>Depressed level of consciousness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - ),<BR><BR>Meningitis aseptic (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - ),<BR><BR>White blood cell count increased (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use])","[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - 100mg - Oral use]),<BR><BR>[ALLOPURINOL] (C - n/a - n/a - [n/a - 100mg - Oral use]),<BR><BR>[PRAVASTATIN SODIUM] (C - n/a - n/a - [n/a - 5mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015654184&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015644450,Spontaneous,2023-07-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Anosmia (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015644450&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015644451,Spontaneous,2023-07-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Arrhythmia (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","IRBESARTAN 300 MG - TABLET  (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015644451&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015646568,Spontaneous,2023-07-31 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Torticollis (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015646568&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015646702,Spontaneous,2023-07-31 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Tachycardia (8d - Recovered/Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])","ELIQUIS [APIXABAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE BESILATE, PERINDOPRIL ARGININE, AMLODIPINE, PERINDOPRIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SOTALOL HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015646702&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015646840,Spontaneous,2023-07-31 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Lymphadenopathy (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015646840&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015646845,Spontaneous,2023-07-31 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Injection site muscle atrophy (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015646845&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015646856,Spontaneous,2023-07-31 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Vaccination site movement impairment (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015646856&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015626919,Spontaneous,2023-07-27 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Dyspnoea (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Myocardial infarction (n/a - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",[COVID-19 VACCINE] (C - COVID-19 immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015626919&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015628584,Spontaneous,2023-07-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - ),<BR><BR>Headache (n/a - Unknown - ),<BR><BR>Myalgia (n/a - Unknown - ),<BR><BR>Vaccination site pain (4d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])","[NAPROXEN] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015628584&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015629897,Spontaneous,2023-07-27 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>ENTRESTO [SACUBITRIL VALSARTAN SODIUM HYDRATE, VALSARTAN, SACUBITRIL] (C - n/a - n/a - [n/a - 100mg - n/a]),<BR><BR>FEBUXOSTAT [FEBUXOSTAT] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[AMIODARONE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL FUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[EZETIMIBE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FERROUS CITRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FUROSEMIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[GLYCERYL TRINITRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ZOPICLONE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015629897&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015630231,Spontaneous,2023-07-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Immunisation reaction (n/a - Recovered/Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])","[ACETYLSALICYLIC ACID, D,L-LYSINE ACETYLSALICYLATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LERCANIDIPINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015630231&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015630239,Spontaneous,2023-07-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Eczema (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])",XARELTO 10 MG FILM-COATED TABLETS [RIVAROXABAN] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015630239&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015630243,Spontaneous,2023-07-27 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Influenza like illness (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015630243&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015618856,Spontaneous,2023-07-26 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Dyspnoea (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015618856&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015619425,Spontaneous,2023-07-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Transient ischaemic attack (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015619425&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015610192,Spontaneous,2023-07-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Arthritis (n/a - Not Recovered/Not Resolved - Disabling),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015610192&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015611803,Spontaneous,2023-07-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Anxiety (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Depression (n/a - Unknown - ),<BR><BR>Electric shock sensation (n/a - Unknown - ),<BR><BR>Emotional disorder (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Grip strength decreased (n/a - Unknown - ),<BR><BR>Hypoaesthesia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Inflammation (n/a - Unknown - ),<BR><BR>Mouth ulceration (n/a - Unknown - ),<BR><BR>Muscular weakness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Panic attack (n/a - Unknown - ),<BR><BR>Paraesthesia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Unknown - ),<BR><BR>Rash (8d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Sensorimotor disorder (n/a - Unknown - ),<BR><BR>Tremor (n/a - Unknown - ),<BR><BR>Vision blurred (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015611803&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015612868,Spontaneous,2023-07-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"COVID-19 immunisation (n/a - Recovered/Resolved With Sequelae - Disabling),<BR><BR>Hypoaesthesia (n/a - Recovered/Resolved With Sequelae - Disabling),<BR><BR>Oedema peripheral (n/a - Recovered/Resolved With Sequelae - Disabling),<BR><BR>Pain in extremity (n/a - Recovered/Resolved With Sequelae - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - Intramuscular use]),<BR><BR>VAXZEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - n/a - n/a - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015612868&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015605833,Spontaneous,2023-07-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dizziness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dizziness (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a])",[ALLOPURINOL] (C - Nephrolithiasis - n/a - [n/a - 100mg - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015605833&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015596234,Spontaneous,2023-07-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Joint range of motion decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lower respiratory tract infection (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015596234&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015584768,Spontaneous,2023-07-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Arthritis (n/a - Unknown - ),<BR><BR>Mobility decreased (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Periarthritis (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015584768&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015586456,Spontaneous,2023-07-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Extrasystoles (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Heart rate irregular (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","LIXIANA [EDOXABAN, EDOXABAN TOSYLATE] (C - Atrial fibrillation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015586456&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015586691,Spontaneous,2023-07-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Atrial fibrillation (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Cough (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),<BR><BR>Influenza (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015586691&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015586693,Spontaneous,2023-07-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Anosmia (n/a - Recovering/Resolving - Disabling),<BR><BR>Arthralgia (n/a - Recovering/Resolving - Disabling),<BR><BR>Chest pain (n/a - Unknown - Disabling),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Fatigue (n/a - Recovering/Resolving - Disabling),<BR><BR>Heart rate irregular (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Myalgia (n/a - Recovering/Resolving - Disabling),<BR><BR>Nasopharyngitis (n/a - Recovered/Resolved With Sequelae - Disabling),<BR><BR>Peripheral vascular disorder (n/a - Unknown - Disabling),<BR><BR>Pyrexia (n/a - Unknown - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015586693&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015586786,Spontaneous,2023-07-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Mobility decreased (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",BENEPALI [ETANERCEPT] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015586786&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015586852,Spontaneous,2023-07-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Back pain (n/a - Unknown - Disabling),<BR><BR>Mobility decreased (n/a - Unknown - Disabling),<BR><BR>Pain in extremity (n/a - Unknown - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[PARACETAMOL] (C - Headache - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015586852&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015577771,Spontaneous,2023-07-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Haematoma (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Limb mass (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Pain (n/a - Unknown - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015577771&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015560028,Spontaneous,2023-07-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015560028&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015561014,Spontaneous,2023-07-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Extrasystoles (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ACETYLSALICYLIC ACID] (C - Myocardial infarction - n/a - [n/a - n/a - n/a]),<BR><BR>[FAMOTIDINE] (C - Gastritis - n/a - [n/a - n/a - n/a]),<BR><BR>[OXYCODONE HYDROCHLORIDE] (C - Pain - n/a - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - Blood cholesterol - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015561014&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015561205,Spontaneous,2023-07-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Burning sensation (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Impaired quality of life (n/a - Unknown - ),<BR><BR>Insomnia (n/a - Unknown - ),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Paraesthesia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Sitting disability (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a])","B-TOTAL [NOT AVAILABLE] (C - n/a - n/a - ),<BR><BR>[ASCORBIC ACID, CALCIUM GLUBIONATE, CALCIUM CARBONATE, CALCIUM, CALCIUM GLUBIONATE, CALCIUM CARBONATE, COLECALCIFEROL, CALCIUM] (C - n/a - n/a - ),<BR><BR>[CYANOCOBALAMIN, VITAMIN B12] (C - n/a - n/a - ),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Graves' disease - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LIOTHYRONINE, THYROID, THYROID, PORCINE] (C - Graves' disease - n/a - [n/a - n/a - n/a]),<BR><BR>[VITAMIN D] (C - n/a - n/a - )","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015561205&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015564193,Spontaneous,2023-07-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),<BR><BR>[COVID-19 VACCINE] (S - n/a - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015564193&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015548730,Spontaneous,2023-07-14 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,Swelling face (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","ZOSTAVAX [VARICELLA VIRUS OKA/MERCK STRAIN (LIVE, ATTENUATED), VARICELLA VIRUS OKA/MERCK STRAIN, (LIVE, ATTENUATED) PRODUCED IN HUMAN DIPLOID (MRC-5) CELLS] (C - Immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015548730&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015549205,Spontaneous,2023-07-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Anosmia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Back pain (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Gait disturbance (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hypoaesthesia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Neuralgia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Spinal pain (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[MESALAZINE] (C - Colitis - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - Dyspnoea - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015549205&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015539105,Spontaneous,2023-07-13 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Acute kidney injury (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use])","[OMEGA-3-ACID ETHYL ESTERS] (C - Dyslipidaemia - n/a - [n/a - n/a - Oral use]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - Dyslipidaemia - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015539105&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015539694,Spontaneous,2023-07-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chills (n/a - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Recovered/Resolved - ),<BR><BR>Myalgia (n/a - Recovered/Resolved - ),<BR><BR>Nightmare (n/a - Unknown - ),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015539694&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015540076,Spontaneous,2023-07-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Musculoskeletal stiffness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","ENTRESTO [SACUBITRIL VALSARTAN SODIUM HYDRATE, VALSARTAN, SACUBITRIL] (C - Cardiac failure - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015540076&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015541058,Spontaneous,2023-07-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,12-17 Years,Not Specified,No,Female,"Diplopia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Interchange of vaccine products (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)","TOZINAMERAN, RILTOZINAMERAN [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015541058&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015541225,Spontaneous,2023-07-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Infective tenosynovitis (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (5d - Recovered/Resolved - ),<BR><BR>Lymphadenopathy (5d - Recovered/Resolved - ),<BR><BR>Pneumonia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Sinusitis (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015541225&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015543919,Spontaneous,2023-07-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Formication (n/a - Not Recovered/Not Resolved - ),<BR><BR>Intermenstrual bleeding (n/a - Not Recovered/Not Resolved - ),<BR><BR>Visual impairment (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - .3mL - Intramuscular use])","[ASCORBIC ACID, MAGNESIUM OXIDE, HEAVY, MAGNESIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE, BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[DERMATOPHAGOIDES PTERONYSSINUS, DERMATOPHAGOIDES FARINAE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[KETOTIFEN, KETOTIFEN HYDROGEN FUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[RUPATADINE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015543919&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015533344,Spontaneous,2023-07-12 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chronic fatigue syndrome (n/a - Not Recovered/Not Resolved - ),<BR><BR>Concomitant disease aggravated (n/a - Not Recovered/Not Resolved - ),<BR><BR>Disturbance in attention (n/a - Unknown - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Gait disturbance (n/a - Unknown - ),<BR><BR>Memory impairment (n/a - Unknown - ),<BR><BR>Pain (n/a - Unknown - ),<BR><BR>Sleep disorder (n/a - Unknown - ),<BR><BR>Visual impairment (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a])","VANIQA 11.5% CREAM [EFLORNITHINE, EFLORNITHINE HYDROCHLORIDE MONOHYDRATE] (C - Hair growth abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID] (C - Thrombosis prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRADIOL] (C - Menopausal symptoms, Prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - n/a]),<BR><BR>[PREDNISOLON] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015533344&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015533407,Spontaneous,2023-07-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Heart rate increased (4d - Recovering/Resolving - ),<BR><BR>Hyperhidrosis (4d - Recovering/Resolving - ),<BR><BR>Listless (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Middle insomnia (n/a - Unknown - ),<BR><BR>Movement disorder (4d - Recovering/Resolving - ),<BR><BR>Palpitations (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Restlessness (n/a - Unknown - ),<BR><BR>Sensory disturbance (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015533407&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015536393,Spontaneous,2023-07-12 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Cognitive disorder (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Feeling cold (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Memory impairment (n/a - Not Recovered/Not Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015536393&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015537315,Spontaneous,2023-07-12 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Anaemia (n/a - Unknown - ),<BR><BR>Arrhythmia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Discomfort (n/a - Unknown - ),<BR><BR>Fatigue (n/a - Unknown - ),<BR><BR>Hepatic mass (n/a - Unknown - ),<BR><BR>Muscular weakness (n/a - Recovering/Resolving - Disabling),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Pain (n/a - Recovering/Resolving - Disabling),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - ),<BR><BR>Pneumonia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pneumonitis (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use])","INVOKANA [CANAGLIFLOZIN] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>METFORMIN HYDROCHLORIDE, VILDAGLIPTIN [METFORMIN HYDROCHLORIDE, VILDAGLIPTIN] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>SPIRONOLACTONE [SPIRONOLACTONE] (C - n/a - n/a - [n/a - 25mg - n/a]),<BR><BR>XARELTO [RIVAROXABAN] (C - Anticoagulant therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[ALFUZOSIN] (C - Prostatic disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[ALPRAZOLAM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - Hypercholesterolaemia - n/a - [n/a - 10mg - n/a]),<BR><BR>[DORZOLAMIDE HYDROCHLORIDE, TIMOLOL, DORZOLAMIDE HYDROCHLORIDE, TIMOLOL MALEATE, DORZOLAMIDE, TIMOLOL] (C - Glaucoma - n/a - [n/a - n/a - n/a]),<BR><BR>[FINASTERIDE] (C - Prostatic disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[FUROSEMIDE, FUROSEMIDE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - Prophylaxis against gastrointestinal ulcer - n/a - [n/a - n/a - n/a]),<BR><BR>[LATANOPROST] (C - Glaucoma - n/a - [n/a - n/a - n/a]),<BR><BR>[VALSARTAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[VERAPAMIL, VERAPAMIL HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015537315&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015524890,Spontaneous,2023-07-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Menstrual disorder (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ESTRADIOL, NORETHISTERONE ACETATE, ESTRADIOL] (C - Menopause - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015524890&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015526787,Spontaneous,2023-07-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Asthenia (2d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Fall (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (2d - Recovered/Resolved - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015526787&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015530063,Spontaneous,2023-07-11 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Blood pressure decreased (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dizziness (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug hypersensitivity (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015530063&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015530127,Spontaneous,2023-07-11 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Pulmonary embolism (n/a - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use])","[ATORVASTATIN] (C - Coronary artery disease - n/a - [n/a - 40mg - Oral use]),<BR><BR>[CANDESARTAN, CANDESARTAN CILEXETIL] (C - Hypertension - n/a - [n/a - 16mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015530127&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015530612,Spontaneous,2023-07-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (S - Influenza immunisation - Unknown - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015530612&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015518130,Spontaneous,2023-07-10 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Acute myocardial infarction (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Angina pectoris (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Arteriospasm coronary (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Chest pain (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Thrombosis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015518130&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015518575,Spontaneous,2023-07-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Disturbance in attention (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Executive dysfunction (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Feeling of body temperature change (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>General physical health deterioration (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Hypersensitivity (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Memory impairment (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Stupor (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Vision blurred (n/a - Not Recovered/Not Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015518575&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015519503,Spontaneous,2023-07-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Vertigo (5d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Blood pressure abnormal - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015519503&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015519792,Spontaneous,2023-07-10 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Erythema (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Sleep disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site mass (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","DULOXETINE [DULOXETINE, DULOXETINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>EMPAGLIFLOZIN [EMPAGLIFLOZIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>TOUJEO [INSULIN GLARGINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>VICTOZA [LIRAGLUTIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ALENDRONATE SODIUM, ALENDRONIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CHLORPHENAMINE MALEATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL, CALCIUM CARBONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[DIHYDROCODEINE, DIHYDROCODEINE TARTRATE BP] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FERROUS FUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FUROSEMIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INSULIN, INSULIN HUMAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LORATADINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PREDNISONE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SODIUM HYALURONATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015519792&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015520125,Spontaneous,2023-07-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Dizziness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Post vaccination syndrome (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015520125&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015521675,Spontaneous,2023-07-10 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Altered state of consciousness (2886h - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Cerebral venous thrombosis (2886h - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Epilepsy (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Seizure (2886h - Recovered/Resolved - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[BACILLUS SUBTILIS, LACTOMIN, BIFIDOBACTERIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FAMOTIDINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MESALAZINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PREDNISOLONE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[URSODEOXYCHOLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015521675&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015521676,Spontaneous,2023-07-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015521676&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015522019,Spontaneous,2023-07-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Cardiac flutter (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hyperaesthesia teeth (n/a - Unknown - Other Medically Important Condition),<BR><BR>Influenza (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Injection site erythema (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in jaw (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Paraesthesia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rash (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rash erythematous (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Restlessness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Somnolence (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination site mass (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site warmth (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","AZATHIOPRINE [AZATHIOPRINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CARBAMAZEPINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[DOXAZOSIN, DOXAZOSIN MESILATE] (C - Blood pressure measurement - n/a - [n/a - n/a - n/a]),<BR><BR>[GABAPENTIN] (C - Neuralgia - n/a - [n/a - n/a - n/a]),<BR><BR>[LETROZOLE] (C - Breast cancer - n/a - [n/a - n/a - n/a]),<BR><BR>[PREDNISOLONE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015522019&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015522395,Spontaneous,2023-07-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Vertigo (8d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015522395&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015506828,Spontaneous,2023-07-07 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Basilar artery occlusion (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Cerebral infarction (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015506828&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015507034,Spontaneous,2023-07-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Chills (n/a - Unknown - ),<BR><BR>Headache (n/a - Unknown - ),<BR><BR>Myalgia (n/a - Unknown - ),<BR><BR>Nausea (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Unknown - ),<BR><BR>Tachycardia (n/a - Unknown - ),<BR><BR>Tremor (n/a - Unknown - )","TOZINAMERAN, RILTOZINAMERAN [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015507034&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015507539,Spontaneous,2023-07-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Decreased appetite (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Insomnia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Paraesthesia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Sinus pain (n/a - Not Recovered/Not Resolved - Disabling)","TOZINAMERAN, RILTOZINAMERAN [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015507539&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015509623,Spontaneous,2023-07-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Alopecia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Autoimmune disorder (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Autoimmune hypothyroidism (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chronic fatigue syndrome (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lung disorder (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Thyrotoxic crisis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015509623&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015512185,Spontaneous,2023-07-07 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Cardio-respiratory arrest (n/a - Fatal - Results in Death),<BR><BR>Dyspnoea (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Interchange of vaccine products (n/a - Fatal - Results in Death),<BR><BR>Pericardial effusion (1wk - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pericarditis (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Pleural effusion (1wk - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pleurisy (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Vasculitis (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015512185&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015512636,Spontaneous,2023-07-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Blindness unilateral (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Eye discharge (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Ocular hyperaemia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Vitreous floaters (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling)","COMIRNATY 30 MICROGRAMS/DOSE [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015512636&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015513320,Spontaneous,2023-07-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015513320&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015499338,Spontaneous,2023-07-06 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015499338&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015501208,Spontaneous,2023-07-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015501208&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015502219,Spontaneous,2023-07-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Heavy menstrual bleeding (13d - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Postmenopausal haemorrhage (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015502219&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015502368,Spontaneous,2023-07-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Arthritis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Joint swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rheumatoid arthritis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",AMGEVITA [ADALIMUMAB] (C - Rheumatoid arthritis - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015502368&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015504104,Spontaneous,2023-07-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ALENDRONATE SODIUM MONOHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015504104&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015493577,Spontaneous,2023-07-05 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015493577&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015495014,Spontaneous,2023-07-05 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Alopecia totalis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015495014&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015495172,Spontaneous,2023-07-05 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Lymphadenopathy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site swelling (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015495172&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015495262,Spontaneous,2023-07-05 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Feeling hot (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Limb discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Musculoskeletal stiffness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015495262&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015496429,Spontaneous,2023-07-05 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Urinary tract infection (n/a - Unknown - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015496429&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015487900,Spontaneous,2023-07-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Calcinosis (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Interchange of vaccine products (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Limb injury (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Musculoskeletal disorder (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Tendon rupture (n/a - Unknown - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015487900&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015487947,Spontaneous,2023-07-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Dyspnoea (n/a - Unknown - Life Threatening, Disabling),<BR><BR>Fatigue (n/a - Unknown - Life Threatening, Disabling),<BR><BR>Palpitations (n/a - Unknown - Life Threatening, Disabling),<BR><BR>Respiratory rate decreased (n/a - Not Recovered/Not Resolved - Life Threatening, Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015487947&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015478114,Spontaneous,2023-07-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hot flush (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hypersensitivity (7d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Menstruation irregular (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rhinorrhoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Sneezing (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[EPLERENONE] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015478114&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015466753,Spontaneous,2023-06-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Diarrhoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hypoaesthesia (n/a - Recovering/Resolving - ),<BR><BR>Seizure (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - Depression - n/a - [n/a - n/a - n/a]),<BR><BR>[FEXOFENADINE, FEXOFENADINE HYDROCHLORIDE] (C - Seasonal allergy - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015466753&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015466892,Spontaneous,2023-06-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (13d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (13d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","METHOTREXATE [METHOTREXATE] (C - Rheumatoid arthritis - n/a - [n/a - 20mg - n/a - More in ICSR]),<BR><BR>[ACETYLSALICYLIC ACID, ACETYLSALICYLIC ACID PH. EUR., ASPIRIN BP] (C - Heart rate abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[FOLIC ACID] (C - n/a - n/a - [n/a - 5mg - n/a]),<BR><BR>[LANSOPRAZOLE] (C - Dyspepsia - n/a - [n/a - n/a - n/a]),<BR><BR>[PRAVASTATIN, PRAVASTATIN SODIUM] (C - Blood cholesterol increased - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015466892&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015471893,Spontaneous,2023-06-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Cerebrovascular accident (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypersensitivity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Migraine (n/a - Unknown - Other Medically Important Condition),<BR><BR>Paralysis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Unknown - Other Medically Important Condition),<BR><BR>Transient ischaemic attack (n/a - Unknown - Other Medically Important Condition),<BR><BR>Urticaria (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Atrial fibrillation - n/a - [n/a - n/a - n/a]),<BR><BR>[CHLORPHENAMINE MALEATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[EPINEPHRINE, EPINEPHRINE BITARTRATE] (C - Throat tightness - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015471893&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015472038,Spontaneous,2023-06-30 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Herpes zoster (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015472038&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015472331,Spontaneous,2023-06-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Not Specified,"Dizziness (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Muscle disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015472331&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015472957,Spontaneous,2023-06-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Diarrhoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling cold (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling hot (n/a - Unknown - Other Medically Important Condition),<BR><BR>Head discomfort (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","METHOTREXATE [METHOTREXATE] (C - Rheumatoid arthritis - n/a - [n/a - 20mg - n/a - More in ICSR]),<BR><BR>[ACETYLSALICYLIC ACID, ACETYLSALICYLIC ACID PH. EUR., ASPIRIN BP] (C - Heart rate - n/a - [n/a - n/a - n/a]),<BR><BR>[FOLIC ACID] (C - n/a - n/a - [n/a - 5mg - n/a]),<BR><BR>[LANSOPRAZOLE] (C - Dyspepsia - n/a - [n/a - n/a - n/a]),<BR><BR>[PRAVASTATIN, PRAVASTATIN SODIUM] (C - Blood cholesterol increased - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015472957&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015460419,Spontaneous,2023-06-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Arthritis (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Condition aggravated (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Inflammation (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Morton's neuralgia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Musculoskeletal stiffness (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - n/a - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015460419&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015465069,Spontaneous,2023-06-29 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Myalgia (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])","[AZELASTINE HYDROCHLORIDE, FLUTICASONE PROPIONATE] (C - Seasonal allergy - n/a - [n/a - 1{DF} - Nasal use]),<BR><BR>[HYDROCHLOROTHIAZIDE, LOSARTAN, LOSARTAN POTASSIUM, HYDROCHLOROTHIAZIDE] (C - Hypertension - n/a - [n/a - 1{DF} - Oral use]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - 1000mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015465069&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015449678,Spontaneous,2023-06-28 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Urticaria (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - Angina pectoris - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[ACETYLSALICYLIC ACID] (C - Angina pectoris - n/a - [n/a - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015449678&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015451312,Spontaneous,2023-06-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Anxiety (n/a - Unknown - Other Medically Important Condition),<BR><BR>Balance disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Confusional state (n/a - Unknown - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a]),<BR><BR>[NITROFURANTOIN] (C - Cystitis - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015451312&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015451519,Spontaneous,2023-06-28 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Anaphylactic reaction (1h - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015451519&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015453055,Spontaneous,2023-06-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Diarrhoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vomiting (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[CYTARABINE] (C - COVID-19 - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015453055&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015443849,Spontaneous,2023-06-27 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Cerebrovascular accident (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Fall (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Memory impairment (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Pneumonia (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015443849&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015444698,Spontaneous,2023-06-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Gait disturbance (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015444698&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015446700,Spontaneous,2023-06-27 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Interchange of vaccine products (n/a - Unknown - Life Threatening),<BR><BR>Triple negative breast cancer (n/a - Unknown - Life Threatening)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015446700&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015449470,Spontaneous,2023-06-27 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Alanine aminotransferase increased (n/a - Unknown - ),<BR><BR>Blister (n/a - Unknown - Other Medically Important Condition),<BR><BR>Gait inability (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pemphigoid (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Rash (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[MIRTAZAPINE] (C - Depression - n/a - [n/a - n/a - Oral use]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015449470&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015436324,Spontaneous,2023-06-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Circulatory collapse (n/a - Unknown - Other Medically Important Condition),<BR><BR>Gait disturbance (n/a - Unknown - ),<BR><BR>Influenza (n/a - Unknown - ),<BR><BR>Muscle fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015436324&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015440102,Spontaneous,2023-06-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dyspepsia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Night sweats (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (12h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Somnolence (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015440102&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015417981,Spontaneous,2023-06-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Menstruation delayed (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a])",[PROPRANOLOL HYDROCHLORIDE] (C - Cardiac fibrillation - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015417981&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015419352,Spontaneous,2023-06-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Condition aggravated (n/a - Unknown - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Extrapyramidal disorder (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Gait disturbance (n/a - Unknown - ),<BR><BR>Headache (n/a - Unknown - ),<BR><BR>Joint effusion (n/a - Unknown - Other Medically Important Condition),<BR><BR>Mobility decreased (n/a - Unknown - ),<BR><BR>Pain in extremity (n/a - Unknown - ),<BR><BR>Peripheral swelling (n/a - Unknown - ),<BR><BR>Physical deconditioning (n/a - Unknown - ),<BR><BR>Taste disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Weight decreased (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015419352&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015421090,Spontaneous,2023-06-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Facial paresis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Ischaemic cerebral infarction (n/a - Unknown - Other Medically Important Condition),<BR><BR>Leukopenia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015421090&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015421654,Spontaneous,2023-06-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015421654&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015423711,Spontaneous,2023-06-22 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Dermatitis (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])","[LOSARTAN POTASSIUM, HYDROCHLOROTHIAZIDE] (C - Product used for unknown indication - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[SIMVASTATIN] (C - Product used for unknown indication - n/a - [n/a - 40mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015423711&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015423916,Spontaneous,2023-06-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Dyspnoea exertional (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Off label use (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use])","CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - Angina pectoris - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Angina pectoris - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - Angina pectoris - n/a - [n/a - n/a - n/a]),<BR><BR>[BUDESONIDE, FORMOTEROL FUMARATE DIHYDRATE, FORMOTEROL FUMARATE, BUDESONIDE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL SULFATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL MICRONIZED, SALBUTAMOL SULFATE] (C - Asthma - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015423916&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015411761,Spontaneous,2023-06-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Cough (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015411761&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015413106,Spontaneous,2023-06-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Angina pectoris (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CANDESARTAN, CANDESARTAN CILEXETIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MORPHINE SULFATE] (C - Idiopathic pulmonary fibrosis - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015413106&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015413130,Spontaneous,2023-06-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Blood pressure increased (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Cough (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Heart rate increased (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hypertension (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Periarthritis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015413130&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015413139,Spontaneous,2023-06-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Muscle spasms (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Supraventricular tachycardia - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015413139&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015413287,Spontaneous,2023-06-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Bradykinesia (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Cerebrovascular accident (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Communication disorder (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Dysarthria (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Dysgraphia (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Incoherent (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Motor dysfunction (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Slow speech (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Transient ischaemic attack (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015413287&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015415747,Spontaneous,2023-06-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,Heavy menstrual bleeding (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015415747&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015400838,Spontaneous,2023-06-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Pyrexia (n/a - Recovering/Resolving - ),<BR><BR>Syncope (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015400838&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015401638,Spontaneous,2023-06-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest discomfort (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chest pain (n/a - Unknown - ),<BR><BR>Heavy menstrual bleeding (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a])","SAXENDA 6 MG/ML SOLUTION FOR INJECTION IN PRE-FILLED PEN [LIRAGLUTIDE] (C - Obesity - n/a - [n/a - n/a - n/a]),<BR><BR>[MIRTAZAPINE] (C - Sleep disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[OXAZEPAM] (C - Anxiety - n/a - [n/a - n/a - n/a]),<BR><BR>[TRIMIPRAMINE] (C - Depression - n/a - [n/a - n/a - n/a]),<BR><BR>[ZOPICLONE] (C - Sleep disorder - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015401638&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015401718,Spontaneous,2023-06-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Asthenia (n/a - Recovering/Resolving - ),<BR><BR>Catarrh (n/a - Recovering/Resolving - ),<BR><BR>Hyperhidrosis (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Sneezing (n/a - Recovering/Resolving - ),<BR><BR>Throat irritation (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 (15/15 MICROGRAMS)/DOSE DISPERSION FOR INJECTION [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015401718&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015402031,Spontaneous,2023-06-20 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthropathy (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>CSF protein increased (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>CSF white blood cell count increased (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Facial paralysis (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Fall (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Hyperaesthesia (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Muscular weakness (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Neuralgia (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [1d - n/a - n/a])","[AMLODIPINE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[LOSARTAN POTASSIUM, HYDROCHLOROTHIAZIDE] (C - n/a - n/a - [15y - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015402031&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015403854,Spontaneous,2023-06-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Asthenia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015403854&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015404249,Spontaneous,2023-06-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Loss of consciousness (1d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Respiratory arrest (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Suspected COVID-19 (7d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015404249&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015404609,Spontaneous,2023-06-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Body temperature fluctuation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dry mouth (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dry throat (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Illness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Influenza (n/a - Unknown - Other Medically Important Condition),<BR><BR>Joint swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Musculoskeletal chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015404609&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015404636,Spontaneous,2023-06-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Amnesia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Cardiac arrest (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015404636&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015404649,Spontaneous,2023-06-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dizziness (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Head discomfort (n/a - Not Recovered/Not Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015404649&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015405207,Spontaneous,2023-06-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,Bell's palsy (n/a - Unknown - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015405207&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015407633,Spontaneous,2023-06-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Loss of consciousness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015407633&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015392645,Spontaneous,2023-06-19 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Myopericarditis (3d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015392645&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015393718,Spontaneous,2023-06-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>SPIKEVAX [ELASOMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015393718&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015395086,Spontaneous,2023-06-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Brain injury (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Cerebral small vessel ischaemic disease (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Eustachian tube dysfunction (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Headache (n/a - Recovering/Resolving - Disabling),<BR><BR>Hypoaesthesia (n/a - Recovered/Resolved - Disabling),<BR><BR>Motion sickness (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Transient ischaemic attack (n/a - Recovered/Resolved With Sequelae - Disabling),<BR><BR>Vertigo (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Visual field defect (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Visual impairment (n/a - Not Recovered/Not Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","RELVAR ELLIPTA [FLUTICASONE FUROATE, VILANTEROL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015395086&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015396415,Spontaneous,2023-06-19 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Atrial fibrillation (n/a - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","AZATHIOPRINE [AZATHIOPRINE] (C - Ocular myasthenia - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015396415&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015396591,Spontaneous,2023-06-19 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"Autoimmune hepatitis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015396591&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015398966,Spontaneous,2023-06-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Joint swelling (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Polymyalgia rheumatica (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015398966&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015386219,Spontaneous,2023-06-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Cardiac flutter (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Extrasystoles (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Palpitations (4d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ALUMINIUM HYDROXIDE GEL, DRIED, MAGNESIUM CARBONATE, SODIUM CARBONATE, ALGINIC ACID, ALUMINIUM HYDROXIDE, SODIUM CARBONATE, CALCIUM CARBONATE, SODIUM ALGINATE, ALUMINIUM HYDROXIDE, SODIUM HYDROGEN CARBONATE, ALGINIC ACID, ALUMINIUM HYDROXIDE, SODIUM HYDROGEN CARBONATE, ALGINIC ACID, ALUMINIUM HYDROXIDE GEL, DRIED, SODIUM HYDROGEN CARBONATE, ALGINIC ACID, ALUMINIUM HYDROXIDE GEL, DRIED USP, SODIUM HYDROGEN CARBONATE, ALGINIC ACID, SODIUM ALGINATE, ALUMINIUM HYDROXIDE, SODIUM HYDROGEN CARBONATE, ALUMINIUM HYDROXIDE GEL, CALCIUM CARBONATE, SODIUM ALGINATE, SODIUM HYDROGEN CARBONATE, CALCIUM CARBONATE, SODIUM ALGINATE, SODIUM HYDROGEN CARBONATE, CALCIUM CARBONATE, SODIUM ALGINATE, ALUMINIUM HYDROXIDE, SODIUM HYDROGEN CARBONATE, SODIUM ALGINATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MEBEVERINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[POTASSIUM, SODIUM, MACROGOL 3350, CHLORIDE ION, HYDROGEN CARBONATE, SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[VITAMIN D] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015386219&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015386567,Spontaneous,2023-06-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,Palpitations (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ASCORBIC ACID, CALCIUM GLUBIONATE, CALCIUM CARBONATE, CALCIUM, CALCIUM GLUBIONATE, CALCIUM CARBONATE, COLECALCIFEROL, CALCIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015386567&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015386776,Spontaneous,2023-06-16 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Bradycardia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Feeling hot (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015386776&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015386843,Spontaneous,2023-06-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Burning sensation (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Diplopia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Eyelid ptosis (n/a - Recovered/Resolved With Sequelae - Disabling, Other Medically Important Condition),<BR><BR>Headache (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Ocular myasthenia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Vision blurred (n/a - Recovered/Resolved With Sequelae - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015386843&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015387931,Spontaneous,2023-06-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chest pain (n/a - Unknown - Life Threatening),<BR><BR>Dyspnoea (n/a - Unknown - Life Threatening),<BR><BR>Fatigue (n/a - Unknown - Life Threatening),<BR><BR>Hepatosplenomegaly (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Interchange of vaccine products (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Lymphadenopathy (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Lymphadenopathy mediastinal (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Palpitations (n/a - Unknown - Life Threatening),<BR><BR>Pericardial effusion (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Pericarditis (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Pleural effusion (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (n/a - Unknown - Life Threatening),<BR><BR>Syncope (n/a - Unknown - Life Threatening),<BR><BR>Tachycardia (n/a - Unknown - Life Threatening)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015387931&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015388006,Spontaneous,2023-06-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Disease recurrence (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),<BR><BR>[SARS-COV-2, STRAIN CZ02, PRODUCED IN VERO CELLS, INACTIVATED] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[TOZINAMERAN NOS] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use - More in ICSR])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015388006&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015374356,Spontaneous,2023-06-15 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Anaphylactic reaction (3h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (3h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Obstructive airways disorder (3h - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[FAMOTIDINE] (C - Anaphylactic reaction - n/a - [n/a - n/a - n/a]),<BR><BR>[OLOPATADINE HYDROCHLORIDE] (C - Anaphylactic reaction - n/a - [n/a - n/a - n/a]),<BR><BR>[PREDNISOLONE, PREDNISOLONE ACETATE] (C - Malaise - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015374356&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015377852,Spontaneous,2023-06-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Carpal tunnel syndrome (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Cyanosis (2wk - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Rheumatoid arthritis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015377852&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015378815,Spontaneous,2023-06-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Asthenia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Gait disturbance (n/a - Not Recovered/Not Resolved - ),<BR><BR>Mobility decreased (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015378815&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015381173,Spontaneous,2023-06-15 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Injection site pain (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[MOMETASONE FUROATE, MOMETASONE FUROATE MONOHYDRATE] (C - Rhinorrhoea - n/a - [n/a - n/a - Nasal use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015381173&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015366040,Spontaneous,2023-06-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Coordination abnormal (n/a - Recovering/Resolving - ),<BR><BR>Gait disturbance (n/a - Recovering/Resolving - ),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015366040&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015367272,Spontaneous,2023-06-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Joint swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Movement disorder (n/a - Not Recovered/Not Resolved - ),<BR><BR>Muscular weakness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Neuralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Sensory disturbance (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015367272&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015370376,Spontaneous,2023-06-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal pain upper (n/a - Unknown - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",BENEPALI [ETANERCEPT] (C - Psoriatic arthropathy - n/a - [n/a - 1{DF} - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015370376&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015370397,Spontaneous,2023-06-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Pyrexia (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015370397&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015370473,Spontaneous,2023-06-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Gait inability (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Migraine (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pollakiuria (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015370473&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015360229,Spontaneous,2023-06-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Diarrhoea (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (5d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Feeding disorder (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (6d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015360229&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015360671,Spontaneous,2023-06-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","IMRALDI [ADALIMUMAB] (C - Rheumatoid arthritis - n/a - [n/a - n/a - n/a]),<BR><BR>METHOTREXATE [METHOTREXATE] (C - Rheumatoid arthritis - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015360671&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015360761,Spontaneous,2023-06-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,12-17 Years,Not Specified,No,Female,"Dyspnoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015360761&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015360785,Spontaneous,2023-06-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Disease recurrence (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Trigeminal neuralgia (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","MELATONIN [MELATONIN] (C - Delayed sleep phase - n/a - [n/a - n/a - n/a]),<BR><BR>[ATOMOXETINE, ATOMOXETINE HYDROCHLORIDE] (C - Attention deficit hyperactivity disorder - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015360785&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015360912,Spontaneous,2023-06-13 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Confusional state (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Disorientation (n/a - Unknown - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015360912&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015361332,Spontaneous,2023-06-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Cold sweat (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Night sweats (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015361332&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015362496,Spontaneous,2023-06-13 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Administration site discomfort (1d - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015362496&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015363165,Spontaneous,2023-06-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Sleep disorder due to a general medical condition (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015363165&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015363400,Spontaneous,2023-06-13 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dizziness (1d - Recovered/Resolved - ),<BR><BR>Dysgeusia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (2d - Recovered/Resolved - ),<BR><BR>Presyncope (1d - Recovered/Resolved - ),<BR><BR>Pyrexia (2d - Recovered/Resolved - ),<BR><BR>Vomiting (1d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015363400&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015363536,Spontaneous,2023-06-13 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Anaphylactic reaction (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Blood pressure decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Respiratory failure (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015363536&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015349981,Spontaneous,2023-06-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dyspnoea (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Fall (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Medication error (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Atrial tachycardia - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015349981&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015351212,Spontaneous,2023-06-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Cough (18d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Decreased appetite (10d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nasal congestion (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Productive cough (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[CANDESARTAN, CANDESARTAN CILEXETIL] (C - Blood pressure abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - Dyspepsia - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015351212&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015353947,Spontaneous,2023-06-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Ataxia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dyskinesia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Impaired quality of life (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Spinal osteoarthritis (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","ESOMEPRAZOLE [ESOMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRADIOL] (C - Hormone replacement therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LIOTHYRONINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[NAPROXEN, NAPROXEN SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015353947&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015340010,Spontaneous,2023-06-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hot flush (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Peripheral coldness (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Poor quality sleep (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vertigo (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vomiting (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BENDROFLUAZIDE] (C - Blood pressure abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL, CALCIUM CARBONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FEXOFENADINE, FEXOFENADINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - Blood cholesterol abnormal - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015340010&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015340445,Spontaneous,2023-06-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,Asthenia (3d - Recovered/Resolved - Disabling),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","HYDROCORTISONE [HYDROCORTISONE, HYDROCORTISONE SODIUM SUCCINATE] (C - Addison's disease - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015340445&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015340680,Spontaneous,2023-06-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Hypoaesthesia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Limb discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[ESTRADIOL] (C - Hot flush - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015340680&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015340763,Spontaneous,2023-06-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Anxiety (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Depressed mood (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Depression (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Morbid thoughts (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Panic reaction (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[NAPROXEN, NAPROXEN SODIUM] (C - Back pain - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - Prophylaxis against gastrointestinal ulcer - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015340763&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015340829,Spontaneous,2023-06-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Loss of consciousness (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Migraine (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015340829&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015343040,Spontaneous,2023-06-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Ageusia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Deafness (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Gait inability (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Head discomfort (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Head lag (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Weight decreased (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CALCIUM CARBONATE, COLECALCIFEROL, CALCIUM CARBONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015343040&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015343817,Spontaneous,2023-06-09 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,Vomiting (n/a - Recovered/Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015343817&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015343818,Spontaneous,2023-06-09 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Vomiting (n/a - Recovered/Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015343818&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015331638,Spontaneous,2023-06-08 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Asthenia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Motor dysfunction (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Multiple sclerosis relapse (n/a - Not Recovered/Not Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - .3mL - Intramuscular use])","VANTAVO [ALENDRONIC ACID, COLECALCIFEROL, COLECALCIFEROL, ALENDRONATE SODIUM TRIHYDRATE] (C - Osteoporosis - n/a - [n/a - 70mg - Oral use]),<BR><BR>[D,L-LYSINE ACETYLSALICYLATE] (C - Myocardial infarction - n/a - [n/a - 160mg - Oral use]),<BR><BR>[EZETIMIBE, ROSUVASTATIN] (C - Hypercholesterolaemia - n/a - [n/a - 15mg - Oral use]),<BR><BR>[NEBIVOLOL] (C - Hypertension - n/a - [n/a - 5mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015331638&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015334803,Spontaneous,2023-06-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Angina pectoris (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Myocardial infarction (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Myocarditis (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015334803&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015337735,Spontaneous,2023-06-08 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"C-reactive protein increased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (4d - Recovered/Resolved - ),<BR><BR>Vaccination site erythema (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site granuloma (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site infection (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site pruritus (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site reaction (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site warmth (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 4, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6B, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9V, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 14, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 18C, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 33F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 22F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 20, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19A, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 17F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 15B, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 12F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 11A, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9N, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 7F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 5, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 3, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 2, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 1, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 10A, PNEUMOCOCCAL POLYSACCHARIDE VACCINE (23 VALENT)] (S - Pneumococcal immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015337735&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015324382,Spontaneous,2023-06-07 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Seizure (135h - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015324382&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015324701,Spontaneous,2023-06-07 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Lymphadenopathy (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015324701&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015326356,Spontaneous,2023-06-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Pain in extremity (3d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015326356&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015327245,Spontaneous,2023-06-07 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Dermatitis (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","EDOXABAN [EDOXABAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>TACROLIMUS [TACROLIMUS, TACROLIMUS MONOHYDRATE] (C - Adverse drug reaction - n/a - [n/a - n/a - n/a]),<BR><BR>[ANHYDROUS FUSIDIC ACID, FUSIDIC ACID, FUSIDIC ACID PH. EUR., SODIUM FUSIDATE, SODIUM FUSIDATE PH. EUR.] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL, CALCIUM CARBONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[TAMSULOSIN, TAMSULOSIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015327245&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015327246,Spontaneous,2023-06-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Cervical vertebral fracture (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Fall (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Syncope (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015327246&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015327304,Spontaneous,2023-06-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Chest pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015327304&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015328303,Spontaneous,2023-06-07 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Status epilepticus (n/a - Recovered/Resolved With Sequelae - Life Threatening, Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015328303&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015330334,Spontaneous,2023-06-07 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Male,Chillblains (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015330334&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015316822,Spontaneous,2023-06-06 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Altered state of consciousness (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Arrhythmia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Cardiovascular disorder (1d - Recovered/Resolved - ),<BR><BR>Fall (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Loss of consciousness (n/a - Recovered/Resolved - Life Threatening, Other Medically Important Condition),<BR><BR>Pulse absent (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Respiration abnormal (3min - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Respiratory arrest (n/a - Recovered/Resolved - Life Threatening, Other Medically Important Condition),<BR><BR>Unresponsive to stimuli (3min - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015316822&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015317122,Spontaneous,2023-06-06 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015317122&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015317283,Spontaneous,2023-06-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Heavy menstrual bleeding (n/a - Not Recovered/Not Resolved - Disabling),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015317283&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015317545,Spontaneous,2023-06-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dark circles under eyes (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dry eye (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Eye disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Facial paralysis (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Inflammation (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Periorbital swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pigmentation disorder (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rash erythematous (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash pruritic (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Sensitive skin (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Skin discolouration (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Swelling face (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Swelling of eyelid (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vision blurred (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015317545&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015319355,Spontaneous,2023-06-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Back pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypersomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Night sweats (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015319355&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015319851,Spontaneous,2023-06-06 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Confusional state (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Fall (n/a - Unknown - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use])","PREGABALIN [PREGABALIN] (C - n/a - n/a - [n/a - 150mg - n/a]),<BR><BR>SPIRONOLACTONE [SPIRONOLACTONE] (C - n/a - n/a - [n/a - 200mg - n/a]),<BR><BR>[ALENDRONATE SODIUM, ALENDRONIC ACID] (C - n/a - n/a - [n/a - 70mg - n/a]),<BR><BR>[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE, BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BECLOMETASONE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CALCIUM CARBONATE] (C - n/a - n/a - [n/a - 120mL - n/a]),<BR><BR>[CARVEDILOL] (C - n/a - n/a - [n/a - 6.25mg - n/a]),<BR><BR>[CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE, CIPROFLOXACIN LACTATE] (C - n/a - n/a - [n/a - 500mg - n/a]),<BR><BR>[COLECALCIFEROL, CALCIUM CARBONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FUROSEMIDE] (C - n/a - n/a - [n/a - 80mg - n/a]),<BR><BR>[LACTULOSE] (C - n/a - n/a - [n/a - 120mL - Oral use]),<BR><BR>[LIDOCAINE, LIDOCAINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MAGNESIUM CHLORIDE] (C - n/a - n/a - [n/a - 120mL - n/a]),<BR><BR>[MIRTAZAPINE] (C - n/a - n/a - [n/a - 15mg - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - 40mg - n/a]),<BR><BR>[ONDANSETRON] (C - n/a - n/a - [n/a - 4mg - n/a]),<BR><BR>[OXYCODONE HYDROCHLORIDE] (C - n/a - n/a - [n/a - 40mg - n/a]),<BR><BR>[OXYCODONE, OXYCODONE HYDROCHLORIDE] (C - n/a - n/a - [n/a - 40mg - n/a]),<BR><BR>[RIFAXIMIN] (C - n/a - n/a - [n/a - 1100mg - n/a]),<BR><BR>[SODIUM MONOFLUOROPHOSPHATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[TAMSULOSIN, TAMSULOSIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - 400ug - n/a]),<BR><BR>[WHEY] (C - n/a - n/a - [n/a - 120mL - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015319851&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015309535,Spontaneous,2023-06-05 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Drug hypersensitivity (n/a - Not Recovered/Not Resolved - Life Threatening),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Life Threatening),<BR><BR>Food allergy (n/a - Not Recovered/Not Resolved - Life Threatening),<BR><BR>Idiopathic environmental intolerance (n/a - Not Recovered/Not Resolved - Life Threatening),<BR><BR>Mast cell activation syndrome (n/a - Not Recovered/Not Resolved - Life Threatening)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015309535&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015313862,Spontaneous,2023-06-05 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Facial paresis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015313862&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015307941,Spontaneous,2023-06-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Maternal exposure during pregnancy (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Overdose (n/a - Unknown - ),<BR><BR>Product preparation error (n/a - Unknown - ),<BR><BR>Uterine hypertonus (n/a - Unknown - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015307941&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015307947,Spontaneous,2023-06-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Foetus,No,Male,"Maternal exposure during pregnancy (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Tachycardia foetal (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Transplacental])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015307947&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015300201,Spontaneous,2023-06-02 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Food allergy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - Product used for unknown indication - Unknown - [n/a - 1{DF} - n/a]),<BR><BR>COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - Product used for unknown indication - Unknown - [n/a - 1{DF} - Intramuscular use]),<BR><BR>SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.1 [ELASOMERAN, IMELASOMERAN] (S - COVID-19 prophylaxis - Unknown - [n/a - 1{DF} - n/a])","EDOXABAN [EDOXABAN] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015300201&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015301658,Spontaneous,2023-06-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Blood pH abnormal (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Thrombosis (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015301658&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015290425,Spontaneous,2023-06-01 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015290425&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015290656,Spontaneous,2023-06-01 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal pain upper (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Migraine with aura (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Postmenopausal haemorrhage (6d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[DILTIAZEM, DILTIAZEM HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRADIOL] (C - Hormone replacement therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PROGESTERONE] (C - Hormone replacement therapy - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015290656&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015293432,Spontaneous,2023-06-01 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Pyrexia (n/a - Recovered/Resolved - ),<BR><BR>Rash maculo-papular (n/a - Recovered/Resolved - ),<BR><BR>Rash papular (n/a - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - .3mL - n/a - More in ICSR])","AVAMYS [FLUTICASONE FUROATE] (C - n/a - n/a - ),<BR><BR>[ANHYDROUS LEVOTHYROXINE SODIUM, LEVOTHYROXINE, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS EP] (C - n/a - n/a - ),<BR><BR>[CALCIUM CARBONATE, COLECALCIFEROL, CALCIUM, COLECALCIFEROL, CALCIUM CARBONATE] (C - n/a - n/a - ),<BR><BR>[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - n/a - n/a - ),<BR><BR>[OLMESARTAN MEDOXOMIL] (C - n/a - n/a - )","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015293432&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015295188,Spontaneous,2023-06-01 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Adult,No,Male,"Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Night sweats (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015295188&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015295353,Spontaneous,2023-06-01 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015295353&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015295500,Spontaneous,2023-06-01 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Acute coronary syndrome (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Anaemia (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Joint swelling (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Thrombocytopenia (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","DEXAMETHASONE [DEXAMETHASONE, DEXAMETHASONE SODIUM PHOSPHATE] (C - Prostate cancer - n/a - [n/a - n/a - n/a]),<BR><BR>[AMFEPRAMONE] (C - Prostate cancer - n/a - [n/a - n/a - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B)] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[CALCIUM CARBONATE, COLECALCIFEROL CONCENTRATE (POWDER FORM) (SDS), COLECALCIFEROL, CALCIUM CARBONATE] (C - Calcium deficiency - n/a - [n/a - n/a - n/a]),<BR><BR>[DOMPERIDONE] (C - Chemotherapy - n/a - [n/a - n/a - n/a]),<BR><BR>[FUROSEMIDE] (C - Polyuria - n/a - [n/a - n/a - n/a]),<BR><BR>[LEUPRORELIN] (C - Prostate cancer - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Hyperthyroidism - n/a - [n/a - n/a - n/a]),<BR><BR>[MORPHINE SULFATE, MORPHINE SULFATE PENTAHYDRATE] (C - Pain - n/a - [n/a - n/a - n/a]),<BR><BR>[MORPHINE SULFATE, MORPHINE SULPHATE BP] (C - Pain - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARAFFIN, LIGHT LIQUID, ISOPROPYL MYRISTATE, SODIUM PYRROLIDONE CARBOXYLATE] (C - Petechiae - n/a - [n/a - n/a - n/a]),<BR><BR>[SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (C - Constipation - n/a - [n/a - n/a - n/a]),<BR><BR>[TAMSULOSIN, TAMSULOSIN HYDROCHLORIDE] (C - Prostatism - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015295500&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015296322,Spontaneous,2023-06-01 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Cutaneous vasculitis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN HYDROCHLORIDE] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015296322&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015296756,Spontaneous,2023-06-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Limb discomfort (n/a - Not Recovered/Not Resolved - ),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (C - Influenza immunisation - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 4, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6B, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9V, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 14, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 18C, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 33F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 22F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 20, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19A, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 17F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 15B, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 12F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 11A, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9N, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 7F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 5, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 3, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 2, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 1, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 10A, PNEUMOCOCCAL POLYSACCHARIDE VACCINE (23 VALENT)] (C - Pneumococcal immunisation - n/a - [n/a - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015296756&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015296778,Spontaneous,2023-06-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Cough (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - ),<BR><BR>Rhinorrhoea (n/a - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015296778&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015283337,Spontaneous,2023-05-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Angiopathy (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Heart rate increased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015283337&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015283922,Spontaneous,2023-05-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Malaise (1d - Recovered/Resolved - ),<BR><BR>Movement disorder (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[ANHYDROUS LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - Unknown - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015283922&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015284317,Spontaneous,2023-05-31 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Asthma (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","RELVAR ELLIPTA [FLUTICASONE FUROATE, VILANTEROL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015284317&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015284385,Spontaneous,2023-05-31 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Burning sensation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Migraine with aura (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Ophthalmic migraine (n/a - Unknown - Other Medically Important Condition),<BR><BR>Paraesthesia oral (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Swollen tongue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","INSULIN GLARGINE [INSULIN GLARGINE] (C - Type 1 diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>METHOTREXATE [METHOTREXATE] (C - Rheumatoid arthritis - n/a - [n/a - n/a - n/a]),<BR><BR>[CYANOCOBALAMIN] (C - Pernicious anaemia - n/a - [n/a - n/a - n/a]),<BR><BR>[FERROUS FUMARATE] (C - Anaemia - n/a - [n/a - n/a - n/a]),<BR><BR>[HYDROXYCHLOROQUINE SULFATE] (C - Rheumatoid arthritis - n/a - [n/a - n/a - n/a]),<BR><BR>[INSULIN, INSULIN HUMAN] (C - Type 1 diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015284385&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015284833,Spontaneous,2023-05-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Heavy menstrual bleeding (n/a - Not Recovered/Not Resolved - ),<BR><BR>Intermenstrual bleeding (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015284833&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015284894,Spontaneous,2023-05-31 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Concussion (n/a - Unknown - Other Medically Important Condition),<BR><BR>Contusion (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fall (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Syncope (1d - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","MYFENAX [MYCOPHENOLATE MOFETIL] (C - Scleroderma - n/a - [n/a - n/a - n/a]),<BR><BR>[PREDNISOLONE] (C - Scleroderma - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015284894&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015285102,Spontaneous,2023-05-31 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Periarthritis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Sleep disorder due to a general medical condition (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Tendonitis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015285102&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015285432,Spontaneous,2023-05-31 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Angina pectoris (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Chest pain (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Coagulopathy (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Dyspnoea (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Fatigue (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Myocarditis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Palpitations (n/a - Unknown - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015285432&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015285723,Spontaneous,2023-05-31 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Diarrhoea (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Ear pain (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Nasal congestion (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","IBUPROFEN [IBUPROFEN, IBUPROFEN SODIUM] (C - Arthritis - n/a - [n/a - n/a - n/a]),<BR><BR>[CANDESARTAN, CANDESARTAN CILEXETIL] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[INDAPAMIDE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[MOXONIDINE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - Antacid therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Back pain - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015285723&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015286928,Spontaneous,2023-05-31 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Alcohol poisoning (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Feeling drunk (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","EDOXABAN [EDOXABAN] (C - Atrial fibrillation - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM TRIHYDRATE] (C - Blood cholesterol increased - n/a - [n/a - n/a - n/a]),<BR><BR>[SOTALOL, SOTALOL HYDROCHLORIDE] (C - Atrial fibrillation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015286928&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015288061,Spontaneous,2023-05-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Crying (n/a - Not Recovered/Not Resolved - ),<BR><BR>Depressed mood (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015288061&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015274462,Spontaneous,2023-05-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Inflammation (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Swelling (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])","[BUDESONIDE, BUDESONIDE, MICRONISED] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015274462&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015274591,Spontaneous,2023-05-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (1d - Recovered/Resolved - ),<BR><BR>Headache (1d - Recovered/Resolved - ),<BR><BR>Pyrexia (2d - Recovered/Resolved - ),<BR><BR>Vaccination site pain (4d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015274591&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015276232,Spontaneous,2023-05-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Malaise (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015276232&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015277109,Spontaneous,2023-05-30 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Neuropathy peripheral (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Pain (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015277109&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015277259,Spontaneous,2023-05-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Seizure (1d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Swelling face (1d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Swollen tongue (1d - Recovered/Resolved - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[CLARITHROMYCIN] (C - Helicobacter infection - n/a - [7d - n/a - n/a]),<BR><BR>[METRONIDAZOLE] (C - Helicobacter infection - n/a - [7d - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - Helicobacter infection - n/a - [7d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015277259&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015277565,Spontaneous,2023-05-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dizziness (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Insomnia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Night sweats (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015277565&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015277747,Spontaneous,2023-05-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Muscle tightness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015277747&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015278509,Spontaneous,2023-05-30 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Alanine aminotransferase increased (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Aspartate aminotransferase increased (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Dizziness (n/a - Recovering/Resolving - ),<BR><BR>Dyspnoea (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Hepatic function abnormal (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015278509&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015278610,Spontaneous,2023-05-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Medication error (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Mobility decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Sleep disorder due to a general medical condition (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site movement impairment (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015278610&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015280787,Spontaneous,2023-05-30 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Diarrhoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])","[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015280787&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015268540,Spontaneous,2023-05-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Interchange of vaccine products (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site erythema (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site oedema (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site warmth (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","PANTOPRAZOLE [PANTOPRAZOLE, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Gastric perforation - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL] (C - Hypovitaminosis - n/a - [n/a - n/a - n/a]),<BR><BR>[FEXOFENADINE, FEXOFENADINE HYDROCHLORIDE] (C - Hypersensitivity - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a]),<BR><BR>[PILOCARPINE, PILOCARPINE HYDROCHLORIDE] (C - Sjogren's syndrome - n/a - [n/a - n/a - n/a]),<BR><BR>[SULFASALAZINE, SULFASALAZINE PH. EUR.] (C - Psoriatic arthropathy - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015268540&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015268938,Spontaneous,2023-05-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Eczema (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015268938&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015269114,Spontaneous,2023-05-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Syncope (5min - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015269114&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015269602,Spontaneous,2023-05-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Ageusia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Decreased appetite (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Insomnia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015269602&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015270131,Spontaneous,2023-05-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Not Specified,"Arthritis (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Fall (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","DARIFENACIN [DARIFENACIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BECLOMETASONE DIPROPIONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[DIETHYLAMINE SALICYLATE, MYRTECAINE, DIETHYLAMINE SALICYLATE, MYRTECAINE, SALICYLIC ACID, DIETHYLAMINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FINASTERIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL, CODEINE PHOSPHATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[TAMSULOSIN, TAMSULOSIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015270131&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015259797,Spontaneous,2023-05-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Interchange of vaccine products (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rheumatoid arthritis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015259797&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015260681,Spontaneous,2023-05-26 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arrhythmia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Balance disorder (n/a - Unknown - ),<BR><BR>Cerebrovascular accident (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - ),<BR><BR>Dyspnoea (n/a - Unknown - ),<BR><BR>Gait disturbance (n/a - Unknown - ),<BR><BR>Influenza like illness (n/a - Unknown - ),<BR><BR>Paraesthesia (n/a - Unknown - ),<BR><BR>Respiratory failure (n/a - Unknown - Other Medically Important Condition),<BR><BR>Seizure (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[BISOPROLOL FUMARATE, BISOPROLOL FUMARATE, ACETYLSALICYLIC ACID, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - 5mg - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - 10mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015260681&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015261922,Spontaneous,2023-05-26 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Cough (n/a - Recovering/Resolving - ),<BR><BR>Influenza like illness (7d - Recovered/Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nasopharyngitis (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])","[CLOBETASOL PROPIONATE] (C - Psoriasis - n/a - [n/a - n/a - Cutaneous use]),<BR><BR>[HYDROXOCOBALAMIN] (C - Vitamin B12 deficiency - n/a - [n/a - n/a - Intramuscular use]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - 1000mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015261922&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015261942,Spontaneous,2023-05-26 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Vaccination site lymphadenopathy (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015261942&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015261956,Spontaneous,2023-05-26 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Muscle spasms (n/a - Unknown - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015261956&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015261972,Spontaneous,2023-05-26 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Erythema (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015261972&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015262007,Spontaneous,2023-05-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Burning sensation (2d - Recovered/Resolved - ),<BR><BR>Pruritus (2d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015262007&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015250137,Spontaneous,2023-05-25 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Guillain-Barre syndrome (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Interchange of vaccine products (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015250137&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015251698,Spontaneous,2023-05-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Arthralgia (5d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dizziness (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fall (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Gait disturbance (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Lethargy (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Listless (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Muscular weakness (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[TAMSULOSIN, TAMSULOSIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015251698&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015251910,Spontaneous,2023-05-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Gastrointestinal disorder (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Illness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site reaction (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015251910&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015251972,Spontaneous,2023-05-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Fatigue (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Fine motor skill dysfunction (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Influenza like illness (5d - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Vertigo (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[HYDROXYCARBAMIDE] (C - Essential thrombocythaemia - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015251972&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015252611,Spontaneous,2023-05-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Cough (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Disorientation (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - 75mg - n/a]),<BR><BR>[ALLOPURINOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FELODIPINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[TAMSULOSIN, TAMSULOSIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015252611&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015252734,Spontaneous,2023-05-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Polymyalgia rheumatica (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015252734&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015253777,Spontaneous,2023-05-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Glossodynia (7d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Inflammation (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Joint stiffness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Musculoskeletal stiffness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015253777&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015238181,Spontaneous,2023-05-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Chest pain (n/a - Unknown - ),<BR><BR>Dizziness (n/a - Unknown - ),<BR><BR>Dyspnoea (n/a - Unknown - ),<BR><BR>Fatigue (n/a - Unknown - ),<BR><BR>Headache (n/a - Unknown - ),<BR><BR>Heart rate irregular (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hypersomnia (n/a - Unknown - ),<BR><BR>Myocarditis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - ),<BR><BR>Palpitations (n/a - Unknown - ),<BR><BR>Pericarditis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - ),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015238181&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015239287,Spontaneous,2023-05-24 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Hypoaesthesia (2150h - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Myocardial infarction (2150h - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Nausea (2150h - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015239287&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015240904,Spontaneous,2023-05-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Asthenia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015240904&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015243227,Spontaneous,2023-05-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea exertional (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Influenza (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015243227&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015243482,Spontaneous,2023-05-24 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Urticaria (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015243482&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015243769,Spontaneous,2023-05-24 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Ischaemic stroke (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Transient global amnesia (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015243769&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015244181,Spontaneous,2023-05-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Abdominal pain upper (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015244181&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015244245,Spontaneous,2023-05-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Otitis media chronic (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015244245&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015244516,Spontaneous,2023-05-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","METHOTREXATE [METHOTREXATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[NAPROXEN, NAPROXEN SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015244516&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015244582,Spontaneous,2023-05-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Brain fog (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Decreased appetite (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Myalgia (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015244582&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015244852,Spontaneous,2023-05-24 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rash (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[PARACETAMOL] (C - Headache - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015244852&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015244976,Spontaneous,2023-05-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dizziness postural (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015244976&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015245115,Spontaneous,2023-05-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Palpitations (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",METHOTREXATE [METHOTREXATE] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015245115&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015245116,Spontaneous,2023-05-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Crohn's disease (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Sleep disorder due to a general medical condition (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015245116&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015245131,Spontaneous,2023-05-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Breast inflammation (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Breast pain (2wk - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Breast swelling (6wk - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Erythema (6wk - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Implant site inflammation (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Skin warm (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015245131&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015245175,Spontaneous,2023-05-24 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Alopecia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Arthralgia (4d - Recovered/Resolved - ),<BR><BR>Dizziness (4d - Recovered/Resolved - ),<BR><BR>Erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Feeling hot (n/a - Unknown - ),<BR><BR>Heavy menstrual bleeding (31d - Recovered/Resolved - Disabling),<BR><BR>Hyperhidrosis (n/a - Unknown - ),<BR><BR>Inflammation (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (4d - Recovered/Resolved - ),<BR><BR>Mass (n/a - Unknown - ),<BR><BR>Menstruation irregular (31d - Recovered/Resolved - Disabling),<BR><BR>Muscle disorder (n/a - Unknown - ),<BR><BR>Myalgia (4d - Recovered/Resolved - ),<BR><BR>Nausea (4d - Recovered/Resolved - ),<BR><BR>Pain (4d - Recovered/Resolved - ),<BR><BR>Pain (5d - Recovered/Resolved - ),<BR><BR>Peripheral swelling (17d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Purulent discharge (15d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (4d - Recovered/Resolved - ),<BR><BR>Rash macular (n/a - Unknown - ),<BR><BR>Skin odour abnormal (n/a - Unknown - ),<BR><BR>Urine abnormality (n/a - Unknown - ),<BR><BR>Vaccination site oedema (4d - Recovered/Resolved - ),<BR><BR>Vaccination site pain (5d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",[THIAMAZOLE] (C - Hyperthyroidism - n/a - [n/a - 10mg - Oral use]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015245175&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015246040,Spontaneous,2023-05-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Condition aggravated (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Musculoskeletal stiffness (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Neck pain (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Pulmonary fibrosis (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015246040&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015246088,Spontaneous,2023-05-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Decreased activity (n/a - Recovered/Resolved - ),<BR><BR>Feeling abnormal (n/a - Recovered/Resolved - ),<BR><BR>Incontinence (n/a - Recovered/Resolved - ),<BR><BR>Insomnia (n/a - Recovered/Resolved - ),<BR><BR>Seizure (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015246088&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015230611,Spontaneous,2023-05-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Myalgia (n/a - Recovering/Resolving - Disabling),<BR><BR>Vaccination site erythema (3d - Recovered/Resolved - Disabling),<BR><BR>Vaccination site swelling (5d - Recovered/Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015230611&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015232270,Spontaneous,2023-05-23 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,Rash pruritic (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (S - Influenza immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])","[PERINDOPRIL, PERINDOPRIL ARGININE, PERINDOPRIL TERT-BUTYLAMIN MONOHYDRATE, PERINDOPRIL TERT-BUTYLAMINE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015232270&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015232291,Spontaneous,2023-05-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Breast pain (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015232291&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015232302,Spontaneous,2023-05-23 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Vaccination site inflammation (n/a - Recovered/Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015232302&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015232512,Spontaneous,2023-05-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015232512&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015234044,Spontaneous,2023-05-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Male,"Erythema (n/a - Recovering/Resolving - ),<BR><BR>Eye swelling (n/a - Recovering/Resolving - ),<BR><BR>Feeling hot (n/a - Recovering/Resolving - ),<BR><BR>Hypersensitivity (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Dose not changed - [n/a - 1{DF} - n/a]),<BR><BR>[NOT AVAILABLE] (S - Paronychia - Drug withdrawn - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015234044&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015235392,Spontaneous,2023-05-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hypoaesthesia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Seizure (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pruritus (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[LAMOTRIGINE] (C - Epilepsy - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Decreased activity - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015235392&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015235401,Spontaneous,2023-05-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Abdominal distension (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Stomach mass (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015235401&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015220791,Spontaneous,2023-05-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Balance disorder (n/a - Unknown - ),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015220791&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015222908,Spontaneous,2023-05-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Lymphadenopathy (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015222908&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015223843,Spontaneous,2023-05-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Graves' disease (n/a - Recovering/Resolving - Life Threatening, Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Recovering/Resolving - Life Threatening, Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - ),<BR><BR>Thyroxine increased (n/a - Unknown - ),<BR><BR>Weight decreased (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015223843&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015224001,Spontaneous,2023-05-22 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Immunisation reaction (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])",SPIKEVAX [ELASOMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015224001&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015224661,Spontaneous,2023-05-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Balance disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspepsia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Flatulence (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015224661&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015224979,Spontaneous,2023-05-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Choking sensation (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Joint swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site erythema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site haemorrhage (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ATENOLOL, ATENOLOL BP] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015224979&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015224991,Spontaneous,2023-05-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Balance disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspepsia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Flatulence (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015224991&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015227865,Spontaneous,2023-05-22 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Dizziness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Neck pain (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[ACICLOVIR] (C - Herpes virus infection - n/a - [n/a - n/a - Oral use]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MESILATE MONOHYDRATE] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[ATORVASTATIN, ATORVASTATIN CALCIUM] (C - Hypercholesterolaemia - n/a - [n/a - n/a - Oral use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MOMETASONE FUROATE, MOMETASONE FUROATE MONOHYDRATE] (C - Rhinorrhoea - n/a - [n/a - n/a - Nasal use]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - Oral use]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015227865&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015227869,Spontaneous,2023-05-22 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Arthralgia (n/a - Unknown - Disabling),<BR><BR>Facial paralysis (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Neck pain (n/a - Unknown - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","LIXIANA [EDOXABAN, EDOXABAN TOSYLATE] (C - Thrombosis prophylaxis - n/a - [n/a - n/a - Oral use]),<BR><BR>[ATORVASTATIN, ATORVASTATIN CALCIUM] (C - Hypercholesterolaemia - n/a - [n/a - n/a - Oral use]),<BR><BR>[BETAMETHASONE, BETAMETHASONE VALERATE] (C - Eczema - n/a - [n/a - n/a - Cutaneous use]),<BR><BR>[METOPROLOL SUCCINATE, METOPROLOL TARTRATE] (C - Heart rate irregular - n/a - [n/a - n/a - Oral use]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - Oral use]),<BR><BR>[PREGABALIN] (C - Neuralgia - n/a - [n/a - n/a - Oral use]),<BR><BR>[ZOPICLONE] (C - Insomnia - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015227869&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015211341,Spontaneous,2023-05-19 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Disease recurrence (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Encephalitis (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Encephalopathy (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Fall (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Interchange of vaccine products (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Myelitis (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","SILODOSIN [SILODOSIN] (C - n/a - n/a - [n/a - 4{DF} - Oral use]),<BR><BR>TADALAFIL [TADALAFIL] (C - n/a - n/a - [n/a - 1{DF} - Oral use]),<BR><BR>[LATANOPROST] (C - n/a - n/a - [n/a - n/a - Ocular use]),<BR><BR>[SODIUM HYALURONATE] (C - n/a - n/a - [n/a - n/a - Ocular use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015211341&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015212320,Spontaneous,2023-05-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dyspnoea (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pulmonary embolism (n/a - Unknown - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015212320&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015212401,Spontaneous,2023-05-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Asthenia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dry skin (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hyperpyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Skin warm (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Tremor (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[CODEINE PHOSPHATE BP, PARACETAMOL PH. EUR., PARACETAMOL, CODEINE PHOSPHATE] (C - Neck pain - n/a - [n/a - n/a - n/a]),<BR><BR>[EXEMESTANE] (C - Breast cancer female - n/a - [n/a - n/a - n/a]),<BR><BR>[PREDNISOLONE] (C - Polymyalgia rheumatica - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015212401&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015212426,Spontaneous,2023-05-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Atrial fibrillation (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hypotension (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Presyncope (3d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","APIXABAN [APIXABAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - Heart rate abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - Blood cholesterol abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Atrial fibrillation - n/a - [n/a - n/a - n/a]),<BR><BR>[FINASTERIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - Blood pressure abnormal - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015212426&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015212579,Spontaneous,2023-05-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Migraine (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ACICLOVIR, ACICLOVIR SODIUM] (C - Herpes zoster - n/a - [n/a - n/a - n/a]),<BR><BR>[MIRTAZAPINE] (C - Depression - n/a - [n/a - n/a - n/a]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - Blood cholesterol abnormal - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015212579&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015213764,Spontaneous,2023-05-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Arthritis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Joint swelling (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Mobility decreased (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Product use issue (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (S - Antiviral prophylaxis - Not applicable - [1d - n/a - n/a])","[HYDROXYCHLOROQUINE] (C - Alopecia - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Autoimmune hypothyroidism - Dose not changed - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015213764&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015213806,Spontaneous,2023-05-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Fall (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Hypoaesthesia (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Memory impairment (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Muscular weakness (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Skull fracture (n/a - Unknown - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Blood pH increased - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015213806&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015214922,Spontaneous,2023-05-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (5d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Loss of consciousness (30s - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Muscle spasms (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Retching (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Syncope (30s - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015214922&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015215350,Spontaneous,2023-05-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (23d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (23d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>SPIKEVAX [ELASOMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>TOZINAMERAN [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ACICLOVIR, ACICLOVIR SODIUM] (C - Herpes zoster - n/a - [n/a - n/a - n/a]),<BR><BR>[MIRTAZAPINE] (C - Depression - n/a - [n/a - n/a - n/a]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - Blood cholesterol - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015215350&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015203093,Spontaneous,2023-05-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovered/Resolved - ),<BR><BR>Drug ineffective (n/a - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - Intramuscular use]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - Intramuscular use - More in ICSR])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015203093&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015203291,Spontaneous,2023-05-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,Diarrhoea (2d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015203291&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015203307,Spontaneous,2023-05-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Asthenia (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Malaise (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tremor (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - Glucose tolerance impaired - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - Blood pressure abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015203307&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015203832,Spontaneous,2023-05-18 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 4, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6B, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9V, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 14, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 18C, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 33F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 22F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 20, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19A, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 17F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 15B, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 12F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 11A, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9N, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 7F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 5, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 3, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 2, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 1, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 10A, PNEUMOCOCCAL POLYSACCHARIDE VACCINE (23 VALENT)] (C - n/a - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015203832&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015205745,Spontaneous,2023-05-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Arthritis (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Blood pressure abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015205745&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015206809,Spontaneous,2023-05-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling cold (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Illness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015206809&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015207080,Spontaneous,2023-05-18 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Thrombotic stroke (n/a - Fatal - Results in Death),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015207080&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015207119,Spontaneous,2023-05-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Aphasia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Body temperature abnormal (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015207119&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015207682,Spontaneous,2023-05-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Inflammatory bowel disease (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (990min - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Myalgia (990min - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Peripheral swelling (990min - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Swelling face (990min - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015207682&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015195348,Spontaneous,2023-05-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Facial paresis (n/a - Not Recovered/Not Resolved - ),<BR><BR>Herpes zoster (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hyperaesthesia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hyperaesthesia eye (n/a - Not Recovered/Not Resolved - ),<BR><BR>Ophthalmic herpes zoster (n/a - Not Recovered/Not Resolved - ),<BR><BR>Trigeminal neuralgia (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015195348&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015195887,Spontaneous,2023-05-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Amnesia (106d - Recovered/Resolved - Life Threatening),<BR><BR>Chills (n/a - Unknown - Life Threatening),<BR><BR>Confusional state (n/a - Unknown - Life Threatening),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Life Threatening),<BR><BR>Hyponatraemia (n/a - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Immune system disorder (n/a - Not Recovered/Not Resolved - Life Threatening),<BR><BR>Loss of consciousness (3d - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Loss of personal independence in daily activities (n/a - Not Recovered/Not Resolved - Life Threatening)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015195887&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015196312,Spontaneous,2023-05-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015196312&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015197429,Spontaneous,2023-05-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","BIMATOPROST [BIMATOPROST] (C - Glaucoma - n/a - [n/a - n/a - n/a]),<BR><BR>RIVAROXABAN [RIVAROXABAN] (C - Thrombosis - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Arrhythmia supraventricular - n/a - [n/a - n/a - n/a]),<BR><BR>[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - Anxiety - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015197429&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015197436,Spontaneous,2023-05-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 4, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6B, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9V, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 14, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 18C, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 33F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 22F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 20, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19A, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 17F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 15B, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 12F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 11A, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9N, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 7F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 5, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 3, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 2, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 1, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 10A, PNEUMOCOCCAL POLYSACCHARIDE VACCINE (23 VALENT)] (C - n/a - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015197436&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015197865,Spontaneous,2023-05-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Abdominal discomfort (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Abdominal distension (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Arthralgia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination site swelling (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[VENLAFAXINE, VENLAFAXINE HYDROCHLORIDE] (C - Glaucoma - n/a - [n/a - 75mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015197865&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015198669,Spontaneous,2023-05-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Axillary pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Bone pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Gait disturbance (n/a - Unknown - Other Medically Important Condition),<BR><BR>Muscle spasms (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[CARBIMAZOLE] (C - Graves' disease - n/a - [n/a - n/a - n/a]),<BR><BR>[CIMETIDINE] (C - Gastritis - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - Blood pressure abnormal - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015198669&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015198927,Spontaneous,2023-05-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Pityriasis rosea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015198927&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015199495,Spontaneous,2023-05-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Balance disorder (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Gait disturbance (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pain (n/a - Unknown - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015199495&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015200223,Spontaneous,2023-05-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Blood immunoglobulin G decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Decreased appetite (8d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (8d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (5d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (5d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>T-lymphocyte count decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vomiting (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Weight decreased (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015200223&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015200349,Spontaneous,2023-05-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Blood pressure increased (0d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Cold sweat (0d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Headache (0d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Nausea (0d - Recovered/Resolved - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015200349&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015201207,Spontaneous,2023-05-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Anxiety (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Depressed mood (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fear of death (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fear-related avoidance of activities (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Toxicity to various agents (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015201207&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015185736,Spontaneous,2023-05-16 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Rash (2d - Recovered/Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015185736&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015187211,Spontaneous,2023-05-16 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Axillary pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chest pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Painful respiration (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",[LEVONORGESTREL] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015187211&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015187502,Spontaneous,2023-05-16 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Pruritus (14d - Recovered/Resolved - ),<BR><BR>Rash erythematous (14d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])","[METOPROLOL, METOPROLOL TARTRATE] (C - n/a - n/a - [n/a - 25mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015187502&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015187879,Spontaneous,2023-05-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Male,Herpes zoster (14d - Recovered/Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015187879&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015187886,Spontaneous,2023-05-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Male,Influenza like illness (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015187886&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015187906,Spontaneous,2023-05-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (5h - Recovered/Resolved - ),<BR><BR>Injection site erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",METHOTREXATE [METHOTREXATE] (C - n/a - Dose not changed - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015187906&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015188429,Spontaneous,2023-05-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015188429&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015188524,Spontaneous,2023-05-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Vision blurred (1d - Recovered/Resolved - Disabling),<BR><BR>Visual impairment (1d - Recovered/Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015188524&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015188840,Spontaneous,2023-05-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chills (2d - Recovered/Resolved - Disabling),<BR><BR>Discomfort (2d - Recovered/Resolved - Disabling),<BR><BR>Fatigue (2d - Recovered/Resolved - Disabling),<BR><BR>Headache (2d - Recovered/Resolved - Disabling),<BR><BR>Influenza like illness (2d - Recovered/Resolved - Disabling),<BR><BR>Injection site reaction (2d - Recovered/Resolved - Disabling),<BR><BR>Malaise (2d - Recovered/Resolved - Disabling),<BR><BR>Vision blurred (n/a - Recovered/Resolved With Sequelae - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015188840&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015189664,Spontaneous,2023-05-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Palpitations (n/a - Unknown - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Pacemaker generated rhythm - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL, CALCIUM CARBONATE] (C - Osteopenia - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015189664&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015189721,Spontaneous,2023-05-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,Migraine (n/a - Not Recovered/Not Resolved - Disabling),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","MELATONIN [MELATONIN] (C - Insomnia - n/a - [n/a - n/a - n/a]),<BR><BR>[AMOXICILLIN] (C - Nail infection - n/a - [n/a - n/a - n/a]),<BR><BR>[CODEINE PHOSPHATE] (C - Adnexa uteri pain - n/a - [n/a - n/a - n/a]),<BR><BR>[DIPHENHYDRAMINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FLUTICASONE PROPIONATE, SALMETEROL, FLUTICASONE PROPIONATE, SALMETEROL XINAFOATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[TRAZODONE, TRAZODONE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015189721&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015189753,Spontaneous,2023-05-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Atrial fibrillation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (19d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Heart rate increased (16d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Palpitations (17d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Pacemaker generated rhythm - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL, CALCIUM CARBONATE] (C - Osteopenia - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015189753&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015190727,Spontaneous,2023-05-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Feeling hot (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nightmare (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Photopsia (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015190727&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015190754,Spontaneous,2023-05-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling of body temperature change (n/a - Unknown - Other Medically Important Condition),<BR><BR>Influenza (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Mobility decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Musculoskeletal stiffness (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015190754&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015190755,Spontaneous,2023-05-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Erythema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling cold (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hyperaesthesia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Rash papular (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Skin swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Swelling (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015190755&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015190814,Spontaneous,2023-05-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Death (n/a - Fatal - Results in Death),<BR><BR>Transient ischaemic attack (n/a - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015190814&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015190851,Spontaneous,2023-05-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Interchange of vaccine products (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Muscle oedema (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Muscle spasms (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","DAPAGLIFLOZIN [DAPAGLIFLOZIN] (C - Type 2 diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>UMECLIDINIUM BROMIDE, FLUTICASONE FUROATE, VILANTEROL [UMECLIDINIUM BROMIDE, FLUTICASONE FUROATE, VILANTEROL] (C - Chronic obstructive pulmonary disease - n/a - [n/a - n/a - n/a]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - Oral herpes - n/a - [n/a - n/a - n/a]),<BR><BR>[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - Fibromyalgia - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Blood pressure abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL, CALCIUM CARBONATE] (C - Hypovitaminosis - n/a - [n/a - n/a - n/a]),<BR><BR>[DOXYCYCLINE, DOXYCYCLINE HYCLATE, DOXYCYCLINE MONOHYDRATE] (C - Tooth abscess - n/a - [n/a - n/a - n/a]),<BR><BR>[FOLIC ACID] (C - Folate deficiency - n/a - [n/a - n/a - n/a]),<BR><BR>[HYDROXYCHLOROQUINE] (C - Sjogren's syndrome - n/a - [n/a - n/a - n/a]),<BR><BR>[MORPHINE, MORPHINE POLY(STYRENE-CO-DIVINYLBENZENE) SULFONATE, MORPHINE SULFATE, MORPHINE SULFATE PENTAHYDRATE, MORPHINE SULFATE PH. EUR.] (C - Peripheral nerve injury - n/a - [n/a - n/a - n/a]),<BR><BR>[PRAVASTATIN, PRAVASTATIN SODIUM] (C - Blood cholesterol increased - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015190851&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015177778,Spontaneous,2023-05-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015177778&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015177781,Spontaneous,2023-05-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,12-17 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (1d - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015177781&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015177813,Spontaneous,2023-05-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015177813&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015180717,Spontaneous,2023-05-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (8d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (8d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - Diastolic hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015180717&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015180875,Spontaneous,2023-05-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vertigo (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[NAPROXEN, NAPROXEN SODIUM] (C - Back pain - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - Back pain - n/a - [n/a - n/a - n/a]),<BR><BR>[TAMSULOSIN HYDROCHLORIDE] (C - Prostate cancer - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015180875&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015180985,Spontaneous,2023-05-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Cancer pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Neuropathy peripheral (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015180985&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015181039,Spontaneous,2023-05-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Illness (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015181039&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015181226,Spontaneous,2023-05-15 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Chills (n/a - Recovered/Resolved - Disabling),<BR><BR>Coma scale abnormal (n/a - Recovered/Resolved - Disabling),<BR><BR>Diarrhoea (n/a - Recovered/Resolved - Disabling),<BR><BR>Heart rate increased (n/a - Recovered/Resolved - Disabling),<BR><BR>Hypertension (n/a - Recovered/Resolved - Disabling),<BR><BR>Oxygen saturation decreased (n/a - Recovered/Resolved - Disabling),<BR><BR>Pneumonia (n/a - Recovering/Resolving - Disabling),<BR><BR>Pneumonia aspiration (n/a - Recovering/Resolving - Disabling),<BR><BR>Pyrexia (n/a - Recovered/Resolved - Disabling),<BR><BR>Tachypnoea (n/a - Recovered/Resolved - Disabling),<BR><BR>Vomiting (n/a - Recovered/Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>HYDROXOCOBALAMIN [HYDROXOCOBALAMIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CASSIA] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CHLORAMPHENICOL] (C - Adverse drug reaction - n/a - [n/a - n/a - n/a]),<BR><BR>[CLOBETASONE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CYCLIZINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FINASTERIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[HYPROMELLOSE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ISOSORBIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015181226&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015181231,Spontaneous,2023-05-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015181231&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015181587,Spontaneous,2023-05-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Rash (n/a - Unknown - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015181587&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015183261,Spontaneous,2023-05-15 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015183261&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015183458,Spontaneous,2023-05-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",VISMODEGIB [VISMODEGIB] (C - Basal cell carcinoma - n/a - [n/a - 150mg - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015183458&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015176773,Spontaneous,2023-05-13 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Acute myocardial infarction (n/a - Not Recovered/Not Resolved - Life Threatening),<BR><BR>Asthenia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Jaundice acholuric (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - Intramuscular use])","[D,L-LYSINE ACETYLSALICYLATE] (C - Myocardial ischaemia - n/a - [n/a - n/a - n/a]),<BR><BR>[NEBIVOLOL] (C - Myocardial ischaemia - n/a - [n/a - n/a - Oral use]),<BR><BR>[PRAVASTATIN SODIUM] (C - Dyslipidaemia - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015176773&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015169899,Spontaneous,2023-05-12 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Maternal exposure during pregnancy (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015169899&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015171049,Spontaneous,2023-05-12 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Acute myocardial infarction (n/a - Unknown - Other Medically Important Condition),<BR><BR>Angiopathy (n/a - Unknown - ),<BR><BR>Arrhythmia (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Atrioventricular block (n/a - Unknown - ),<BR><BR>Cardiac failure (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chest discomfort (n/a - Unknown - ),<BR><BR>Chest pain (n/a - Unknown - ),<BR><BR>Cholelithiasis (n/a - Unknown - ),<BR><BR>Depression (n/a - Unknown - ),<BR><BR>Dysphagia (n/a - Unknown - ),<BR><BR>Dyspnoea exertional (n/a - Unknown - ),<BR><BR>Hyperlipidaemia (n/a - Unknown - ),<BR><BR>Ischaemia (n/a - Unknown - ),<BR><BR>Prinzmetal angina (n/a - Unknown - Other Medically Important Condition),<BR><BR>Respiratory failure (n/a - Unknown - Other Medically Important Condition),<BR><BR>Ventricular extrasystoles (n/a - Unknown - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015171049&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015173019,Spontaneous,2023-05-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",[LETROZOLE] (C - Neoplasm malignant - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015173019&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015164889,Spontaneous,2023-05-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Male,"Chest pain (24h - Recovered/Resolved - ),<BR><BR>Dyspnoea exertional (24h - Recovered/Resolved - ),<BR><BR>Fatigue (1d - Recovered/Resolved - ),<BR><BR>Limb discomfort (24h - Recovered/Resolved - ),<BR><BR>Palpitations (24h - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015164889&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015165066,Spontaneous,2023-05-11 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Pulmonary embolism (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015165066&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015166700,Spontaneous,2023-05-11 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest pain (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Fibrin D dimer increased (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Haemoglobin decreased (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pulmonary embolism (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Viral upper respiratory tract infection (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","APIXABAN [APIXABAN] (C - n/a - n/a - [n/a - 10mg - n/a]),<BR><BR>[ATORVASTATIN] (C - Ill-defined disorder - n/a - [n/a - 20mg - n/a]),<BR><BR>[HYOSCINE BUTYLBROMIDE] (C - Ill-defined disorder - n/a - [n/a - 60mg - n/a]),<BR><BR>[LANSOPRAZOLE] (C - Ill-defined disorder - n/a - [n/a - 15mg - n/a]),<BR><BR>[MIRTAZAPINE] (C - Ill-defined disorder - n/a - [n/a - 45mg - n/a]),<BR><BR>[PROPRANOLOL, PROPRANOLOL HYDROCHLORIDE] (C - Ill-defined disorder - n/a - [n/a - 40mg - n/a]),<BR><BR>[SALBUTAMOL SULFATE] (C - Ill-defined disorder - n/a - [n/a - 2{DF} - Inhalation use]),<BR><BR>[TRAMADOL, TRAMADOL HYDROCHLORIDE] (C - Ill-defined disorder - n/a - [7d - 1{DF} - n/a]),<BR><BR>[VENLAFAXINE, VENLAFAXINE HYDROCHLORIDE] (C - Ill-defined disorder - n/a - [n/a - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015166700&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015154452,Spontaneous,2023-05-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,Rheumatoid arthritis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - Immunisation - Unknown - [n/a - 1{DF} - n/a]),<BR><BR>SPIKEVAX [ELASOMERAN] (S - Immunisation - Unknown - [n/a - 1{DF} - n/a])",METHOTREXATE [METHOTREXATE] (C - Adverse drug reaction - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015154452&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015154848,Spontaneous,2023-05-10 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Cough (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Extrasystoles (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Palpitations (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - n/a])","[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - 75mg - n/a]),<BR><BR>[ALENDRONATE SODIUM, ALENDRONIC ACID] (C - n/a - n/a - [n/a - 70mg - n/a]),<BR><BR>[AMOXICILLIN TRIHYDRATE, CLAVULANIC ACID, AMOXICILLIN TRIHYDRATE, POTASSIUM CLAVULANATE, AMOXICILLIN, CLAVULANIC ACID, AMOXICILLIN, POTASSIUM CLAVULANATE] (C - n/a - n/a - [n/a - 3{DF} - n/a]),<BR><BR>[AMOXICILLIN, AMOXICILLIN TRIHYDRATE] (C - n/a - n/a - [n/a - 1500mg - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - 1.25mg - n/a - More in ICSR]),<BR><BR>[CANDESARTAN, CANDESARTAN CILEXETIL] (C - n/a - n/a - [n/a - 2mg - n/a]),<BR><BR>[CEFALEXIN] (C - n/a - n/a - [n/a - 250mg - n/a]),<BR><BR>[CHLORHEXIDINE DIGLUCONATE SOLUTION, METHYL PARAHYDROXYBENZOATE, PROPYL PARAHYDROXYBENZOATE, LIDOCAINE HYDROCHLORIDE, CHLORHEXIDINE GLUCONATE, LIDOCAINE HYDROCHLORIDE, CHLORHEXIDINE GLUCONATE, LIDOCAINE HYDROCHLORIDE MONOHYDRATE, CHLORHEXIDINE GLUCONATE, METHYL PARAHYDROXYBENZOATE, PROPYL PARAHYDROXYBENZOATE, LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL] (C - n/a - n/a - [n/a - 1000[iU] - n/a]),<BR><BR>[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - n/a - n/a - [n/a - 20ug - n/a]),<BR><BR>[LORATADINE] (C - n/a - n/a - [n/a - 10mg - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - 20mg - n/a]),<BR><BR>[TAMSULOSIN, TAMSULOSIN HYDROCHLORIDE] (C - Urinary tract infection - n/a - [n/a - 400ug - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015154848&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015154979,Spontaneous,2023-05-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,Tinnitus (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",[ESTRADIOL VALERATE] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015154979&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015155215,Spontaneous,2023-05-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Myocarditis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Myopericarditis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015155215&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015155917,Spontaneous,2023-05-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Neck pain (5d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Paraesthesia oral (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination site erythema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pruritus (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","METHOTREXATE [METHOTREXATE] (C - Arthritis - n/a - [n/a - n/a - n/a]),<BR><BR>[AMOXICILLIN, AMOXICILLIN TRIHYDRATE] (C - n/a - n/a - [7d - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FOLIC ACID] (C - Arthritis - n/a - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[SOLIFENACIN] (C - Hypertonic bladder - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015155917&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015156038,Spontaneous,2023-05-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypertension (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015156038&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015156204,Spontaneous,2023-05-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Musculoskeletal stiffness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (S - Immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015156204&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015156238,Spontaneous,2023-05-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Breast swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Swelling (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015156238&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015156565,Spontaneous,2023-05-10 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","ESOMEPRAZOLE [ESOMEPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - Adverse drug reaction - n/a - [n/a - n/a - n/a]),<BR><BR>[PRAZOSIN] (C - Psychiatric symptom - n/a - [n/a - n/a - n/a]),<BR><BR>[TRAZODONE, TRAZODONE HYDROCHLORIDE] (C - Psychiatric symptom - n/a - [n/a - n/a - n/a]),<BR><BR>[VENLAFAXINE, VENLAFAXINE HYDROCHLORIDE] (C - Depression - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015156565&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015156567,Spontaneous,2023-05-10 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest pain (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Pericarditis (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>ESOMEPRAZOLE [ESOMEPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - Adverse drug reaction - n/a - [n/a - n/a - n/a]),<BR><BR>[PRAZOSIN] (C - Psychiatric symptom - n/a - [n/a - n/a - n/a]),<BR><BR>[TRAZODONE, TRAZODONE HYDROCHLORIDE] (C - Psychiatric symptom - n/a - [n/a - n/a - n/a]),<BR><BR>[VENLAFAXINE, VENLAFAXINE HYDROCHLORIDE] (C - Depression - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015156567&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015156728,Spontaneous,2023-05-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Illness (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015156728&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015156907,Spontaneous,2023-05-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Blister (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Erythema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015156907&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015156946,Spontaneous,2023-05-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Brain fog (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Disturbance in attention (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Sensory overload (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015156946&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015157078,Spontaneous,2023-05-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Cardiac flutter (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Heart rate irregular (n/a - Unknown - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015157078&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015157080,Spontaneous,2023-05-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal pain upper (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vertigo (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015157080&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015157190,Spontaneous,2023-05-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Pain (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015157190&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015157669,Spontaneous,2023-05-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Illness (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015157669&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015149079,Spontaneous,2023-05-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Syncope (1d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015149079&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015149404,Spontaneous,2023-05-09 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Polymyalgia rheumatica (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015149404&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015149558,Spontaneous,2023-05-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015149558&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015149642,Spontaneous,2023-05-09 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Diarrhoea (1wk - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015149642&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015149654,Spontaneous,2023-05-09 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015149654&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015149693,Spontaneous,2023-05-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Heart rate decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015149693&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015137226,Spontaneous,2023-05-08 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Eye pruritus (n/a - Recovered/Resolved - ),<BR><BR>Fatigue (2d - Recovered/Resolved - ),<BR><BR>Headache (2d - Recovered/Resolved - ),<BR><BR>Pruritus (2d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 prophylaxis - Not applicable - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015137226&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015137591,Spontaneous,2023-05-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Facial paralysis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Lower respiratory tract infection (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",METHOTREXATE [METHOTREXATE] (C - Arthritis - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015137591&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015137721,Spontaneous,2023-05-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Tremor (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015137721&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015140151,Spontaneous,2023-05-08 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,Tinnitus (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015140151&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015136130,Spontaneous,2023-05-06 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>TOZINAMERAN [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[CANDESARTAN, CANDESARTAN CILEXETIL] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015136130&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015129156,Spontaneous,2023-05-05 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Herpes zoster (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015129156&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015132727,Spontaneous,2023-05-05 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chills (n/a - Unknown - Disabling),<BR><BR>Diarrhoea (n/a - Unknown - Disabling),<BR><BR>Gastrointestinal pain (20d - Recovered/Resolved With Sequelae - Disabling),<BR><BR>Gastrointestinal pain (n/a - Unknown - Disabling),<BR><BR>Haematochezia (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Unknown - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015132727&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015118396,Spontaneous,2023-05-04 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Injection site pain (2d - Recovered/Resolved - ),<BR><BR>Vaccination site joint swelling (2d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015118396&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015118928,Spontaneous,2023-05-04 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"IgA nephropathy (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Interchange of vaccine products (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015118928&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015119758,Spontaneous,2023-05-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Back pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015119758&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015119759,Spontaneous,2023-05-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Hypertension (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015119759&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015119865,Spontaneous,2023-05-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[FELODIPINE] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015119865&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015120680,Spontaneous,2023-05-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Muscular weakness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Night sweats (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","ESOMEPRAZOLE [ESOMEPRAZOLE] (C - Impaired gastric emptying - n/a - [n/a - n/a - n/a]),<BR><BR>[DOMPERIDONE] (C - Impaired gastric emptying - n/a - [n/a - n/a - n/a]),<BR><BR>[HYDROXYCHLOROQUINE] (C - Systemic scleroderma - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Thyroiditis - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015120680&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015120891,Spontaneous,2023-05-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Inappropriate schedule of product administration (n/a - Unknown - ),<BR><BR>Pruritus (n/a - Unknown - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[CROTAMITON, CROTAMITON, HYDROCORTISONE] (C - Pruritus - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015120891&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015123392,Spontaneous,2023-05-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Chest discomfort (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Extrasystoles (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Heart sounds abnormal (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Loss of consciousness (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Myocarditis (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pericarditis (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Syncope (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015123392&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015123430,Spontaneous,2023-05-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Palpitations (n/a - Unknown - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015123430&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015124206,Spontaneous,2023-05-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Chills (2h - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Presyncope (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ASCORBIC ACID, PARACETAMOL, ANHYDROUS CAFFEINE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015124206&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015124870,Spontaneous,2023-05-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthma (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - ),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[BUDESONIDE, FORMOTEROL FUMARATE DIHYDRATE, FORMOTEROL FUMARATE, BUDESONIDE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015124870&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015125494,Spontaneous,2023-05-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Palpitations (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015125494&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015126463,Spontaneous,2023-05-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015126463&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015111497,Spontaneous,2023-05-03 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Pyrexia (4d - Recovered/Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015111497&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015111952,Spontaneous,2023-05-03 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015111952&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015112163,Spontaneous,2023-05-03 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Balance disorder (n/a - Recovering/Resolving - ),<BR><BR>Dizziness (2d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - ),<BR><BR>Sinus disorder (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site pruritus (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])","[AZELASTINE HYDROCHLORIDE, FLUTICASONE PROPIONATE] (C - n/a - n/a - [n/a - n/a - Nasal use]),<BR><BR>[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE, BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE, FORMOTEROL FUMARATE DIHYDRATE, BECLOMETASONE DIPROPIONATE ANHYDROUS] (C - n/a - n/a - [n/a - n/a - Inhalation use]),<BR><BR>[BUPROPION, BUPROPION HYDROCHLORIDE] (C - n/a - n/a - [n/a - 150mg - Oral use]),<BR><BR>[CICLESONIDE] (C - n/a - n/a - [n/a - n/a - Inhalation use]),<BR><BR>[ENALAPRIL MALEATE] (C - n/a - n/a - [n/a - 10mg - Oral use]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - n/a - n/a - [n/a - n/a - Inhalation use]),<BR><BR>[TIOTROPIUM, TIOTROPIUM BROMIDE, TIOTROPIUM BROMIDE MONOHYDRATE] (C - n/a - n/a - [n/a - n/a - Inhalation use]),<BR><BR>[VENLAFAXINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - 150mg - Oral use]),<BR><BR>[VENLAFAXINE] (C - n/a - n/a - [n/a - 75mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015112163&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015112979,Spontaneous,2023-05-03 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Heavy menstrual bleeding (n/a - Unknown - ),<BR><BR>Polymenorrhoea (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015112979&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015113705,Spontaneous,2023-05-03 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","NOT AVAILABLE (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ASCORBIC ACID, PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015113705&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015113916,Spontaneous,2023-05-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Body temperature increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fear of death (n/a - Unknown - Other Medically Important Condition),<BR><BR>Illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Seizure (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tremor (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015113916&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015113917,Spontaneous,2023-05-03 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Delirium (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fall (n/a - Unknown - ),<BR><BR>Interchange of vaccine products (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Seronegative arthritis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","APIXABAN [APIXABAN] (C - n/a - n/a - [n/a - 2{DF} - Oral use]),<BR><BR>ESOMEPRAZOLE [ESOMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - 1{DF} - Oral use]),<BR><BR>[DIGOXIN] (C - n/a - n/a - [n/a - 1{DF} - Oral use]),<BR><BR>[ESTAZOLAM] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[ISOSORBIDE MONONITRATE] (C - n/a - n/a - [n/a - 2{DF} - Oral use]),<BR><BR>[LIMAPROST] (C - n/a - n/a - [n/a - 3{DF} - Oral use]),<BR><BR>[MAGNESIUM OXIDE] (C - n/a - n/a - [n/a - 6{DF} - Oral use]),<BR><BR>[MIROGABALIN] (C - n/a - n/a - [n/a - 2{DF} - Oral use]),<BR><BR>[VERAPAMIL, VERAPAMIL HYDROCHLORIDE] (C - n/a - n/a - [n/a - 4{DF} - Oral use]),<BR><BR>[ZOLPIDEM, ZOLPIDEM TARTRATE] (C - n/a - n/a - [n/a - 1{DF} - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015113917&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015114261,Spontaneous,2023-05-03 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Postmenopausal haemorrhage (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015114261&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015114264,Spontaneous,2023-05-03 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (3d - Recovered/Resolved - ),<BR><BR>Chills (2h - Recovered/Resolved - ),<BR><BR>Fatigue (3d - Recovered/Resolved - ),<BR><BR>Headache (36h - Recovered/Resolved - ),<BR><BR>Malaise (36h - Recovered/Resolved - ),<BR><BR>Myalgia (24h - Recovered/Resolved - ),<BR><BR>Nausea (2h - Recovered/Resolved - ),<BR><BR>Pyrexia (36h - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015114264&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015114859,Spontaneous,2023-05-03 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015114859&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015114862,Spontaneous,2023-05-03 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (4h - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (6h - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015114862&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015114863,Spontaneous,2023-05-03 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Injection site pain (3d - Recovered/Resolved - ),<BR><BR>Intermenstrual bleeding (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (2d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LYNESTRENOL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015114863&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015114866,Spontaneous,2023-05-03 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (1d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (3d - Recovered/Resolved - ),<BR><BR>Injection site pain (3d - Recovered/Resolved - ),<BR><BR>Injection site swelling (3d - Recovered/Resolved - ),<BR><BR>Injection site warmth (3d - Recovered/Resolved - ),<BR><BR>Myalgia (2d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",[LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015114866&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015115399,Spontaneous,2023-05-03 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Lymphadenopathy (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015115399&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015116568,Spontaneous,2023-05-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Balance disorder (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Blindness transient (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Cold sweat (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Feeling hot (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Hypertension (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Syncope (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Vertigo (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Vision blurred (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension - n/a - [n/a - 5mg - n/a - More in ICSR]),<BR><BR>[RAMIPRIL] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015116568&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015117615,Spontaneous,2023-05-03 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Blister (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Dermatitis allergic (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Infection (n/a - Unknown - ),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Rash erythematous (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Scab (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use])","[AMLODIPINE, AMLODIPINE BESILATE] (C - Hypertension - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015117615&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015103804,Spontaneous,2023-05-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Dysphonia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nasopharyngitis (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015103804&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015104368,Spontaneous,2023-05-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chest discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015104368&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015104443,Spontaneous,2023-05-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015104443&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015104462,Spontaneous,2023-05-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Gait disturbance (n/a - Recovered/Resolved - ),<BR><BR>Nausea (n/a - Recovered/Resolved - ),<BR><BR>Vertigo (n/a - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015104462&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015105278,Spontaneous,2023-05-02 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>COVID-19 (8d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (8d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015105278&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015105397,Spontaneous,2023-05-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Asthma (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hypertension (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Oedema peripheral (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015105397&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015105705,Spontaneous,2023-05-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ATENOLOL, ATENOLOL BP] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BENDROFLUAZIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - Hypercholesterolaemia - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015105705&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015105829,Spontaneous,2023-05-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Death (n/a - Fatal - Results in Death),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015105829&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015106031,Spontaneous,2023-05-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Erythema (n/a - Recovering/Resolving - ),<BR><BR>Rash maculo-papular (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - Immunisation - Not applicable - [n/a - .3mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015106031&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015106099,Spontaneous,2023-05-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Cerebrovascular accident (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Deafness unilateral (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Eye movement disorder (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Illness (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Inappropriate schedule of product administration (n/a - Unknown - ),<BR><BR>Movement disorder (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Vertigo (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Vomiting (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[CARBAMAZEPINE, CARBAMAZEPINE (PH. EUR.)] (C - Epilepsy - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015106099&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015106257,Spontaneous,2023-05-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Oedema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[BENDROFLUMETHIAZIDE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[ESOMEPRAZOLE] (C - Dyspepsia - n/a - [n/a - n/a - n/a]),<BR><BR>[ROPINIROLE] (C - Restless legs syndrome - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015106257&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015099513,Spontaneous,2023-05-01 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Cerebrovascular accident (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hemiplegia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015099513&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015099533,Spontaneous,2023-05-01 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Dizziness (n/a - Not Recovered/Not Resolved - Life Threatening, Disabling, Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Unknown - Life Threatening, Disabling, Other Medically Important Condition),<BR><BR>Hypertension (n/a - Not Recovered/Not Resolved - Life Threatening, Disabling, Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Life Threatening, Disabling, Other Medically Important Condition),<BR><BR>Vertigo (n/a - Unknown - Life Threatening, Disabling, Other Medically Important Condition),<BR><BR>Vomiting (n/a - Unknown - Life Threatening, Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015099533&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015099583,Spontaneous,2023-05-01 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Balance disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Disorientation (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","METHOTREXATE [METHOTREXATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FOLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015099583&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015099584,Spontaneous,2023-05-01 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Balance disorder (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Blindness (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Chest discomfort (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Confusional state (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Dyspnoea (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Dysstasia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Fall (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Fatigue (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Gait inability (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Vomiting (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015099584&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015099718,Spontaneous,2023-05-01 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Angioedema (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015099718&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015100701,Spontaneous,2023-05-01 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015100701&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015100783,Spontaneous,2023-05-01 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Angina pectoris (n/a - Unknown - Other Medically Important Condition),<BR><BR>Arteriosclerosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Coronary artery occlusion (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - ),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Supraventricular extrasystoles (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachyarrhythmia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","IRBESARTAN [IRBESARTAN] (C - Blood pressure abnormal - n/a - [n/a - 150mg - Oral use]),<BR><BR>LINAGLIPTIN [LINAGLIPTIN] (C - Diabetes mellitus - n/a - [n/a - 5mg - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Blood pressure abnormal - n/a - [n/a - 5mg - Oral use]),<BR><BR>[OMEPRAZOLE] (C - Dyspepsia - n/a - [n/a - 20mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015100783&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015101059,Spontaneous,2023-05-01 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[COVID-19 VACCINE] (C - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015101059&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015088566,Spontaneous,2023-04-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>SPIKEVAX [ELASOMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015088566&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015088613,Spontaneous,2023-04-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Asthenia (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Chest discomfort (1d - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Dizziness (1d - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Morning sickness (1d - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Palpitations (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015088613&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015089336,Spontaneous,2023-04-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Mobility decreased (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Neck pain (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[TRAMADOL, TRAMADOL HYDROCHLORIDE] (C - Arthropathy - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015089336&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015089340,Spontaneous,2023-04-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015089340&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015089358,Spontaneous,2023-04-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Anxiety (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Autonomic nervous system imbalance (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Blood pressure increased (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Loss of personal independence in daily activities (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Postural orthostatic tachycardia syndrome (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ANHYDROUS LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a]),<BR><BR>[MIRTAZAPINE] (C - Depression, Generalised anxiety disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[QUETIAPINE, QUETIAPINE FUMARATE] (C - Depression, Generalised anxiety disorder - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015089358&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015089416,Spontaneous,2023-04-28 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Blood pressure increased (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Flushing (1d - Recovered/Resolved - ),<BR><BR>Hypersensitivity (n/a - Recovered/Resolved - ),<BR><BR>Interchange of vaccine products (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tremor (1d - Recovered/Resolved - ),<BR><BR>Yawning (n/a - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015089416&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015089420,Spontaneous,2023-04-28 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",[DESOGESTREL] (C - Contraception - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015089420&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015089877,Spontaneous,2023-04-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arteriosclerosis (n/a - Fatal - Results in Death),<BR><BR>Arteriosclerosis coronary artery (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Coronary artery thrombosis (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Malaise (n/a - Fatal - Results in Death),<BR><BR>Malaise (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Myocardial infarction (1d - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Tendon calcification (n/a - Fatal - Results in Death),<BR><BR>Tendon rupture (n/a - Fatal - Results in Death)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),<BR><BR>SPIKEVAX [ELASOMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015089877&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015093781,Spontaneous,2023-04-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Back pain (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Burning sensation (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Chest pain (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Gait disturbance (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Menstrual disorder (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Musculoskeletal pain (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Pain in jaw (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Sensory loss (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","IRON [IRON] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FOLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[VITAMINS NOS] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015093781&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015093815,Spontaneous,2023-04-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Cough (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dysgeusia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Rhinorrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Sneezing (7d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015093815&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015077927,Spontaneous,2023-04-27 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Adrenal insufficiency (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Adrenocortical insufficiency acute (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Dizziness (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Eating disorder (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Hypotension (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Nausea (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Unresponsive to stimuli (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Vertigo positional (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Vomiting (n/a - Unknown - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","DULOXETINE [DULOXETINE, DULOXETINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>SENNA [SENNOSIDE A+B] [SENNOSIDE A+B] (C - n/a - n/a - [n/a - 1.5g - n/a]),<BR><BR>[ACONITE] (C - n/a - n/a - [n/a - 7.5g - n/a]),<BR><BR>[ALPRAZOLAM] (C - n/a - n/a - [n/a - 3{DF} - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[AMOXAPINE] (C - n/a - n/a - [n/a - 2{DF} - n/a]),<BR><BR>[BACTERIA NOS] (C - n/a - n/a - [n/a - 3{DF} - n/a]),<BR><BR>[BROTIZOLAM] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[CLONAZEPAM] (C - n/a - n/a - [n/a - 3{DF} - n/a]),<BR><BR>[ESZOPICLONE] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[FLUNITRAZEPAM] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[HYDROXYZINE, HYDROXYZINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[LEMBOREXANT] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[LIMAPROST] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[LUBIPROSTONE] (C - n/a - n/a - [n/a - 2{DF} - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - 6{DF} - n/a]),<BR><BR>[QUETIAPINE, QUETIAPINE FUMARATE] (C - n/a - n/a - [n/a - 2{DF} - n/a]),<BR><BR>[TRIAZOLAM] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[VALPROIC ACID] (C - n/a - n/a - [n/a - 2{DF} - n/a]),<BR><BR>[VIBEGRON] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[VONOPRAZAN] (C - n/a - n/a - [n/a - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015077927&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015079081,Spontaneous,2023-04-27 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Palindromic rheumatism (n/a - Recovered/Resolved With Sequelae - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015079081&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015081997,Spontaneous,2023-04-27 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Cardiovascular disorder (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Condition aggravated (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Cyanosis (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Limb discomfort (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Livedo reticularis (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Medication error (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Peripheral coldness (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015081997&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015082082,Spontaneous,2023-04-27 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Chills (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015082082&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015082127,Spontaneous,2023-04-27 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chest discomfort (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hypopnoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","OPATANOL [OLOPATADINE, OLOPATADINE HYDROCHLORIDE] (C - Seasonal allergy - n/a - [n/a - n/a - n/a]),<BR><BR>[FEXOFENADINE, FEXOFENADINE HYDROCHLORIDE] (C - Seasonal allergy - n/a - [n/a - n/a - n/a]),<BR><BR>[MOMETASONE FUROATE] (C - Seasonal allergy - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015082127&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015082202,Spontaneous,2023-04-27 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015082202&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015083763,Spontaneous,2023-04-27 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Atrial fibrillation (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Disease recurrence (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015083763&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015083789,Spontaneous,2023-04-27 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fall (n/a - Unknown - Other Medically Important Condition),<BR><BR>Head injury (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Syncope (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015083789&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015083944,Spontaneous,2023-04-27 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Bursitis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Heart rate abnormal (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Migraine (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Rheumatoid arthritis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Sinusitis (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015083944&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015085015,Spontaneous,2023-04-27 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015085015&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015085191,Spontaneous,2023-04-27 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Seizure (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - n/a])","LEVETIRACETAM [LEVETIRACETAM] (C - Epilepsy - n/a - [n/a - n/a - n/a]),<BR><BR>MIDAZOLAM [MIDAZOLAM, MIDAZOLAM HYDROCHLORIDE] (C - Seizure - n/a - [n/a - n/a - n/a]),<BR><BR>[AMOXICILLIN] (C - Lower respiratory tract infection - n/a - [5d - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - Cerebrovascular accident - n/a - [n/a - n/a - n/a]),<BR><BR>[CARBAMAZEPINE] (C - Epilepsy - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[NICOTINAMIDE, RIBOFLAVIN, THIAMINE NITRATE, PYRIDOXINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE, NICOTINAMIDE, RIBOFLAVIN, PYRIDOXINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PHENYTOIN] (C - Epilepsy - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[VITAMIN D] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015085191&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015073104,Spontaneous,2023-04-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Hypertension (n/a - Unknown - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015073104&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015074052,Spontaneous,2023-04-26 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Myalgia (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])","COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),<BR><BR>SPIKEVAX [ELASOMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015074052&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015074633,Spontaneous,2023-04-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Deafness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Ear pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015074633&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015075043,Spontaneous,2023-04-26 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"C-reactive protein increased (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Fall (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Fatigue (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Headache (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Seizure (1d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Tachycardia (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>White blood cell count increased (n/a - Unknown - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015075043&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015075646,Spontaneous,2023-04-26 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest pain (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Panic attack (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","ARIPIPRAZOLE [ARIPIPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015075646&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015075780,Spontaneous,2023-04-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Drug ineffective (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Antiviral prophylaxis - n/a - [1d - n/a - n/a]),<BR><BR>[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE, BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE] (C - Dyspnoea - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRADIOL] (C - Fatigue - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015075780&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015075932,Spontaneous,2023-04-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Foetus,Yes,Not Specified,"Abortion induced (n/a - Fatal - Results in Death, Congenital Anomaly, Other Medically Important Condition),<BR><BR>Congenital central nervous system anomaly (n/a - Fatal - Results in Death, Congenital Anomaly, Other Medically Important Condition),<BR><BR>Foetal death (n/a - Fatal - Results in Death, Congenital Anomaly, Other Medically Important Condition),<BR><BR>Foetal exposure during pregnancy (n/a - Fatal - Results in Death, Congenital Anomaly, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Transplacental])",[FOLIC ACID] (C - Vitamin supplementation - n/a - [n/a - 400ug - Transplacental]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015075932&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015076719,Spontaneous,2023-04-26 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Sensory disturbance (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","VICTOZA [LIRAGLUTIDE] (C - Type 2 diabetes mellitus - n/a - [n/a - n/a - Subcutaneous use]),<BR><BR>[AMLODIPINE] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[ATORVASTATIN] (C - Hypercholesterolaemia - n/a - [n/a - n/a - Oral use]),<BR><BR>[CARVEDILOL] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[CHLORZOXAZONE] (C - Muscle relaxant therapy - n/a - [742d - n/a - Oral use]),<BR><BR>[CITALOPRAM HYDROBROMIDE] (C - Depression - n/a - [n/a - n/a - Oral use]),<BR><BR>[DOXAZOSIN, DOXAZOSIN MESILATE] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[GABAPENTIN] (C - Pain - n/a - [400d - n/a - Oral use]),<BR><BR>[LOSARTAN POTASSIUM] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[METFORMIN HYDROCHLORIDE] (C - Diabetes mellitus - n/a - [n/a - n/a - Oral use]),<BR><BR>[MOXONIDINE] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - Oral use]),<BR><BR>[SILDENAFIL] (C - Erectile dysfunction - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015076719&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015061372,Spontaneous,2023-04-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Arthralgia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Lymph node pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015061372&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015062776,Spontaneous,2023-04-25 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Polymyalgia rheumatica (n/a - Unknown - Caused/Prolonged Hospitalisation),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])",[METHYLPREDNISOLONE] (C - n/a - n/a - [n/a - 16mg - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015062776&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015064296,Spontaneous,2023-04-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Balance disorder (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Gait inability (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015064296&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015065239,Spontaneous,2023-04-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Foetus,Yes,Not Specified,"Foetal growth restriction (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Foetal heart rate deceleration abnormality (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Foetal hypokinesia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Maternal exposure during pregnancy (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Transplacental])","[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - Transplacental]),<BR><BR>[FOLIC ACID] (C - Vitamin supplementation - n/a - [n/a - 400ug - Transplacental])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015065239&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015066014,Spontaneous,2023-04-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Angina pectoris (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Chest pain (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Dyspnoea (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Fatigue (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Heart rate irregular (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Myocardial injury (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Palpitations (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Polymyalgia rheumatica (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Pyrexia (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ISOSORBIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PREDNISOLONE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015066014&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015067049,Spontaneous,2023-04-25 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Blood glucose increased (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Sleep disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Thirst (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (S - Influenza immunisation - Not applicable - [1d - n/a - n/a])","EMPAGLIFLOZIN [EMPAGLIFLOZIN] (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>INSULIN GLARGINE [INSULIN GLARGINE] (C - Diabetes mellitus - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[GLICLAZIDE] (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Congenital hypothyroidism - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - Diabetes mellitus - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - n/a - Dose not changed - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015067049&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015067623,Spontaneous,2023-04-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Chest pain (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Dysphagia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Leukaemia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Lung neoplasm (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Pharyngeal swelling (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Pulmonary mass (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Swelling (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Swelling face (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015067623&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015055879,Spontaneous,2023-04-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Herpes zoster (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE, BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE] (C - Dyspnoea - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRADIOL] (C - Fatigue - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015055879&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015057669,Spontaneous,2023-04-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chills (8h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Condition aggravated (28h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Confusional state (28h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dyspnoea (28h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Essential tremor (28h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Migraine (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Muscle fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Muscle tightness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Neurological symptom (28h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Tension (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (S - Influenza immunisation - Not applicable - [1d - n/a - n/a])","IBUPROFEN [IBUPROFEN, IBUPROFEN SODIUM] (C - Headache - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - Blood cholesterol - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - Diabetes mellitus - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Headache - Dose not changed - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015057669&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015058976,Spontaneous,2023-04-24 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Back pain (n/a - Recovered/Resolved - ),<BR><BR>Immunisation reaction (n/a - Unknown - ),<BR><BR>Myalgia (n/a - Unknown - ),<BR><BR>Peripheral swelling (n/a - Unknown - ),<BR><BR>Vaccination site erythema (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","HYDROCORTISONE [HYDROCORTISONE, HYDROCORTISONE SODIUM SUCCINATE] (C - Addison's disease - n/a - [n/a - 30mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015058976&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015059241,Spontaneous,2023-04-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015059241&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015043273,Spontaneous,2023-04-21 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Neuralgic amyotrophy (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - .3mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015043273&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015035453,Spontaneous,2023-04-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Cardiac flutter (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Mental fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Muscle fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Muscular weakness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Poor quality sleep (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015035453&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015036655,Spontaneous,2023-04-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Electric shock sensation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hypersensitivity (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - ),<BR><BR>Skin disorder (n/a - Not Recovered/Not Resolved - ),<BR><BR>Sleep disorder (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015036655&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015037995,Spontaneous,2023-04-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Amnesia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Heart rate abnormal (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015037995&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015038620,Spontaneous,2023-04-20 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Acute macular neuroretinopathy (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Autoimmune disorder (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Visual field defect (n/a - Not Recovered/Not Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015038620&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015039242,Spontaneous,2023-04-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Headache (n/a - Recovering/Resolving - Disabling),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Ocular discomfort (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Photophobia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Visual acuity reduced (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Visual impairment (n/a - Not Recovered/Not Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015039242&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015039546,Spontaneous,2023-04-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Asthenia (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Gait disturbance (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Joint swelling (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Loss of personal independence in daily activities (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Lymphoedema (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Osteoarthritis (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015039546&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015039708,Spontaneous,2023-04-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dizziness (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015039708&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015025608,Spontaneous,2023-04-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),<BR><BR>COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>SPIKEVAX [ELASOMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015025608&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015026074,Spontaneous,2023-04-19 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Asthmatic crisis (0d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015026074&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015027100,Spontaneous,2023-04-19 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Injected limb mobility decreased (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Shoulder injury related to vaccine administration (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015027100&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015030247,Spontaneous,2023-04-19 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),<BR><BR>SPIKEVAX [ELASOMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015030247&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015032746,Spontaneous,2023-04-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Not Specified,"Dyspnoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rash erythematous (3wk - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Rhinorrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Sneezing (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015032746&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015034053,Spontaneous,2023-04-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015034053&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015018210,Spontaneous,2023-04-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Anxiety (n/a - Unknown - Other Medically Important Condition),<BR><BR>Head discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypertension (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Thyroid disorder - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015018210&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015018644,Spontaneous,2023-04-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Cough (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hypertension (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nasopharyngitis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Sinusitis (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015018644&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015018958,Spontaneous,2023-04-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015018958&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015019388,Spontaneous,2023-04-18 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Pruritus (n/a - Recovered/Resolved - ),<BR><BR>Rash maculo-papular (16d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Subcutaneous use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015019388&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015019972,Spontaneous,2023-04-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Not Specified,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015019972&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015021184,Spontaneous,2023-04-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Amnesia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Heart rate abnormal (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015021184&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015021871,Spontaneous,2023-04-18 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Cardiac failure (n/a - Recovered/Resolved With Sequelae - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015021871&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015022731,Spontaneous,2023-04-18 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Loss of consciousness (1d - Recovered/Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015022731&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015023312,Spontaneous,2023-04-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Tinnitus (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",[INFLUENZA VIRUS] (C - Immunisation - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015023312&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015024391,Spontaneous,2023-04-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Flushing (n/a - Unknown - Disabling),<BR><BR>Headache (n/a - Unknown - Disabling),<BR><BR>Hyperacusis (n/a - Unknown - Disabling),<BR><BR>Hyperhidrosis (n/a - Unknown - Disabling),<BR><BR>Labyrinthitis (n/a - Unknown - Disabling),<BR><BR>Vertigo (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Visual impairment (n/a - Unknown - Disabling),<BR><BR>Wrong product administered (n/a - Unknown - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015024391&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015024507,Spontaneous,2023-04-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Pyrexia (n/a - Recovered/Resolved - ),<BR><BR>Vaccination site pain (n/a - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015024507&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015010214,Spontaneous,2023-04-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Interchange of vaccine products (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Loss of personal independence in daily activities (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Mobility decreased (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",[INFLUENZA VIRUS] (C - Immunisation - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015010214&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015012815,Spontaneous,2023-04-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Altered state of consciousness (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Asthenia (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Confusional state (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Delirium (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Dysstasia (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Syncope (4d - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Traumatic shock (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015012815&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015013191,Spontaneous,2023-04-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Feeling of body temperature change (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (3d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [1d - 1{DF} - n/a])","[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Decreased activity - n/a - [n/a - n/a - n/a]),<BR><BR>[TOPIRAMATE] (C - Migraine - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015013191&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015013335,Spontaneous,2023-04-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Loss of personal independence in daily activities (n/a - Unknown - ),<BR><BR>Shoulder injury related to vaccine administration (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015013335&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015015452,Spontaneous,2023-04-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Alanine aminotransferase abnormal (n/a - Unknown - ),<BR><BR>Aspartate aminotransferase abnormal (n/a - Unknown - ),<BR><BR>Blood albumin decreased (n/a - Unknown - ),<BR><BR>Blood lactate dehydrogenase increased (n/a - Unknown - ),<BR><BR>Haemoglobin decreased (n/a - Unknown - ),<BR><BR>Hypoaesthesia (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Inflammation (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Interleukin-2 receptor increased (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Lymphadenitis (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Lymphoma (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Lymphoproliferative disorder (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Post procedural discharge (n/a - Unknown - ),<BR><BR>White blood cell count increased (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use])","[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ELDECALCITOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PREDNISOLONE] (C - Rheumatoid arthritis - n/a - [n/a - 15mg - Oral use]),<BR><BR>[RABEPRAZOLE, RABEPRAZOLE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[REBAMIPIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[TACROLIMUS, TACROLIMUS MONOHYDRATE] (C - Rheumatoid arthritis - n/a - [n/a - 1mg - n/a]),<BR><BR>[ZOLPIDEM, ZOLPIDEM TARTRATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015015452&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015010017,Spontaneous,2023-04-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Heart rate increased (2h - Recovered/Resolved - ),<BR><BR>Palpitations (2h - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015010017&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015010131,Spontaneous,2023-04-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Body temperature increased (2d - Recovered/Resolved - ),<BR><BR>Chills (2d - Recovered/Resolved - ),<BR><BR>Headache (2d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015010131&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015007390,Spontaneous,2023-04-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>SIFROL 0.26 MG PROLONGED-RELEASE TABLETS [PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015007390&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015008479,Spontaneous,2023-04-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Injection site erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pruritus (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015008479&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015001071,Spontaneous,2023-04-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Interchange of vaccine products (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Polymyalgia rheumatica (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015001071&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015002166,Spontaneous,2023-04-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Prurigo (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",LEFLUNOMIDE [LEFLUNOMIDE] (C - Rheumatoid arthritis - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015002166&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015002319,Spontaneous,2023-04-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Abdominal hernia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Anaemia (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Epistaxis (6wk - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Interchange of vaccine products (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Knee arthroplasty (n/a - Unknown - Other Medically Important Condition),<BR><BR>Thrombosis (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use])","[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - n/a - n/a - [n/a - 10mg - n/a - More in ICSR]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015002319&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015005721,Spontaneous,2023-04-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chest pain (n/a - Unknown - Life Threatening, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Life Threatening, Other Medically Important Condition),<BR><BR>Extrasystoles (n/a - Unknown - Life Threatening, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Life Threatening, Other Medically Important Condition),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - Life Threatening, Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Life Threatening, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015005721&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015005886,Spontaneous,2023-04-14 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Cerebrovascular accident (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015005886&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015005980,Spontaneous,2023-04-14 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Acute kidney injury (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Acute respiratory failure (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Arthritis bacterial (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Multiple organ dysfunction syndrome (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Myocarditis (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Sepsis (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Septic shock (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition)","AUBAGIO [TERIFLUNOMIDE] (S - Multiple sclerosis - Unknown - [981d - n/a - n/a]),<BR><BR>COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[COLECALCIFEROL] (C - n/a - n/a - ),<BR><BR>[ETHINYLESTRADIOL, LEVONORGESTREL] (C - n/a - n/a - ),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM, HYDRATE] (C - n/a - n/a - [n/a - 100ug - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL MICRONIZED, SALBUTAMOL SULFATE] (C - n/a - n/a - )","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015005980&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015007576,Spontaneous,2023-04-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Inflammation (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Sensory disturbance (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Thrombosis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015007576&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014992965,Spontaneous,2023-04-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Angina pectoris (n/a - Recovered/Resolved - ),<BR><BR>Chest pain (n/a - Recovered/Resolved - ),<BR><BR>Musculoskeletal chest pain (n/a - Recovered/Resolved - ),<BR><BR>Pain in extremity (n/a - Recovered/Resolved - ),<BR><BR>Sinus tachycardia (n/a - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014992965&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014996480,Spontaneous,2023-04-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Aphonia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Axillary pain (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dysphonia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (3d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (S - Influenza immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014996480&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014997215,Spontaneous,2023-04-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Urticaria chronic (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014997215&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014998743,Spontaneous,2023-04-13 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Acute motor axonal neuropathy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Unknown - ),<BR><BR>Guillain-Barre syndrome (54d - Recovered/Resolved With Sequelae - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Spinal osteoarthritis (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","LIXIANA [EDOXABAN, EDOXABAN TOSYLATE] (C - Atrial fibrillation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014998743&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014999069,Spontaneous,2023-04-13 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Pain in extremity (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[ALENDRONATE SODIUM, ALENDRONIC ACID] (C - Osteoporosis - n/a - [n/a - n/a - Oral use]),<BR><BR>[ATORVASTATIN] (C - Hypercholesterolaemia - n/a - [n/a - n/a - Oral use]),<BR><BR>[CLOPIDOGREL] (C - Thrombosis prophylaxis - n/a - [n/a - n/a - Oral use]),<BR><BR>[CYANOCOBALAMIN] (C - Vitamin B12 deficiency - n/a - [n/a - n/a - Oral use]),<BR><BR>[DULOXETINE] (C - Depression - n/a - [n/a - n/a - Oral use]),<BR><BR>[ENALAPRIL MALEATE] (C - Hypertension - n/a - [2503d - n/a - Oral use]),<BR><BR>[LERCANIDIPINE HYDROCHLORIDE] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[MAGNESIUM HYDROXIDE, MAGNESIUM OXIDE, MAGNESIUM OXIDE, LIGHT] (C - Constipation - n/a - [n/a - n/a - Oral use]),<BR><BR>[MIRTAZAPINE] (C - Depression - n/a - [n/a - n/a - Oral use]),<BR><BR>[QUETIAPINE, QUETIAPINE FUMARATE, QUETIAPINE HEMIFUMARATE] (C - Restlessness - n/a - [425d - n/a - Oral use]),<BR><BR>[VITAMIN D, CALCIUM] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014999069&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014988937,Spontaneous,2023-04-12 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Irritable bowel syndrome (n/a - Unknown - ),<BR><BR>Muscle spasms (n/a - Recovered/Resolved - ),<BR><BR>Sleep disorder due to a general medical condition (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014988937&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014989925,Spontaneous,2023-04-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Blood pressure increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dysgeusia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Formication (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>SPIKEVAX [ELASOMERAN] (S - COVID-19 immunisation - Unknown - [1d - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014989925&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014975178,Spontaneous,2023-04-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,12-17 Years,Not Specified,No,Female,Myopia (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - Immunisation - Not applicable - [n/a - .3mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014975178&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014977901,Spontaneous,2023-04-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site erythema (2d - Recovered/Resolved - ),<BR><BR>Injection site haematoma (2d - Recovered/Resolved - ),<BR><BR>Injection site inflammation (2d - Recovered/Resolved - ),<BR><BR>Injection site pain (2d - Recovered/Resolved - ),<BR><BR>Injection site swelling (2d - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>PROBIOTICA [NOT AVAILABLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ASCORBIC ACID, MAGNESIUM OXIDE, HEAVY, MAGNESIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014977901&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014978853,Spontaneous,2023-04-11 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Asthenia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Back pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Body temperature abnormal (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - n/a - Not applicable - [n/a - n/a - n/a]),<BR><BR>VAXZEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - n/a - Unknown - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014978853&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014980687,Spontaneous,2023-04-11 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","LIXIANA [EDOXABAN, EDOXABAN TOSYLATE] (C - Atrial fibrillation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014980687&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014981242,Spontaneous,2023-04-11 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Bell's palsy (20d - Recovered/Resolved - Caused/Prolonged Hospitalisation),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[CARVEDILOL] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[LOSARTAN POTASSIUM, HYDROCHLOROTHIAZIDE] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014981242&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014981348,Spontaneous,2023-04-11 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Myelitis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])","[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - Influenza immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014981348&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014970338,Spontaneous,2023-04-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Dyspnoea (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Gait inability (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014970338&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014970833,Spontaneous,2023-04-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Palpitations (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014970833&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014967978,Spontaneous,2023-04-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Nerve injury (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Paralysis (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014967978&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014960274,Spontaneous,2023-04-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Balance disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Condition aggravated (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Confusional state (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Impaired work ability (n/a - Unknown - Other Medically Important Condition),<BR><BR>Migraine (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[FLUOXETINE, FLUOXETINE HYDROCHLORIDE] (C - Depression - n/a - [n/a - n/a - n/a]),<BR><BR>[TOPIRAMATE] (C - Migraine - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014960274&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014961558,Spontaneous,2023-04-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Recovering/Resolving - Disabling),<BR><BR>Headache (n/a - Recovering/Resolving - Disabling),<BR><BR>Hypothyroidism (n/a - Recovering/Resolving - Disabling),<BR><BR>Myalgia (n/a - Recovering/Resolving - Disabling),<BR><BR>Thyroid disorder (n/a - Recovering/Resolving - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014961558&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014963354,Spontaneous,2023-04-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,Pain (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (S - Immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014963354&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014963677,Spontaneous,2023-04-07 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lichen planus (n/a - Unknown - Other Medically Important Condition),<BR><BR>Oral lichen planus (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Vaccination site mass (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>VAXZEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - n/a - Unknown - [n/a - n/a - Intramuscular use])","[ALENDRONATE SODIUM, ALENDRONIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PERINDOPRIL, PERINDOPRIL TERT-BUTYLAMINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014963677&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014955324,Spontaneous,2023-04-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenia (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Headache (2d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Loss of consciousness (2d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Vomiting (2d - Recovered/Resolved - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[BENDROFLUMETHIAZIDE] (C - Fluid retention - n/a - [n/a - n/a - n/a]),<BR><BR>[FELODIPINE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - Blood cholesterol increased - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014955324&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014957197,Spontaneous,2023-04-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Asthenia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Giant cell arteritis (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Hypersensitivity (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Immune enhancement therapy (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Movement disorder (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Musculoskeletal stiffness (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Nuchal rigidity (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pneumonia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Polymyalgia rheumatica (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pulmonary embolism (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Rash (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Respiratory distress (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014957197&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014957827,Spontaneous,2023-04-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014957827&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014959521,Spontaneous,2023-04-06 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Coma (1mo - Recovered/Resolved With Sequelae - Disabling, Other Medically Important Condition),<BR><BR>Disorientation (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Disseminated intravascular coagulation (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Gait disturbance (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Muscular weakness (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Neuropathy peripheral (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Oedema (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Pain in extremity (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Paralysis (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pulmonary artery thrombosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (1mo - Recovered/Resolved With Sequelae - Disabling),<BR><BR>Thrombosis with thrombocytopenia syndrome (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014959521&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014945440,Spontaneous,2023-04-05 00:00:00,Healthcare Professional,Non European Economic Area,Not available,12-17 Years,Not Specified,No,Male,"Decreased appetite (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Orthostatic intolerance (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Post lumbar puncture syndrome (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Pyrexia (n/a - Recovered/Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014945440&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014947685,Spontaneous,2023-04-05 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Myalgia (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014947685&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014949096,Spontaneous,2023-04-05 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Female,"Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hyperhidrosis (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014949096&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014949099,Spontaneous,2023-04-05 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014949099&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014949266,Spontaneous,2023-04-05 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (11d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (11d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[CANDESARTAN, CANDESARTAN CILEXETIL] (C - Hypertension - n/a - [n/a - 8mg - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[TAMSULOSIN, TAMSULOSIN HYDROCHLORIDE] (C - Prostatomegaly - n/a - [n/a - 400ug - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014949266&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014950937,Spontaneous,2023-04-05 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Deep vein thrombosis (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain in extremity (n/a - Unknown - ),<BR><BR>Product use issue (n/a - Unknown - ),<BR><BR>Pulmonary embolism (n/a - Fatal - Results in Death, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014950937&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014935036,Spontaneous,2023-04-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Drug ineffective (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014935036&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014935100,Spontaneous,2023-04-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dysarthria (44d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Foreign body sensation in eyes (20d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Glossodynia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain of skin (20d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Speech disorder (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Stomatitis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Tremor (23d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014935100&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014935118,Spontaneous,2023-04-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014935118&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014935938,Spontaneous,2023-04-04 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Tinnitus (n/a - Unknown - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014935938&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014936737,Spontaneous,2023-04-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Brain fog (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Sight disability (n/a - Unknown - Other Medically Important Condition),<BR><BR>Sleep disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Speech disorder (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014936737&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014936827,Spontaneous,2023-04-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Erythema multiforme (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypersensitivity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rash pruritic (n/a - Unknown - Other Medically Important Condition),<BR><BR>Skin exfoliation (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014936827&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014937833,Spontaneous,2023-04-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chest pain (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Eye injury (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Migraine (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Myocarditis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pericarditis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014937833&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014938067,Spontaneous,2023-04-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Cerebral haemorrhage (11d - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014938067&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014938849,Spontaneous,2023-04-04 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Lymphadenopathy (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - .3mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014938849&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014939318,Spontaneous,2023-04-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Infant,Yes,Male,"Exposure via breast milk (n/a - Unknown - Other Medically Important Condition),<BR><BR>Urticaria (24h - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Transmammary])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014939318&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014940348,Spontaneous,2023-04-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Abortion missed (n/a - Unknown - Other Medically Important Condition),<BR><BR>Maternal exposure during pregnancy (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014940348&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014941934,Spontaneous,2023-04-04 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Pain in extremity (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LAMOTRIGINE] (C - Mood swings - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014941934&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014942423,Spontaneous,2023-04-04 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Condition aggravated (n/a - Not Recovered/Not Resolved - ),<BR><BR>Muscle contracture (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014942423&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014926810,Spontaneous,2023-04-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","ZONISAMIDE [ZONISAMIDE] (C - Epilepsy - n/a - [n/a - n/a - n/a]),<BR><BR>[ALENDRONATE SODIUM, ALENDRONIC ACID] (C - Prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[ANASTROZOLE] (C - Cancer hormonal therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[BECLOMETASONE DIPROPIONATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[CLOBAZAM] (C - Epilepsy - n/a - [n/a - n/a - n/a]),<BR><BR>[LAMOTRIGINE] (C - Epilepsy - n/a - [8065d - n/a - n/a]),<BR><BR>[OXCARBAZEPINE] (C - Epilepsy - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014926810&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014927632,Spontaneous,2023-04-03 00:00:00,Healthcare Professional,Non European Economic Area,Not available,12-17 Years,Not Specified,No,Female,"Altered state of consciousness (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Aphasia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>C-reactive protein increased (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Diplopia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Dysstasia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Enophthalmos (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Eye movement disorder (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Hypoaesthesia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Malaise (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Muscular weakness (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Pallor (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Quadriplegia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Sensory disturbance (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>VIth nerve paralysis (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014927632&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014928140,Spontaneous,2023-04-03 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Facial paresis (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014928140&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014928781,Spontaneous,2023-04-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Behaviour disorder (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hypertension (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rash (n/a - Unknown - Other Medically Important Condition),<BR><BR>Thrombosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vision blurred (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","PREGABALIN [PREGABALIN] (C - Inflammation - n/a - [n/a - n/a - n/a]),<BR><BR>[DOXAZOSIN, DOXAZOSIN MESILATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[FUROSEMIDE] (C - Swelling - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - n/a]),<BR><BR>[LERCANIDIPINE, LERCANIDIPINE HYDROCHLORIDE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[LISINOPRIL, LISINOPRIL DIHYDRATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[TERBINAFINE, TERBINAFINE HYDROCHLORIDE] (C - Fungal infection - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014928781&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014931666,Spontaneous,2023-04-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Abdominal discomfort (n/a - Unknown - ),<BR><BR>Malaise (n/a - Unknown - ),<BR><BR>Vertigo positional (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vestibular neuronitis (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[CANDESARTAN, CANDESARTAN CILEXETIL] (C - Hypertension - n/a - [n/a - 8mg - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Prophylaxis - n/a - [1d - n/a - n/a]),<BR><BR>[TAMSULOSIN, TAMSULOSIN HYDROCHLORIDE] (C - Prostatomegaly - n/a - [n/a - 400ug - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014931666&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014934365,Spontaneous,2023-04-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Erythema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rash erythematous (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash macular (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash pruritic (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014934365&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014917587,Spontaneous,2023-03-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Abdominal discomfort (3mo - Recovered/Resolved - ),<BR><BR>Arrhythmia (3mo - Recovered/Resolved - ),<BR><BR>Ear inflammation (3mo - Recovered/Resolved - ),<BR><BR>Fatigue (3mo - Recovered/Resolved - ),<BR><BR>Headache (3mo - Recovered/Resolved - ),<BR><BR>Influenza like illness (3mo - Recovered/Resolved - ),<BR><BR>Malaise (3mo - Recovered/Resolved - ),<BR><BR>Nausea (3mo - Recovered/Resolved - ),<BR><BR>Ophthalmic migraine (n/a - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[PNEUMOCOCCAL POLYSACCHARIDE VACCINE (23 VALENT)] (S - Pneumococcal immunisation - Not applicable - [n/a - 1{DF} - n/a])","NOT AVAILABLE (C - Nasal polyps - n/a - [n/a - n/a - n/a]),<BR><BR>[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL, CALCIUM] (C - Osteoporosis - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014917587&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014917862,Spontaneous,2023-03-31 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Muscle atrophy (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Muscular weakness (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Neck pain (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Product use issue (n/a - Unknown - ),<BR><BR>Tremor (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (S - Immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014917862&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014920379,Spontaneous,2023-03-31 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Burning sensation (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Pruritus (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Rash (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Skin lesion (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[LOSARTAN, LOSARTAN POTASSIUM] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014920379&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014921709,Spontaneous,2023-03-31 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Recovered/Resolved With Sequelae - Disabling, Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovered/Resolved With Sequelae - Disabling, Other Medically Important Condition),<BR><BR>Post-acute COVID-19 syndrome (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014921709&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014922407,Spontaneous,2023-03-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,Condition aggravated (n/a - Recovering/Resolving - Disabling),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014922407&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014923460,Spontaneous,2023-03-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Bronchiectasis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Productive cough (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[BUDESONIDE, FORMOTEROL, BUDESONIDE, FORMOTEROL FUMARATE DIHYDRATE, BUDESONIDE, FORMOTEROL FUMARATE HYDRATE, FORMOTEROL FUMARATE, BUDESONIDE] (C - Asthma - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[FLUTICASONE PROPIONATE] (C - Asthma - n/a - [n/a - 500ug - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014923460&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014908935,Spontaneous,2023-03-30 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014908935&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014909943,Spontaneous,2023-03-30 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Heavy menstrual bleeding (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Postmenopausal haemorrhage (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Unknown])","[ESTRADIOL, LEVONORGESTREL, LEVONORGESTREL, ESTRADIOL HEMIHYDRATE] (C - n/a - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014909943&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014914149,Spontaneous,2023-03-30 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Arthralgia (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","ENTRESTO [SACUBITRIL VALSARTAN SODIUM HYDRATE, VALSARTAN, SACUBITRIL] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>JARDIANCE [EMPAGLIFLOZIN] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>PROLIA [DENOSUMAB] (C - n/a - n/a - [n/a - n/a - Subcutaneous use]),<BR><BR>[EPLERENONE] (C - Cardiac failure - n/a - [n/a - n/a - Oral use]),<BR><BR>[METFORMIN HYDROCHLORIDE] (C - Type 2 diabetes mellitus - n/a - [n/a - n/a - Oral use]),<BR><BR>[METOPROLOL, METOPROLOL SUCCINATE, METOPROLOL TARTRATE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[SIMVASTATIN] (C - Hypercholesterolaemia - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014914149&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014914227,Spontaneous,2023-03-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Chills (5d - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Fatal - Results in Death),<BR><BR>Limb discomfort (5d - Not Recovered/Not Resolved - ),<BR><BR>Sudden death (n/a - Fatal - Results in Death)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014914227&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014898300,Spontaneous,2023-03-29 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"C-reactive protein increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Unknown - ),<BR><BR>Headache (n/a - Unknown - ),<BR><BR>Malaise (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Unknown - ),<BR><BR>White blood cell count increased (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014898300&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014898557,Spontaneous,2023-03-29 00:00:00,Healthcare Professional,Non European Economic Area,Not available,12-17 Years,Not Specified,No,Male,"Chest pain (6d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Myocarditis (6d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014898557&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014900304,Spontaneous,2023-03-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Axillary pain (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Burning sensation (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Chills (2d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Feeling cold (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Incoherent (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pericarditis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Sensory disturbance (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014900304&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014900630,Spontaneous,2023-03-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[BECLOMETASONE DIPROPIONATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[CETIRIZINE, CETIRIZINE DIHYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014900630&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014902343,Spontaneous,2023-03-29 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Cardio-respiratory arrest (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Eosinophilic myocarditis (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Myocarditis (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pulmonary congestion (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pulmonary oedema (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Ventricular fibrillation (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use])",[TOCOPHEROL] (C - Osteoporosis - n/a - [n/a - n/a - Oral use]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014902343&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014902733,Spontaneous,2023-03-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Rash (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rash pruritic (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Urticaria (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","ZONISAMIDE [ZONISAMIDE] (C - Epilepsy - n/a - [n/a - n/a - n/a]),<BR><BR>[ALENDRONATE SODIUM, ALENDRONIC ACID] (C - Prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[ANASTROZOLE] (C - Cancer hormonal therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[BECLOMETASONE DIPROPIONATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[CLOBAZAM] (C - Epilepsy - n/a - [n/a - n/a - n/a]),<BR><BR>[LAMOTRIGINE] (C - Epilepsy - n/a - [8065d - n/a - n/a]),<BR><BR>[OXCARBAZEPINE] (C - Epilepsy - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014902733&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014904041,Spontaneous,2023-03-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"COVID-19 (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[FAMOTIDINE] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014904041&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014904688,Spontaneous,2023-03-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Heart rate increased (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Supraventricular tachycardia (n/a - Unknown - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - Blood uric acid increased - n/a - [n/a - n/a - n/a]),<BR><BR>[NAPROXEN, NAPROXEN SODIUM] (C - Knee arthroplasty - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Knee arthroplasty - n/a - [n/a - n/a - n/a]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014904688&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014889845,Spontaneous,2023-03-28 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Condition aggravated (n/a - Unknown - Other Medically Important Condition),<BR><BR>Eye pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Head discomfort (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Sinusitis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Tension headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014889845&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014890242,Spontaneous,2023-03-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Migraine (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014890242&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014890488,Spontaneous,2023-03-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Medication error (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Tremor (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014890488&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014890659,Spontaneous,2023-03-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Cerebrovascular accident (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Transient ischaemic attack (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014890659&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014890745,Spontaneous,2023-03-28 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Arthralgia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014890745&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014891048,Spontaneous,2023-03-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Heavy menstrual bleeding (n/a - Not Recovered/Not Resolved - ),<BR><BR>Intermenstrual bleeding (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014891048&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014891142,Spontaneous,2023-03-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (9d - Recovered/Resolved With Sequelae - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Drug ineffective (10d - Recovered/Resolved With Sequelae - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014891142&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014891143,Spontaneous,2023-03-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Heart rate increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Loss of consciousness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Parosmia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Skin discolouration (n/a - Unknown - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014891143&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014891478,Spontaneous,2023-03-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,Syncope (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014891478&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014891485,Spontaneous,2023-03-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chest pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (4d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (4d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014891485&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014891488,Spontaneous,2023-03-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Male,Tinnitus (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014891488&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014891621,Spontaneous,2023-03-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Compulsions (15d - Recovered/Resolved - Disabling),<BR><BR>Condition aggravated (n/a - Unknown - Disabling),<BR><BR>Depersonalisation/derealisation disorder (n/a - Unknown - Disabling),<BR><BR>Dizziness (15d - Recovered/Resolved - Disabling),<BR><BR>Herpes zoster (n/a - Unknown - Disabling),<BR><BR>Muscle fatigue (15d - Recovered/Resolved - Disabling),<BR><BR>Psychomotor hyperactivity (10d - Recovered/Resolved - Disabling),<BR><BR>Skin lesion (n/a - Recovering/Resolving - Disabling),<BR><BR>Vision blurred (15d - Recovered/Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[LORAZEPAM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ZOPICLONE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014891621&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014891741,Spontaneous,2023-03-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chest pain (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Myocardial injury (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Vascular injury (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014891741&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014891753,Spontaneous,2023-03-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Myalgia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Neuralgia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Visual impairment (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014891753&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014891786,Spontaneous,2023-03-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthritis (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Spinal osteoarthritis (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Stenosis (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014891786&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014891955,Spontaneous,2023-03-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Chest pain (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Malaise (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Pain in extremity (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Pleuritic pain (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Pneumonia (5d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Product use issue (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Unknown - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (S - Immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014891955&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014891967,Spontaneous,2023-03-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (9d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chills (11d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Diarrhoea (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (5d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (9d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Paraesthesia (19d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (6d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014891967&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014891974,Spontaneous,2023-03-28 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling abnormal (2wk - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Haematochezia (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hypomenorrhoea (14d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Mucous stools (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014891974&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014892155,Spontaneous,2023-03-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Female,"Chest pain (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Lichen planus (n/a - Recovering/Resolving - ),<BR><BR>Skin disorder (n/a - Recovering/Resolving - ),<BR><BR>Tachycardia (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[PANTOPRAZOLE, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - n/a - Unknown - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014892155&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014892225,Spontaneous,2023-03-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Autoimmune hepatitis (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Hepatitis toxic (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Yellow skin (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014892225&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014892860,Spontaneous,2023-03-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Amnesia (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Arthralgia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Brain fog (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Coma (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Eczema (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Fall (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014892860&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014893454,Spontaneous,2023-03-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Male,"Axillary pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014893454&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014895007,Spontaneous,2023-03-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest pain (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Incontinence (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014895007&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014896660,Spontaneous,2023-03-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Multiple organ dysfunction syndrome (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Sepsis (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Thrombosis (n/a - Fatal - Results in Death, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014896660&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014896669,Spontaneous,2023-03-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Anxiety (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Condition aggravated (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Confusional state (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Panic reaction (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Stress (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Viral load abnormal (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ACICLOVIR, ACICLOVIR SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014896669&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014896678,Spontaneous,2023-03-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Diarrhoea (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Lip swelling (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Paraesthesia oral (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Product use issue (n/a - Unknown - ),<BR><BR>Pyrexia (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Throat tightness (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (S - Immunisation - Not applicable - [1d - n/a - n/a])",[ESTRADIOL] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014896678&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014897169,Spontaneous,2023-03-28 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Guillain-Barre syndrome (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014897169&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014880977,Spontaneous,2023-03-27 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Monoparesis (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Movement disorder (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[CODEINE PHOSPHATE] (C - Irritable bowel syndrome - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014880977&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014881017,Spontaneous,2023-03-27 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Bell's palsy (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","DAPAGLIFLOZIN [DAPAGLIFLOZIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>PREGABALIN [PREGABALIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ASCORBIC ACID, BETACAROTENE, BIOTIN, ERGOCALCIFEROL, CYANOCOBALAMIN, FOLIC ACID, NICOTINAMIDE, PYRIDOXINE, RIBOFLAVIN, THIAMINE, ZINC, CALCIUM, CHROMIUM, COPPER, IODINE, IRON, MAGNESIUM, MANGANESE, PANTOTHENIC ACID, PHOSPHORUS, POTASSIUM, SELENIUM, TOCOPHERYL ACETATE, MOLYBDENUM, ASCORBIC ACID, BETACAROTENE, ERGOCALCIFEROL, CYANOCOBALAMIN, FOLIC ACID, NICOTINAMIDE, PYRIDOXINE, RIBOFLAVIN, THIAMINE, ZINC, CALCIUM, CHROMIUM, COPPER, IODINE, IRON, MAGNESIUM, MANGANESE, PANTOTHENIC ACID, PHOSPHORUS, POTASSIUM, SELENIUM, MOLYBDENUM, DL-ALPHA TOCOPHEROL ACETATE, D-BIOTIN, ERGOCALCIFEROL, RETINOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FINASTERIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FUROSEMIDE] (C - n/a - n/a - [n/a - 60mg - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MORPHINE, MORPHINE POLY(STYRENE-CO-DIVINYLBENZENE) SULFONATE, MORPHINE SULFATE, MORPHINE SULFATE PENTAHYDRATE, MORPHINE SULFATE PH. EUR.] (C - n/a - n/a - [n/a - 20mg - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[TAMSULOSIN, TAMSULOSIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014881017&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014881065,Spontaneous,2023-03-27 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Asthenia (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Hypokinesia (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Muscular weakness (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Musculoskeletal stiffness (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Shoulder injury related to vaccine administration (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014881065&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014881189,Spontaneous,2023-03-27 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Abdominal discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Asthenia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Confusional state (n/a - Unknown - Other Medically Important Condition),<BR><BR>Discomfort (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hypersomnia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hypotension (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Inflammation (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Rhinorrhoea (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[BECLOMETASONE DIPROPIONATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[CETIRIZINE, CETIRIZINE DIHYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014881189&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014881967,Spontaneous,2023-03-27 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Balance disorder (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Disease recurrence (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fall (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Product use issue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vertigo (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (S - Immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014881967&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014882512,Spontaneous,2023-03-27 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Deafness (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Deafness unilateral (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014882512&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014882594,Spontaneous,2023-03-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,Arrhythmia (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014882594&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014882847,Spontaneous,2023-03-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Intermenstrual bleeding (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaginal haemorrhage (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014882847&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014883276,Spontaneous,2023-03-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Male,Vaccination site recall reaction (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014883276&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014883932,Spontaneous,2023-03-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,Glaucoma (n/a - Not Recovered/Not Resolved - Disabling),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014883932&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014884353,Spontaneous,2023-03-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Loss of personal independence in daily activities (n/a - Unknown - ),<BR><BR>Mobility decreased (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [1d - n/a - Unknown])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014884353&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014884675,Spontaneous,2023-03-27 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Haemorrhagic stroke (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Ischaemic stroke (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014884675&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014886109,Spontaneous,2023-03-27 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Deep vein thrombosis (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Pulmonary embolism (n/a - Fatal - Results in Death, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ALLOPURINOL] (C - n/a - n/a - [n/a - 100mg - n/a]),<BR><BR>[PERINDOPRIL, PERINDOPRIL TERT-BUTYLAMINE] (C - n/a - n/a - [n/a - 4mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014886109&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014886126,Spontaneous,2023-03-27 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Dyspnoea (3d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Hepatic cyst (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Interchange of vaccine products (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Oxygen saturation decreased (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (3d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Renal cyst (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Wheezing (3d - Recovered/Resolved - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use])","[BLONANSERIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CLONAZEPAM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014886126&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014886160,Spontaneous,2023-03-27 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Brain fog (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014886160&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014886169,Spontaneous,2023-03-27 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Pulmonary embolism (n/a - Recovering/Resolving - Life Threatening, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Extrasystoles - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - Hiatus hernia - n/a - [n/a - n/a - n/a]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - Depression - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014886169&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014887001,Spontaneous,2023-03-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Female,"Arthralgia (n/a - Recovered/Resolved - ),<BR><BR>Body temperature increased (2d - Recovered/Resolved - ),<BR><BR>Chills (n/a - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (2d - Recovered/Resolved - ),<BR><BR>Injection site erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pruritus (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (2d - Recovered/Resolved - ),<BR><BR>Myalgia (2d - Recovered/Resolved - ),<BR><BR>Nausea (2d - Recovered/Resolved - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014887001&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014880550,Spontaneous,2023-03-26 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Haemorrhage subcutaneous (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Immune thrombocytopenia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Platelet count decreased (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Thrombocytopenic purpura (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014880550&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014878772,Spontaneous,2023-03-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chills (1d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (1d - Recovered/Resolved - ),<BR><BR>Nausea (1d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014878772&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014879003,Spontaneous,2023-03-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Cyanosis (n/a - Recovering/Resolving - ),<BR><BR>Hypoaesthesia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Muscle spasms (n/a - Not Recovered/Not Resolved - ),<BR><BR>Peripheral swelling (n/a - Recovering/Resolving - ),<BR><BR>Polyneuropathy (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Pruritus (3d - Recovered/Resolved With Sequelae - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - .3mL - Intramuscular use])","INVOKANA [CANAGLIFLOZIN] (C - n/a - n/a - ),<BR><BR>PRADAXA [DABIGATRAN ETEXILATE, DABIGATRAN ETEXILATE MESILATE] (C - n/a - n/a - ),<BR><BR>REPATHA [EVOLOCUMAB] (C - n/a - n/a - ),<BR><BR>[ATORVASTATIN, ATORVASTATIN CALCIUM] (C - n/a - n/a - ),<BR><BR>[ESCITALOPRAM OXALATE] (C - n/a - n/a - ),<BR><BR>[SOTALOL, SOTALOL HYDROCHLORIDE] (C - n/a - n/a - )","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014879003&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014870746,Spontaneous,2023-03-24 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Blood pressure decreased (n/a - Recovering/Resolving - ),<BR><BR>Hypersensitivity (n/a - Unknown - ),<BR><BR>Pruritus (n/a - Recovering/Resolving - ),<BR><BR>Somnolence (n/a - Unknown - ),<BR><BR>Urticaria (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014870746&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014871728,Spontaneous,2023-03-24 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Guillain-Barre syndrome (n/a - Unknown - Other Medically Important Condition),<BR><BR>Muscular weakness (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014871728&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014872235,Spontaneous,2023-03-24 00:00:00,Healthcare Professional,Non European Economic Area,Not available,12-17 Years,Not Specified,No,Male,Myocarditis (202h - Recovered/Resolved - Caused/Prolonged Hospitalisation),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014872235&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014873165,Spontaneous,2023-03-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Male,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Unknown - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - ),<BR><BR>Subacute endocarditis (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014873165&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014875568,Spontaneous,2023-03-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Suspected COVID-19 (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014875568&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014875633,Spontaneous,2023-03-24 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Blood pressure increased (n/a - Fatal - Results in Death),<BR><BR>Brain stem haemorrhage (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Cerebral haemorrhage (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Fall (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Loss of consciousness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use])","ABILIFY [ARIPIPRAZOLE] (C - Schizophrenia - n/a - [n/a - n/a - Intramuscular use]),<BR><BR>TELMISARTAN [TELMISARTAN] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[ATENOLOL, ATENOLOL BP] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[DILTIAZEM HYDROCHLORIDE] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[SPIRONOLACTONE] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[SUVOREXANT] (C - Insomnia - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014875633&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014875661,Spontaneous,2023-03-24 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthritis (n/a - Not Recovered/Not Resolved - ),<BR><BR>C-reactive protein increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Ligament injury (n/a - Unknown - ),<BR><BR>Matrix metalloproteinase-3 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Polyarthritis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014875661&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014862300,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Asthenia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Gait disturbance (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Hyperhidrosis (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Limb discomfort (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Memory impairment (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Muscular weakness (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014862300&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014863150,Spontaneous,2023-03-23 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,Vertigo (n/a - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014863150&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014863152,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014863152&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014863153,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Blood pressure increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Heart rate increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - Poor quality sleep - n/a - [n/a - n/a - n/a]),<BR><BR>[CANDESARTAN, CANDESARTAN CILEXETIL] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[GABAPENTIN] (C - Arthritis - n/a - [n/a - n/a - n/a]),<BR><BR>[PROPRANOLOL, PROPRANOLOL HYDROCHLORIDE] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014863153&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014863166,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Pemphigoid (n/a - Unknown - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014863166&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014863177,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal pain (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Chest pain (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Diarrhoea (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Head injury (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Headache (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Hypertension (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Loss of consciousness (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Nausea (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Palpitations (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Vomiting (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014863177&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014863188,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dyspnoea (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pulmonary embolism (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014863188&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014863197,Spontaneous,2023-03-23 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,Arthritis (n/a - Not Recovered/Not Resolved - Disabling),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014863197&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014863198,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Back pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Feeling cold (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014863198&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014863199,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Maternal exposure during pregnancy (n/a - Unknown - ),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[FOLIC ACID] (C - Vitamin supplementation - n/a - [n/a - 400ug - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014863199&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014863200,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,12-17 Years,Not Specified,No,Female,"Dehydration (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014863200&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014863205,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014863205&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014863206,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Gingival swelling (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Lip swelling (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Mouth swelling (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Oral discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pharyngeal swelling (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Swelling face (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[FEXOFENADINE, FEXOFENADINE HYDROCHLORIDE] (C - Hypersensitivity - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - Gastritis - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014863206&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014863207,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site mass (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014863207&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014863208,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014863208&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014863209,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"C-reactive protein increased (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Henoch-Schonlein purpura (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Thrombocytopenia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014863209&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014863214,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Neck pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014863214&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014863215,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal discomfort (n/a - Unknown - Disabling),<BR><BR>Abdominal pain upper (n/a - Unknown - Disabling),<BR><BR>Head injury (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Loss of consciousness (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Rectal haemorrhage (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Syncope (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014863215&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014863218,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Urticaria (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014863218&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014863221,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,Gastrooesophageal reflux disease (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PREDNISOLONE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014863221&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014863226,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"Headache (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Tunnel vision (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014863226&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014863229,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Extrasystoles (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014863229&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014863230,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Musculoskeletal pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Swelling (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014863230&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014863231,Spontaneous,2023-03-23 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - n/a])","[BECLOMETASONE DIPROPIONATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRADIOL, NORETHISTERONE, NORETHISTERONE ACETATE, ESTRADIOL, NORETHISTERONE ACETATE, ESTRADIOL HEMIHYDRATE] (C - Menopause - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRADIOL] (C - Menopause - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRIOL] (C - Menopause - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRONE] (C - Menopause - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014863231&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014863414,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Male,Infection susceptibility increased (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014863414&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014864502,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dizziness (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Gait disturbance (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014864502&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014864987,Spontaneous,2023-03-23 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Cerebral infarction (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Hemiplegia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014864987&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014864999,Spontaneous,2023-03-23 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Anaphylactic reaction (n/a - Fatal - Results in Death),<BR><BR>Arrhythmia (n/a - Fatal - Results in Death),<BR><BR>Cardiac failure (n/a - Fatal - Results in Death),<BR><BR>Cardio-respiratory arrest (n/a - Fatal - Results in Death),<BR><BR>Hyperkalaemia (n/a - Fatal - Results in Death),<BR><BR>Pulmonary hypertension (n/a - Fatal - Results in Death),<BR><BR>Respiratory arrest (n/a - Fatal - Results in Death),<BR><BR>Sputum retention (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","CELECOXIB [CELECOXIB] (C - Pain in extremity, Polyneuropathy alcoholic - n/a - [n/a - n/a - Oral use]),<BR><BR>CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - Cerebral infarction - n/a - [n/a - n/a - Oral use]),<BR><BR>FEBUXOSTAT [FEBUXOSTAT] (C - Blood uric acid increased - n/a - [n/a - n/a - Oral use]),<BR><BR>LEVETIRACETAM [LEVETIRACETAM] (C - Cerebral infarction, Epilepsy - n/a - [n/a - n/a - Oral use]),<BR><BR>PREGABALIN [PREGABALIN] (C - Pain in extremity, Polyneuropathy alcoholic - n/a - [n/a - n/a - Oral use]),<BR><BR>SAMSCA [TOLVAPTAN] (C - Cardiac failure chronic, Pulmonary hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>SPIRONOLACTONE [SPIRONOLACTONE] (C - Pulmonary hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[AMBROXOL HYDROCHLORIDE] (C - Productive cough, Respiratory disorder - n/a - [n/a - n/a - Oral use]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Cardiac failure, Tachycardia - n/a - [n/a - n/a - n/a]),<BR><BR>[CILOSTAZOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FEXOFENADINE, FEXOFENADINE HYDROCHLORIDE] (C - Pruritus - n/a - [n/a - n/a - Oral use]),<BR><BR>[FUROSEMIDE] (C - Pulmonary hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[NITRAZEPAM, NITRAZEPAM BP] (C - Insomnia - n/a - [n/a - n/a - Oral use]),<BR><BR>[VONOPRAZAN, VONOPRAZAN FUMARATE, VONOPRAZAN HYDROGEN FUMARATE] (C - Gastrooesophageal reflux disease, Haematemesis - n/a - [n/a - n/a - Oral use]),<BR><BR>[ZOPICLONE] (C - Insomnia - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014864999&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014865003,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Condition aggravated (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myelopathy (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014865003&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014865022,Spontaneous,2023-03-23 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Apnoea (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Cardiac death (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Cardiac dysfunction (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Cardiac failure (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Foaming at mouth (n/a - Fatal - Results in Death),<BR><BR>Hypersomnia (n/a - Unknown - ),<BR><BR>Interchange of vaccine products (n/a - Fatal - Results in Death),<BR><BR>Jugular vein distension (n/a - Fatal - Results in Death),<BR><BR>Oral discharge (n/a - Fatal - Results in Death),<BR><BR>Pallor (n/a - Fatal - Results in Death),<BR><BR>Pulse absent (n/a - Fatal - Results in Death),<BR><BR>Pupillary reflex impaired (n/a - Fatal - Results in Death),<BR><BR>Respiratory arrest (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Rhinorrhoea (n/a - Fatal - Results in Death),<BR><BR>Sputum abnormal (n/a - Fatal - Results in Death),<BR><BR>Sudden death (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Wheezing (n/a - Fatal - Results in Death)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])","RISPERIDONE [RISPERIDONE] (C - Schizophrenia - n/a - [n/a - n/a - Oral use]),<BR><BR>[ARTEMETHER] (C - Parkinsonism - n/a - [n/a - n/a - Oral use]),<BR><BR>[CELLULASE AP3] (C - Gastrointestinal disorder - n/a - [n/a - n/a - Oral use]),<BR><BR>[DIAZEPAM] (C - Anxiety, Sedation - n/a - [n/a - n/a - Oral use]),<BR><BR>[FLUNITRAZEPAM] (C - Insomnia - n/a - [n/a - n/a - Oral use]),<BR><BR>[LEVOMEPROMAZINE MALEATE] (C - Schizophrenia - n/a - [n/a - n/a - Oral use]),<BR><BR>[MAGNESIUM OXIDE] (C - Constipation - n/a - [n/a - n/a - Oral use]),<BR><BR>[PANTETHINE] (C - Constipation - n/a - [n/a - n/a - Oral use]),<BR><BR>[PROMETHAZINE HYDROCHLORIDE] (C - Parkinsonism - n/a - [n/a - n/a - Oral use]),<BR><BR>[SENNOSIDE A+B] (C - Constipation - n/a - [n/a - n/a - Oral use]),<BR><BR>[SULPIRIDE] (C - Schizophrenia - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014865022&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014865865,Spontaneous,2023-03-23 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Artery dissection (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014865865&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014865933,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Axillary pain (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Blister (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Herpes zoster (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Neuralgia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Rash (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",GILENYA [FINGOLIMOD] (C - Multiple sclerosis - n/a - [530d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014865933&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866591,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,Dizziness postural (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866591&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866592,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Eyelid oedema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Graves' disease (n/a - Unknown - Other Medically Important Condition),<BR><BR>Influenza (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[LOSARTAN, LOSARTAN POTASSIUM] (C - n/a - n/a - [n/a - 50mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866592&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866593,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Drug ineffective (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866593&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866594,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Back pain (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Eye pain (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Sensitive skin (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","LUCENTIS [RANIBIZUMAB] (C - Neovascular age-related macular degeneration - n/a - [n/a - n/a - n/a]),<BR><BR>[NITROFURANTOIN] (C - n/a - n/a - [2d - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866594&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866596,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Angina pectoris (1d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866596&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866599,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[DOXAZOSIN, DOXAZOSIN MESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FAMOTIDINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FLUTICASONE PROPIONATE, SALMETEROL, FLUTICASONE PROPIONATE, SALMETEROL XINAFOATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MOMETASONE FUROATE, MOMETASONE FUROATE MONOHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866599&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866600,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Eye pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Feeling of body temperature change (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Illness (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nasopharyngitis (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Retching (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tremor (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866600&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866605,Spontaneous,2023-03-23 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Sinus tachycardia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866605&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866607,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Dizziness (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866607&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866610,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dizziness (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Somnolence (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[PARACETAMOL] (C - n/a - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866610&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866611,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lethargy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Thirst (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[INSULIN, INSULIN HUMAN] (C - Type 1 diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[METHOTREXATE SODIUM] (C - n/a - n/a - [n/a - n/a - Intramuscular use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866611&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866613,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Depressed mood (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Gait inability (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[DILTIAZEM HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[VITAMIN D] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866613&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866614,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dysphagia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lethargy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866614&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866615,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Cough (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hallucination (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Muscle spasms (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Rhinorrhoea (3d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866615&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866620,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Anxiety (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866620&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866621,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MIRTAZAPINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866621&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866622,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Immunisation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Incorrect dose administered (n/a - Unknown - Other Medically Important Condition),<BR><BR>Migraine (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Off label use (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866622&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866623,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rhinorrhoea (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","ESOMEPRAZOLE [ESOMEPRAZOLE] (C - Reflux gastritis - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866623&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866624,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Breast mass (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Breast pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Burning sensation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Ear discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Swelling (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Swelling face (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[BETAHISTINE, BETAHISTINE DIHYDROCHLORIDE, BETAHISTINE MESILATE] (C - Meniere's disease - n/a - [n/a - n/a - n/a]),<BR><BR>[GABAPENTIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[PROPRANOLOL, PROPRANOLOL HYDROCHLORIDE] (C - Migraine - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866624&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866625,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dizziness postural (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Feeling of body temperature change (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lethargy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Limb discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tenderness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866625&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866626,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Chest pain (n/a - Unknown - Disabling),<BR><BR>Dizziness (n/a - Recovering/Resolving - Disabling),<BR><BR>Dyspnoea (n/a - Unknown - Disabling),<BR><BR>Fatigue (n/a - Unknown - Disabling),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Palpitations (n/a - Unknown - Disabling),<BR><BR>Tachycardia (n/a - Unknown - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866626&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866630,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Back pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866630&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866631,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Dizziness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866631&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866632,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866632&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866633,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Brain fog (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Hypersomnia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Post-acute COVID-19 syndrome (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Vertigo (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866633&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866635,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Ear pain (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Injection related reaction (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Rash (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866635&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866636,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Body temperature increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Glossodynia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Lower respiratory tract infection (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",METHOTREXATE [METHOTREXATE] (C - Rheumatoid arthritis - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866636&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866637,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Disease recurrence (n/a - Unknown - Other Medically Important Condition),<BR><BR>Ear discomfort (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Ear infection (n/a - Unknown - Other Medically Important Condition),<BR><BR>Ear pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Ear swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tympanic membrane perforation (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[BECLOMETASONE DIPROPIONATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[BECLOMETASONE] (C - Prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - Asthma - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866637&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866642,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Bundle branch block left (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pacemaker generated arrhythmia (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866642&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866644,Spontaneous,2023-03-23 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthritis reactive (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Loss of personal independence in daily activities (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Myalgia (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[BECLOMETASONE DIPROPIONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CLOBETASONE BUTYRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[GABAPENTIN] (C - n/a - n/a - [n/a - 300mg - n/a - More in ICSR]),<BR><BR>[MEBEVERINE] (C - Abdominal pain - n/a - [n/a - n/a - n/a]),<BR><BR>[METHOCARBAMOL] (C - n/a - n/a - [28d - n/a - n/a]),<BR><BR>[MONTELUKAST, MONTELUKAST SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866644&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866645,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Chills (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Lymph node pain (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Myalgia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Tremor (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (3d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866645&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866650,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Central vision loss (n/a - Unknown - Other Medically Important Condition),<BR><BR>Disorientation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (1d - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Migraine (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Photophobia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Sudden visual loss (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866650&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866651,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Atrial fibrillation (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",BENEPALI [ETANERCEPT] (C - Psoriatic arthropathy - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866651&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866653,Spontaneous,2023-03-23 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Dyspnoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Syncope (n/a - Unknown - Other Medically Important Condition),<BR><BR>Wheezing (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866653&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866654,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest discomfort (n/a - Unknown - Disabling),<BR><BR>Cough (n/a - Unknown - Disabling),<BR><BR>Headache (n/a - Unknown - Disabling),<BR><BR>Hypersomnia (n/a - Unknown - Disabling),<BR><BR>Muscle swelling (n/a - Unknown - Disabling),<BR><BR>Pain in extremity (n/a - Unknown - Disabling),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Somnolence (n/a - Unknown - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866654&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866655,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Drooling (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Dyskinesia (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Hypopnoea (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Loss of consciousness (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Seizure (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","IRON [IRON] (C - Anaemia - n/a - [n/a - n/a - n/a]),<BR><BR>PREGABALIN [PREGABALIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[AMOXICILLIN, CLAVULANIC ACID] (C - Chest wall abscess - n/a - [n/a - n/a - n/a]),<BR><BR>[FOLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[TRAMADOL, TRAMADOL HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866655&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866659,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rash (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rash erythematous (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","IBUPROFEN [IBUPROFEN, IBUPROFEN SODIUM] (C - Cancer surgery - n/a - [n/a - n/a - n/a]),<BR><BR>[ENOXAPARIN SODIUM] (C - Cancer surgery - n/a - [28d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Cancer surgery - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866659&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866661,Spontaneous,2023-03-23 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Anaphylactic reaction (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866661&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866663,Spontaneous,2023-03-23 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Circulatory collapse (n/a - Unknown - Other Medically Important Condition),<BR><BR>Loss of consciousness (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866663&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866665,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Bladder pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Feeling cold (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Influenza (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pollakiuria (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866665&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866667,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[ESTRADIOL] (C - Menopause - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866667&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866668,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspepsia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Feeling of body temperature change (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Gastrooesophageal reflux disease (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Wheezing (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866668&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866669,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Inappropriate schedule of product administration (n/a - Unknown - ),<BR><BR>Menstrual disorder (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Postmenopausal haemorrhage (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866669&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866670,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Body temperature increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Night sweats (n/a - Unknown - Other Medically Important Condition),<BR><BR>Renal pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Sleep disorder due to a general medical condition (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vertigo (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866670&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866672,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Depressed mood (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hallucination (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nightmare (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Thinking abnormal (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>METHOTREXATE [METHOTREXATE] (C - Rheumatoid arthritis - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FOLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[HYDROXYCHLOROQUINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SULFASALAZINE] (C - Rheumatoid arthritis - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866672&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866675,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Abdominal pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dyspepsia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866675&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866677,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Blood pressure increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Heart rate increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Weight decreased (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866677&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866682,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Lethargy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Loss of personal independence in daily activities (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866682&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866683,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866683&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866686,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866686&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866687,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Fatigue (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (7d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Impaired work ability (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866687&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866689,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (48h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (48h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (48h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphoedema (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nasopharyngitis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (48h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (48h - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866689&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866692,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Amnesia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Basal cell carcinoma (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866692&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866697,Spontaneous,2023-03-23 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Acute kidney injury (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Off label use (n/a - Unknown - Other Medically Important Condition),<BR><BR>Presyncope (15min - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Product use issue (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",[INFLUENZA VIRUS] (C - n/a - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866697&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866699,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Dizziness (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (2h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (1d - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866699&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866700,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Eye pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a]),<BR><BR>[LISINOPRIL, LISINOPRIL DIHYDRATE] (C - Blood pressure abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - Blood cholesterol abnormal - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866700&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866701,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Chills (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Night sweats (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866701&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866703,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Back pain (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Chest discomfort (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Pleurisy (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Pulmonary embolism (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866703&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866705,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Dysphagia (n/a - Unknown - Disabling),<BR><BR>Ear pain (n/a - Unknown - Disabling),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866705&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866716,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Tremor (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[ALLOPURINOL] (C - Gout - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866716&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866721,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Heart rate increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Migraine (n/a - Unknown - Other Medically Important Condition),<BR><BR>Musculoskeletal stiffness (3d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866721&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866722,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Muscle injury (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Musculoskeletal stiffness (n/a - Unknown - ),<BR><BR>Tendon pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Recovered/Resolved - ),<BR><BR>Vaccination site swelling (n/a - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",IRBESARTAN [IRBESARTAN] (C - Hypertension - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866722&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866724,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Heavy menstrual bleeding (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hot flush (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypomenorrhoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Infertility (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Intermenstrual bleeding (n/a - Unknown - Other Medically Important Condition),<BR><BR>Menstruation irregular (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",[FROVATRIPTAN] (C - Migraine - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866724&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866725,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vomiting (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866725&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866728,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Eye pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hemiparesis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypoaesthesia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Muscular weakness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866728&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866729,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Poor peripheral circulation (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","TESTOSTERONE [TESTOSTERONE] (C - Hormone replacement therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTROGENS CONJUGATED] (C - Hormone replacement therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[PROGESTERONE] (C - Hormone replacement therapy - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866729&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866730,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Illness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866730&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866731,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Asthma (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","EDOXABAN [EDOXABAN] (C - Atrial fibrillation - n/a - [n/a - n/a - n/a]),<BR><BR>ESOMEPRAZOLE [ESOMEPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - n/a]),<BR><BR>PRUCALOPRIDE [PRUCALOPRIDE] (C - Scleroderma - n/a - [n/a - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID] (C - Atrial fibrillation - n/a - [n/a - n/a - n/a]),<BR><BR>[ALUMINIUM HYDROXIDE GEL, DRIED, MAGNESIUM CARBONATE, SODIUM CARBONATE, ALGINIC ACID, ALUMINIUM HYDROXIDE, SODIUM CARBONATE, CALCIUM CARBONATE, SODIUM ALGINATE, ALUMINIUM HYDROXIDE, SODIUM HYDROGEN CARBONATE, ALGINIC ACID, ALUMINIUM HYDROXIDE, SODIUM HYDROGEN CARBONATE, ALGINIC ACID, ALUMINIUM HYDROXIDE GEL, DRIED, SODIUM HYDROGEN CARBONATE, ALGINIC ACID, ALUMINIUM HYDROXIDE GEL, DRIED USP, SODIUM HYDROGEN CARBONATE, ALGINIC ACID, SODIUM ALGINATE, ALUMINIUM HYDROXIDE, SODIUM HYDROGEN CARBONATE, ALUMINIUM HYDROXIDE GEL, CALCIUM CARBONATE, SODIUM ALGINATE, SODIUM HYDROGEN CARBONATE, CALCIUM CARBONATE, SODIUM ALGINATE, SODIUM HYDROGEN CARBONATE, CALCIUM CARBONATE, SODIUM ALGINATE, ALUMINIUM HYDROXIDE, SODIUM HYDROGEN CARBONATE, SODIUM ALGINATE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - n/a]),<BR><BR>[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE, BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Atrial fibrillation - n/a - [n/a - n/a - n/a]),<BR><BR>[CALCIUM CARBONATE, CHOLECALCIFEROL CONCENTRATE (POWDER FORM), COLECALCIFEROL, CALCIUM CARBONATE] (C - Osteoporosis - n/a - [n/a - n/a - n/a]),<BR><BR>[DOXAZOSIN, DOXAZOSIN MESILATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[FUROSEMIDE] (C - Cardiac failure - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Autoimmune thyroiditis - n/a - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[MYCOPHENOLATE MOFETIL] (C - Scleroedema - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Lumbar spinal stenosis - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - Asthma - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866731&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866732,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Gingival pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain in jaw (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Toothache (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866732&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866733,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Mental impairment (n/a - Unknown - Other Medically Important Condition),<BR><BR>Musculoskeletal stiffness (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866733&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866736,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Hypokinesia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[PARACETAMOL] (C - Myalgia - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866736&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866740,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Eczema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Eye pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866740&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866746,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Herpes zoster (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - Transient ischaemic attack - n/a - [n/a - n/a - n/a]),<BR><BR>[LERCANIDIPINE, LERCANIDIPINE HYDROCHLORIDE] (C - Blood pressure measurement - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866746&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866747,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Diarrhoea (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Syncope (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866747&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866748,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest pain (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Migraine (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vision blurred (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866748&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866751,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dysmenorrhoea (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hot flush (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaginal haemorrhage (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866751&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866753,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Anxiety (n/a - Unknown - Other Medically Important Condition),<BR><BR>Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Bone pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Breast pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chest discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymph node pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Migraine (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Muscle disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Musculoskeletal discomfort (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Oropharyngeal discomfort (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866753&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866756,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Cough (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dysphonia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Lymphadenopathy (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Sneezing (6d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[LERCANIDIPINE HYDROCHLORIDE] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866756&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866760,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Lymph node pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[BECLOMETASONE DIPROPIONATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[CETIRIZINE, CETIRIZINE DIHYDROCHLORIDE] (C - Multiple allergies - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRADIOL, NORETHISTERONE, NORETHISTERONE ACETATE, ESTRADIOL, NORETHISTERONE ACETATE, ESTRADIOL HEMIHYDRATE] (C - Menopause - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - Type 2 diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[MOMETASONE FUROATE, MOMETASONE FUROATE MONOHYDRATE] (C - Sinus pain - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866760&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866762,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal pain upper (n/a - Unknown - Other Medically Important Condition),<BR><BR>Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Unknown - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Illness (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866762&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866767,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866767&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866769,Spontaneous,2023-03-23 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Postural orthostatic tachycardia syndrome (n/a - Not Recovered/Not Resolved - Disabling),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866769&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866770,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Ageusia (n/a - Unknown - ),<BR><BR>Anosmia (n/a - Unknown - ),<BR><BR>Cough (n/a - Unknown - ),<BR><BR>Nasopharyngitis (n/a - Unknown - ),<BR><BR>Sinus congestion (n/a - Unknown - ),<BR><BR>Suspected COVID-19 (n/a - Not Recovered/Not Resolved - ),<BR><BR>Syncope (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866770&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866775,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Hypokinesia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Musculoskeletal stiffness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866775&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866777,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Back pain (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Neck pain (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866777&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014866783,Spontaneous,2023-03-23 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Brain fog (n/a - Unknown - Disabling),<BR><BR>Cognitive disorder (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Condition aggravated (n/a - Unknown - Disabling),<BR><BR>Confusional state (n/a - Unknown - Disabling),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Gastroenteritis (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Palpitations (n/a - Recovering/Resolving - Disabling),<BR><BR>Post-acute COVID-19 syndrome (n/a - Unknown - Disabling),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014866783&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014868154,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014868154&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014868156,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Gastritis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lethargy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014868156&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014868157,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Gait disturbance (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Myalgia (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ATENOLOL, ATENOLOL BP] (C - Blood pressure abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[BENDROFLUAZIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014868157&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014868163,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dyspnoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014868163&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014868175,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dysgeusia (2d - Recovered/Resolved - Disabling),<BR><BR>Eye pain (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Hypoaesthesia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Loss of personal independence in daily activities (n/a - Unknown - Disabling),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Pyrexia (n/a - Unknown - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014868175&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014868176,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Body temperature abnormal (4h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chills (4h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Influenza (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014868176&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014868196,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,12-17 Years,Not Specified,No,Male,"Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vomiting projectile (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014868196&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014868199,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[NAPROXEN, NAPROXEN SODIUM] (C - Tendonitis - n/a - [25d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014868199&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014868200,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dyspnoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Panic attack (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Skin burning sensation (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Swelling (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Throat tightness (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014868200&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014868202,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,12-17 Years,Not Specified,No,Not Specified,"Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014868202&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014868205,Spontaneous,2023-03-23 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Hemiparesis (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Lacunar infarction (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Middle cerebral artery stroke (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014868205&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014868227,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthma (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Cough (n/a - Unknown - Disabling),<BR><BR>Headache (n/a - Unknown - Disabling),<BR><BR>Malaise (n/a - Unknown - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014868227&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014868242,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Rash (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rash erythematous (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014868242&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014868245,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Tendon disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[CANDESARTAN, CANDESARTAN CILEXETIL] (C - Blood pressure abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL, CODEINE PHOSPHATE] (C - Back pain - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Myalgia - n/a - [n/a - n/a - n/a]),<BR><BR>[SUMATRIPTAN, SUMATRIPTAN SUCCINATE] (C - Migraine - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014868245&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014868246,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Vertigo (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014868246&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014868251,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenia (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Hypersomnia (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Migraine (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Pyrexia (3d - Recovered/Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014868251&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014868254,Spontaneous,2023-03-23 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","HUMALOG [INSULIN LISPRO] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATENOLOL, ATENOLOL BP] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BENDROFLUMETHIAZIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[INSULIN HUMAN, INSULIN HUMAN, INSULIN INJECTION SOLUBLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[NICORANDIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014868254&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014868258,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Chills (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Feeling cold (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Syncope (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tremor (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014868258&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014868259,Spontaneous,2023-03-23 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Anaphylactic reaction (1d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014868259&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014868265,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Asthenia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dizziness postural (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site erythema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Wheezing (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","AVAMYS [FLUTICASONE FUROATE] (C - Multiple allergies - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[BUDESONIDE, FORMOTEROL FUMARATE DIHYDRATE, FORMOTEROL FUMARATE, BUDESONIDE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[FEXOFENADINE, FEXOFENADINE HYDROCHLORIDE] (C - Hypersensitivity - n/a - [n/a - n/a - n/a]),<BR><BR>[FOLIC ACID] (C - Anaemia - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - n/a]),<BR><BR>[PREDNISOLONE] (C - Severe asthma with fungal sensitisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014868265&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014868271,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Diarrhoea (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","BUMETANIDE [BUMETANIDE] (C - Dyspnoea - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014868271&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014868273,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Restlessness (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014868273&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014868276,Spontaneous,2023-03-23 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Lymph node pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Lymphoedema (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014868276&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014868283,Spontaneous,2023-03-23 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Atrioventricular block first degree (n/a - Recovering/Resolving - ),<BR><BR>Blood pressure increased (n/a - Unknown - ),<BR><BR>Coagulation time prolonged (n/a - Unknown - ),<BR><BR>Electrocardiogram PR prolongation (n/a - Recovering/Resolving - ),<BR><BR>Platelet aggregation decreased (n/a - Unknown - ),<BR><BR>Platelet function test abnormal (n/a - Unknown - ),<BR><BR>Retinal artery occlusion (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use])",[COLECALCIFEROL] (C - Vitamin D deficiency - n/a - [n/a - 1000[iU] - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014868283&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014868291,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chest discomfort (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Illness (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014868291&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014868294,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Lymphadenopathy (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[DESOGESTREL] (C - Menopause - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014868294&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014868295,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Conjunctivitis viral (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Disease recurrence (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Inflammation (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Loss of personal independence in daily activities (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Pityriasis rosea (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014868295&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014868297,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Bell's palsy (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Ear pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Loss of personal independence in daily activities (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain in jaw (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014868297&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014868301,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Peripheral swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site erythema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pruritus (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site warmth (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014868301&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014868307,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Cold sweat (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Periorbital swelling (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[CODEINE PHOSPHATE HEMIHYDRATE PHEUR, CAFFEINE PH. EUR., PARACETAMOL PH. EUR., PARACETAMOL, CAFFEINE, CODEINE PHOSPHATE HEMIHYDRATE, PARACETAMOL, CODEINE PHOSPHATE HEMIHYDRATE] (C - Neck pain - n/a - [7d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [3d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014868307&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014868318,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014868318&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014868321,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Muscular weakness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[DESOGESTREL] (C - Oral contraception - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014868321&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014868323,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"Asthenia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Back pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Somnolence (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014868323&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014868336,Spontaneous,2023-03-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Night sweats (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014868336&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014869004,Spontaneous,2023-03-23 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Fatigue (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","NOVORAPID FLEXPEN [INSULIN ASPART] (C - Diabetes mellitus - n/a - [n/a - n/a - Subcutaneous use]),<BR><BR>TRESIBA SOLUTION FOR INJECTION IN PRE-FILLED PEN [INSULIN DEGLUDEC] (C - n/a - n/a - [n/a - n/a - Subcutaneous use]),<BR><BR>[ACETYLSALICYLIC ACID] (C - Thrombosis prophylaxis - n/a - [n/a - n/a - Oral use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BISACODYL] (C - Constipation - n/a - [n/a - n/a - Oral use]),<BR><BR>[CANDESARTAN CILEXETIL] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[CIPROFLOXACIN, FLUOCINOLONE, CIPROFLOXACIN, FLUOCINOLONE ACETONIDE] (C - Ear infection - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - Hormone therapy - n/a - [n/a - n/a - Vaginal use]),<BR><BR>[ESTRIOL] (C - Hormone therapy - n/a - [n/a - n/a - Vaginal use]),<BR><BR>[FUROSEMIDE, FUROSEMIDE SODIUM] (C - Diuretic therapy - n/a - [n/a - n/a - Oral use]),<BR><BR>[HYDROCORTISONE BUTYRATE] (C - Eczema - n/a - [n/a - n/a - Cutaneous use]),<BR><BR>[LERCANIDIPINE HYDROCHLORIDE] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[MAGNESIUM HYDROXIDE, MAGNESIUM OXIDE, MAGNESIUM OXIDE, LIGHT] (C - Constipation - n/a - [n/a - n/a - Oral use]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - Oral use]),<BR><BR>[VITAMIN D, CALCIUM] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014869004&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014854053,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[PARACETAMOL, CODEINE PHOSPHATE] (C - Back pain - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014854053&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014854056,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Influenza like illness (8d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (8d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (9d - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Primary stabbing headache (7d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014854056&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014854057,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Axillary pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Swelling (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014854057&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014854060,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Vomiting (1d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014854060&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014854061,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014854061&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014854073,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014854073&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014854085,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Body temperature increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vomiting (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[TAMOXIFEN, TAMOXIFEN CITRATE] (C - Breast cancer female - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014854085&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014854098,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nocturia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014854098&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014854764,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Axillary mass (n/a - Unknown - ),<BR><BR>Chest pain (n/a - Unknown - ),<BR><BR>Feeling abnormal (n/a - Unknown - ),<BR><BR>Inflammation (n/a - Unknown - ),<BR><BR>Lymphadenopathy (n/a - Unknown - ),<BR><BR>Myocarditis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014854764&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014854903,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dyspnoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Immunisation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Incorrect dose administered (n/a - Unknown - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lethargy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Off label use (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","AMGEVITA [ADALIMUMAB] (C - Psoriatic arthropathy - n/a - [n/a - n/a - n/a]),<BR><BR>METHOTREXATE [METHOTREXATE] (C - Psoriatic arthropathy - n/a - [n/a - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - Dyspepsia - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014854903&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014854916,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Axillary pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Contusion (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lymph node pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Musculoskeletal stiffness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tenderness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - 100mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014854916&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014854935,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Back pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dyspepsia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014854935&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014854940,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Dyspnoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Middle insomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014854940&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014854943,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Axillary pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Oedema peripheral (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014854943&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014855049,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Tenderness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tissue injury (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014855049&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014855953,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[BECLOMETASONE DIPROPIONATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - Hormone replacement therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[PROGESTERONE, PROGESTERONE, MICRONISED] (C - Hormone replacement therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL SULFATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[SALMETEROL] (C - Asthma - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014855953&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014855956,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Balance disorder (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Feeling cold (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hypoaesthesia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Joint range of motion decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Muscular weakness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Night sweats (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain in jaw (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Peripheral coldness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Viral pharyngitis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[IPRATROPIUM, IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE ANHYDROUS, IPRATROPIUM BROMIDE MONOHYDRATE] (C - Asthma - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014855956&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014855959,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Lymph node pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Muscular weakness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[BECLOMETASONE DIPROPIONATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - Asthma - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014855959&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014855961,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Axillary pain (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vertigo (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014855961&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014855968,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Cold sweat (3h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tremor (3h - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014855968&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014855970,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Aphonia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dysphonia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014855970&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014855972,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Abdominal pain upper (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Abdominal tenderness (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Headache (5d - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Influenza like illness (5d - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Nausea (5d - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Neck pain (5d - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Pyrexia (2d - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Suspected COVID-19 (5d - Recovered/Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - Migraine - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014855972&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014855976,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Axillary pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymph node pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014855976&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014855982,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chest pain (n/a - Unknown - ),<BR><BR>Dyspnoea (n/a - Unknown - ),<BR><BR>Fatigue (n/a - Unknown - ),<BR><BR>Palpitations (n/a - Unknown - ),<BR><BR>Pericarditis (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 30ug - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014855982&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014855987,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Mouth haemorrhage (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Oral discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Oral pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Thrombosis (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014855987&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014855991,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Cough (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lacrimation increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lower respiratory tract infection (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rhinorrhoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Throat irritation (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014855991&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014855992,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chest pain (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Dyspnoea (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Myocarditis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014855992&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856003,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Migraine (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856003&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856005,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Axillary pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856005&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856008,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856008&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856012,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Palpitations (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856012&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856016,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dysgeusia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dysphagia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Glossodynia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tongue discomfort (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Tongue ulceration (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856016&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856020,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Peripheral swelling (4d - Recovered/Resolved - Disabling),<BR><BR>Rash (n/a - Not Recovered/Not Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856020&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856024,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856024&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856027,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Mobility decreased (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[ATORVASTATIN] (C - Blood cholesterol increased - n/a - [n/a - n/a - n/a]),<BR><BR>[PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE BP] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[SULFASALAZINE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856027&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856028,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Hemihypoaesthesia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856028&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856029,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Rash erythematous (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856029&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856031,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Deafness neurosensory (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Disease recurrence (n/a - Not Recovered/Not Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856031&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856036,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Peripheral swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Skin swelling (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856036&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856046,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Dizziness (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Immunisation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Incorrect dose administered (n/a - Unknown - ),<BR><BR>Joint range of motion decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Off label use (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vertigo (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - n/a - n/a])","DUORESP SPIROMAX [BUDESONIDE, FORMOTEROL FUMARATE DIHYDRATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[CANDESARTAN, CANDESARTAN CILEXETIL] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[CODEINE PHOSPHATE] (C - Pain - n/a - [n/a - n/a - n/a]),<BR><BR>[DIAZEPAM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FOLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INDAPAMIDE, INDAPAMIDE HEMIHYDRATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[MORPHINE SULFATE, MORPHINE SULPHATE BP] (C - Pain - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - n/a]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856046&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856047,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ETHINYLESTRADIOL, LEVONORGESTREL] (C - Oral contraception - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL SULFATE] (C - Post-acute COVID-19 syndrome - n/a - [n/a - n/a - n/a]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - Autism spectrum disorder - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856047&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856052,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Condition aggravated (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Migraine (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash erythematous (7d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856052&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856070,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>General physical health deterioration (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Heart rate increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypertension (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (8d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856070&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856073,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856073&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856078,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Epistaxis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Limb discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[COLCHICINE] (C - Gout - n/a - [5d - n/a - n/a]),<BR><BR>[NAPROXEN, NAPROXEN SODIUM] (C - Gout - n/a - [3d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856078&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856080,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Pyrexia (2d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856080&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856082,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest pain (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Diplopia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856082&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856087,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dysmenorrhoea (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Inflammation (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Swelling (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856087&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856090,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Feeling cold (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856090&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856093,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Abdominal pain (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Hepatic enzyme increased (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856093&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856096,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Syncope (1d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856096&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856097,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Swelling (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856097&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856099,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Chest pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Ear pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Influenza (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[ZOPICLONE] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856099&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856101,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Chills (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856101&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856102,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Heart valve operation - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - Heart valve operation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856102&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856106,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest discomfort (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Disorientation (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856106&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856108,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Insomnia (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Vaccination site erythema (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856108&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856109,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Drug ineffective (8d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (8d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856109&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856116,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Vaccination site pain (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Decreased activity - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856116&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856126,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Blood glucose increased (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hyperglycaemia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856126&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856128,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Facial paralysis (1d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856128&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856131,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Cold sweat (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Influenza (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856131&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856133,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Hypertension (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - Depression - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856133&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856135,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Contusion (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Epistaxis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fall (n/a - Unknown - Other Medically Important Condition),<BR><BR>Syncope (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ATORVASTATIN] (C - Blood cholesterol abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[BENDROFLUMETHIAZIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856135&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856139,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Deep vein thrombosis (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Gait inability (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856139&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856142,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chest pain (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Gastritis (12d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Headache (2d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856142&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856145,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Chills (2d - Recovered/Resolved - Disabling),<BR><BR>Chronic fatigue syndrome (n/a - Unknown - Disabling),<BR><BR>Condition aggravated (n/a - Unknown - Disabling),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Feeling abnormal (n/a - Unknown - Disabling),<BR><BR>Night sweats (1d - Recovered/Resolved - Disabling),<BR><BR>Somnolence (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Thirst (2d - Recovered/Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856145&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856146,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Erythema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Formication (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856146&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856149,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tremor (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[NAPROXEN, NAPROXEN SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856149&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856186,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Mouth ulceration (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856186&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856187,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856187&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856189,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arrhythmia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Off label use (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - ),<BR><BR>Ventricular extrasystoles (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Immunisation - n/a - [1d - n/a - Subcutaneous use]),<BR><BR>[VALPROIC ACID] (C - Migraine - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856189&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856191,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Acute disseminated encephalomyelitis (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Aphonia (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Asthenia (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Autoimmune demyelinating disease (n/a - Recovered/Resolved With Sequelae - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Balance disorder (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Blindness (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Diplopia (36d - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Dysarthria (29d - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Dysphagia (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Eye pain (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Fall (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Fatigue (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Gait disturbance (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Hypoaesthesia (33d - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Hypokinesia (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Paraesthesia (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Renal pain (34d - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Respiration abnormal (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Urinary retention (34d - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856191&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856193,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Bell's palsy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Disease recurrence (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856193&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856197,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Bradycardia (0d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dizziness (0d - Recovered/Resolved - ),<BR><BR>Dysphoria (0d - Recovered/Resolved - ),<BR><BR>Presyncope (n/a - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856197&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856198,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Axillary mass (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Sleep disorder (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","BRIVIACT [BRIVARACETAM] (C - Epilepsy - n/a - [n/a - n/a - n/a]),<BR><BR>[BUDESONIDE, FORMOTEROL FUMARATE DIHYDRATE, FORMOTEROL FUMARATE, BUDESONIDE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[CLOBAZAM] (C - Epilepsy - n/a - [n/a - n/a - n/a]),<BR><BR>[SODIUM VALPROATE] (C - Epilepsy - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856198&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856200,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Anxiety (n/a - Unknown - ),<BR><BR>Back pain (n/a - Unknown - ),<BR><BR>Fatigue (n/a - Unknown - ),<BR><BR>Guillain-Barre syndrome (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypoaesthesia (n/a - Unknown - ),<BR><BR>Movement disorder (n/a - Recovered/Resolved - ),<BR><BR>Myalgia (n/a - Unknown - ),<BR><BR>Pain in extremity (n/a - Recovered/Resolved - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856200&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856201,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Axillary pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lethargy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymph node pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856201&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856202,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Abdominal pain upper (n/a - Recovering/Resolving - Disabling),<BR><BR>Arthralgia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Bone pain (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Chills (n/a - Recovering/Resolving - Disabling),<BR><BR>Depression (n/a - Unknown - Disabling),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - Disabling),<BR><BR>Dry eye (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Eye pain (n/a - Unknown - Disabling),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Gastrooesophageal reflux disease (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Hepatic pain (n/a - Unknown - Disabling),<BR><BR>Lymph node pain (n/a - Unknown - Disabling),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Nausea (n/a - Recovering/Resolving - Disabling),<BR><BR>Tendonitis (n/a - Not Recovered/Not Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856202&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856203,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Fatigue (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Lethargy (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Listless (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pulmonary embolism (n/a - Recovered/Resolved With Sequelae - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856203&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856204,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Axillary pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856204&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014856975,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Myoclonus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014856975&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014857356,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,12-17 Years,Not Specified,No,Female,"Autoimmune disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hyperthermia (n/a - Unknown - ),<BR><BR>Orthostatic intolerance (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Somatic symptom disorder (n/a - Unknown - ),<BR><BR>Viral infection (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014857356&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014857362,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Lymphadenopathy (n/a - Unknown - ),<BR><BR>Malaise (n/a - Unknown - ),<BR><BR>Peripheral swelling (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014857362&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014857372,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use])","[ATORVASTATIN] (C - n/a - n/a - [n/a - 40mg - n/a]),<BR><BR>[LISINOPRIL, LISINOPRIL DIHYDRATE] (C - n/a - n/a - [n/a - 5mg - n/a]),<BR><BR>[PREDNISONE] (C - n/a - n/a - [n/a - 5mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014857372&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014857385,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Anxiety (730min - Recovered/Resolved - ),<BR><BR>Chills (710min - Recovered/Resolved - ),<BR><BR>Cold sweat (728min - Recovered/Resolved - ),<BR><BR>Dysstasia (728min - Recovered/Resolved - ),<BR><BR>Fall (728min - Recovered/Resolved - ),<BR><BR>Hyperventilation (730min - Recovered/Resolved - ),<BR><BR>Loss of consciousness (728min - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (685min - Recovered/Resolved - ),<BR><BR>Pallor (728min - Recovered/Resolved - ),<BR><BR>Presyncope (730min - Recovered/Resolved - ),<BR><BR>Seizure (730min - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Syncope (730min - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tetany (730min - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014857385&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014857394,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Feeling abnormal (n/a - Unknown - ),<BR><BR>Hypoaesthesia (n/a - Unknown - ),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - ),<BR><BR>Monoplegia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014857394&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014857395,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Deep vein thrombosis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Pulmonary embolism (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pulmonary hypertension (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Ventricular tachycardia (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014857395&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014857400,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Internal haemorrhage (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - ),<BR><BR>Pruritus (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","ENERZAIR BREEZHALER [MOMETASONE FUROATE, GLYCOPYRRONIUM BROMIDE, INDACATEROL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[AMBROXOL HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BROMAZEPAM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BROTIZOLAM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[DESLORATADINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LORAZEPAM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MONTELUKAST, MONTELUKAST SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014857400&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014857868,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Neuralgia (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014857868&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858226,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Male,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Depressed level of consciousness (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858226&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858227,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Chest pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hypertension (n/a - Not Recovered/Not Resolved - ),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Dose not changed - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858227&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858231,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858231&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858339,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Sleep disorder due to general medical condition, insomnia type (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858339&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858340,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Medication error (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rotator cuff syndrome (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858340&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858341,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Diarrhoea (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Fatigue (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Vomiting (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858341&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858344,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858344&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858345,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Axillary pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Sleep disorder (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[OMEPRAZOLE] (C - Dyspepsia - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858345&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858347,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Cough (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dyspnoea exertional (n/a - Unknown - ),<BR><BR>Gastrooesophageal reflux disease (n/a - Unknown - ),<BR><BR>Pneumonitis (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858347&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858349,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (10d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (10d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858349&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858353,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",[SIMVASTATIN] (C - Blood cholesterol increased - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858353&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858354,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Cerebrovascular accident (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Disease recurrence (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Eyelid ptosis (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Facial paralysis (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Idiopathic intracranial hypertension (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","PREGABALIN [PREGABALIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[DESOGESTREL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858354&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858357,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Haematuria (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Immunisation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Incorrect dose administered (n/a - Unknown - ),<BR><BR>Off label use (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858357&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858358,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Illness (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Syncope (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858358&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858360,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Ageusia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Body temperature abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Somnolence (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pruritus (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858360&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858361,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Abdominal discomfort (n/a - Unknown - Disabling),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Headache (n/a - Unknown - Disabling),<BR><BR>Hyperhidrosis (n/a - Unknown - Disabling),<BR><BR>Medication error (n/a - Unknown - Disabling),<BR><BR>Nausea (n/a - Unknown - Disabling),<BR><BR>Pain (n/a - Unknown - Disabling),<BR><BR>Vaccination site movement impairment (n/a - Unknown - Disabling),<BR><BR>Vaccination site pain (n/a - Unknown - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858361&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858365,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>SPIKEVAX [ELASOMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858365&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858369,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Erythema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Inflammation (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Middle insomnia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[LOSARTAN, LOSARTAN POTASSIUM] (C - Hypertension - n/a - [n/a - 50mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858369&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858371,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Road traffic accident (n/a - Unknown - Other Medically Important Condition),<BR><BR>Syncope (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858371&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858372,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Balance disorder (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Blindness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858372&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858375,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Thrombosis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858375&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858377,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Facial discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Mouth swelling (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Toothache (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858377&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858379,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Impaired work ability (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Joint range of motion decreased (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Superficial vein thrombosis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Thrombophlebitis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858379&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858380,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Axillary pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Breast pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Burning sensation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ESTRADIOL] (C - Menopausal symptoms - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[PROGESTERONE] (C - Menopausal symptoms - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858380&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858382,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Arthralgia (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Asthenia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Diarrhoea (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Rash (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Urticaria (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858382&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858383,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - n/a - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858383&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858385,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal discomfort (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Abdominal pain lower (n/a - Unknown - Other Medically Important Condition),<BR><BR>Abdominal pain upper (n/a - Unknown - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspepsia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Gastrooesophageal reflux disease (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858385&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858388,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Cardiac flutter (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858388&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858389,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ESTRADIOL, NORETHISTERONE, NORETHISTERONE ACETATE, ESTRADIOL, NORETHISTERONE ACETATE, ESTRADIOL HEMIHYDRATE] (C - Hormone therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858389&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858391,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pulmonary pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858391&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858394,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Dysuria (n/a - Unknown - Other Medically Important Condition),<BR><BR>Micturition urgency (n/a - Unknown - Other Medically Important Condition),<BR><BR>Poor quality sleep (n/a - Unknown - Other Medically Important Condition),<BR><BR>Urinary tract infection (n/a - Unknown - Other Medically Important Condition),<BR><BR>Urinary tract pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858394&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858395,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chest pain (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Illness (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Syncope (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858395&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858397,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Hypertension (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - n/a])","[WARFARIN, WARFARIN SODIUM] (C - Portal vein thrombosis - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858397&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858398,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Diplopia (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Hypertension (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Vertigo (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858398&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858399,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Limb discomfort (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858399&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858402,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","APIDRA [INSULIN GLULISINE] (C - Type 1 diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[EZETIMIBE] (C - Blood cholesterol abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858402&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858404,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Disabling),<BR><BR>Joint range of motion decreased (n/a - Unknown - Disabling),<BR><BR>Pain in extremity (2mo - Recovered/Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858404&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858405,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858405&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858407,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vertigo (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",[MEDROXYPROGESTERONE ACETATE] (C - Contraception - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858407&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858408,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Cough (n/a - Unknown - Other Medically Important Condition),<BR><BR>Endocrine disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lower respiratory tract infection (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nasopharyngitis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Night sweats (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858408&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858410,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Erythema multiforme (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Impaired work ability (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash macular (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Atrial fibrillation - n/a - [n/a - n/a - n/a]),<BR><BR>[DABIGATRAN] (C - Atrial fibrillation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858410&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858411,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Axillary mass (n/a - Unknown - Other Medically Important Condition),<BR><BR>Axillary pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858411&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858413,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"African trypanosomiasis (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Obesity (n/a - Unknown - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858413&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858414,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Rash (6d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","KEPPRA [LEVETIRACETAM] (C - Partial seizures - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL, CALCIUM CARBONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - Hormone replacement therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[LAMOTRIGINE] (C - Partial seizures - n/a - [n/a - n/a - n/a]),<BR><BR>[PROGESTERONE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858414&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858415,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858415&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858416,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858416&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858417,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Asthenia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chills (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Cold sweat (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","ULTIBRO BREEZHALER [GLYCOPYRRONIUM BROMIDE, INDACATEROL MALEATE] (C - Chronic obstructive pulmonary disease - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858417&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858419,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858419&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858421,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"Body temperature increased (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chest discomfort (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chills (5h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Cold sweat (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dysarthria (5h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling of body temperature change (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (5d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Malaise (36d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Neck pain (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pallor (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ERYTHROMYCIN] (C - Skin disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[FEXOFENADINE, FEXOFENADINE HYDROCHLORIDE] (C - Hypersensitivity - n/a - [n/a - n/a - n/a]),<BR><BR>[NARATRIPTAN] (C - Migraine - n/a - [n/a - n/a - n/a]),<BR><BR>[PROPRANOLOL, PROPRANOLOL HYDROCHLORIDE] (C - Migraine - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858421&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858422,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,Trigeminal neuralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858422&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858423,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chills (24h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858423&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858424,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"Angina pectoris (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Palpitations (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858424&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858425,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Hypokinesia (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Musculoskeletal pain (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Rotator cuff syndrome (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Vaccination site swelling (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[CODEINE PHOSPHATE BP, PARACETAMOL PH. EUR., PARACETAMOL, CODEINE PHOSPHATE] (C - Arthritis - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858425&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858591,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Postmenopausal haemorrhage (5d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - Hormone replacement therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - Hormone replacement therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRADIOL, NORETHISTERONE, NORETHISTERONE ACETATE, ESTRADIOL, NORETHISTERONE ACETATE, ESTRADIOL HEMIHYDRATE] (C - Hormone replacement therapy - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858591&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858592,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Axillary pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (S - Influenza immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858592&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858595,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Pain (n/a - Not Recovered/Not Resolved - Disabling),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858595&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858596,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,Conjunctivitis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858596&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858597,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Cerebrovascular accident (15min - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Disease recurrence (15min - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Transient ischaemic attack (15min - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[WARFARIN, WARFARIN SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858597&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858598,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Cough (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Influenza (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Loss of personal independence in daily activities (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[ATORVASTATIN] (C - Blood cholesterol abnormal - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858598&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858601,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Cardiac arrest (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Circulatory collapse (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Hypoxia (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Myocardial injury (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Pulmonary embolism (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858601&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858605,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Acute myocardial infarction (n/a - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Brain hypoxia (n/a - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Cardiac arrest (n/a - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Embolism (n/a - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ACETYLSALICYLIC ACID] (C - Heart valve replacement - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[WARFARIN, WARFARIN SODIUM] (C - Heart valve operation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858605&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858609,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal pain upper (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Axillary pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858609&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858611,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Insomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Mobility decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site warmth (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","APIXABAN [APIXABAN] (C - Cardiac disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - Blood cholesterol abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Cardiac disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[CANDESARTAN, CANDESARTAN CILEXETIL] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[DIGOXIN] (C - Cardiac disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[DOXAZOSIN, DOXAZOSIN MESILATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN HYDROCHLORIDE] (C - Type 2 diabetes mellitus - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858611&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858614,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Axillary pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tenderness (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858614&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858618,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"COVID-19 (7d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (7d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[DYDROGESTERONE, ESTRADIOL, DYDROGESTERONE, ESTRADIOL HEMIHYDRATE, ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - Hormone replacement therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858618&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858619,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Cardiomegaly (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Dyspnoea (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Influenza (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858619&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858624,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Gait disturbance (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Joint range of motion decreased (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Joint swelling (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858624&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858626,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Disease recurrence (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Supraventricular tachycardia (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ATORVASTATIN] (C - Blood cholesterol - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Supraventricular tachycardia - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - Hiatus hernia - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Thyroid therapy - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858626&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858627,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858627&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858628,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chest pain (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Pericarditis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[RAMIPRIL] (C - Blood pressure abnormal - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858628&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858629,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Burning sensation (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Dyspnoea (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Myositis (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LETROZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858629&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858630,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Anaphylactic reaction (1d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858630&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858631,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Hypokinesia (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Loss of bladder sensation (2d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Muscular weakness (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858631&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858633,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Aphasia (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Arthralgia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Asthenia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Bone pain (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Cognitive disorder (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Hypokinesia (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Myalgia (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Paraesthesia oral (2d - Recovered/Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858633&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858634,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Tonsillar hypertrophy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","PREGABALIN [PREGABALIN] (C - Neuralgia - n/a - [160d - n/a - n/a]),<BR><BR>[ALENDRONATE SODIUM, ALENDRONIC ACID] (C - Osteoporosis - n/a - [2027d - n/a - n/a]),<BR><BR>[COLECALCIFEROL, CALCIUM] (C - Osteoporosis - n/a - [n/a - n/a - n/a]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - Blood cholesterol increased - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858634&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858636,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>SPIKEVAX [ELASOMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>TOZINAMERAN [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858636&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858640,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Fatigue (18h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (17h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vomiting (885min - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858640&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858641,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858641&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858644,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Herpes zoster (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - n/a])","BARICITINIB [BARICITINIB] (C - Eczema - n/a - [n/a - n/a - n/a]),<BR><BR>[CETIRIZINE, CETIRIZINE DIHYDROCHLORIDE] (C - Eczema - n/a - [n/a - n/a - n/a]),<BR><BR>[PREDNISOLONE] (C - Eczema - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858644&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858645,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Burning sensation (3d - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Lethargy (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Pain in extremity (5d - Recovered/Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858645&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858647,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[ANASTROZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858647&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858648,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Gait disturbance (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypoaesthesia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858648&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858649,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenia (3mo - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (3mo - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Gait disturbance (3mo - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Muscle swelling (3mo - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Myalgia (10wk - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Peripheral swelling (39d - Recovered/Resolved With Sequelae - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858649&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858661,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Blindness transient (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (5d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Photopsia (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858661&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858662,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaginal haemorrhage (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858662&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858663,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PROGESTERONE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858663&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858664,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Cough (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Feeling of body temperature change (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pharyngeal swelling (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858664&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858665,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chest pain (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[LETROZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858665&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858666,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Rash erythematous (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858666&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858668,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthma (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Disease recurrence (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858668&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858669,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Eye pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Toothache (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858669&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858672,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Heart rate increased (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Presyncope (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858672&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858675,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[BECLOMETASONE DIPROPIONATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[FEXOFENADINE, FEXOFENADINE HYDROCHLORIDE] (C - Hypersensitivity - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL SULFATE] (C - Asthma - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858675&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858677,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dyspepsia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Blood pressure increased - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858677&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858680,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal distension (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858680&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858681,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Injection related reaction (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858681&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858682,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858682&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858683,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Inflammation (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[INDAPAMIDE, INDAPAMIDE HEMIHYDRATE] (C - Blood pressure abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - Dyspepsia - n/a - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - Blood cholesterol abnormal - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858683&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858707,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Migraine (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vomiting (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858707&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858708,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chills (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Heart rate increased (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858708&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858709,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Lymphadenopathy (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858709&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858711,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal pain upper (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hot flush (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Peripheral coldness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858711&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858712,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Balance disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dysphagia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Ear pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Glossodynia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Metamorphopsia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pharyngeal swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Sinus pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Swollen tongue (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858712&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858713,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Malaise (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858713&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858714,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Herpes zoster reactivation (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858714&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858716,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Back pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dysmenorrhoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pelvic pain (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858716&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858717,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Migraine (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Paraesthesia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vomiting (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[DESOGESTREL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FLUTICASONE PROPIONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LOPERAMIDE, LOPERAMIDE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LORATADINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MEBEVERINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[VITAMIN D] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858717&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858720,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dizziness (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[OLMESARTAN, OLMESARTAN MEDOXOMIL] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - Hypercholesterolaemia - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858720&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858963,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Chest discomfort (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Cough (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lower respiratory tract infection (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Lymph node pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Wheezing (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858963&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858964,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Migraine (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (3d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",METHOTREXATE [METHOTREXATE] (C - Crohn's disease - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858964&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858965,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE, BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE] (C - Asthma - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858965&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858970,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenopia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858970&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858971,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling cold (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vomiting (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858971&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858972,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Amblyopia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vitreous floaters (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858972&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858977,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Ear pain (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858977&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858978,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Diarrhoea (n/a - Unknown - Disabling),<BR><BR>Dry mouth (n/a - Unknown - Disabling),<BR><BR>Dysarthria (n/a - Unknown - Disabling),<BR><BR>Feeling drunk (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Gait disturbance (n/a - Unknown - Disabling),<BR><BR>Headache (n/a - Unknown - Disabling),<BR><BR>Somnolence (n/a - Unknown - Disabling),<BR><BR>Thinking abnormal (n/a - Unknown - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[GABAPENTIN] (C - Nerve injury - n/a - [n/a - n/a - n/a]),<BR><BR>[PAROXETINE, PAROXETINE HYDROCHLORIDE HEMIHYDRATE] (C - Depression - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858978&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858979,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Inflammation (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[CANDESARTAN, CANDESARTAN CILEXETIL] (C - Blood pressure abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Graves' disease - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858979&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858982,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Seizure (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Shoulder fracture (n/a - Unknown - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858982&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858983,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Influenza (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Irritable bowel syndrome (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858983&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858985,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Muscle spasms (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858985&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858986,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Cerebrovascular accident (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Fatigue (32d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Influenza (30d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858986&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858987,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling cold (n/a - Unknown - Other Medically Important Condition),<BR><BR>Gait inability (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Loss of personal independence in daily activities (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858987&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858988,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Migraine (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[FLUOXETINE, FLUOXETINE HYDROCHLORIDE] (C - Menopause - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858988&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858991,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"Dyspnoea (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Heart rate increased (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Palpitations (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858991&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014858998,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Limb injury (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Pain in extremity (n/a - Unknown - Disabling),<BR><BR>Sleep disorder due to a general medical condition (n/a - Unknown - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[BETAHISTINE, BETAHISTINE DIHYDROCHLORIDE, BETAHISTINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014858998&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859000,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Tremor (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Uterine haemorrhage (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Vaginal haemorrhage (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859000&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859001,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Circulatory collapse (n/a - Recovering/Resolving - Life Threatening, Other Medically Important Condition),<BR><BR>Cold sweat (n/a - Recovering/Resolving - Life Threatening, Other Medically Important Condition),<BR><BR>Extensor plantar response (n/a - Recovering/Resolving - Life Threatening, Other Medically Important Condition),<BR><BR>Foaming at mouth (n/a - Recovering/Resolving - Life Threatening, Other Medically Important Condition),<BR><BR>Haematemesis (n/a - Recovering/Resolving - Life Threatening, Other Medically Important Condition),<BR><BR>Heart rate increased (n/a - Recovering/Resolving - Life Threatening, Other Medically Important Condition),<BR><BR>Muscle twitching (n/a - Recovering/Resolving - Life Threatening, Other Medically Important Condition),<BR><BR>Oxygen saturation decreased (n/a - Recovering/Resolving - Life Threatening, Other Medically Important Condition),<BR><BR>Pupillary light reflex tests abnormal (n/a - Recovering/Resolving - Life Threatening, Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Life Threatening, Other Medically Important Condition),<BR><BR>Seizure (n/a - Recovering/Resolving - Life Threatening, Other Medically Important Condition),<BR><BR>Transient ischaemic attack (n/a - Recovering/Resolving - Life Threatening, Other Medically Important Condition),<BR><BR>Unresponsive to stimuli (1d - Recovered/Resolved - Life Threatening, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[FINASTERIDE] (C - Benign prostatic hyperplasia - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859001&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859004,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Bursitis (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Restlessness (n/a - Unknown - ),<BR><BR>Sleep disorder (n/a - Unknown - ),<BR><BR>Vaccination site pain (n/a - Unknown - ),<BR><BR>Wrong technique in product usage process (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859004&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859005,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Decreased appetite (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Migraine (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Sleep disorder (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859005&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859006,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Lymphoma (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859006&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859007,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Dyspepsia (n/a - Recovered/Resolved - ),<BR><BR>Hyperhidrosis (n/a - Recovered/Resolved - ),<BR><BR>Joint injury (n/a - Unknown - ),<BR><BR>Migraine (n/a - Recovered/Resolved - ),<BR><BR>Mobility decreased (n/a - Recovered/Resolved - ),<BR><BR>Syncope (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859007&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859009,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Burning sensation (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Joint range of motion decreased (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Lymph node pain (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Vaginal haemorrhage (3d - Recovered/Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[DESOGESTREL] (C - Contraception - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859009&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859012,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Abscess (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Myalgia (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Swelling (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[TAMSULOSIN, TAMSULOSIN HYDROCHLORIDE] (C - Pollakiuria - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859012&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859013,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (6d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (6d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a - More in ICSR])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859013&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859016,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859016&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859017,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Unresponsive to stimuli (1d - Recovered/Resolved - Disabling),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859017&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859023,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Bell's palsy (n/a - Unknown - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859023&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859024,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Back pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859024&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859027,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (8h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dry skin (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Feeling cold (8h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (8h - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","ESOMEPRAZOLE [ESOMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ALENDRONATE SODIUM, ALENDRONIC ACID] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[COLECALCIFEROL, CALCIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859027&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859028,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension - n/a - [n/a - 5mg - n/a - More in ICSR]),<BR><BR>[RAMIPRIL] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859028&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859029,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859029&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859030,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Asthenia (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Incontinence (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Pemphigoid (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859030&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859033,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859033&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859035,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Limb discomfort (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Muscular weakness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859035&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859036,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Abdominal pain upper (n/a - Unknown - Other Medically Important Condition),<BR><BR>Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dry throat (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859036&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859037,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Axillary pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hypoaesthesia (n/a - Unknown - ),<BR><BR>Illness (n/a - Unknown - ),<BR><BR>Insomnia (n/a - Unknown - ),<BR><BR>Lymphadenopathy (n/a - Unknown - ),<BR><BR>Paraesthesia (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859037&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859038,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Anxiety (n/a - Unknown - Other Medically Important Condition),<BR><BR>Cold sweat (n/a - Unknown - Other Medically Important Condition),<BR><BR>Condition aggravated (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Muscle spasms (n/a - Unknown - Other Medically Important Condition),<BR><BR>Post-traumatic stress disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Psychogenic seizure (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Unresponsive to stimuli (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vision blurred (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859038&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859039,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pruritus (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site swelling (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - Hormone replacement therapy - n/a - [41d - n/a - n/a]),<BR><BR>[FLURAZEPAM, FLURAZEPAM HYDROCHLORIDE, FLURAZEPAM MONOHYDROCHLORIDE] (C - Insomnia - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859039&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859040,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Drug ineffective (6d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (6d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859040&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859042,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chest pain (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Cold sweat (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Migraine (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Tremor (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","DEXAMETHASONE [DEXAMETHASONE, DEXAMETHASONE SODIUM PHOSPHATE] (C - COVID-19 pneumonia - n/a - [13d - n/a - n/a]),<BR><BR>PREGABALIN [PREGABALIN] (C - Intervertebral disc protrusion - n/a - [n/a - n/a - n/a]),<BR><BR>RIVAROXABAN [RIVAROXABAN] (C - Polycythaemia vera - n/a - [n/a - n/a - n/a]),<BR><BR>SOTROVIMAB [SOTROVIMAB] (C - COVID-19 - n/a - [6d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[OXYGEN] (C - COVID-19 - n/a - [23d - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - Depression - n/a - [n/a - n/a - n/a]),<BR><BR>[TERBINAFINE, TERBINAFINE HYDROCHLORIDE] (C - Nail disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[TRAMADOL, TRAMADOL HYDROCHLORIDE] (C - Back pain - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859042&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859043,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Menstruation irregular (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Syncope (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vomiting (3d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859043&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859044,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Anal incontinence (n/a - Recovering/Resolving - Disabling),<BR><BR>Cough (n/a - Recovering/Resolving - Disabling),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Respiratory rate increased (6d - Recovered/Resolved - Disabling),<BR><BR>Urinary incontinence (n/a - Recovering/Resolving - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859044&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859047,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Back pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859047&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859048,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Cluster headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[ANHYDROUS LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859048&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859049,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Axillary pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Swelling (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ESTRADIOL] (C - Menopause - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859049&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859050,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Blood pressure increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Erythema of eyelid (n/a - Unknown - Other Medically Important Condition),<BR><BR>Heart rate increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - n/a])",[CHLORPHENAMINE MALEATE] (C - Anaphylactic reaction - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859050&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859057,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Axillary pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Joint stiffness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","AVAMYS [FLUTICASONE FUROATE] (C - Sinusitis - n/a - [n/a - n/a - n/a]),<BR><BR>[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - Fibromyalgia - n/a - [n/a - n/a - n/a]),<BR><BR>[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE, BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[DESOGESTREL] (C - Contraception - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[MONTELUKAST, MONTELUKAST SODIUM] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - Reflux gastritis - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - Anxiety - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859057&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859058,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Axillary pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859058&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859059,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Influenza (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - Fibromyalgia - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[CANDESARTAN, CANDESARTAN CILEXETIL] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRADIOL, NORETHISTERONE, NORETHISTERONE ACETATE, ESTRADIOL, NORETHISTERONE ACETATE, ESTRADIOL HEMIHYDRATE] (C - Menopause - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Headache - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859059&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859063,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site mass (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859063&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859064,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Back pain (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Haematemesis (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pneumonia (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859064&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859066,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Flushing (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Peripheral coldness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Skin burning sensation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vomiting (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859066&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859068,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859068&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859069,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>SPIKEVAX [ELASOMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ESTRADIOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859069&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859160,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Capillary disorder (n/a - Unknown - ),<BR><BR>Headache (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859160&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859163,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Joint range of motion decreased (n/a - Recovering/Resolving - ),<BR><BR>Off label use (n/a - Unknown - ),<BR><BR>Polymyalgia rheumatica (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Product use issue (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - n/a - Not applicable - [n/a - n/a - n/a]),<BR><BR>[PNEUMOCOCCAL VACCINE] (S - n/a - Not applicable - [n/a - n/a - n/a]),<BR><BR>[VARICELLA VACCINE (LIVE)] (S - n/a - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859163&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859180,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Disturbance in attention (n/a - Unknown - ),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - ),<BR><BR>Headache (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859180&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859192,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859192&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859195,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenia (n/a - Unknown - ),<BR><BR>Fatigue (n/a - Unknown - ),<BR><BR>Headache (n/a - Unknown - ),<BR><BR>Joint range of motion decreased (n/a - Unknown - ),<BR><BR>Limb discomfort (n/a - Unknown - ),<BR><BR>Loss of employment (n/a - Unknown - ),<BR><BR>Myalgia (n/a - Unknown - ),<BR><BR>Pain in extremity (n/a - Unknown - ),<BR><BR>Thrombosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vascular pain (n/a - Unknown - ),<BR><BR>Vasospasm (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",XARELTO [RIVAROXABAN] (C - Coagulopathy - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859195&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859196,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Fatigue (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Pleural effusion (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Stridor (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Tachycardia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (S - Immunisation - Unknown - [1d - n/a - Intramuscular use])","RIVASTIGMINE [RIVASTIGMINE, RIVASTIGMINE HYDROGEN TARTRATE] (C - Vascular dementia - n/a - [n/a - 9.5mg - Transdermal use]),<BR><BR>[ACENOCOUMAROL] (C - Anticoagulant therapy - n/a - [n/a - n/a - Oral use]),<BR><BR>[AMILORIDE HYDROCHLORIDE, HYDROCHLOROTHIAZIDE, AMILORIDE, HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE DIHYDRATE, HYDROCHLOROTHIAZIDE, ANHYDROUS AMILORIDE HYDROCHLORIDE] (C - Hypertension - n/a - [n/a - 55mg - Oral use]),<BR><BR>[ATORVASTATIN] (C - Hypercholesterolaemia - n/a - [n/a - 10mg - Oral use]),<BR><BR>[CYANOCOBALAMIN] (C - Hypovitaminosis - n/a - [n/a - n/a - Oral use]),<BR><BR>[DRY EXTRACT OF GINKGO BILOBA LEAVES (35-67:1), EXTRACTION SOLVENT: ACETONE 60% ( M / M), GINKGO BILOBA, GINKGO BILOBA EXTRACT, REFINED AND QUANTIFIED DRY EXTRACT FROM GINKGO LEAF (35-67:1), QUANTIFIED  TO 17,6-21,6 MG OF FLAVONOIDS EXPRESSED AS FLAVONE GLYCOSIDES, 2,08-2,56 MG OF BILOBALIDE, 2,24-2,72 MG OF GINKGOLIDES A, B AND C, EXTRACTION SOLVENT: ACETONE 60% (M/M)] (C - Angiopathy - n/a - [n/a - 160mg - Oral use]),<BR><BR>[ESCITALOPRAM OXALATE] (C - Vascular dementia - n/a - [n/a - 10mg - Oral use]),<BR><BR>[FUROSEMIDE] (C - Cardiac failure - n/a - [n/a - 40mg - Oral use]),<BR><BR>[LANSOPRAZOLE] (C - Prophylaxis against gastrointestinal ulcer - n/a - [n/a - 15mg - Oral use]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - Blood thyroid stimulating hormone abnormal - n/a - [n/a - n/a - Oral use]),<BR><BR>[PENTOXIFYLLINE] (C - Angiopathy - n/a - [n/a - 800mg - Oral use]),<BR><BR>[QUETIAPINE, QUETIAPINE FUMARATE] (C - Vascular dementia - n/a - [n/a - 50mg - Oral use]),<BR><BR>[RAMIPRIL] (C - Cardiac failure - n/a - [n/a - 1.25mg - Oral use]),<BR><BR>[SPIRONOLACTONE] (C - Cardiac failure - n/a - [n/a - 12.5mg - Oral use]),<BR><BR>[VALPROATE SEMISODIUM, VALPROIC ACID] (C - Vascular dementia - n/a - [n/a - 250mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859196&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859202,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Dizziness (n/a - Unknown - ),<BR><BR>Dysstasia (n/a - Unknown - ),<BR><BR>Grip strength decreased (n/a - Unknown - ),<BR><BR>Paralysis (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859202&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859207,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal pain upper (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Interchange of vaccine products (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Liver function test increased (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>SPIKEVAX [ELASOMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[CHONDROITIN SULFATE, CHONDROITIN SULFATE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OLMESARTAN, OLMESARTAN MEDOXOMIL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859207&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859215,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Anaphylactic reaction (n/a - Unknown - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859215&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859222,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Anaphylactic reaction (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Conjunctival hyperaemia (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859222&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859228,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Dizziness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dysstasia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hypoxia (n/a - Recovered/Resolved - Life Threatening, Other Medically Important Condition),<BR><BR>Oxygen saturation decreased (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Somnolence (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Speech disorder (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859228&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859232,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Gingival cancer (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Weight decreased (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859232&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859249,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Blood pressure increased (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Cough (n/a - Recovered/Resolved - ),<BR><BR>Hypersensitivity (n/a - Recovered/Resolved - ),<BR><BR>Throat irritation (n/a - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859249&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859256,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Blood pressure systolic increased (n/a - Recovered/Resolved - ),<BR><BR>Feeling abnormal (n/a - Recovered/Resolved - ),<BR><BR>Heart rate increased (n/a - Recovered/Resolved - ),<BR><BR>Interchange of vaccine products (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovered/Resolved - ),<BR><BR>Nausea (n/a - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Recovered/Resolved - ),<BR><BR>Seizure (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tremor (n/a - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859256&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859548,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Transient ischaemic attack (3d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",METHOTREXATE [METHOTREXATE] (C - Psoriasis - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859548&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859552,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Crohn's disease (n/a - Unknown - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Haematochezia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Mucous stools (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859552&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859553,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Breast swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Erythema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Limb discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Swelling (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859553&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859555,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenia (n/a - Unknown - Disabling),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Feeling abnormal (n/a - Unknown - Disabling),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Malaise (n/a - Unknown - Disabling),<BR><BR>Muscular weakness (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Pain in extremity (n/a - Unknown - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859555&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859556,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Brain fog (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness postural (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859556&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859557,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (11d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fall (n/a - Unknown - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachyphrenia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[FLUOXETINE, FLUOXETINE HYDROCHLORIDE] (C - Intentional self-injury - n/a - [n/a - n/a - n/a]),<BR><BR>[SODIUM VALPROATE] (C - Seizure - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859557&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859558,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Condition aggravated (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Torticollis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859558&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859560,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[FLUOXETINE] (C - Depression - n/a - [n/a - n/a - n/a]),<BR><BR>[ISPAGHULA HUSK BP, MEBEVERINE HYDROCHLORIDE, ISPAGHULA HUSK] (C - Irritable bowel syndrome - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a]),<BR><BR>[RIZATRIPTAN, RIZATRIPTAN BENZOATE] (C - Migraine - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859560&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859561,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Musculoskeletal stiffness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Night sweats (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination site erythema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site warmth (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859561&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859562,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Inflammation (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Joint swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Peripheral swelling (32h - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859562&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859564,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Deafness unilateral (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Ear discomfort (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Tinnitus (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859564&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859565,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Feeling hot (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hyperhidrosis (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Limb discomfort (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Neck pain (36h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Poor quality sleep (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859565&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859566,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Atrial tachycardia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Cognitive disorder (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lethargy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","DOVATO [LAMIVUDINE, DOLUTEGRAVIR] (C - HIV infection - n/a - [n/a - n/a - n/a]),<BR><BR>RIVAROXABAN [RIVAROXABAN] (C - Atrial fibrillation - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[HYDROCHLOROTHIAZIDE, LOSARTAN] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859566&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859567,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","SPIRONOLACTONE [SPIRONOLACTONE] (C - Myocardial infarction - n/a - [n/a - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID] (C - Myocardial infarction - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - Myocardial infarction - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Myocardial infarction - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[PERINDOPRIL, PERINDOPRIL TERT-BUTYLAMINE] (C - Myocardial infarction - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859567&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859568,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Pruritus (n/a - Not Recovered/Not Resolved - Disabling),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859568&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859569,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest discomfort (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859569&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859570,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Diarrhoea (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (10d - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859570&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859576,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859576&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859582,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ESTRIOL] (C - Female sex hormone level, Hormone replacement therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[PROPRANOLOL, PROPRANOLOL HYDROCHLORIDE] (C - Anxiety - n/a - [n/a - n/a - n/a]),<BR><BR>[SERTRALINE HYDROCHLORIDE] (C - Anxiety - n/a - [n/a - n/a - n/a]),<BR><BR>[VITAMIN D, CALCIUM] (C - Osteoporosis - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859582&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859584,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Feeling cold (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Feeling hot (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Gastrooesophageal reflux disease (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Sleep disorder (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Tremor (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[OMEPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - 10mg - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859584&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859585,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Facial paralysis (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859585&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859587,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Myositis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859587&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859588,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Deep vein thrombosis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dyspnoea exertional (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[FLUTICASONE PROPIONATE, SALMETEROL, FLUTICASONE PROPIONATE, SALMETEROL XINAFOATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[MOMETASONE] (C - Nasal polyps - n/a - [n/a - n/a - n/a]),<BR><BR>[MONTELUKAST, MONTELUKAST SODIUM] (C - Asthma - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859588&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859590,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Loss of consciousness (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Recovered/Resolved - ),<BR><BR>Presyncope (n/a - Recovered/Resolved - ),<BR><BR>Syncope (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[BETAHISTINE MESILATE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[CANDESARTAN, CANDESARTAN CILEXETIL] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859590&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859591,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Dysstasia (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Vertigo (1d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Vomiting (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859591&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859592,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Cold sweat (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Migraine (n/a - Unknown - Other Medically Important Condition),<BR><BR>Musculoskeletal stiffness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859592&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859594,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Pruritus (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Urticaria (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Antiviral prophylaxis - n/a - [n/a - .5mL - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - 5mg - n/a]),<BR><BR>[ATORVASTATIN] (C - Blood cholesterol increased - n/a - [n/a - 20mg - n/a]),<BR><BR>[INDAPAMIDE, INDAPAMIDE HEMIHYDRATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - Hiatus hernia - n/a - [n/a - 20mg - Oral use]),<BR><BR>[RAMIPRIL] (C - Hypertension - n/a - [n/a - 5mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859594&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859598,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Myocarditis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859598&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859599,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arrhythmia (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Atrial fibrillation (54h - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859599&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859600,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Rash (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rash erythematous (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859600&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859601,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Axillary pain (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Soft tissue swelling (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Swelling (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","CELECOXIB [CELECOXIB] (C - Arthritis - n/a - [n/a - n/a - n/a]),<BR><BR>OXYBUTYNIN [OXYBUTYNIN, OXYBUTYNIN HYDROCHLORIDE] (C - Cystitis interstitial - n/a - [n/a - n/a - n/a]),<BR><BR>PREGABALIN [PREGABALIN] (C - Fibromyalgia - n/a - [n/a - n/a - n/a]),<BR><BR>[DIHYDROCODEINE, DIHYDROCODEINE TARTRATE BP] (C - Arthralgia - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[TRAMADOL, TRAMADOL HYDROCHLORIDE] (C - Analgesic therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[VENLAFAXINE, VENLAFAXINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859601&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859602,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Back pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Gait disturbance (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site erythema (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859602&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859603,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Diarrhoea (15h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (15h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hyperhidrosis (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (15h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vomiting (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859603&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859788,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,"Kimura, H.. A case of drug-induced hypersensitivity syndrome-like skin eruption with purpura after COVID-19 vaccination. The 52nd Annual Meeting of the Japanese Society for Cutaneous Immunology and. 2022;52nd:194",65-85 Years,Not Specified,No,Female,"Conjunctival hyperaemia (n/a - Recovering/Resolving - ),<BR><BR>Drug reaction with eosinophilia and systemic symptoms (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Erythema (n/a - Recovering/Resolving - ),<BR><BR>Erythema multiforme (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Face oedema (n/a - Recovering/Resolving - ),<BR><BR>Purpura (n/a - Recovering/Resolving - ),<BR><BR>Rash (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859788&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859799,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Blood test abnormal (n/a - Unknown - ),<BR><BR>Death (n/a - Fatal - Results in Death)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859799&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859830,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859830&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859853,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Erythema multiforme (n/a - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859853&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859856,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Acute kidney injury (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Back pain (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Headache (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Malaise (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Peripheral coldness (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Tremor (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859856&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859862,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Facial paralysis (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859862&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859868,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Pericarditis (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859868&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859871,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Erythema (4d - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Nausea (3d - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Pain (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Pruritus (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Syncope (1d - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Vaccination site erythema (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Vaccination site pruritus (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Vaccination site swelling (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Vomiting (1d - Recovered/Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859871&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859888,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Cough (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859888&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859891,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859891&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859894,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Angioedema (2d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859894&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859900,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Pityriasis lichenoides et varioliformis acuta (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pustule (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - Transient ischaemic attack - n/a - [n/a - n/a - n/a]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - Transient ischaemic attack - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859900&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859904,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Immunisation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myocarditis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Off label use (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pericarditis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tremor (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tremor (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859904&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859907,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859907&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859909,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (S - Immunisation - Not applicable - [1d - n/a - n/a])","[CLARITHROMYCIN] (C - Hidradenitis - n/a - [22d - n/a - n/a]),<BR><BR>[ETHINYLESTRADIOL, LEVONORGESTREL] (C - Oral contraception - n/a - [n/a - n/a - n/a]),<BR><BR>[FLUCLOXACILLIN, FLUCLOXACILLIN SODIUM, FLUCLOXACILLIN SODIUM MONOHYDRATE] (C - Hidradenitis - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859909&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014859921,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Death (n/a - Fatal - Results in Death),<BR><BR>Interchange of vaccine products (n/a - Fatal - Results in Death)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[METHYLPHENIDATE HYDROCHLORIDE] (C - Attention deficit hyperactivity disorder - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014859921&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014860022,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Abdominal pain upper (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Immunisation (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lethargy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Off label use (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014860022&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014860060,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014860060&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014860082,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Alanine aminotransferase increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Aspartate aminotransferase increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Blood lactate dehydrogenase increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chromaturia (8d - Recovered/Resolved - ),<BR><BR>Gamma-glutamyltransferase increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hepatic failure (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hepatic function abnormal (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (8d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use])","[BILASTINE] (C - Hypersensitivity - n/a - [n/a - n/a - Oral use]),<BR><BR>[MONTELUKAST, MONTELUKAST SODIUM] (C - Hypersensitivity - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014860082&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014860160,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Blood pressure increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Unknown - ),<BR><BR>Urticaria (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014860160&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014860161,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014860161&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014860167,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Cold sweat (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014860167&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014860172,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Blood pressure increased (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Palpitations (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tachycardia (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014860172&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014860178,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Axillary pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pulmonary pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014860178&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014860180,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Body temperature abnormal (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014860180&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014860181,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Abdominal pain upper (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Joint noise (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Sleep terror (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014860181&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014860191,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Pain (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[TRAMADOL, TRAMADOL HYDROCHLORIDE] (C - Back pain - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014860191&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014860193,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[TRAMADOL, TRAMADOL HYDROCHLORIDE] (C - Back pain - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014860193&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014860195,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Breast cancer (n/a - Unknown - Other Medically Important Condition),<BR><BR>Eczema (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014860195&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014860196,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014860196&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014860349,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Heart rate increased (20min - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Heart rate irregular (n/a - Unknown - Other Medically Important Condition),<BR><BR>Supraventricular tachycardia (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[COLECALCIFEROL] (C - Vitamin D deficiency - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014860349&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014860371,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Immunisation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Incorrect dose administered (n/a - Unknown - ),<BR><BR>Maternal exposure during pregnancy (n/a - Unknown - ),<BR><BR>Off label use (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rhinorrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[FOLIC ACID] (C - Vitamin supplementation - n/a - [n/a - 5mg - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014860371&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014860394,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Unknown - Disabling),<BR><BR>Nasopharyngitis (n/a - Unknown - Disabling),<BR><BR>Neuralgia (n/a - Not Recovered/Not Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014860394&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014860399,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014860399&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014860401,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Lower respiratory tract infection (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","IBUPROFEN [IBUPROFEN, IBUPROFEN SODIUM] (C - Plantar fasciitis - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014860401&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014860402,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Asthenia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chills (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Renal pain (3d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014860402&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014860404,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Abdominal pain upper (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chest pain (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Frequent bowel movements (n/a - Unknown - Other Medically Important Condition),<BR><BR>Movement disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Somnolence (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014860404&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014860408,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Cellulitis (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Deep vein thrombosis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[PROPRANOLOL, PROPRANOLOL HYDROCHLORIDE] (C - Anxiety - n/a - [n/a - n/a - n/a]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - Depression - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014860408&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014860410,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"Bloody discharge (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chronic sinusitis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Ear disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nasal obstruction (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Secretion discharge (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Sneezing (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014860410&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014860411,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Neuropathy peripheral (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014860411&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014860416,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Influenza (n/a - Unknown - ),<BR><BR>Limb discomfort (n/a - Unknown - ),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - ),<BR><BR>Swelling (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014860416&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014860419,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling of body temperature change (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Influenza (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014860419&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014860424,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Hypoaesthesia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Ulnar nerve palsy (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014860424&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014860427,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,Rash erythematous (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014860427&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014860430,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Breast discharge (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Breast haemorrhage (n/a - Unknown - Other Medically Important Condition),<BR><BR>Breast mass (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Breast pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Menstruation delayed (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014860430&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014860446,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Pain in extremity (n/a - Not Recovered/Not Resolved - Disabling),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014860446&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014860449,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Confusional state (n/a - Unknown - Other Medically Important Condition),<BR><BR>Diarrhoea (4h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling hot (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hallucination (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Illness (4h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Rhinorrhoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Sinus pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[DESOGESTREL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[DOXYCYCLINE, DOXYCYCLINE HYCLATE, DOXYCYCLINE MONOHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014860449&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014860459,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Lymph node pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Musculoskeletal stiffness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014860459&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014860466,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Acute left ventricular failure (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Cardiac failure congestive (n/a - Fatal - Results in Death),<BR><BR>Emphysema (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myocardial ischaemia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ACETYLSALICYLIC ACID] (C - Myocardial ischaemia - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - Myocardial ischaemia - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Myocardial ischaemia - n/a - [n/a - n/a - n/a]),<BR><BR>[DIGOXIN] (C - Atrial fibrillation - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a]),<BR><BR>[MORPHINE SULFATE, MORPHINE SULPHATE BP] (C - Back pain - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL, CODEINE PHOSPHATE] (C - Back pain - n/a - [n/a - n/a - n/a]),<BR><BR>[WARFARIN, WARFARIN SODIUM] (C - Atrial fibrillation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014860466&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014860468,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tremor (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014860468&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014860488,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Somnolence (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Immunisation - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014860488&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014860491,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (3d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014860491&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014860567,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Cough (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Loss of personal independence in daily activities (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Somnolence (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014860567&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014860568,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vertigo positional (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014860568&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014860699,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Disabling),<BR><BR>Cerebrovascular accident (n/a - Recovering/Resolving - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014860699&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014860701,Spontaneous,2023-03-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Migraine (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vomiting projectile (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Asthma - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014860701&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014860832,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abnormal sensation in eye (n/a - Unknown - ),<BR><BR>Conjunctival haemorrhage (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Superficial injury of eye (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014860832&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014860857,Spontaneous,2023-03-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,12-17 Years,Not Specified,No,Male,"Blood pressure systolic increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014860857&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014844637,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Drug eruption (n/a - Unknown - ),<BR><BR>Pruritus (n/a - Unknown - ),<BR><BR>Rash (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use])",[LUBIPROSTONE] (C - n/a - n/a - [18d - n/a - Oral use]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014844637&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014845425,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Hypokinesia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site joint pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[TRAMADOL, TRAMADOL HYDROCHLORIDE] (C - Back pain - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014845425&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014846809,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Cardiac disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Extrasystoles (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014846809&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014847051,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Condition aggravated (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Dyspnoea (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Pulseless electrical activity (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014847051&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014847055,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Back pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Blood urine present (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lethargy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Renal pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014847055&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014847057,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Cerebrovascular accident (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Hypoaesthesia (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014847057&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014847060,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Haemorrhage subcutaneous (445h - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pigmentation disorder (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site bruising (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014847060&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014847063,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Dizziness (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014847063&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014847064,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chest pain (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Pulmonary embolism (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014847064&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014847065,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Cold sweat (42min - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Erythema (20min - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (42min - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pruritus (20min - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014847065&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014847069,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Body temperature increased (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Limb discomfort (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site swelling (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - n/a - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014847069&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014847074,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Eosinophil count increased (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Gastritis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Swelling face (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014847074&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014847078,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Cough (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014847078&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014847083,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Condition aggravated (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lip swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Swelling face (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014847083&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014847091,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Respiratory arrest (n/a - Recovered/Resolved - Life Threatening, Other Medically Important Condition),<BR><BR>Transient ischaemic attack (n/a - Unknown - Life Threatening, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MAGNESIUM OXIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM HYDRATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014847091&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014847092,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014847092&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014847095,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hyperhidrosis (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vomiting (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[NORETHISTERONE ACETATE, ESTRADIOL, NORETHISTERONE, ESTRADIOL HEMIHYDRATE] (C - Hormone replacement therapy - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014847095&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014847105,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hypoaesthesia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Influenza (n/a - Unknown - Other Medically Important Condition),<BR><BR>Shoulder injury related to vaccine administration (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014847105&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014847110,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Bell's palsy (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[LOSARTAN POTASSIUM] (C - Hypertension - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014847110&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014847112,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])","[ATORVASTATIN] (C - Hypercholesterolaemia - n/a - [n/a - n/a - Oral use]),<BR><BR>[ESAXERENONE, PLACEBO] (C - Hypertension - n/a - [n/a - 2{DF} - Oral use]),<BR><BR>[TRICHLORMETHIAZIDE] (C - Hypertension - n/a - [n/a - 2mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014847112&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014847113,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chills (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dizziness (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Influenza like illness (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Skin laceration (n/a - Unknown - Other Medically Important Condition),<BR><BR>Syncope (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014847113&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014847119,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Tension headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ACETYLSALICYLIC ACID] (C - Cardiomegaly - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - Cardiomegaly - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - Cardiomegaly - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - Cardiomegaly - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014847119&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014847122,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Axillary pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Back pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014847122&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014847126,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Diarrhoea (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Illness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Initial insomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Loss of consciousness (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Syncope (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vomiting (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[BECLOMETASONE DIPROPIONATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[DILTIAZEM HYDROCHLORIDE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014847126&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014847129,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Acute myocardial infarction (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Myocardial rupture (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Pericardial haemorrhage (n/a - Fatal - Results in Death, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014847129&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014847130,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Incontinence (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Micturition urgency (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ESTRADIOL, NORETHISTERONE, NORETHISTERONE ACETATE, ESTRADIOL, NORETHISTERONE ACETATE, ESTRADIOL HEMIHYDRATE] (C - Hormone replacement therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - Asthma - n/a - [n/a - n/a - Inhalation use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014847130&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014847134,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Sinus arrhythmia (n/a - Unknown - ),<BR><BR>Syncope (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014847134&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014847138,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Chills (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014847138&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014847141,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Choking sensation (n/a - Unknown - ),<BR><BR>Muscle spasms (n/a - Recovering/Resolving - ),<BR><BR>Musculoskeletal stiffness (4d - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - ),<BR><BR>Seizure (4d - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Suffocation feeling (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014847141&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014847145,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"Chest pain (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Dyspnoea (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Neck pain (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Palpitations (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Pericarditis (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Tachycardia (n/a - Unknown - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014847145&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014847149,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Feeling cold (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Influenza (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nasopharyngitis (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain of skin (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014847149&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014847167,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,Sweating fever (n/a - Unknown - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014847167&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014847170,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Periarthritis (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014847170&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014847175,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthritis (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Chest pain (n/a - Unknown - Disabling),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Dyspnoea (n/a - Unknown - Disabling),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Nausea (n/a - Recovering/Resolving - Disabling),<BR><BR>Palpitations (n/a - Unknown - Disabling),<BR><BR>Pyrexia (n/a - Unknown - Disabling),<BR><BR>Sensitive skin (2d - Recovered/Resolved - Disabling),<BR><BR>Sinus headache (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Tachycardia (n/a - Unknown - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014847175&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014847178,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vertigo (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014847178&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014847184,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Chills (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Joint stiffness (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Myalgia (3d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014847184&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014847186,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Axillary pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014847186&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014847190,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Axillary pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Oedema (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014847190&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014847191,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Lethargy (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014847191&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014847199,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Neck pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014847199&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014847204,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Illness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lymph node pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[MIRTAZAPINE] (C - Depression - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014847204&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014847212,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Lymph node pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Night sweats (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014847212&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014847219,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Pneumonia (5d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pulmonary embolism (5d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014847219&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014847224,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Diarrhoea (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Muscular weakness (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Spinal pain (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[CALCIUM CARBONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[VALSARTAN] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014847224&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014847225,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Hypoaesthesia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Neuropathy peripheral (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014847225&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014847226,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),<BR><BR>TOZINAMERAN [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[DESOGESTREL] (C - Contraception - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014847226&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014847229,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,12-17 Years,Not Specified,No,Male,"Epilepsy (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Generalised tonic-clonic seizure (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Seizure (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014847229&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014847231,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Immunisation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Incorrect dose administered (n/a - Unknown - ),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Off label use (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014847231&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014847565,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Brain fog (n/a - Recovered/Resolved - Disabling),<BR><BR>Chills (n/a - Recovered/Resolved - Disabling),<BR><BR>Dizziness (n/a - Recovered/Resolved - Disabling),<BR><BR>Dizziness postural (n/a - Recovered/Resolved - Disabling),<BR><BR>Feeling cold (n/a - Recovered/Resolved - Disabling),<BR><BR>Insomnia (n/a - Recovered/Resolved - Disabling),<BR><BR>Malaise (n/a - Recovered/Resolved - Disabling),<BR><BR>Nausea (n/a - Recovered/Resolved - Disabling),<BR><BR>Presyncope (n/a - Recovered/Resolved - Disabling),<BR><BR>Vaccination site pain (n/a - Recovered/Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Unknown]),<BR><BR>[INFLUENZA VIRUS] (S - Influenza immunisation - Not applicable - [1d - n/a - Unknown])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014847565&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014848663,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Hypoaesthesia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Neuropathy peripheral (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014848663&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014848684,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Erythema (n/a - Recovered/Resolved - ),<BR><BR>Mental impairment (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014848684&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014848686,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Blood pressure decreased (10min - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Shock symptom (10min - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014848686&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014848691,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,12-17 Years,Not Specified,No,Female,Syncope (10min - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014848691&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014848701,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Abdominal distension (1330min - Recovered/Resolved - ),<BR><BR>Back pain (1710min - Recovered/Resolved - ),<BR><BR>Disturbance in attention (10h - Recovered/Resolved - ),<BR><BR>Dizziness (2225min - Recovered/Resolved - ),<BR><BR>Feeling abnormal (2190min - Recovered/Resolved - ),<BR><BR>Feeling hot (2130min - Recovered/Resolved - ),<BR><BR>Flatulence (19h - Recovered/Resolved - ),<BR><BR>Headache (2225min - Recovered/Resolved - ),<BR><BR>Hot flush (2130min - Recovered/Resolved - ),<BR><BR>Hyperhidrosis (2130min - Recovered/Resolved - ),<BR><BR>Malaise (1710min - Recovered/Resolved - ),<BR><BR>Mental impairment (19h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nasopharyngitis (19h - Recovered/Resolved - ),<BR><BR>Pain (19h - Recovered/Resolved - ),<BR><BR>Pain in extremity (2130min - Recovered/Resolved - ),<BR><BR>Peripheral coldness (2190min - Recovered/Resolved - ),<BR><BR>Pyrexia (2130min - Recovered/Resolved - ),<BR><BR>Somnolence (33h - Recovered/Resolved - ),<BR><BR>Thirst (2225min - Recovered/Resolved - ),<BR><BR>Vaccination site pain (2025min - Recovered/Resolved - ),<BR><BR>Vision blurred (920min - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014848701&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014848736,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Dizziness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hypersensitivity (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Oxygen saturation decreased (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pallor (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vertigo (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])","PREGABALIN [PREGABALIN] (C - n/a - n/a - [n/a - 75mg - n/a]),<BR><BR>[BILASTINE] (C - Hypersensitivity - n/a - [n/a - 20mg - n/a]),<BR><BR>[DOMPERIDONE] (C - Faeces hard - n/a - [n/a - 10mg - n/a]),<BR><BR>[ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM TRIHYDRATE, ESOMEPRAZOLE SODIUM] (C - Abdominal discomfort - n/a - [n/a - n/a - n/a]),<BR><BR>[MAGNESIUM OXIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PANTETHINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[REBAMIPIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014848736&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014848769,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Panic attack (n/a - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014848769&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014849585,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014849585&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014849586,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"Feeding disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Somnolence (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014849586&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014849588,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Neurological symptom (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[BALSALAZIDE] (C - Colitis ulcerative - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014849588&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014849591,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Disease recurrence (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>SPIKEVAX [ELASOMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014849591&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014849593,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Herpes zoster (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014849593&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014849596,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,Dizziness postural (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014849596&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014849599,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Syncope (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014849599&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014849600,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Feeling of body temperature change (n/a - Unknown - Other Medically Important Condition),<BR><BR>Loss of personal independence in daily activities (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Neuralgic amyotrophy (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tremor (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014849600&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014849603,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Abnormal dreams (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hallucination (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypersomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014849603&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850262,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,Myalgia (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850262&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850267,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850267&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850268,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850268&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850270,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Diarrhoea (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (1d - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Heart rate increased (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Loss of consciousness (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Myalgia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Paralysis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vomiting (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850270&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850272,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Back pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Troponin increased (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - Relaxation therapy - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850272&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850273,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Paraesthesia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Immunisation - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850273&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850287,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Bell's palsy (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850287&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850289,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Abdominal discomfort (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Abdominal pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Back pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Body temperature increased (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Heart rate increased (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850289&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850290,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vertigo (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vestibulitis (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - n/a - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850290&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850291,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Asthenia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Chills (2d - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Illness (1d - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PROPRANOLOL, PROPRANOLOL HYDROCHLORIDE] (C - n/a - n/a - [n/a - 40mg - n/a]),<BR><BR>[RAMIPRIL] (C - Hypertension - n/a - [n/a - 2.5mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850291&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850292,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Back pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Somnolence (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850292&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850293,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850293&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850294,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Axillary mass (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850294&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850296,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Apnoea (2d - Recovered/Resolved - Life Threatening),<BR><BR>Dyspnoea (n/a - Unknown - Life Threatening),<BR><BR>Febrile convulsion (2d - Recovered/Resolved - Life Threatening),<BR><BR>Hypotension (n/a - Unknown - Life Threatening),<BR><BR>Malaise (n/a - Unknown - Life Threatening),<BR><BR>Pyrexia (2d - Recovered/Resolved - Life Threatening),<BR><BR>Tremor (n/a - Unknown - Life Threatening)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850296&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850298,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Skin lesion (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - Gastrooesophageal reflux disease, Hiatus hernia - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850298&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850304,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Bone pain (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Unknown - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Erythema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Face oedema (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Facial pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Swelling face (27h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850304&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850531,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Autoimmune disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Depression (n/a - Unknown - ),<BR><BR>Impaired work ability (n/a - Unknown - ),<BR><BR>Loss of personal independence in daily activities (n/a - Unknown - ),<BR><BR>Nail psoriasis (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850531&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850547,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Depressed level of consciousness (1d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850547&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850635,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Convulsions local (n/a - Unknown - Other Medically Important Condition),<BR><BR>Seizure (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850635&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850782,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,12-17 Years,Not Specified,No,Female,"Feeling abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypoaesthesia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Loss of consciousness (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850782&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850783,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Anaphylactic reaction (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Bronchostenosis (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Cough (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Heart rate increased (22min - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hypertension (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Throat irritation (22min - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tongue pruritus (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Wheezing (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850783&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850790,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,12-17 Years,Not Specified,No,Male,"Chills (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Dysstasia (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Gait disturbance (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Malaise (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Movement disorder (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Muscular weakness (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - n/a - n/a - [1d - n/a - Subcutaneous use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850790&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850807,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850807&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850918,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Erythema (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Inflammation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Wound complication (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[MIRTAZAPINE] (C - Anxiety - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850918&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850919,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Loss of personal independence in daily activities (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850919&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850920,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Cough (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lower respiratory tract infection (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850920&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850922,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Drug ineffective (11d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (11d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850922&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850924,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,12-17 Years,Not Specified,No,Male,"Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pallor (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850924&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850926,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Abdominal pain upper (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850926&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850928,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Balance disorder (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Motion sickness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vomiting (4d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/BRISBANE/59/2007 (H1N1)-LIKE STRAIN, A/BRISBANE/10/2007 (H3N2)-LIKE STRAIN, B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1) V REASS. X - 179 A, A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/NANCHANG 933/95 (H3N2), A/BAYERN/7/95 (H1N1) - LIKE STRAIN (A/JOHANNESBURG/82/96), B/BEIJING/184/93-LIKE STRAIN (B/HARBIN/7/94), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN (A/NEW CALEDONIA/20/99 REASS. IVR-116), A/CALIFORNIA/7/2004 (H3N2) - LIKE STRAIN (A/NEW YORK/55/2004 REASS. NYMC X-157), B/SHANGHAI/361/2002 - LIKE STRAIN (B/JIANGSU/10/2003), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN (A/NEW CALEDONIA/20/99 REASS. IVR-116), A/MOSCOW/10/99 (H3N2) - LIKE STRAIN (A/PANAMA/2007/99 REASS. RESVIR-17), B/SICHUAN/379/99-LIKE STRAIN (B/JOHANNESBURG/5/99), A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), A/CALIFORNIA/7/2009 (H1N1)-DERIVED STRAIN USED NYMC X-181, B/BRISBANE/60/2008, A/SWITZERLAND/9715293/2013 (H3N2)-LIKE STRAIN (A/SWITZERLAND/9715293/2013, NIB-88), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN B, A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1), A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1)V-LIKE VIRUS, A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/MASSACHUSETTS/2/2012 -DERIVED STRAIN USED (NYMC BX-51B), A/TEXAS/50/2012 (H3N2) – DERIVED STRAIN USED (NYMC X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/MASSACHUSETTS/2/2012 -DERIVED STRAIN USED (NYMC BX-51B), A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN A (H1N1), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN A (H3N2), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN B] (C - Influenza immunisation - n/a - [1d - n/a - n/a])...","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850928&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850931,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,Insomnia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850931&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850932,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Chills (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850932&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850933,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Feeling cold (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tremor (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","IBUPROFEN [IBUPROFEN, IBUPROFEN SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FERROUS FUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[NEFOPAM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PIZOTIFEN, PIZOTIFEN MALATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[RIZATRIPTAN, RIZATRIPTAN BENZOATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850933&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850943,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Herpes zoster (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850943&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850944,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphoedema (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site warmth (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Autoimmune thyroiditis - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - Asthma - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850944&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850945,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Ataxia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Confusional state (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Incontinence (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lethargy (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Loss of personal independence in daily activities (n/a - Unknown - Other Medically Important Condition),<BR><BR>Muscular weakness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nervousness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in jaw (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Sinus headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850945&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850947,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Migraine (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850947&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850949,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Menstrual disorder (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Postmenopausal haemorrhage (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850949&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850951,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Cystitis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Kidney infection (n/a - Unknown - Other Medically Important Condition),<BR><BR>Urticaria chronic (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Decreased activity - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850951&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850953,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Haematoma (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/BRISBANE/59/2007 (H1N1)-LIKE STRAIN, A/BRISBANE/10/2007 (H3N2)-LIKE STRAIN, B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1) V REASS. X - 179 A, A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/NANCHANG 933/95 (H3N2), A/BAYERN/7/95 (H1N1) - LIKE STRAIN (A/JOHANNESBURG/82/96), B/BEIJING/184/93-LIKE STRAIN (B/HARBIN/7/94), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN (A/NEW CALEDONIA/20/99 REASS. IVR-116), A/CALIFORNIA/7/2004 (H3N2) - LIKE STRAIN (A/NEW YORK/55/2004 REASS. NYMC X-157), B/SHANGHAI/361/2002 - LIKE STRAIN (B/JIANGSU/10/2003), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN (A/NEW CALEDONIA/20/99 REASS. IVR-116), A/MOSCOW/10/99 (H3N2) - LIKE STRAIN (A/PANAMA/2007/99 REASS. RESVIR-17), B/SICHUAN/379/99-LIKE STRAIN (B/JOHANNESBURG/5/99), A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), A/CALIFORNIA/7/2009 (H1N1)-DERIVED STRAIN USED NYMC X-181, B/BRISBANE/60/2008, A/SWITZERLAND/9715293/2013 (H3N2)-LIKE STRAIN (A/SWITZERLAND/9715293/2013, NIB-88), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN B, A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1), A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1)V-LIKE VIRUS, A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/MASSACHUSETTS/2/2012 -DERIVED STRAIN USED (NYMC BX-51B), A/TEXAS/50/2012 (H3N2) – DERIVED STRAIN USED (NYMC X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/MASSACHUSETTS/2/2012 -DERIVED STRAIN USED (NYMC BX-51B), A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN A (H1N1), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN A (H3N2), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN B] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850953&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850954,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Erythema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling hot (n/a - Unknown - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850954&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850961,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Aphonia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (7d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","METHOTREXATE [METHOTREXATE] (C - Arthritis - n/a - [n/a - 20mg - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[SULFASALAZINE] (C - Arthritis - n/a - [n/a - 3mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850961&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850962,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850962&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850964,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[LANSOPRAZOLE] (C - Dyspepsia - n/a - [n/a - n/a - n/a]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850964&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850970,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Anaphylactic reaction (n/a - Recovered/Resolved With Sequelae - Life Threatening, Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Reaction to excipient (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Ventricular extrasystoles (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[MACROGOL, SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (S - n/a - Unknown - [1d - n/a - n/a])","[AMOXICILLIN, AMOXICILLIN TRIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850970&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850971,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Lactose intolerance (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Migraine (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850971&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850973,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - Hiatus hernia - n/a - [n/a - n/a - n/a]),<BR><BR>[NIFEDIPINE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850973&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850975,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Anaphylactic reaction (1d - Recovered/Resolved - Life Threatening, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","PANTOPRAZOLE [PANTOPRAZOLE, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - n/a - n/a - [n/a - 2{DF} - n/a]),<BR><BR>PREGABALIN [PREGABALIN] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[AMOXICILLIN, AMOXICILLIN TRIHYDRATE] (C - n/a - n/a - [8d - 3{DF} - n/a]),<BR><BR>[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE, BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE] (C - n/a - n/a - [n/a - 4{DF} - n/a]),<BR><BR>[CARBOCISTEINE] (C - n/a - n/a - [n/a - 6{DF} - n/a]),<BR><BR>[MIRTAZAPINE] (C - n/a - n/a - [116d - 1{DF} - n/a]),<BR><BR>[MONTELUKAST, MONTELUKAST SODIUM] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - n/a - n/a - [n/a - n/a - Inhalation use]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - n/a - n/a - [1d - 1{DF} - n/a]),<BR><BR>[SOLIFENACIN] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[TIOTROPIUM] (C - n/a - n/a - [n/a - 2{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850975&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850977,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Sleep disorder due to a general medical condition (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - Tinnitus - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850977&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850986,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chest pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850986&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014850989,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Diverticulitis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014850989&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851001,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Sneezing (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851001&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851003,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abnormal dreams (n/a - Unknown - Other Medically Important Condition),<BR><BR>Cold sweat (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Confusional state (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dissociation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dysgeusia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Loss of personal independence in daily activities (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Migraine (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nasopharyngitis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Somnolence (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[BECLOMETASONE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL MICRONIZED, SALBUTAMOL SULFATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851003&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851004,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Erythema (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Unknown - Other Medically Important Condition),<BR><BR>Somnolence (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Vomiting (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Wheezing (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","ESOMEPRAZOLE [ESOMEPRAZOLE] (C - Hiatus hernia - n/a - [n/a - n/a - n/a]),<BR><BR>[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - Spinal osteoarthritis - n/a - [n/a - n/a - n/a]),<BR><BR>[CODEINE PHOSPHATE BP, PARACETAMOL PH. EUR., PARACETAMOL, CODEINE PHOSPHATE] (C - Fibromyalgia, Spinal osteoarthritis - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851004&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851008,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Eye swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Skin discolouration (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851008&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851009,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851009&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851011,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",APIXABAN [APIXABAN] (C - Deep vein thrombosis - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851011&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851014,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Back pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myocarditis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension - n/a - [28d - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE] (C - Hypertension - n/a - [27d - n/a - n/a]),<BR><BR>[CANDESARTAN, CANDESARTAN CILEXETIL] (C - Hypertension - n/a - [20d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851014&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851016,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Arthritis reactive (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chest discomfort (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Erythromelalgia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Rash (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[TAMSULOSIN, TAMSULOSIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851016&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851019,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Blood pressure increased (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chest discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Heart rate increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hot flush (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","IBUPROFEN [IBUPROFEN, IBUPROFEN SODIUM] (C - Analgesic therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRADIOL] (C - Hormone replacement therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Analgesic therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[PROGESTERONE, PROGESTERONE, MICRONISED] (C - Hormone replacement therapy - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851019&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851020,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Blood pressure measurement - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - Blood triglycerides increased - n/a - [n/a - n/a - n/a]),<BR><BR>[INDAPAMIDE, INDAPAMIDE HEMIHYDRATE] (C - Blood pressure measurement - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - Gastric ulcer - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Arthralgia - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - Blood pressure measurement - n/a - [n/a - n/a - n/a]),<BR><BR>[REBOXETINE] (C - Depression - n/a - [n/a - n/a - n/a]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - Depression - n/a - [n/a - n/a - n/a]),<BR><BR>[SOTALOL, SOTALOL HYDROCHLORIDE] (C - Blood pressure measurement - n/a - [n/a - n/a - n/a]),<BR><BR>[TAMSULOSIN, TAMSULOSIN HYDROCHLORIDE] (C - Urinary incontinence - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851020&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851023,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Axillary pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Swelling (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",PREGABALIN [PREGABALIN] (C - Multiple sclerosis - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851023&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851025,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chest discomfort (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Disorientation (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Somnolence (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vomiting (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851025&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851026,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Atrial fibrillation (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Back pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (2d - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851026&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851027,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Confusional state (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (7d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain in extremity (7d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (4d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[LANSOPRAZOLE] (C - Gastrointestinal disorder - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851027&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851031,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dyspepsia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Glossodynia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Influenza (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Immunisation - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851031&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851033,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Migraine (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[LEVONORGESTREL, LEVONORGESTREL MICRONISED] (C - Contraception - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851033&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851034,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - ),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (1d - Recovered/Resolved - ),<BR><BR>Oral pain (1d - Recovered/Resolved - ),<BR><BR>Palpitations (1d - Recovered/Resolved - ),<BR><BR>Paraesthesia oral (1d - Recovered/Resolved - ),<BR><BR>Urticaria (2d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[ESTRADIOL] (C - Artificial menopause - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851034&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851036,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Heart rate increased (28h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851036&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851037,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851037&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851039,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Body temperature abnormal (n/a - Recovering/Resolving - ),<BR><BR>Cough (n/a - Recovering/Resolving - ),<BR><BR>Hypoacusis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Immunisation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Incorrect dose administered (n/a - Unknown - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Night sweats (n/a - Recovering/Resolving - ),<BR><BR>Off label use (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tympanic membrane perforation (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851039&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851040,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Menstruation irregular (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Mouth ulceration (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Postmenopausal haemorrhage (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pruritus (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site rash (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination site swelling (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[PARACETAMOL, CODEINE PHOSPHATE] (C - Pain in extremity - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851040&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851041,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chills (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851041&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851043,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Blood triglycerides increased (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dermatitis atopic (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hypersensitivity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Iron deficiency (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lichen planus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Non-alcoholic fatty liver (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rash (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851043&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851045,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,Swelling (n/a - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851045&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851182,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Glomerulonephritis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Haematuria (n/a - Recovering/Resolving - ),<BR><BR>IgA nephropathy (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851182&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851183,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Fall (n/a - Unknown - ),<BR><BR>Haemorrhage (n/a - Unknown - Other Medically Important Condition),<BR><BR>Sensory disturbance (n/a - Unknown - ),<BR><BR>Wound (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851183&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851192,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Asthenia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Blood pressure increased (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Dysstasia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Malaise (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Nausea (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851192&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851193,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Anaphylactic reaction (n/a - Unknown - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851193&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851195,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Adult,No,Female,Hypothermia (n/a - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851195&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851196,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Urticaria (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851196&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851222,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Lymph node pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851222&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851223,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Bone pain (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Ear pain (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Lip swelling (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Speech disorder (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851223&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851225,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851225&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851226,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Pleurisy (20d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851226&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851228,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Limb discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851228&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851229,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal discomfort (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Gastrointestinal pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hunger (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Migraine (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Unknown - Other Medically Important Condition),<BR><BR>Urticaria (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851229&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851230,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dizziness postural (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Muscle spasms (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - Mixed anxiety and depressive disorder - n/a - [n/a - 125mg - n/a - More in ICSR]),<BR><BR>[CHLORDIAZEPOXIDE] (C - Mixed anxiety and depressive disorder - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851230&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851233,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Lymph node pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Somnolence (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site bruising (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site erythema (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pruritus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","PREGABALIN [PREGABALIN] (C - Fibromyalgia - n/a - [n/a - n/a - n/a]),<BR><BR>[CYANOCOBALAMIN] (C - Vitamin B12 deficiency - n/a - [n/a - n/a - n/a]),<BR><BR>[FLUCLOXACILLIN, FLUCLOXACILLIN SODIUM, FLUCLOXACILLIN SODIUM MONOHYDRATE] (C - Infection - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - n/a]),<BR><BR>[PROPRANOLOL, PROPRANOLOL HYDROCHLORIDE] (C - Vestibular migraine - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851233&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851234,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (16d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (16d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851234&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851237,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arrhythmia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Atrial fibrillation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Syncope (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851237&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851240,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Anaphylactic reaction (n/a - Recovering/Resolving - Life Threatening),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851240&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851241,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Sciatica (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851241&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851242,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Musculoskeletal pain (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Myalgia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Restlessness (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/BRISBANE/59/2007 (H1N1)-LIKE STRAIN, A/BRISBANE/10/2007 (H3N2)-LIKE STRAIN, B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1) V REASS. X - 179 A, A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/NANCHANG 933/95 (H3N2), A/BAYERN/7/95 (H1N1) - LIKE STRAIN (A/JOHANNESBURG/82/96), B/BEIJING/184/93-LIKE STRAIN (B/HARBIN/7/94), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN (A/NEW CALEDONIA/20/99 REASS. IVR-116), A/CALIFORNIA/7/2004 (H3N2) - LIKE STRAIN (A/NEW YORK/55/2004 REASS. NYMC X-157), B/SHANGHAI/361/2002 - LIKE STRAIN (B/JIANGSU/10/2003), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN (A/NEW CALEDONIA/20/99 REASS. IVR-116), A/MOSCOW/10/99 (H3N2) - LIKE STRAIN (A/PANAMA/2007/99 REASS. RESVIR-17), B/SICHUAN/379/99-LIKE STRAIN (B/JOHANNESBURG/5/99), A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), A/CALIFORNIA/7/2009 (H1N1)-DERIVED STRAIN USED NYMC X-181, B/BRISBANE/60/2008, A/SWITZERLAND/9715293/2013 (H3N2)-LIKE STRAIN (A/SWITZERLAND/9715293/2013, NIB-88), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN B, A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1), A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1)V-LIKE VIRUS, A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/MASSACHUSETTS/2/2012 -DERIVED STRAIN USED (NYMC BX-51B), A/TEXAS/50/2012 (H3N2) – DERIVED STRAIN USED (NYMC X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/MASSACHUSETTS/2/2012 -DERIVED STRAIN USED (NYMC BX-51B), A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN A (H1N1), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN A (H3N2), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN B] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851242&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851243,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Cold sweat (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Condition aggravated (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dysstasia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Heart rate increased (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nasopharyngitis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nervousness (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Presyncope (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (2260min - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Retching (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Sleep disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tremor (28h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vision blurred (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851243&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851244,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Abdominal pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Abnormal faeces (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Blood pressure measurement - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - Blood cholesterol - n/a - [n/a - n/a - n/a]),<BR><BR>[CANDESARTAN, CANDESARTAN CILEXETIL] (C - Blood pressure measurement - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851244&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851246,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Sleep disorder (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851246&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851247,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Unknown - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lethargy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Somnolence (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination site swelling (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Diabetes mellitus - n/a - [1d - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BENDROFLUMETHIAZIDE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[GLICLAZIDE] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN HYDROCHLORIDE] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851247&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851248,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Ear pain (n/a - Unknown - ),<BR><BR>Eye pain (n/a - Unknown - ),<BR><BR>Eyelid ptosis (n/a - Unknown - ),<BR><BR>Facial paralysis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851248&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851249,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Agitation (n/a - Unknown - Disabling),<BR><BR>Arthralgia (n/a - Recovering/Resolving - Disabling),<BR><BR>Erythema (n/a - Recovered/Resolved With Sequelae - Disabling),<BR><BR>Fatigue (n/a - Recovered/Resolved With Sequelae - Disabling),<BR><BR>Feeling abnormal (n/a - Unknown - Disabling),<BR><BR>Headache (n/a - Recovered/Resolved - Disabling),<BR><BR>Insomnia (n/a - Recovered/Resolved With Sequelae - Disabling),<BR><BR>Interchange of vaccine products (n/a - Unknown - Disabling),<BR><BR>Myalgia (n/a - Recovering/Resolving - Disabling),<BR><BR>Peripheral swelling (n/a - Recovered/Resolved - Disabling),<BR><BR>Urticaria (n/a - Not Recovered/Not Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[CANDESARTAN, CANDESARTAN CILEXETIL] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851249&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851250,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Myocardial infarction (n/a - Recovered/Resolved With Sequelae - Life Threatening, Caused/Prolonged Hospitalisation, Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","BUMETANIDE [BUMETANIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>RANOLAZINE [RANOLAZINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>TICAGRELOR [TICAGRELOR] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID, ACETYLSALICYLIC ACID PH. EUR., ASPIRIN BP] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CANDESARTAN, CANDESARTAN CILEXETIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[EPLERENONE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ISOSORBIDE MONONITRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851250&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851251,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chest pain (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Cluster headache (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851251&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851252,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[ESTRADIOL] (C - Oral contraception - n/a - [n/a - n/a - n/a]),<BR><BR>[MEDROXYPROGESTERONE] (C - Oral contraception - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851252&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851253,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851253&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851254,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"Arthralgia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Body temperature fluctuation (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Ear infection (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Ear pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Excessive cerumen production (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Gingival swelling (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Otitis externa (n/a - Unknown - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Tinnitus (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851254&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851257,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Head discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Ocular discomfort (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/BRISBANE/59/2007 (H1N1)-LIKE STRAIN, A/BRISBANE/10/2007 (H3N2)-LIKE STRAIN, B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1) V REASS. X - 179 A, A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/NANCHANG 933/95 (H3N2), A/BAYERN/7/95 (H1N1) - LIKE STRAIN (A/JOHANNESBURG/82/96), B/BEIJING/184/93-LIKE STRAIN (B/HARBIN/7/94), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN (A/NEW CALEDONIA/20/99 REASS. IVR-116), A/CALIFORNIA/7/2004 (H3N2) - LIKE STRAIN (A/NEW YORK/55/2004 REASS. NYMC X-157), B/SHANGHAI/361/2002 - LIKE STRAIN (B/JIANGSU/10/2003), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN (A/NEW CALEDONIA/20/99 REASS. IVR-116), A/MOSCOW/10/99 (H3N2) - LIKE STRAIN (A/PANAMA/2007/99 REASS. RESVIR-17), B/SICHUAN/379/99-LIKE STRAIN (B/JOHANNESBURG/5/99), A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), A/CALIFORNIA/7/2009 (H1N1)-DERIVED STRAIN USED NYMC X-181, B/BRISBANE/60/2008, A/SWITZERLAND/9715293/2013 (H3N2)-LIKE STRAIN (A/SWITZERLAND/9715293/2013, NIB-88), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN B, A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1), A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1)V-LIKE VIRUS, A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/MASSACHUSETTS/2/2012 -DERIVED STRAIN USED (NYMC BX-51B), A/TEXAS/50/2012 (H3N2) – DERIVED STRAIN USED (NYMC X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/MASSACHUSETTS/2/2012 -DERIVED STRAIN USED (NYMC BX-51B), A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN A (H1N1), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN A (H3N2), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN B] (C - Influenza immunisation - n/a - [1d - n/a - n/a])...","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851257&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851260,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Cardiac contusion (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851260&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851261,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Tremor (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851261&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851262,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Blepharospasm (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851262&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851263,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Discoloured vomit (n/a - Unknown - Other Medically Important Condition),<BR><BR>Faecal vomiting (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Lethargy (24h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Oesophageal pain (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (24h - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851263&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851264,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Neurological symptom (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Thunderclap headache (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851264&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851265,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Cough (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Nausea (2d - Recovered/Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851265&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851266,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Epistaxis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Feeding disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Haemoptysis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypersomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pleurisy (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","XARELTO [RIVAROXABAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM TRIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FEXOFENADINE, FEXOFENADINE HYDROCHLORIDE] (C - Hypersensitivity - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - n/a]),<BR><BR>[PREDNISOLONE] (C - Pulmonary pain - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851266&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851267,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Gait disturbance (n/a - Unknown - Other Medically Important Condition),<BR><BR>Gait inability (n/a - Unknown - Other Medically Important Condition),<BR><BR>Mobility decreased (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Neuralgia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851267&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851268,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Bursitis (n/a - Recovered/Resolved - ),<BR><BR>Condition aggravated (n/a - Unknown - ),<BR><BR>Herpes zoster (n/a - Unknown - ),<BR><BR>Renal impairment (n/a - Unknown - Other Medically Important Condition),<BR><BR>Renal pain (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851268&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851269,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Movement disorder (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Product use issue (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (S - Influenza immunisation - Not applicable - [1d - n/a - n/a])",[FELODIPINE] (C - n/a - n/a - [n/a - 5mg - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851269&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851272,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Abnormal faeces (27d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dizziness (26d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Epilepsy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (26d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (26d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (42d - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Rhinorrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Sciatica (43d - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Sleep disorder (32d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tremor (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851272&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851273,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Sciatica (n/a - Unknown - Other Medically Important Condition),<BR><BR>Spinal pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851273&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851274,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851274&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851275,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Feeling hot (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Inflammation (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Rash erythematous (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851275&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851276,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chest pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hypertension (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851276&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851277,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest pain (2d - Recovered/Resolved - ),<BR><BR>Dizziness (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - ),<BR><BR>Syncope (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tinnitus (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851277&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851278,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (9d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pallor (7d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Rash (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Rash papular (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash pruritic (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (24h - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851278&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851279,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Immunisation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Incorrect dose administered (n/a - Unknown - Other Medically Important Condition),<BR><BR>Influenza (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Myalgia (10d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Off label use (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[BOTULINUM ANTITOXIN TYPE A PH. EUR., BOTULINUM TOXIN TYPE A, CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A (900 KD)] (S - Migraine - Unknown - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851279&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851281,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Cough (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Influenza (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nasopharyngitis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Night sweats (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Sneezing (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851281&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851282,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Muscle fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851282&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851283,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Asthenia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hypersensitivity (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Night sweats (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Off label use (n/a - Unknown - ),<BR><BR>Product use issue (n/a - Unknown - ),<BR><BR>Pruritus (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851283&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851285,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Maternal exposure during pregnancy (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[FOLIC ACID] (C - Vitamin supplementation - n/a - [n/a - 5mg - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851285&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851287,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthritis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","INFLECTRA [INFLIXIMAB] (C - Arthritis - n/a - [n/a - n/a - n/a]),<BR><BR>METHOTREXATE [METHOTREXATE] (C - Arthritis - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[PREDNISOLONE] (C - Arthritis - n/a - [15d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851287&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851288,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851288&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851289,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Brain fog (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Gastrooesophageal reflux disease (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Influenza (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Muscle twitching (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - Fibromyalgia - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851289&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851292,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Chest pain (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851292&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851293,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (6d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[NAPROXEN] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851293&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851294,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[CANDESARTAN, CANDESARTAN CILEXETIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INDAPAMIDE, INDAPAMIDE HEMIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851294&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851295,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Atrial fibrillation (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[CANDESARTAN, CANDESARTAN CILEXETIL] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[INDAPAMIDE, INDAPAMIDE HEMIHYDRATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[TIMOLOL, TAFLUPROST] (C - Ocular hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851295&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851296,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Body temperature abnormal (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Gait disturbance (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lip discolouration (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pallor (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Syncope (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851296&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851297,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Chest pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Heart rate increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nasopharyngitis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE, BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851297&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851299,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Axillary pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851299&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851300,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Atrial fibrillation (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fall (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypertension (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Troponin increased (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851300&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851301,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"Arthritis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Constipation (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Diarrhoea (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Sluggishness (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMOXICILLIN] (C - Tooth infection - n/a - [7d - n/a - n/a]),<BR><BR>[DROSPIRENONE, ETHINYLESTRADIOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ETODOLAC] (C - Systemic scleroderma - n/a - [n/a - n/a - n/a]),<BR><BR>[HYDROXYCHLOROQUINE] (C - Systemic scleroderma - n/a - [n/a - n/a - n/a]),<BR><BR>[LISDEXAMFETAMINE] (C - Attention deficit hyperactivity disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851301&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851302,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Body temperature increased (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling of body temperature change (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Injection related reaction (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Lethargy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Serum sickness-like reaction (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Swelling (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851302&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851303,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal pain upper (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Burning sensation (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Diarrhoea (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dry mouth (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dry throat (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Eye pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Feeling hot (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Feeling jittery (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Initial insomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Muscular weakness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Palpitations (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Taste disorder (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Tinnitus (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - Transient ischaemic attack - n/a - [n/a - n/a - n/a]),<BR><BR>[AMOXICILLIN, AMOXICILLIN TRIHYDRATE] (C - Lower respiratory tract infection - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL, CALCIUM CARBONATE] (C - Bone loss - n/a - [n/a - n/a - n/a]),<BR><BR>[FLECAINIDE, FLECAINIDE ACETATE] (C - Ventricular tachycardia - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Fibromyalgia - n/a - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - Transient ischaemic attack - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851303&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851304,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Cardiac flutter (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (6d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851304&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851305,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Anaphylactic reaction (1d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851305&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851309,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Inappropriate antidiuretic hormone secretion (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851309&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851310,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Adrenocortical insufficiency acute (n/a - Recovering/Resolving - Life Threatening, Other Medically Important Condition),<BR><BR>Condition aggravated (n/a - Recovering/Resolving - Life Threatening, Other Medically Important Condition),<BR><BR>Vomiting projectile (n/a - Recovered/Resolved - Life Threatening, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851310&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851311,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Erythema (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Feeling hot (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Retinal detachment (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[NORETHISTERONE] (C - Contraception - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851311&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851312,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Joint swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851312&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851313,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Piloerection (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","IBUPROFEN [IBUPROFEN, IBUPROFEN SODIUM] (C - Arthralgia - n/a - [n/a - n/a - n/a]),<BR><BR>[CODEINE] (C - Arthralgia - n/a - [n/a - n/a - n/a]),<BR><BR>[DEXIBUPROFEN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Arthralgia - n/a - [n/a - n/a - n/a]),<BR><BR>[TRAMADOL, TRAMADOL HYDROCHLORIDE] (C - Arthralgia - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851313&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851314,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851314&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851315,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Arthralgia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Back pain (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chest discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Immunisation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Incorrect dose administered (n/a - Unknown - ),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Neck pain (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Off label use (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain in jaw (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Product use issue (n/a - Unknown - ),<BR><BR>Pyrexia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (S - Immunisation - Not applicable - [n/a - n/a - n/a])",[GABAPENTIN] (C - Neuralgia - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851315&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851420,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (3d - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (3d - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Headache (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","BUPRENORPHINE [BUPRENORPHINE] (C - Analgesic therapy - n/a - [n/a - n/a - n/a]),<BR><BR>HUMIRA [ADALIMUMAB] (C - Psoriatic arthropathy - n/a - [n/a - n/a - n/a]),<BR><BR>METHOTREXATE [METHOTREXATE] (C - Psoriatic arthropathy - n/a - [n/a - n/a - n/a]),<BR><BR>[FERROUS FUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FOLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Antiviral prophylaxis, Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[NAPROXEN, NAPROXEN SODIUM] (C - Psoriatic arthropathy - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851420&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851421,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Photopsia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vitreous floaters (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851421&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851426,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dizziness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851426&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851427,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Balance disorder (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851427&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851428,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Decreased appetite (n/a - Unknown - Other Medically Important Condition),<BR><BR>Somnolence (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851428&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851429,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dizziness postural (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851429&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851430,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal pain upper (n/a - Unknown - Other Medically Important Condition),<BR><BR>Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Condition aggravated (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Diarrhoea (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Insomnia (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851430&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851431,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Eye pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Photophobia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Uveitis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vision blurred (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[CANDESARTAN, CANDESARTAN CILEXETIL] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[NAPROXEN, NAPROXEN SODIUM] (C - Fibromyalgia - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL, CODEINE PHOSPHATE] (C - Fibromyalgia - n/a - [n/a - n/a - n/a]),<BR><BR>[SUMATRIPTAN, SUMATRIPTAN SUCCINATE] (C - Migraine - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851431&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851432,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Incontinence (n/a - Unknown - Other Medically Important Condition),<BR><BR>Loss of consciousness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Overdose (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pulse absent (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .5mL - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851432&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851433,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Cardiac arrest (n/a - Fatal - Results in Death),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851433&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851434,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chest discomfort (n/a - Unknown - ),<BR><BR>Decreased appetite (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - ),<BR><BR>Feeling abnormal (n/a - Unknown - ),<BR><BR>Limb discomfort (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Middle insomnia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Musculoskeletal discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Musculoskeletal stiffness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Night sweats (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ANHYDROUS LEVOTHYROXINE SODIUM, LEVOTHYROXINE, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS EP] (C - n/a - n/a - [n/a - 100g - n/a]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - n/a - n/a - [n/a - 10mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851434&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851435,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Energy increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypertension (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tension headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Tinnitus (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851435&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851436,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Cardiomegaly (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypertension (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","SAXAGLIPTIN [SAXAGLIPTIN] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[DILTIAZEM HYDROCHLORIDE] (C - Cardiac disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Thyroid disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - Blood cholesterol increased - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851436&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851439,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dysmenorrhoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Postmenopausal haemorrhage (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pulmonary thrombosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Respiratory disorder (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","APREMILAST [APREMILAST] (C - Arthritis - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRADIOL] (C - Hormone replacement therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[ETORICOXIB] (C - Arthritis - n/a - [n/a - n/a - n/a]),<BR><BR>[NORETHISTERONE] (C - Hormone replacement therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL, CODEINE PHOSPHATE] (C - Arthritis - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851439&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851440,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Hypotension (n/a - Unknown - ),<BR><BR>Oxygen saturation decreased (n/a - Unknown - ),<BR><BR>Presyncope (n/a - Recovered/Resolved - ),<BR><BR>Syncope (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[DESMOPRESSIN, DESMOPRESSIN ACETATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851440&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851441,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Unknown - Other Medically Important Condition),<BR><BR>Influenza (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Listless (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Antiviral prophylaxis - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851441&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851442,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Axillary pain (10d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (9d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Swelling (10d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851442&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851443,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Heart rate increased (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Hypersensitivity (1d - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Syncope (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Throat tightness (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Tremor (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",HYDROXYCARBAMIDE [HYDROXYCARBAMIDE] (C - Thrombocytopenia - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851443&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851446,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Pyrexia (1d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851446&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851448,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Night sweats (n/a - Unknown - Other Medically Important Condition),<BR><BR>Stupor (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[CODEINE PHOSPHATE BP, PARACETAMOL PH. EUR., PARACETAMOL, CODEINE PHOSPHATE] (C - Pain - n/a - [n/a - n/a - n/a]),<BR><BR>[NAPROXEN, NAPROXEN SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851448&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851454,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Insomnia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851454&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851455,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Abdominal pain upper (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Abdominal tenderness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspepsia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Flatulence (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[LISINOPRIL, LISINOPRIL DIHYDRATE] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851455&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851456,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Axillary mass (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Axillary pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Swelling (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851456&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851461,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Ear discomfort (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[FELODIPINE] (C - Hypertension - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851461&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851462,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"Arthralgia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Delirium (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851462&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851466,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Hypoaesthesia (2d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851466&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851467,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Confusional state (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851467&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851470,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chills (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Muscular weakness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851470&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851471,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Condition aggravated (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hearing disability (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hyperacusis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851471&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851472,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INDAPAMIDE, INDAPAMIDE HEMIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851472&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851474,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Anaphylactoid reaction (2d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851474&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851475,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Abdominal pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851475&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851476,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851476&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851477,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851477&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851480,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypersomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","FREMANEZUMAB [FREMANEZUMAB] (C - Migraine prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[BUPRENORPHINE] (C - Ehlers-Danlos syndrome - n/a - [n/a - n/a - n/a]),<BR><BR>[CELECOXIB] (C - Pain - n/a - [n/a - n/a - n/a]),<BR><BR>[DESOGESTREL] (C - Contraception - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - n/a]),<BR><BR>[MORPHINE SULFATE, MORPHINE SULFATE PENTAHYDRATE] (C - Pain - n/a - [n/a - n/a - n/a]),<BR><BR>[NORTRIPTYLINE, NORTRIPTYLINE HYDROCHLORIDE] (C - Anxiety disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - Depression - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851480&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851482,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Blood pressure increased (n/a - Unknown - ),<BR><BR>Erythema (n/a - Unknown - ),<BR><BR>Joint swelling (n/a - Unknown - ),<BR><BR>Muscle spasms (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/H1N1 INFLUENZA VACCINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - Hiatus hernia - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851482&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851485,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash macular (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site erythema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site swelling (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851485&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851486,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Lymph node pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851486&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851489,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myocarditis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851489&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851492,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,Alopecia areata (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851492&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851495,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Not Specified,"Dyspnoea (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Gait inability (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ALLOPURINOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CANDESARTAN, CANDESARTAN CILEXETIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FOLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METOPROLOL, METOPROLOL TARTRATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851495&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851497,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Dizziness (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Paraesthesia (n/a - Recovering/Resolving - Disabling),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","ZONISAMIDE [ZONISAMIDE] (C - Seizure - n/a - [n/a - n/a - n/a]),<BR><BR>[GABAPENTIN] (C - Pain - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851497&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851500,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Eye pruritus (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (1d - Recovered/Resolved - ),<BR><BR>Pyrexia (2d - Recovered/Resolved - ),<BR><BR>Rhinorrhoea (n/a - Recovering/Resolving - ),<BR><BR>Syncope (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851500&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851501,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851501&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851502,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chest pain (7d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (7d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (S - Immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851502&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851503,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,12-17 Years,Not Specified,No,Male,Pancreatitis acute (9d - Recovered/Resolved - Caused/Prolonged Hospitalisation),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851503&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851504,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,12-17 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851504&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851506,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Deep vein thrombosis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Phlebitis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851506&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851507,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Balance disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Type 2 diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[BENDROFLUMETHIAZIDE] (C - Type 2 diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851507&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851508,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Cardiac arrest (8d - Recovered/Resolved With Sequelae - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Unresponsive to stimuli (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851508&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851509,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Axillary pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Intermenstrual bleeding (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lethargy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851509&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851510,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Immunisation - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851510&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851511,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851511&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851512,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Communication disorder (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dysarthria (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Speech disorder (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[CETIRIZINE, CETIRIZINE DIHYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Antiviral prophylaxis - n/a - [1d - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851512&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851513,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dizziness (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Heavy menstrual bleeding (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","CAPSAICIN [CAPSAICIN] (C - Analgesic therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - Herpes zoster - n/a - [n/a - n/a - n/a]),<BR><BR>[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - Analgesic therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[CARBOMER, CARBOMER 980] (C - Dry eye - n/a - [n/a - n/a - n/a]),<BR><BR>[ETORICOXIB] (C - Psoriatic arthropathy - n/a - [n/a - n/a - n/a]),<BR><BR>[MORPHINE SULFATE, MORPHINE SULFATE PENTAHYDRATE] (C - Analgesic therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PREDNISOLONE] (C - Arthritis - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851513&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851516,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chest discomfort (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Urticaria (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851516&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851518,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Asthenia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Sleep disorder due to a general medical condition (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tinnitus (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851518&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851519,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851519&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851520,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Myositis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Off label use (n/a - Unknown - ),<BR><BR>Product use issue (n/a - Unknown - ),<BR><BR>Vaccination site pain (8wk - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),<BR><BR>[INFLUENZA VIRUS] (S - Influenza immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851520&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851522,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Rash erythematous (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851522&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851523,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Decreased appetite (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Disturbance in attention (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (3d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851523&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851524,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Balance disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness postural (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851524&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851526,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Atrial fibrillation (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851526&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851528,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Asthenia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chest discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Heart rate increased (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Immunisation (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myocarditis (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Off label use (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851528&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851531,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Heart rate irregular (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851531&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851634,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Loss of personal independence in daily activities (n/a - Unknown - Other Medically Important Condition),<BR><BR>Shoulder injury related to vaccine administration (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851634&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851635,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dizziness (n/a - Unknown - ),<BR><BR>Erythema (n/a - Unknown - ),<BR><BR>Feeling hot (n/a - Unknown - ),<BR><BR>Pain in extremity (n/a - Unknown - ),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Product administered at inappropriate site (n/a - Unknown - ),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pruritus (n/a - Unknown - ),<BR><BR>Target skin lesion (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","ZOLEDRONIC ACID [ZOLEDRONIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CALCIUM CARBONATE, COLECALCIFEROL CONCENTRATE (POWDER FORM) (SDS), COLECALCIFEROL, CALCIUM CARBONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FEXOFENADINE, FEXOFENADINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - 180mg - n/a]),<BR><BR>[FOLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[GOSERELIN, GOSERELIN ACETATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[TAMOXIFEN, TAMOXIFEN CITRATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851635&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851637,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Cardiac flutter (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Discomfort (30h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Blood pressure abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[CANDESARTAN, CANDESARTAN CILEXETIL] (C - Blood pressure abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851637&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851638,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling cold (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Seizure (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","BUDESONIDE [BUDESONIDE] (C - Crohn's disease - n/a - [n/a - 3mg - n/a]),<BR><BR>[FOLIC ACID] (C - Osteoporosis - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851638&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851640,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Syncope (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851640&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851641,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"Breast pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Mastitis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851641&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851642,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dry skin (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Eye irritation (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Eye pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Eye swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lip pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lip swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain of skin (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rash (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Swelling face (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Urticaria (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[PARACETAMOL, CODEINE PHOSPHATE] (C - Intervertebral disc protrusion - n/a - [n/a - n/a - n/a]),<BR><BR>[PROPRANOLOL, PROPRANOLOL HYDROCHLORIDE] (C - Migraine - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851642&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851643,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Rash (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site mass (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851643&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851645,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Deafness unilateral (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Influenza (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Lymphadenitis (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Nasopharyngitis (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[ALLOPURINOL] (C - Gout - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851645&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851648,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"Headache (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Muscle swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Musculoskeletal stiffness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myofascial pain syndrome (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","LYRICA [PREGABALIN] (C - Fibromyalgia - n/a - [n/a - n/a - n/a]),<BR><BR>TESTOSTERONE [TESTOSTERONE] (C - Transgender hormonal therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[CETIRIZINE, CETIRIZINE DIHYDROCHLORIDE] (C - Multiple allergies - n/a - [n/a - n/a - n/a]),<BR><BR>[ESCITALOPRAM, ESCITALOPRAM OXALATE] (C - Depression - n/a - [n/a - n/a - n/a]),<BR><BR>[HYDROXYCHLOROQUINE] (C - Undifferentiated connective tissue disease - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - n/a - n/a - [1d - n/a - n/a]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - Post procedural hypothyroidism - n/a - [n/a - n/a - n/a]),<BR><BR>[LISDEXAMFETAMINE DIMESYLATE] (C - Attention deficit hyperactivity disorder - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851648&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851650,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Bleeding time shortened (n/a - Unknown - Other Medically Important Condition),<BR><BR>Coagulopathy (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypomenorrhoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lethargy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Migraine with aura (2055min - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Wound (n/a - Unknown - Other Medically Important Condition),<BR><BR>Wound haemorrhage (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[LORATADINE] (C - Rhinitis allergic - n/a - [n/a - 10mg - n/a]),<BR><BR>[OMEPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - 20mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851650&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851652,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Hypoglycaemia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Immunisation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Incorrect dose administered (n/a - Unknown - ),<BR><BR>Loss of consciousness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Off label use (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","INSULIN ASPART [INSULIN ASPART] (C - Type 1 diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>INSULIN GLARGINE [INSULIN GLARGINE] (C - Type 1 diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>LANTUS [INSULIN GLARGINE] (C - Type 1 diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>NOVORAPID [INSULIN ASPART] (C - Type 1 diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851652&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851653,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Aphonia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Chest pain (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Fatigue (18d - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Heart rate irregular (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Hypotension (6d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Stridor (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Tongue spasm (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Tremor (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Urticaria (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851653&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851654,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chills (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851654&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851657,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Neck mass (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AZITHROMYCIN, AZITHROMYCIN DIHYDRATE, AZITHROMYCIN HYDRATE] (C - Infection - n/a - [n/a - n/a - n/a]),<BR><BR>[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE, BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[CANDESARTAN, CANDESARTAN CILEXETIL] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[CARBOCISTEINE] (C - Rales - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Antiviral prophylaxis - n/a - [1d - n/a - n/a]),<BR><BR>[MONTELUKAST, MONTELUKAST SODIUM] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[TIOTROPIUM, TIOTROPIUM BROMIDE, TIOTROPIUM BROMIDE MONOHYDRATE] (C - Asthma - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851657&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851659,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Immunisation (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Incorrect dose administered (n/a - Unknown - ),<BR><BR>Migraine (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Off label use (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ANHYDROUS LEVOTHYROXINE SODIUM] (C - Autoimmune disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Congenital hypothyroidism - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851659&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851660,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Chills (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Feeling hot (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851660&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851662,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenopia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Formication (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Impaired work ability (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Monoparesis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Unknown - Other Medically Important Condition),<BR><BR>Somnolence (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[CODEINE PHOSPHATE BP, PARACETAMOL PH. EUR., PARACETAMOL, CODEINE PHOSPHATE] (C - Myalgia - n/a - [n/a - n/a - n/a]),<BR><BR>[GABAPENTIN] (C - Neuralgia - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - Dyspepsia - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851662&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851663,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Back pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Blood pressure abnormal (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Heart rate abnormal (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain of skin (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rhinorrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851663&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851664,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Burning sensation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Herpes zoster (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Herpes zoster oticus (n/a - Unknown - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nerve injury (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Sensitive skin (n/a - Unknown - Other Medically Important Condition),<BR><BR>Skin reaction (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851664&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851667,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Tinnitus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851667&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851669,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Lip swelling (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Paraesthesia oral (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pharyngeal swelling (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - n/a])","[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [438d - n/a - n/a]),<BR><BR>[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE, BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[DESOGESTREL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[DOXYCYCLINE, DOXYCYCLINE HYCLATE, DOXYCYCLINE MONOHYDRATE] (C - n/a - n/a - [14d - n/a - n/a]),<BR><BR>[FOLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LABETALOL HYDROCHLORIDE] (C - n/a - n/a - [466d - n/a - n/a]),<BR><BR>[MONTELUKAST, MONTELUKAST SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PREDNISOLONE] (C - n/a - n/a - [5d - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - Blood pressure measurement - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851669&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851670,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851670&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851671,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Anxiety (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Depression (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Irritability (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[MIRTAZAPINE] (C - Depression - n/a - [n/a - n/a - n/a]),<BR><BR>[PERICIAZINE] (C - Anxiety - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851671&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851672,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Epistaxis (8d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851672&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851673,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Dyspnoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SODIUM HYDROGEN CARBONATE, CALCIUM CARBONATE, SODIUM ALGINATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851673&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851675,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Sciatica (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vertigo (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851675&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851678,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Fatigue (n/a - Recovered/Resolved - ),<BR><BR>Headache (n/a - Recovered/Resolved - ),<BR><BR>Myalgia (n/a - Recovered/Resolved - ),<BR><BR>Myocarditis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pericarditis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovered/Resolved - ),<BR><BR>Vaccination site pain (n/a - Recovered/Resolved - ),<BR><BR>Vaccination site swelling (n/a - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Immunisation - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851678&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851694,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851694&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851695,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dizziness (1d - Recovered/Resolved - ),<BR><BR>Hypotension (1d - Recovered/Resolved - ),<BR><BR>Pallor (n/a - Unknown - ),<BR><BR>Syncope (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851695&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851697,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dizziness (n/a - Recovering/Resolving - Disabling),<BR><BR>Fatigue (n/a - Recovering/Resolving - Disabling),<BR><BR>Hyperhidrosis (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Insomnia (2d - Recovered/Resolved - Disabling),<BR><BR>Migraine (3d - Recovered/Resolved - Disabling),<BR><BR>Palpitations (n/a - Recovering/Resolving - Disabling),<BR><BR>Pyrexia (46h - Recovered/Resolved - Disabling),<BR><BR>Tremor (2d - Recovered/Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","DEXAMETHASONE [DEXAMETHASONE, DEXAMETHASONE SODIUM PHOSPHATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>PACLITAXEL [PACLITAXEL] (C - Neoplasm malignant - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE, BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CALCIUM CARBONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CARBOPLATIN] (C - Neoplasm malignant - n/a - [n/a - n/a - n/a]),<BR><BR>[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ENALAPRIL, ENALAPRIL MALEATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SUMATRIPTAN, SUMATRIPTAN SUCCINATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851697&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851698,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dry mouth (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851698&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851699,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Vomiting (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851699&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851700,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Migraine with aura (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851700&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851701,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Influenza like illness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851701&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851704,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Abdominal pain upper (n/a - Recovering/Resolving - ),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - ),<BR><BR>Haematochezia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851704&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851705,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthritis (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Inflammation (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Joint stiffness (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Musculoskeletal stiffness (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851705&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851706,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Eye pruritus (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Eye swelling (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rhinorrhoea (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Swelling face (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE, BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851706&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851709,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Not Specified,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Joint swelling (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (3d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ALENDRONATE SODIUM, ALENDRONIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[VITAMIN D] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851709&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851711,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Brain fog (n/a - Recovering/Resolving - Disabling),<BR><BR>Cough (n/a - Recovering/Resolving - Disabling),<BR><BR>Fatigue (n/a - Recovering/Resolving - Disabling),<BR><BR>Headache (n/a - Recovering/Resolving - Disabling),<BR><BR>Movement disorder (n/a - Unknown - Disabling),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Oropharyngeal pain (n/a - Recovering/Resolving - Disabling),<BR><BR>Pain (n/a - Recovering/Resolving - Disabling),<BR><BR>Rhinorrhoea (n/a - Recovering/Resolving - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851711&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851714,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Headache (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Heart rate increased (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Influenza (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Insomnia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Oedema (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851714&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851716,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Lymph node pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",XARELTO [RIVAROXABAN] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851716&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851717,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Ocular discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851717&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851718,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dizziness (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (5d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (36h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tremor (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851718&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851719,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Feeling jittery (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Illness (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Restlessness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851719&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851720,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Cold sweat (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Tremor (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Vomiting (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[DYDROGESTERONE, ESTRADIOL] (C - Hormone replacement therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[LYMECYCLINE] (C - Acne - n/a - [n/a - n/a - n/a]),<BR><BR>[PROPRANOLOL, PROPRANOLOL HYDROCHLORIDE] (C - Anxiety - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851720&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851723,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Discomfort (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pruritus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851723&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851725,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Feeling abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hypoaesthesia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851725&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851729,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851729&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851732,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Chills (5d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851732&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851734,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Fatigue (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Illness (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Immunisation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Incorrect dose administered (n/a - Unknown - ),<BR><BR>Musculoskeletal stiffness (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Off label use (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851734&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851735,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Migraine (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Night sweats (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851735&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851736,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Erythema (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Swelling (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851736&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851737,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Abdominal pain upper (n/a - Unknown - Other Medically Important Condition),<BR><BR>Asthenia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Cold sweat (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Diarrhoea (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dizziness (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Gait disturbance (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vomiting (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851737&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851738,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Condition aggravated (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Inflammatory pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Influenza (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Neuralgia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Somnolence (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site inflammation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site warmth (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[CODEINE] (C - Arthritis, Pain - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851738&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851739,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Abdominal distension (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hot flush (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Postmenopausal haemorrhage (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851739&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851740,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chest pain (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Cough (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Pericarditis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Secretion discharge (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851740&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851741,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest pain (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Sinus tachycardia (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - Migraine - n/a - [n/a - n/a - n/a]),<BR><BR>[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - Depression - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851741&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851742,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chest pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pulmonary oedema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851742&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851753,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hypoaesthesia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851753&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851754,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Chest pain (1d - Recovered/Resolved With Sequelae - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Interchange of vaccine products (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Myocardial infarction (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851754&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851755,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Blood pressure increased (n/a - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovered/Resolved - ),<BR><BR>Syncope (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851755&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851759,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Myalgia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Off label use (n/a - Unknown - ),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Product use issue (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (S - Immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851759&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851760,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Hypokinesia (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Sleep disorder due to a general medical condition (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[NAPROXEN, NAPROXEN SODIUM] (C - Arthralgia - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851760&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851761,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Blister (43d - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Hypoaesthesia (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Joint stiffness (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Joint swelling (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Skin discolouration (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851761&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851796,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851796&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851797,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Cardiac failure (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Cardiomegaly (n/a - Unknown - ),<BR><BR>Dyspnoea (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Dyspnoea exertional (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Generalised oedema (n/a - Unknown - ),<BR><BR>Pleural effusion (n/a - Unknown - ),<BR><BR>Wheezing (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])","ABILIFY [ARIPIPRAZOLE] (C - Schizophrenia - n/a - [n/a - n/a - Oral use]),<BR><BR>[DYDROGESTERONE] (C - Amenorrhoea - n/a - [n/a - n/a - Oral use]),<BR><BR>[ENALAPRIL MALEATE] (C - Aortic stenosis - n/a - [n/a - n/a - Oral use]),<BR><BR>[ESTRADIOL] (C - Amenorrhoea - n/a - [n/a - n/a - n/a]),<BR><BR>[MEXILETINE HYDROCHLORIDE] (C - Aortic stenosis - n/a - [n/a - n/a - Oral use]),<BR><BR>[WARFARIN, WARFARIN SODIUM] (C - Aortic stenosis - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851797&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851802,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851802&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851954,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Anaphylactic reaction (1d - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Overdose (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .5mL - n/a])",[PREDNISONE] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851954&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014851959,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Asthenia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Bradyphrenia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Cold sweat (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Cough (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Insomnia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014851959&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014852176,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chills (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Influenza like illness (4d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014852176&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014852186,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Headache (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Lethargy (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vomiting (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014852186&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014852188,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Flushing (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Food allergy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypertension (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Sinus tachycardia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Urticaria (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaginal haemorrhage (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014852188&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014852190,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Anaphylactic reaction (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Blood pressure increased (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014852190&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014852200,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"Insomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymph node pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Mobility decreased (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014852200&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014852256,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Complex regional pain syndrome (n/a - Unknown - Other Medically Important Condition),<BR><BR>Grip strength decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nerve block (n/a - Unknown - Other Medically Important Condition),<BR><BR>Oedema peripheral (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Skin discolouration (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014852256&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014852279,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Chills (2d - Recovered/Resolved - Disabling),<BR><BR>Lethargy (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Lip swelling (n/a - Recovering/Resolving - Disabling),<BR><BR>Pyrexia (2d - Recovered/Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014852279&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014852282,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[EXAMETAZIME] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[GOSERELIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014852282&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014852290,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Axillary pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014852290&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014852417,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Axillary pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014852417&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014852442,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Influenza (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014852442&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014852460,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Photopsia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014852460&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014852464,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Brain fog (n/a - Unknown - Other Medically Important Condition),<BR><BR>Confusional state (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dizziness (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (5d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (5d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (4d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014852464&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014852470,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Dyspnoea (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Hypersensitivity (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Inflammation (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Oropharyngeal pain (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Pharyngeal swelling (n/a - Unknown - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014852470&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014852505,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Disorientation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness postural (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014852505&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014852507,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Gait disturbance (n/a - Recovering/Resolving - ),<BR><BR>Gait inability (n/a - Recovering/Resolving - ),<BR><BR>Guillain-Barre syndrome (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014852507&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014852525,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Flushing (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014852525&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014852562,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Axillary pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hypersomnia (24h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Migraine (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Musculoskeletal discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site discomfort (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014852562&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014852804,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Palpitations (n/a - Unknown - ),<BR><BR>Sinus tachycardia (n/a - Unknown - ),<BR><BR>Tachycardia (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014852804&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014853102,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014853102&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014853109,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014853109&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014853195,Spontaneous,2023-03-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Hypertension (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014853195&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014853265,Spontaneous,2023-03-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Syncope (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014853265&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014835562,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Influenza like illness (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vision blurred (3d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Asthma - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014835562&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014835563,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Insomnia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Middle insomnia (n/a - Unknown - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014835563&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014835564,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Breast pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014835564&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014835566,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014835566&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014835567,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Flatulence (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Influenza (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Night sweats (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014835567&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014835568,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vertigo (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - Menopause - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[PROGESTERONE, PROGESTERONE, MICRONISED] (C - Menopause - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014835568&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014835578,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014835578&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014835582,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Peripheral artery thrombosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Peripheral coldness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pulse absent (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014835582&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014835583,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Tremor (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014835583&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014835585,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Pulmonary embolism (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014835585&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014835586,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chest pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Heart rate abnormal (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014835586&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014835587,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Cardiac arrest (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Chest pain (n/a - Fatal - Results in Death),<BR><BR>Paraesthesia oral (n/a - Fatal - Results in Death),<BR><BR>Swelling face (n/a - Fatal - Results in Death),<BR><BR>Swollen tongue (n/a - Fatal - Results in Death)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - n/a])","BUMETANIDE [BUMETANIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>RIVAROXABAN [RIVAROXABAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BUDESONIDE, FORMOTEROL FUMARATE DIHYDRATE, FORMOTEROL FUMARATE, BUDESONIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014835587&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014835593,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dizziness (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Extrasystoles (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Heart rate decreased (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Heart rate increased (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Heart rate irregular (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Interchange of vaccine products (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Loss of consciousness (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Off label use (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Presyncope (n/a - Unknown - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","PROLIA [DENOSUMAB] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - n/a - n/a - [1d - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - 75mg - n/a]),<BR><BR>[COLECALCIFEROL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LISINOPRIL, LISINOPRIL DIHYDRATE] (C - n/a - n/a - [n/a - 2.5mg - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - n/a - n/a - [n/a - 20mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014835593&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014835595,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Feeling cold (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tremor (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[BETAHISTINE, BETAHISTINE DIHYDROCHLORIDE, BETAHISTINE MESILATE] (C - Meniere's disease - n/a - [n/a - n/a - n/a]),<BR><BR>[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - Anxiety - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014835595&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014835598,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arrhythmia supraventricular (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Cardiomyopathy (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Heart rate increased (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Hypervolaemia (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Loss of personal independence in daily activities (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014835598&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014835600,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Deafness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014835600&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014835602,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,Papilloedema (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014835602&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014835603,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"Chillblains (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Condition aggravated (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014835603&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014835605,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Joint stiffness (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pharyngeal erythema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pharyngeal swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Retching (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Sensation of foreign body (n/a - Unknown - Other Medically Important Condition),<BR><BR>Speech disorder (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014835605&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014835609,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Illness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014835609&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014835610,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014835610&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014835611,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Generalised tonic-clonic seizure (1d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Syncope (n/a - Unknown - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014835611&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014835743,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,Cardiac pacemaker insertion (n/a - Unknown - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014835743&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014836038,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dyspepsia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lip swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Urticaria (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014836038&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014837408,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Acalculia (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Agnosia (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Agraphia (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Aphasia (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Apraxia (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Blood pressure increased (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Cerebral haemorrhage (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Cognitive disorder (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Dizziness (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Dysarthria (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Gait disturbance (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Haemorrhage (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Hemianopia homonymous (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Visual field defect (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])","[ACETYLSALICYLIC ACID] (C - Cerebral ischaemia, Lacunar infarction - n/a - [n/a - 100mg - Oral use]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE] (C - Hypertension - n/a - [n/a - 2.5mg - Oral use]),<BR><BR>[CANDESARTAN CILEXETIL, HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL] (C - Hypertension - n/a - [n/a - 8mg - Oral use]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - Dyslipidaemia - n/a - [n/a - 5mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014837408&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014837698,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal distension (n/a - Unknown - Other Medically Important Condition),<BR><BR>Anxiety (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Influenza like illness (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Migraine (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Poor quality sleep (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Postmenopausal haemorrhage (7d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Sleep disorder (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ESTRADIOL, ESTRADIOL HEMIHYDRATE, ESTRADIOL, NORETHISTERONE, NORETHISTERONE ACETATE, NORETHISTERONE ACETATE, ESTRADIOL, NORETHISTERONE ACETATE, ESTRADIOL HEMIHYDRATE] (C - Hormone replacement therapy - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014837698&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014837699,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Cough (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Joint range of motion decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pharyngeal swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rhinorrhoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Swelling face (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - Rhinitis allergic - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014837699&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014837700,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Axillary pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014837700&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014837704,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Fear (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nightmare (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Tremor (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014837704&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014837713,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chills (n/a - Recovering/Resolving - Disabling),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - Disabling),<BR><BR>Fatigue (n/a - Recovering/Resolving - Disabling),<BR><BR>Malaise (n/a - Recovering/Resolving - Disabling),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - Hiatus hernia - n/a - [n/a - n/a - n/a]),<BR><BR>[NIFEDIPINE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014837713&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014837714,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Palpitations (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[FLUOXETINE, FLUOXETINE HYDROCHLORIDE] (C - Anxiety - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014837714&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014837725,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Influenza like illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014837725&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014837734,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Erythema multiforme (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",DAPAGLIFLOZIN [DAPAGLIFLOZIN] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014837734&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014837735,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Abdominal pain lower (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Back pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dysmenorrhoea (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014837735&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014837742,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Lacrimation increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Optic discs blurred (n/a - Unknown - Other Medically Important Condition),<BR><BR>Retinal detachment (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vision blurred (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vitreous degeneration (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014837742&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014837743,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Disorientation (n/a - Unknown - ),<BR><BR>Malaise (n/a - Unknown - ),<BR><BR>Pyrexia (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Urticaria (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014837743&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014837746,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Postmenopausal haemorrhage (n/a - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[BUTYLSCOPOLAMINE, HYOSCINE BUTYLBROMIDE] (C - Irritable bowel syndrome - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014837746&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014837749,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Tinnitus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014837749&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014837750,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Aphonia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Cough (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dysphonia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014837750&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014837752,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Angioedema (6d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Rash pruritic (n/a - Unknown - Other Medically Important Condition),<BR><BR>Skin lesion (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - n/a])","[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[NAPROXEN, NAPROXEN SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PROGESTERONE, PROGESTERONE, MICRONISED] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014837752&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014837756,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014837756&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014837757,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Condition aggravated (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nasopharyngitis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014837757&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014837758,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE, BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE] (C - n/a - n/a - [n/a - n/a - Inhalation use]),<BR><BR>[FEXOFENADINE, FEXOFENADINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MONTELUKAST, MONTELUKAST SODIUM] (C - Asthma - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014837758&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014837760,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"Fall (n/a - Unknown - Other Medically Important Condition),<BR><BR>Head injury (n/a - Unknown - Other Medically Important Condition),<BR><BR>Illness (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Loss of consciousness (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014837760&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014837763,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Injected limb mobility decreased (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014837763&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014837769,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Mobility decreased (n/a - Unknown - Disabling),<BR><BR>Pain (n/a - Unknown - Disabling),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014837769&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014837773,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lethargy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tremor (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - Anxiety - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014837773&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014837774,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Dermatitis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Rash (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash erythematous (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash pruritic (n/a - Unknown - Other Medically Important Condition),<BR><BR>Skin warm (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vomiting (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014837774&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014837776,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Pyrexia (2d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014837776&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014837780,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Headache (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014837780&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014837782,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest discomfort (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Subarachnoid haemorrhage (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014837782&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014837784,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Urticaria (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","FREMANEZUMAB [FREMANEZUMAB] (C - Migraine - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL, CODEINE PHOSPHATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ZOLMITRIPTAN] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014837784&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014837785,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Anosognosia (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Dizziness (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Eustachian tube disorder (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Gait inability (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Inner ear disorder (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Nystagmus (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Vertigo (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014837785&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014837788,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Cardiac failure acute (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Shock (n/a - Fatal - Results in Death, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014837788&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014837789,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Loss of personal independence in daily activities (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Sleep disorder (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014837789&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014837790,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chest pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014837790&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014837793,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (72h - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[LAMOTRIGINE] (C - Epilepsy - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014837793&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014837794,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014837794&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014837800,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Influenza (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014837800&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014837801,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Cerebrovascular accident (32d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Metamorphopsia (7d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[NORTRIPTYLINE, NORTRIPTYLINE HYDROCHLORIDE] (C - Small fibre neuropathy - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014837801&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014837802,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014837802&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014837803,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Joint range of motion decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Sleep disorder (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014837803&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014837804,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Deep vein thrombosis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[PROPRANOLOL HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PROPRANOLOL, PROPRANOLOL HYDROCHLORIDE] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014837804&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014837809,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Erythema (n/a - Unknown - ),<BR><BR>Musculoskeletal stiffness (n/a - Unknown - ),<BR><BR>Odynophagia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014837809&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014837811,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Tonic convulsion (1d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Immunisation - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014837811&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014837816,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Deafness unilateral (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","METHOTREXATE [METHOTREXATE] (C - Rheumatoid arthritis - n/a - [n/a - 15mg - n/a]),<BR><BR>[FOLIC ACID] (C - n/a - n/a - [n/a - 5mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014837816&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014837817,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (2d - Recovered/Resolved - Disabling),<BR><BR>Dizziness (n/a - Recovering/Resolving - Disabling),<BR><BR>Dyspepsia (2d - Recovered/Resolved - Disabling),<BR><BR>Dyspnoea (n/a - Recovering/Resolving - Disabling),<BR><BR>Fibromyalgia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Hyperhidrosis (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Lymph node pain (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - Disabling),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Mobility decreased (n/a - Recovering/Resolving - Disabling),<BR><BR>Neck pain (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Pain in extremity (n/a - Unknown - Disabling),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Swelling (n/a - Unknown - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","DULOXETINE [DULOXETINE, DULOXETINE HYDROCHLORIDE] (C - Depression - n/a - [n/a - n/a - n/a]),<BR><BR>PREGABALIN [PREGABALIN] (C - Fibromyalgia - n/a - [n/a - n/a - n/a]),<BR><BR>[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE, BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[DOXYCYCLINE, DOXYCYCLINE HYCLATE, DOXYCYCLINE MONOHYDRATE] (C - Lower respiratory tract infection - n/a - [6d - n/a - n/a]),<BR><BR>[NARATRIPTAN] (C - Migraine - n/a - [n/a - n/a - n/a]),<BR><BR>[NORTRIPTYLINE, NORTRIPTYLINE HYDROCHLORIDE] (C - Fibromyalgia - n/a - [n/a - n/a - n/a]),<BR><BR>[PIZOTIFEN, PIZOTIFEN MALATE] (C - Migraine - n/a - [n/a - n/a - n/a]),<BR><BR>[PREDNISONE] (C - Lower respiratory tract infection - n/a - [8d - n/a - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[TRAMADOL, TRAMADOL HYDROCHLORIDE] (C - Pain - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014837817&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014839053,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Recovered/Resolved With Sequelae - ),<BR><BR>Asthenia (n/a - Recovered/Resolved With Sequelae - ),<BR><BR>Disturbance in attention (n/a - Recovered/Resolved With Sequelae - ),<BR><BR>Dizziness (n/a - Recovered/Resolved With Sequelae - ),<BR><BR>Fatigue (n/a - Recovered/Resolved With Sequelae - ),<BR><BR>Hypoaesthesia (n/a - Recovered/Resolved With Sequelae - ),<BR><BR>Limb discomfort (n/a - Recovered/Resolved With Sequelae - ),<BR><BR>Muscular weakness (n/a - Recovered/Resolved With Sequelae - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014839053&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014839244,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Anaphylactic shock (n/a - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Blood pressure decreased (9h - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Blood pressure immeasurable (9h - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Interchange of vaccine products (n/a - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Tachypnoea (532min - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Vomiting (532min - Recovered/Resolved - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014839244&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014839246,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (6d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (6d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014839246&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014839255,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Depressed level of consciousness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Epilepsy (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hyperventilation (n/a - Recovering/Resolving - ),<BR><BR>Seizure (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014839255&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014839295,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014839295&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014839302,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Hyperhidrosis (n/a - Recovering/Resolving - ),<BR><BR>Presyncope (n/a - Recovering/Resolving - ),<BR><BR>Syncope (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014839302&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014839307,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Urinary retention (n/a - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014839307&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014839308,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Angina pectoris (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hyperventilation (n/a - Unknown - ),<BR><BR>Palpitations (n/a - Unknown - ),<BR><BR>Panic reaction (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014839308&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014839310,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,Hyperpyrexia (n/a - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014839310&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014839311,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014839311&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014839316,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenia (n/a - Unknown - ),<BR><BR>Diplegia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fall (n/a - Unknown - ),<BR><BR>Feeling abnormal (n/a - Unknown - ),<BR><BR>Guillain-Barre syndrome (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - ),<BR><BR>Muscular weakness (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014839316&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840104,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Allodynia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Sleep disorder due to a general medical condition (n/a - Unknown - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840104&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840107,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Chest pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840107&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840108,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Feeling abnormal (24h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Injected limb mobility decreased (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rash papular (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash pruritic (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site mass (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","KEPPRA [LEVETIRACETAM] (C - Epilepsy - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[TRAMADOL, TRAMADOL HYDROCHLORIDE] (C - Intervertebral disc degeneration - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840108&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840109,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Heart rate increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840109&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840110,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vertigo (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Viral infection (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/BRISBANE/59/2007 (H1N1)-LIKE STRAIN, A/BRISBANE/10/2007 (H3N2)-LIKE STRAIN, B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1) V REASS. X - 179 A, A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/NANCHANG 933/95 (H3N2), A/BAYERN/7/95 (H1N1) - LIKE STRAIN (A/JOHANNESBURG/82/96), B/BEIJING/184/93-LIKE STRAIN (B/HARBIN/7/94), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN (A/NEW CALEDONIA/20/99 REASS. IVR-116), A/CALIFORNIA/7/2004 (H3N2) - LIKE STRAIN (A/NEW YORK/55/2004 REASS. NYMC X-157), B/SHANGHAI/361/2002 - LIKE STRAIN (B/JIANGSU/10/2003), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN (A/NEW CALEDONIA/20/99 REASS. IVR-116), A/MOSCOW/10/99 (H3N2) - LIKE STRAIN (A/PANAMA/2007/99 REASS. RESVIR-17), B/SICHUAN/379/99-LIKE STRAIN (B/JOHANNESBURG/5/99), A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), A/CALIFORNIA/7/2009 (H1N1)-DERIVED STRAIN USED NYMC X-181, B/BRISBANE/60/2008, A/SWITZERLAND/9715293/2013 (H3N2)-LIKE STRAIN (A/SWITZERLAND/9715293/2013, NIB-88), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN B, A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1), A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1)V-LIKE VIRUS, A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/MASSACHUSETTS/2/2012 -DERIVED STRAIN USED (NYMC BX-51B), A/TEXAS/50/2012 (H3N2) – DERIVED STRAIN USED (NYMC X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/MASSACHUSETTS/2/2012 -DERIVED STRAIN USED (NYMC BX-51B), A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN A (H1N1), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN A (H3N2), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN B] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840110&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840111,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Abdominal pain upper (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Asthenia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ATORVASTATIN] (C - Blood cholesterol abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Cardiac valve disease - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840111&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840113,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Atrial fibrillation (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840113&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840115,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Electrolyte imbalance (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Hypertensive crisis (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Infection (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>White blood cell count increased (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[LOSARTAN, LOSARTAN POTASSIUM] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840115&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840116,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Back pain (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>COVID-19 (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Chills (n/a - Unknown - Disabling),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Dyspnoea (n/a - Unknown - Disabling),<BR><BR>Eye pain (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Hyperhidrosis (n/a - Unknown - Disabling),<BR><BR>Malaise (n/a - Unknown - Disabling),<BR><BR>Pain (n/a - Unknown - Disabling),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Disabling),<BR><BR>Sneezing (n/a - Not Recovered/Not Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Thyroid cancer - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840116&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840117,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224)] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - Angina unstable - n/a - [n/a - n/a - n/a]),<BR><BR>[ISOSORBIDE MONONITRATE] (C - Angina unstable - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - Blood pressure abnormal - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840117&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840118,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Anxiety (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Panic attack (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840118&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840119,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Back pain (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Body temperature abnormal (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Heart rate abnormal (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Heart rate increased (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Hypertension (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840119&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840121,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myocarditis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840121&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840126,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Limb discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pruritus (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840126&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840128,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chills (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Decreased appetite (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Night sweats (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Sinus disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Sinus headache (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840128&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840130,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840130&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840131,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal pain upper (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Night sweats (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840131&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840132,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Body temperature fluctuation (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dry throat (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pharyngitis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Sleep disorder (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840132&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840133,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymph node pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840133&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840134,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Back pain (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Diarrhoea (1d - Recovered/Resolved - Disabling),<BR><BR>Myalgia (n/a - Recovering/Resolving - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840134&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840136,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal pain (n/a - Unknown - ),<BR><BR>Abnormal dreams (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Anosmia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Anxiety (n/a - Not Recovered/Not Resolved - ),<BR><BR>Asthenia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Brain fog (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Dissociation (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Dry eye (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Eye pain (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Facial pain (n/a - Unknown - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Gait inability (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Guillain-Barre syndrome (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Insomnia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Interchange of vaccine products (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Lethargy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Motion sickness (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Muscular weakness (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Panic attack (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Photophobia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Reflux gastritis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Respiratory muscle weakness (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","CIRCADIN [MELATONIN] (C - n/a - n/a - [n/a - 2mg - n/a]),<BR><BR>[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - 50mg - n/a]),<BR><BR>[CARBOMER, CARBOMER 980] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CARBOMER] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CEFALEXIN] (C - n/a - n/a - [n/a - 250mg - n/a]),<BR><BR>[CLOBETASOL PROPIONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FAMOTIDINE] (C - n/a - n/a - [n/a - 40mg - n/a]),<BR><BR>[FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE PH. EUR, NEOMYCIN SULFATE, POLYMYXIN B SULFATE, FLUOCINOLONE ACETONIDE, NEOMYCIN, POLYMYXIN B, FLUOCINOLONE ACETONIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[HYALURONIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - Hiatus hernia, Oesophagitis - n/a - [n/a - 30mg - n/a]),<BR><BR>[LAUROMACROGOL 400, SOYA-BEAN OIL REFINED, LAUROMACROGOL 400, UREA, MACROGOL LAURYL ETHER, SOYA OIL, MACROGOL LAURYL ETHER, UREA, SOYA BEAN OIL REFINED PH.EUR., LAUROMACROGOL 400 (PH. EUR.)] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARAFFIN, LIGHT LIQUID, PARAFFIN, LIGHT LIQUID, PARAFFIN WHITE SOFT] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PREDNISOLONE SODIUM PHOSPHATE] (C - Conjunctivitis allergic - n/a - [n/a - n/a - n/a]),<BR><BR>[SODIUM CROMOGLICATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[UREA] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[VENLAFAXINE, VENLAFAXINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - 75mg - n/a]),<BR><BR>[ZOLPIDEM, ZOLPIDEM TARTRATE] (C - Insomnia - n/a - [n/a - 5mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840136&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840138,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Bone pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Joint stiffness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Musculoskeletal stiffness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ATORVASTATIN] (C - Blood cholesterol increased - n/a - [n/a - n/a - n/a]),<BR><BR>[FINASTERIDE] (C - Penile haemorrhage - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - Blood pH increased - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840138&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840141,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,12-17 Years,Not Specified,No,Female,"Back pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840141&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840143,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chest discomfort (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840143&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840144,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840144&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840145,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Autoimmune encephalopathy (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840145&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840148,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Brain fog (n/a - Unknown - Disabling),<BR><BR>Chills (n/a - Recovering/Resolving - Disabling),<BR><BR>Diarrhoea (n/a - Recovered/Resolved - Disabling),<BR><BR>Dizziness (n/a - Recovered/Resolved - Disabling),<BR><BR>Headache (n/a - Recovered/Resolved - Disabling),<BR><BR>Hypoacusis (n/a - Unknown - Disabling),<BR><BR>Interchange of vaccine products (n/a - Unknown - Disabling),<BR><BR>Nasopharyngitis (n/a - Recovered/Resolved - Disabling),<BR><BR>Nausea (n/a - Unknown - Disabling),<BR><BR>Palpitations (n/a - Unknown - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","SHINGRIX [RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E, RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E, STIMULON, MONOPHOSPHORYL LIPID A] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[OMEPRAZOLE SODIUM] (C - COVID-19 - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840148&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840149,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Cough (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nasal congestion (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nasopharyngitis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (3d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - Hormone replacement therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a]),<BR><BR>[PROGESTERONE, PROGESTERONE, MICRONISED] (C - Hormone replacement therapy - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840149&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840150,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hyperaesthesia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ATORVASTATIN] (C - Hypercholesterolaemia - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840150&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840151,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840151&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840152,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Toothache (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE, BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE] (C - Asthma - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840152&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840154,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Cardiac flutter (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATENOLOL, ATENOLOL BP] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840154&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840156,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chills (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Eye pain (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Feeling abnormal (n/a - Unknown - Disabling),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Influenza like illness (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Pain in extremity (n/a - Unknown - Disabling),<BR><BR>Vomiting (n/a - Not Recovered/Not Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ATORVASTATIN] (C - Blood cholesterol increased - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840156&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840158,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vertigo (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840158&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840159,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Illness (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Loss of consciousness (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Malaise (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Somnolence (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840159&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840161,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site swelling (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840161&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840162,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hunger (n/a - Unknown - Other Medically Important Condition),<BR><BR>Immunisation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Off label use (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain of skin (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Unknown - Other Medically Important Condition),<BR><BR>Restlessness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Thirst (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840162&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840163,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Lymphadenopathy (n/a - Unknown - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840163&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840166,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840166&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840168,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Diplopia (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Transient ischaemic attack (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840168&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840173,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nasopharyngitis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Tremor (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840173&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840175,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Hypertension (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[BICALUTAMIDE] (C - Prostate cancer - n/a - [n/a - n/a - n/a]),<BR><BR>[TAMSULOSIN, TAMSULOSIN HYDROCHLORIDE] (C - Dysuria - n/a - [n/a - n/a - n/a]),<BR><BR>[UMECLIDINIUM] (C - Chronic obstructive pulmonary disease - n/a - [n/a - n/a - n/a]),<BR><BR>[VILANTEROL] (C - Chronic obstructive pulmonary disease - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840175&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840178,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Angioedema (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Aphasia (2d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Dizziness (2d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Headache (3d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Malaise (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Rash (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Swelling (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Vasculitis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Vomiting (2d - Recovered/Resolved - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[NEBIVOLOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[WARFARIN, WARFARIN SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840178&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840179,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dermatitis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hypersensitivity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lichen planus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rash (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840179&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840181,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[MESALAZINE] (C - n/a - n/a - [n/a - 2400mg - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840181&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840185,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Arthralgia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840185&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840187,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Anaphylactic reaction (1d - Recovered/Resolved - Life Threatening),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840187&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840189,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Heart rate increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tremor (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840189&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840190,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Malaise (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840190&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840191,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Brain fog (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840191&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840199,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840199&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840201,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vertigo (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",AZATHIOPRINE [AZATHIOPRINE] (C - Colitis ulcerative - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840201&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840210,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Malaise (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840210&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840211,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Gait inability (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840211&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840212,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840212&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840213,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Maternal exposure during pregnancy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[FOLIC ACID] (C - Vitamin supplementation - n/a - [n/a - 5mg - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840213&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840214,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Drug ineffective (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840214&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840217,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Lower respiratory tract infection (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Pulmonary embolism (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840217&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840224,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Axillary pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Muscular weakness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Periarthritis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site swelling (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840224&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840410,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal pain (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (4d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840410&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840414,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nystagmus (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vertigo (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","OLAPARIB [OLAPARIB] (C - Neoplasm malignant - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[MONTELUKAST SODIUM] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - Reflux gastritis - n/a - [n/a - n/a - n/a]),<BR><BR>[ROPINIROLE] (C - Restless legs syndrome - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840414&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840415,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Gait disturbance (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840415&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840416,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[TRAMADOL, TRAMADOL HYDROCHLORIDE] (C - Knee deformity - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840416&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840418,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Cough (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dysphonia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lacrimation increased (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Paraesthesia oral (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Sneezing (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840418&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840419,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Eye swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840419&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840421,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840421&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840422,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Arthritis (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Gait inability (n/a - Unknown - Disabling),<BR><BR>Grip strength decreased (n/a - Unknown - Disabling),<BR><BR>Loss of personal independence in daily activities (n/a - Unknown - Disabling),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[LETROZOLE] (C - Hormone suppression therapy - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840422&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840423,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Asthenia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840423&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840424,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness postural (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRADIOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PROGESTERONE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840424&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840425,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Cough (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hallucination (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nasopharyngitis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Poor quality sleep (n/a - Unknown - Other Medically Important Condition),<BR><BR>Psychomotor hyperactivity (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - n/a - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840425&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840428,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Vulval haemorrhage (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840428&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840430,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Body temperature abnormal (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Feeling cold (n/a - Unknown - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","ESOMEPRAZOLE [ESOMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CODEINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ROPINIROLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL SULFATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[TIOTROPIUM, OLODATEROL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[VENLAFAXINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840430&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840431,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Burning sensation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lethargy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymph node pain (7d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (7d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site warmth (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840431&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840433,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthritis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myositis (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[ANHYDROUS LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FLUOXETINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INSULIN, INSULIN HUMAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, OMEPRAZOLE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840433&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840434,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Epistaxis (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[BENSERAZIDE HYDROCHLORIDE, LEVODOPA, BENSERAZIDE, LEVODOPA] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840434&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840435,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Hepatitis (56d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","ULTIBRO BREEZHALER [GLYCOPYRRONIUM BROMIDE, INDACATEROL MALEATE] (C - Chronic obstructive pulmonary disease - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - Gastritis - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL] (C - Chronic obstructive pulmonary disease - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840435&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840809,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,12-17 Years,Not Specified,No,Female,"Fall (n/a - Unknown - ),<BR><BR>Presyncope (n/a - Unknown - ),<BR><BR>Syncope (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Immunisation - n/a - [1d - n/a - Subcutaneous use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840809&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840810,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Angioedema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Disease recurrence (n/a - Unknown - Other Medically Important Condition),<BR><BR>Eye pruritus (n/a - Unknown - ),<BR><BR>Eye swelling (n/a - Unknown - ),<BR><BR>Pruritus (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840810&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840818,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Cardio-respiratory arrest (n/a - Fatal - Results in Death, Life Threatening, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Immunisation - n/a - [1d - n/a - Subcutaneous use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840818&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840840,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Inflammation (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Interchange of vaccine products (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Microangiopathy (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>VIth nerve paralysis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ESZOPICLONE] (C - Depression, Insomnia - n/a - [n/a - n/a - n/a]),<BR><BR>[MIRTAZAPINE] (C - Depression, Insomnia - n/a - [n/a - n/a - n/a]),<BR><BR>[SUVOREXANT] (C - Depression, Insomnia - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840840&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840849,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenia (n/a - Unknown - Disabling),<BR><BR>Loss of consciousness (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Disabling),<BR><BR>Oedema (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840849&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840853,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Facial paralysis (31d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840853&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014840950,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Menstruation delayed (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014840950&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841025,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Urticaria (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841025&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841030,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Condition aggravated (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myelopathy (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841030&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841036,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Asthenia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Contusion (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Presyncope (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841036&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841038,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Altered state of consciousness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Blood pressure decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Gait inability (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hallucination, visual (n/a - Unknown - Other Medically Important Condition),<BR><BR>Heart rate decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Muscular weakness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nystagmus (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Seizure (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","VIMPAT [LACOSAMIDE] (C - Seizure - n/a - [n/a - n/a - Oral use]),<BR><BR>[CLONAZEPAM] (C - Seizure - n/a - [n/a - n/a - Oral use]),<BR><BR>[RAMELTEON] (C - Brain neoplasm - n/a - [n/a - n/a - Oral use]),<BR><BR>[SODIUM VALPROATE, VALPROIC ACID] (C - Seizure - n/a - [n/a - n/a - Oral use]),<BR><BR>[SUVOREXANT] (C - Brain neoplasm - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841038&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841176,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Shoulder injury related to vaccine administration (n/a - Unknown - Disabling),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841176&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841177,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Erythema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841177&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841178,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Localised oedema (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Neck pain (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Oedema peripheral (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use])","[NAPROXEN, NAPROXEN SODIUM] (C - n/a - n/a - [n/a - 3{DF} - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[TRAMADOL, TRAMADOL HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841178&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841179,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Condition aggravated (n/a - Unknown - Other Medically Important Condition),<BR><BR>Immune thrombocytopenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Platelet count decreased (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841179&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841180,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Blood pressure increased (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - Vascular device user - n/a - [n/a - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID] (C - Angina pectoris - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - Blood cholesterol abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Blood pressure abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841180&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841181,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Syncope (n/a - Unknown - Other Medically Important Condition),<BR><BR>Throat irritation (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841181&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841183,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Bone pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Constipation (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","PREGABALIN [PREGABALIN] (C - Neuropathy peripheral - n/a - [n/a - n/a - n/a]),<BR><BR>[BEZAFIBRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CANDESARTAN, CANDESARTAN CILEXETIL] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MYCOPHENOLATE MOFETIL] (C - Mononeuropathy multiplex - n/a - [n/a - n/a - n/a]),<BR><BR>[URSODEOXYCHOLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841183&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841185,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841185&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841186,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841186&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841189,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Illness (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Immunodeficiency (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),<BR><BR>Meningitis bacterial (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Palpitations (n/a - Unknown - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841189&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841190,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Brain fog (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chest discomfort (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hypersomnia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hypertension (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hypotension (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Impaired work ability (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Myocarditis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - Arthralgia - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841190&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841191,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841191&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841192,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Feeding disorder (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Loss of personal independence in daily activities (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841192&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841193,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Abdominal pain upper (n/a - Unknown - Other Medically Important Condition),<BR><BR>Ageusia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness postural (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Heart rate increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypotension (n/a - Unknown - Other Medically Important Condition),<BR><BR>Illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Irritability (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Tremor (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","RITUXIMAB [RITUXIMAB] (C - Rheumatoid arthritis - n/a - [n/a - n/a - n/a]),<BR><BR>[AMOXICILLIN TRIHYDRATE, CLAVULANIC ACID, AMOXICILLIN TRIHYDRATE, POTASSIUM CLAVULANATE, AMOXICILLIN, CLAVULANIC ACID, AMOXICILLIN, POTASSIUM CLAVULANATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE, CIPROFLOXACIN LACTATE] (C - Lower respiratory tract infection, Pneumonia pseudomonal - n/a - [39d - n/a - n/a]),<BR><BR>[PREDNISONE] (C - Lower respiratory tract infection - n/a - [69d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841193&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841195,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nervousness (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tremor (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",HYDROXYCARBAMIDE [HYDROXYCARBAMIDE] (C - Essential thrombocythaemia - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841195&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841196,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Disabling),<BR><BR>Back pain (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Eye pain (n/a - Unknown - Disabling),<BR><BR>Headache (n/a - Unknown - Disabling),<BR><BR>Myalgia (n/a - Unknown - Disabling),<BR><BR>Oropharyngeal pain (n/a - Unknown - Disabling),<BR><BR>Pyrexia (n/a - Unknown - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[CHLORPHENAMINE MALEATE] (C - Immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[FLUTAMIDE] (C - Immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[PHENYLEPHRINE HYDROCHLORIDE] (C - Immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841196&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841197,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Ear pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Herpes zoster (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Immunisation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Incorrect dose administered (n/a - Unknown - ),<BR><BR>Influenza like illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lethargy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Off label use (n/a - Unknown - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain of skin (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841197&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841200,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Anxiety (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841200&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841201,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Cerebrovascular accident (n/a - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Coordination abnormal (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Hypoaesthesia (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Transient ischaemic attack (n/a - Recovered/Resolved With Sequelae - Life Threatening, Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841201&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841202,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Atrial tachycardia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Fatigue (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Interchange of vaccine products (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Myocarditis (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Pericarditis (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","APIXABAN [APIXABAN] (C - Atrial fibrillation - n/a - [n/a - n/a - n/a]),<BR><BR>[HYDROCORTISONE] (C - Pituitary tumour benign - n/a - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841202&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841204,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841204&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841205,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Limb injury (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841205&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841206,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Abdominal pain upper (n/a - Unknown - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Gastrointestinal disorder (n/a - Unknown - ),<BR><BR>Infection (n/a - Unknown - ),<BR><BR>Tremor (n/a - Unknown - ),<BR><BR>Vomiting (n/a - Unknown - ),<BR><BR>White blood cell count increased (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[A/BRISBANE/59/2007 (H1N1)-LIKE STRAIN, A/BRISBANE/10/2007 (H3N2)-LIKE STRAIN, B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1) V REASS. X - 179 A, A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/NANCHANG 933/95 (H3N2), A/BAYERN/7/95 (H1N1) - LIKE STRAIN (A/JOHANNESBURG/82/96), B/BEIJING/184/93-LIKE STRAIN (B/HARBIN/7/94), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN (A/NEW CALEDONIA/20/99 REASS. IVR-116), A/CALIFORNIA/7/2004 (H3N2) - LIKE STRAIN (A/NEW YORK/55/2004 REASS. NYMC X-157), B/SHANGHAI/361/2002 - LIKE STRAIN (B/JIANGSU/10/2003), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN (A/NEW CALEDONIA/20/99 REASS. IVR-116), A/MOSCOW/10/99 (H3N2) - LIKE STRAIN (A/PANAMA/2007/99 REASS. RESVIR-17), B/SICHUAN/379/99-LIKE STRAIN (B/JOHANNESBURG/5/99), A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), A/CALIFORNIA/7/2009 (H1N1)-DERIVED STRAIN USED NYMC X-181, B/BRISBANE/60/2008, A/SWITZERLAND/9715293/2013 (H3N2)-LIKE STRAIN (A/SWITZERLAND/9715293/2013, NIB-88), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN B, A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1), A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1)V-LIKE VIRUS, A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/MASSACHUSETTS/2/2012 -DERIVED STRAIN USED (NYMC BX-51B), A/TEXAS/50/2012 (H3N2) – DERIVED STRAIN USED (NYMC X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/MASSACHUSETTS/2/2012 -DERIVED STRAIN USED (NYMC BX-51B), A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN A (H1N1), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN A (H3N2), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN B] (C - Influenza immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841206&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841208,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Epistaxis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Haemoptysis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Haemoptysis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myocarditis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pericarditis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pulmonary pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841208&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841211,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Migraine (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",NIRAPARIB [NIRAPARIB] (C - Ovarian cancer - n/a - [17d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841211&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841212,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Headache (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Vision blurred (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","CIRCADIN [MELATONIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BECLOMETASONE DIPROPIONATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[ZOPICLONE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841212&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841213,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"Erythema (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Lip swelling (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination site erythema (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841213&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841214,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea at rest (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea exertional (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymph node pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Muscular weakness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ALLOPURINOL] (C - Gout - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[NIFEDIPINE] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841214&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841217,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abortion spontaneous (n/a - Unknown - Other Medically Important Condition),<BR><BR>Biochemical pregnancy (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Contusion (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[FOLIC ACID] (C - Vitamin supplementation - n/a - [n/a - 400ug - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841217&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841219,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal pain upper (n/a - Unknown - Other Medically Important Condition),<BR><BR>Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (3d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841219&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841223,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Cough (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Heart rate abnormal (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Lymph node pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Syncope (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[ALENDRONATE SODIUM, ALENDRONIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BUDESONIDE, FORMOTEROL FUMARATE DIHYDRATE, FORMOTEROL FUMARATE, BUDESONIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CALCIUM, CALCIUM CARBONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841223&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841224,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fixed eruption (n/a - Not Recovered/Not Resolved - ),<BR><BR>Lyme disease (n/a - Unknown - Other Medically Important Condition),<BR><BR>Skin infection (n/a - Unknown - ),<BR><BR>Skin lesion (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841224&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841225,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Somnolence (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841225&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841226,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Periarthritis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841226&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841228,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Dizziness postural (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/BRISBANE/59/2007 (H1N1)-LIKE STRAIN (A/BRISBANE/59/2007 REASS. IVR-148), A/BRISBANE/10/2007 (H3N2)-LIKE STRAIN (A/URUGUAY/716/2007 REASS. NYMC X-175C), B/BRISBANE/60/2008-LIKE VIRUS, A/BRISBANE/59/2007 (H1N1)-LIKE STRAIN (A/BRISBANE/59/2007 REASS. IVR-148), A/BRISBANE/10/2007 (H3N2)-LIKE STRAIN (A/URUGUAY/716/2007 REASS. NYMC X-175C), B/FLORIDA/4/2006-LIKE STRAIN (B/FLORIDA/4/2006), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN (A/NEW CALEDONIA/20/99 REASS. IVR-116), B/MALAYSIA/2506/2004 - LIKE STRAIN (B/MALAYSIA/2506/2004), A/WISCONSIN/67/2005 (H3N2) - LIKE STRAIN (A/HIROSHIMA/52/2005 REASS. IVR-142), ANTIGENS OF THE INFLUENZA VIRUS A/CALIFORNIA/7/2009 (H1N1)-LIKE VIRUS PDM09, ANTIGENS OF THE INFLUENZA VIRUS A/VICTORIA/361/2011 (H3N2)-LIKE VIRUS, ANTIGENS OF THE INFLUENZA VIRUS B/WISCONSIN/1/2010-LIKE VIRUS, B/BRISBANE/60/2008-LIKE VIRUS, A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), A/CALIFORNIA/7/2009 (H1N1)-DERIVED STRAIN USED NYMC X-181, B/MALAYSIA/2506/2004 - LIKE STRAIN (B/MALAYSIA/2506/2004), A/WISCONSIN/67/2005 (H3N2) - LIKE STRAIN (A/WISCONSIN/67/2005 REASS. NYMCX-161-B), A/SOLOMON ISLANDS/3/2006 (H1N1) - LIKE STRAIN (A/SOLOMON ISLANDS/3/2006 REASS. IVR-145), SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/GUANDONG-MAONAN/SWL1536/2019 (H1N1)PDM09-LIKE VIRUS (A/VICTORIA/2454/2019 IVR-207), SQUALENE, CITRIC ACID, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), SQUALENE, CITRIC ACID, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, CITRIC ACID ANHYDROUS, A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/GUANDONG-MAONAN/SWL1536/2019 (H1N1)PDM09-LIKE VIRUS (A/VICTORIA/2454/2019 IVR-207), SQUALENE, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, CITRIC ACID ANHYDROUS, A/SWITZERLAND/9715293/2013 (H3N2)-LIKE STRAIN (A/SWITZERLAND/9715293/2013, NIB-88), B/BRISBANE/9/2014 (WILD TYPE), SQUALENE, A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, CITRIC ACID ANHYDROUS, B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), SQUALENE, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, CITRIC ACID ANHYDROUS, B/MASSACHUSETTS/2/2012-LIKE STRAIN USED B/MASSACHUSETTS/2/2012 WILD TYPE, A/TEXAS/50/2012 (H3N2) – DERIVED STRAIN USED (NYMC X-223), SQUALENE, A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181)] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841228&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841230,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","PREGABALIN [PREGABALIN] (C - Neuropathy peripheral - n/a - [n/a - n/a - n/a]),<BR><BR>[BEZAFIBRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CANDESARTAN, CANDESARTAN CILEXETIL] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MYCOPHENOLATE MOFETIL] (C - Mononeuropathy multiplex - n/a - [n/a - n/a - n/a]),<BR><BR>[URSODEOXYCHOLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841230&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841232,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Abdominal pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841232&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841235,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthma (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841235&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841237,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (8d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Influenza like illness (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (3d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841237&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841239,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Herpes zoster (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[TERBINAFINE, TERBINAFINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841239&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841240,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Hangover (n/a - Unknown - Other Medically Important Condition),<BR><BR>Heart rate decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Immunisation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Incorrect dose administered (n/a - Unknown - ),<BR><BR>Off label use (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (36h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841240&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841241,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"Cardiac arrest (n/a - Unknown - Life Threatening),<BR><BR>Cerebrovascular accident (n/a - Not Recovered/Not Resolved - Life Threatening)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841241&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841244,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Axillary pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Back pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Musculoskeletal pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nasopharyngitis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Skin irritation (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841244&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841245,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chest pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nasopharyngitis (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841245&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841247,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Heart rate abnormal (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Nausea (n/a - Unknown - Disabling),<BR><BR>Oxygen saturation decreased (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Somnolence (n/a - Not Recovered/Not Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841247&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841248,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Rash pruritic (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",OZEMPIC [SEMAGLUTIDE] (C - Type 2 diabetes mellitus - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841248&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841250,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Blood pressure increased (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - Menopause - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841250&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841252,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling hot (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Musculoskeletal stiffness (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - n/a - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841252&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841253,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - Depression - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841253&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841254,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Headache (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Heart rate increased (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rash (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841254&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841255,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Feeling abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Joint range of motion decreased (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lipoma (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Heart rate irregular - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Decreased activity - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841255&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841256,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Influenza (n/a - Unknown - Disabling),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841256&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841260,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Syncope (1d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841260&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841261,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Balance disorder (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Nystagmus (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Romberg test positive (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","TADALAFIL [TADALAFIL] (C - Erectile dysfunction - n/a - [n/a - n/a - n/a]),<BR><BR>[ENALAPRIL, ENALAPRIL MALEATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - Hypercholesterolaemia - n/a - [n/a - n/a - n/a]),<BR><BR>[TAMSULOSIN, TAMSULOSIN HYDROCHLORIDE] (C - Prostatism - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841261&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841262,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Herpes simplex reactivation (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Oral herpes (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841262&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841263,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Headache (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841263&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841266,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Bell's palsy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Bone pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841266&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841269,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness postural (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hypokinesia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Syncope (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841269&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841270,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (9d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (9d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - n/a - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841270&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841271,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (3d - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Migraine with aura (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841271&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841272,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Delirium (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Illness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841272&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841273,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest pain (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Dyspnoea (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Fatigue (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Palpitations (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Stress cardiomyopathy (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Tachycardia (n/a - Unknown - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841273&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841276,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,12-17 Years,Not Specified,No,Female,"Angina pectoris (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Inappropriate schedule of product administration (n/a - Unknown - ),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[PREDNISONE] (C - n/a - n/a - [8d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841276&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841277,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Chills (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Immunisation - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841277&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841278,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Hypoxia (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Pneumonia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Tachycardia (n/a - Unknown - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841278&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841279,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Postmenopausal haemorrhage (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841279&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841281,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Cough (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841281&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841282,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hypokinesia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Muscle spasms (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Off label use (n/a - Unknown - ),<BR><BR>Product use issue (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Tremor (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (S - Immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841282&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841288,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Erythema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Swelling face (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - Depression - n/a - [n/a - n/a - n/a]),<BR><BR>[FEXOFENADINE, FEXOFENADINE HYDROCHLORIDE] (C - Hypersensitivity - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841288&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841291,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Body temperature increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Sudden hearing loss (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841291&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841293,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Aphasia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (7d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Influenza (n/a - Unknown - Other Medically Important Condition),<BR><BR>Syncope (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Urinary incontinence (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841293&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841294,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Pain (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vertigo (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ETHINYLESTRADIOL, NORGESTIMATE] (C - Contraception - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841294&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841295,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841295&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841297,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Formication (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Neurodermatitis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Urticaria chronic (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841297&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841301,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[FLUOXETINE, FLUOXETINE HYDROCHLORIDE] (C - Depression - n/a - [n/a - n/a - n/a]),<BR><BR>[LISDEXAMFETAMINE] (C - Attention deficit hyperactivity disorder - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841301&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841303,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Cough (n/a - Unknown - Other Medically Important Condition),<BR><BR>Erythema (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain of skin (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rhinorrhoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Skin fissures (n/a - Unknown - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[OMEPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841303&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841306,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Chills (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Somnolence (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vomiting (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841306&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841462,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Polymyalgia rheumatica (n/a - Unknown - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841462&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841762,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal discomfort (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Anaphylactic reaction (1890min - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Back pain (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Chest discomfort (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Depressed level of consciousness (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Feeling abnormal (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Hypoaesthesia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Muscular weakness (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Seizure (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841762&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841791,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841791&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841792,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Eczema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Rash (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841792&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841797,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Adult,No,Female,"Cardiovascular disorder (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Cutaneous symptom (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Gastrointestinal disorder (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841797&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014841820,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal pain upper (n/a - Unknown - ),<BR><BR>Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Back pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - ),<BR><BR>Gastrointestinal pain (n/a - Unknown - ),<BR><BR>Hypersomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypophagia (n/a - Recovered/Resolved - ),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","TELMISARTAN [TELMISARTAN] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - n/a]),<BR><BR>[RISPERIDONE] (C - Mental disorder - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014841820&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842213,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Agitated depression (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[RAMIPRIL] (C - Hypertension - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842213&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842231,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Facial paralysis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Migraine (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vomiting (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - Hormone replacement therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[FEXOFENADINE, FEXOFENADINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842231&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842236,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842236&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842251,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Ear pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","IBUPROFEN [IBUPROFEN, IBUPROFEN SODIUM] (C - Back pain - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Back pain - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842251&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842259,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842259&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842274,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal discomfort (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Illness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Oral discomfort (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Paraesthesia oral (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BECLOMETASONE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL MICRONIZED, SALBUTAMOL SULFATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842274&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842293,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Balance disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842293&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842295,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dysuria (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pollakiuria (n/a - Unknown - Other Medically Important Condition),<BR><BR>Urinary tract infection (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Urine odour abnormal (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[LANSOPRAZOLE] (C - Pain - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842295&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842301,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Anxiety (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Unknown - Other Medically Important Condition),<BR><BR>Swollen tongue (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842301&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842320,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842320&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842321,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Feeling drunk (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vertigo (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[CLINDAMYCIN, CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN PHOSPHATE] (C - Dental care - n/a - [6d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842321&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842322,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Cluster headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842322&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842323,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Neuropathy peripheral (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842323&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842325,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vomiting (1d - Recovered/Resolved With Sequelae - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","TADALAFIL [TADALAFIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - Depression - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842325&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842326,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Abdominal pain upper (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspepsia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Feeling cold (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[CALCIUM CARBONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842326&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842327,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Axillary pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INDAPAMIDE, INDAPAMIDE HEMIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842327&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842328,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Cardiac disorder (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Dyspnoea (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Palpitations (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Rhinitis (n/a - Unknown - ),<BR><BR>Sinus tachycardia (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Tachycardia (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (S - Influenza immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842328&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842329,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Heavy menstrual bleeding (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842329&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842330,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal pain upper (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chills (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Movement disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Night sweats (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tremor (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842330&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842331,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Hypokinesia (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Impaired driving ability (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Insomnia (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Loss of personal independence in daily activities (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Myalgia (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","JARDIANCE [EMPAGLIFLOZIN] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - Blood cholesterol abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[DOXAZOSIN, DOXAZOSIN MESILATE] (C - Blood pressure abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - Blood pressure abnormal - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842331&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842332,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Atrial fibrillation (n/a - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Chest pain (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Fatigue (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Heart rate increased (n/a - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Influenza like illness (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Interchange of vaccine products (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Palpitations (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Tachycardia (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Vomiting (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842332&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842335,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Loss of personal independence in daily activities (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site lymphadenopathy (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842335&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842336,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Heart rate increased (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Sleep disorder due to a general medical condition (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842336&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842337,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dyspepsia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Feeling cold (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Limb discomfort (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Periorbital swelling (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vomiting (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842337&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842338,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rhinorrhoea (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842338&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842339,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dry skin (n/a - Unknown - Other Medically Important Condition),<BR><BR>Erythema (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Feeling hot (5d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Gait disturbance (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (5d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nasopharyngitis (5d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Swelling face (5d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842339&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842340,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dizziness (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Erythema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Eye pruritus (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Flushing (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Off label use (n/a - Unknown - Other Medically Important Condition),<BR><BR>Paraesthesia oral (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pharyngeal erythema (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash erythematous (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Swollen tongue (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842340&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842341,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Discomfort (n/a - Unknown - Disabling),<BR><BR>Emotional distress (n/a - Unknown - Disabling),<BR><BR>Formication (2d - Recovered/Resolved - Disabling),<BR><BR>Pruritus (7d - Recovered/Resolved - Disabling),<BR><BR>Pyrexia (2d - Recovered/Resolved - Disabling),<BR><BR>Sleep disorder due to a general medical condition (n/a - Unknown - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[PROPRANOLOL, PROPRANOLOL HYDROCHLORIDE] (C - Anxiety - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842341&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842343,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypoaesthesia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hypoaesthesia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Limb discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site swelling (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","PREGABALIN [PREGABALIN] (C - Neuralgia - n/a - [n/a - n/a - n/a]),<BR><BR>[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - Fatigue - n/a - [n/a - n/a - n/a]),<BR><BR>[MIRTAZAPINE] (C - Anxiety - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842343&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842344,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Illness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Musculoskeletal stiffness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Syncope (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842344&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842345,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Dyspnoea (n/a - Unknown - Life Threatening, Disabling, Other Medically Important Condition),<BR><BR>Pulmonary embolism (n/a - Recovering/Resolving - Life Threatening, Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842345&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842346,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Cardiac arrest (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Circulatory collapse (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Fatal - Results in Death, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","ABASAGLAR [INSULIN GLARGINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - n/a - n/a - [n/a - 75mg - n/a]),<BR><BR>[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - 75mg - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - 80mg - n/a]),<BR><BR>[GLICLAZIDE] (C - n/a - n/a - [n/a - 160mg - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - 15mg - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - 1.25mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842346&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842347,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dry throat (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Head discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Irritability (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lethargy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Musculoskeletal discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842347&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842348,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Cough (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Influenza (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nasopharyngitis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (2d - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Respiratory tract congestion (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tremor (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842348&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842349,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Breath sounds abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dysphagia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dysstasia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Eye movement disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Gait inability (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Respiratory rate increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Syncope (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tremor (n/a - Unknown - Other Medically Important Condition),<BR><BR>Unresponsive to stimuli (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842349&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842350,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Aphasia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Arthralgia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Asthenia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chills (1350min - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Confusional state (1350min - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Eye pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Renal pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Sweating fever (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vomiting (15h - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - Depression - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842350&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842351,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Erythema (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Illness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842351&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842352,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dizziness (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hypotension (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842352&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842353,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Angina unstable (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[LATANOPROST] (C - Ocular hypertension - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842353&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842354,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Angina pectoris (n/a - Unknown - Other Medically Important Condition),<BR><BR>Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[ATORVASTATIN] (C - Hypertension - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842354&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842356,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,12-17 Years,Not Specified,No,Female,"Pyrexia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Sinus tachycardia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vomiting (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842356&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842357,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Asthma (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Disease recurrence (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Syncope (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842357&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842358,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Cough (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Productive cough (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842358&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842359,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Muscle spasms (n/a - Unknown - Other Medically Important Condition),<BR><BR>Musculoskeletal pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site haemorrhage (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[BUDESONIDE, FORMOTEROL FUMARATE DIHYDRATE, FORMOTEROL FUMARATE, BUDESONIDE] (C - Bronchiectasis - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL] (C - Nutritional supplementation - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - Hormone replacement therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - Dyspepsia - n/a - [n/a - n/a - n/a]),<BR><BR>[MONTELUKAST, MONTELUKAST SODIUM] (C - Bronchiectasis - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842359&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842360,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Feeling hot (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (3d - Recovered/Resolved With Sequelae - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842360&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842361,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Chills (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tremor (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842361&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842363,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Amnesia (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Delirium (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Dementia (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Encephalitis autoimmune (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Hallucination (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - n/a])","DEXAMETHASONE [DEXAMETHASONE] (C - Oesophageal carcinoma - n/a - [n/a - 4mg - n/a - More in ICSR]),<BR><BR>FENTANYL [FENTANYL, FENTANYL CITRATE] (C - Pain - n/a - [n/a - n/a - n/a]),<BR><BR>UMECLIDINIUM BROMIDE, FLUTICASONE FUROATE, VILANTEROL [UMECLIDINIUM BROMIDE, FLUTICASONE FUROATE, VILANTEROL] (C - Chronic obstructive pulmonary disease - n/a - [n/a - n/a - n/a]),<BR><BR>[BUDESONIDE, FORMOTEROL FUMARATE DIHYDRATE, FORMOTEROL FUMARATE, BUDESONIDE] (C - Chronic obstructive pulmonary disease - n/a - [n/a - n/a - n/a]),<BR><BR>[DANTRON, POLOXAMER 188] (C - Constipation - n/a - [57d - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - n/a]),<BR><BR>[MIRTAZAPINE] (C - Depressed mood - n/a - [14d - n/a - n/a]),<BR><BR>[TIOTROPIUM BROMIDE] (C - Chronic obstructive pulmonary disease - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842363&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842364,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Arthritis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chills (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Feeling cold (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling hot (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Injection site pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842364&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842365,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Asthenia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Ear pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Limb discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Musculoskeletal stiffness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Ocular discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Photophobia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site swelling (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ESTROGENS CONJUGATED, ESTRONE SODIUM SULFATE, EQUILIN SULFATE SODIUM] (C - Hormone replacement therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[FEXOFENADINE, FEXOFENADINE HYDROCHLORIDE] (C - Rhinitis allergic - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842365&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842366,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842366&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842367,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymph node pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",CYTARABINE [CYTARABINE] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842367&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842369,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest pain (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Tremor (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842369&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842370,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Gingival pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hyperaesthesia teeth (n/a - Unknown - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Toothache (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842370&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842372,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842372&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842373,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Blood urine present (10d - Recovered/Resolved With Sequelae - Disabling, Other Medically Important Condition),<BR><BR>Chest pain (11d - Recovered/Resolved With Sequelae - Disabling, Other Medically Important Condition),<BR><BR>Cold sweat (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Dysuria (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Feeling hot (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Lower respiratory tract infection (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Nasopharyngitis (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Night sweats (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Renal pain (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Throat irritation (11d - Recovered/Resolved With Sequelae - Disabling, Other Medically Important Condition),<BR><BR>Urinary tract infection (6d - Recovered/Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842373&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842374,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hypersomnia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site erythema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842374&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842377,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Body temperature decreased (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chills (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dizziness postural (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Heart rate increased (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Myalgia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Urinary incontinence (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vomiting (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842377&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842378,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Musculoskeletal stiffness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842378&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842379,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Asthenia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Blepharospasm (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dry eye (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dry skin (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Extraocular muscle disorder (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lichen sclerosus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Macular degeneration (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Sjogren's syndrome (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Visual impairment (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842379&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842380,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Lethargy (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842380&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842381,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Back pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842381&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842383,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ALENDRONATE SODIUM, ALENDRONIC ACID] (C - Osteoporosis - n/a - [n/a - n/a - n/a]),<BR><BR>[ASCORBIC ACID, CALCIUM GLUBIONATE, CALCIUM CARBONATE, CALCIUM, CALCIUM GLUBIONATE, CALCIUM CARBONATE, COLECALCIFEROL, CALCIUM] (C - Osteoporosis - n/a - [n/a - n/a - n/a]),<BR><BR>[CEFALEXIN] (C - Urinary tract infection - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTROGENS CONJUGATED] (C - Menopause - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842383&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842384,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Asthenia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Diarrhoea (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Impaired quality of life (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Night sweats (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Presyncope (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tremor (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pruritus (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[FEXOFENADINE, FEXOFENADINE HYDROCHLORIDE] (C - Hypersensitivity - n/a - [n/a - n/a - n/a]),<BR><BR>[INDAPAMIDE, PERINDOPRIL ARGININE, PERINDOPRIL TERT-BUTYLAMINE, INDAPAMIDE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842384&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842385,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Illness (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842385&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842387,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Muscular weakness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [1d - n/a - n/a])","[LACIDIPINE] (C - Blood pressure abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[REBOXETINE, REBOXETINE METHANESULFONATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842387&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842388,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Anaphylactic reaction (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Chest pain (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842388&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842390,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[PROCHLORPERAZINE, PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE BP, PROCHLORPERAZINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842390&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842391,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842391&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842392,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest discomfort (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Feeling abnormal (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Feeling hot (n/a - Unknown - Other Medically Important Condition),<BR><BR>Heart rate increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Rash pruritic (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tachycardia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Urticaria (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","AJOVY [FREMANEZUMAB] (C - Migraine - n/a - [n/a - n/a - n/a]),<BR><BR>[DESOGESTREL] (C - Oral contraception - n/a - [n/a - n/a - n/a]),<BR><BR>[TOPIRAMATE] (C - Migraine - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842392&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842393,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Epilepsy (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Seizure (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","BRIVARACETAM [BRIVARACETAM] (C - Epilepsy - n/a - [n/a - n/a - n/a]),<BR><BR>LACOSAMIDE [LACOSAMIDE] (C - Epilepsy - n/a - [n/a - n/a - n/a]),<BR><BR>ZONISAMIDE [ZONISAMIDE] (C - Epilepsy - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842393&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842394,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dizziness exertional (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Influenza (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[SILDENAFIL, SILDENAFIL CITRATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842394&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842395,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Bursitis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Musculoskeletal disorder (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842395&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842396,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Apathy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Disorientation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Herpes simplex (n/a - Unknown - Other Medically Important Condition),<BR><BR>Herpes zoster (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lip swelling (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Oral herpes (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Paraesthesia oral (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Poor quality sleep (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842396&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842397,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRADIOL] (C - Hormone therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842397&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842398,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest discomfort (30min - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chest pain (30min - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Heart rate increased (30min - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hypertension (30min - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hyperventilation (30min - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Paraesthesia (30min - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842398&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842399,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Axillary pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Back pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hallucination (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (3d - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ALLOPURINOL] (C - Purines - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - Blood cholesterol - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842399&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842402,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Axillary pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Breast pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Musculoskeletal pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842402&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842403,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lymph node pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphoedema (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination site mass (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site warmth (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842403&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842404,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Immune system disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Kidney infection (n/a - Unknown - Other Medically Important Condition),<BR><BR>Renal impairment (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rosacea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Urinary retention (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842404&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842405,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Pharyngeal swelling (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Sensitive skin (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (S - Immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842405&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842406,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Pulmonary embolism (n/a - Recovering/Resolving - Life Threatening, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842406&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842407,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Swelling (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - Hormone replacement therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[TESTOSTERONE] (C - Hormone replacement therapy - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842407&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842408,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Influenza (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842408&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842409,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Decreased appetite (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Heart rate increased (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Lethargy (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Nasal congestion (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Somnolence (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Vertigo (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842409&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842410,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Headache (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Illness (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Syncope (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/BRISBANE/59/2007 (H1N1)-LIKE STRAIN, A/BRISBANE/10/2007 (H3N2)-LIKE STRAIN, B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1) V REASS. X - 179 A, A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/NANCHANG 933/95 (H3N2), A/BAYERN/7/95 (H1N1) - LIKE STRAIN (A/JOHANNESBURG/82/96), B/BEIJING/184/93-LIKE STRAIN (B/HARBIN/7/94), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN (A/NEW CALEDONIA/20/99 REASS. IVR-116), A/CALIFORNIA/7/2004 (H3N2) - LIKE STRAIN (A/NEW YORK/55/2004 REASS. NYMC X-157), B/SHANGHAI/361/2002 - LIKE STRAIN (B/JIANGSU/10/2003), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN (A/NEW CALEDONIA/20/99 REASS. IVR-116), A/MOSCOW/10/99 (H3N2) - LIKE STRAIN (A/PANAMA/2007/99 REASS. RESVIR-17), B/SICHUAN/379/99-LIKE STRAIN (B/JOHANNESBURG/5/99), A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), A/CALIFORNIA/7/2009 (H1N1)-DERIVED STRAIN USED NYMC X-181, B/BRISBANE/60/2008, A/SWITZERLAND/9715293/2013 (H3N2)-LIKE STRAIN (A/SWITZERLAND/9715293/2013, NIB-88), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN B, A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1), A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1)V-LIKE VIRUS, A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/MASSACHUSETTS/2/2012 -DERIVED STRAIN USED (NYMC BX-51B), A/TEXAS/50/2012 (H3N2) – DERIVED STRAIN USED (NYMC X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/MASSACHUSETTS/2/2012 -DERIVED STRAIN USED (NYMC BX-51B), A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN A (H1N1), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN A (H3N2), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN B] (C - Immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842410&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842411,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Anaphylactic reaction (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842411&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842412,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,12-17 Years,Not Specified,No,Female,"Chest pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dry throat (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842412&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842413,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Cerebrovascular accident (n/a - Unknown - Other Medically Important Condition),<BR><BR>Speech disorder (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","APIXABAN [APIXABAN] (C - n/a - n/a - [n/a - 2.5mg - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - 5mg - n/a]),<BR><BR>[FELODIPINE] (C - n/a - n/a - [n/a - 5mg - n/a]),<BR><BR>[INDAPAMIDE, INDAPAMIDE HEMIHYDRATE] (C - n/a - n/a - [n/a - 1.5mg - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - 30mg - n/a]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - n/a - n/a - [n/a - 50mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842413&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842414,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Vaccination site inflammation (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842414&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842415,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Feeling cold (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Sinusitis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Immunisation - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842415&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842416,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842416&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842417,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Swelling face (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tremor (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842417&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842419,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842419&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842421,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Feeling abnormal (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Migraine (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[CANDESARTAN, CANDESARTAN CILEXETIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRADIOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PROGESTERONE, PROGESTERONE, MICRONISED] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SOLIFENACIN] (C - Bladder irritation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842421&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842423,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Axillary pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dysgeusia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Respiration abnormal (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE, BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CARBOMER, CARBOMER 980] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FEXOFENADINE, FEXOFENADINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OXAZEPAM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SUMATRIPTAN, SUMATRIPTAN SUCCINATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842423&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842437,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Herpes zoster (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842437&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842438,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Influenza (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842438&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842439,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dyspnoea (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pleural effusion (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pleuritic pain (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pulmonary embolism (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842439&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842446,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,Rash erythematous (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842446&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842449,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Axillary pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Balance disorder (5d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hypersomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Rash (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","METHOTREXATE [METHOTREXATE] (C - Rheumatoid arthritis - n/a - [n/a - n/a - n/a]),<BR><BR>[CHLORPHENAMINE MALEATE] (C - Rash erythematous - n/a - [3d - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Malaise - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842449&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842450,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vomiting (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842450&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842451,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chills (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842451&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842452,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842452&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842454,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Arthritis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842454&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842456,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Gastrointestinal pain (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842456&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842457,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Dyspnoea (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Hypotension (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Oxygen saturation decreased (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842457&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842458,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vomiting (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842458&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842459,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Thrombosis (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[LOSARTAN, LOSARTAN POTASSIUM] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842459&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842461,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842461&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842462,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Arthritis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Inflammation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myositis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - n/a - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842462&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842464,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal symptom (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Asthenia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Somnolence (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[FERROUS FUMARATE] (C - Anaemia - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[MELOXICAM] (C - Pain - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL, CODEINE PHOSPHATE] (C - Pain - n/a - [n/a - n/a - n/a]),<BR><BR>[RABEPRAZOLE, RABEPRAZOLE SODIUM] (C - Abdominal pain upper - n/a - [n/a - n/a - n/a]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - Depressed mood - n/a - [n/a - n/a - n/a]),<BR><BR>[TRAMADOL, TRAMADOL HYDROCHLORIDE] (C - Pain - n/a - [n/a - n/a - n/a]),<BR><BR>[ZOPICLONE] (C - Insomnia - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842464&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842465,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Immunisation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Migraine (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Off label use (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[ALGELDRATE, INACTIVATED HEPATITIS A VIRUS (GBM STRAIN), ALUMINIUM HYDROXIDE, INACTIVATED HEPATITIS A VIRUS (GBM STRAIN), ALUMINIUM, HEPATITIS A VIRUS GBM STRAIN (INACTIVATED) PRODUCED ON MRC-5 HUMAN DIPLOID CELLS ADSORBED ON ALUMINIUM HYDROXIDE, ALUMINIUM, INACTIVATED HEPATITIS A VIRUS (GBM STRAIN), HEPATITIS A VIRUS (INACTIVATED ) ADSORBED ON ALUMINIUM HYDROXIDE HYDRATED PRODUCED ON HUMAN DIPLOID (MRC-5) CELLS, ALGELDRATE, HEPATITIS A VIRUS (INACTIVATED ) ADSORBED ON ALUMINIUM HYDROXIDE HYDRATED PRODUCED ON HUMAN DIPLOID (MRC-5) CELLS, ALUMINIUM HYDROXIDE, HEPATITIS A VIRUS (INACTIVATED), HEPATITIS A VIRUS GBM STRAIN (INACTIVATED) PRODUCED ON MRC-5 HUMAN DIPLOID CELLS ADSORBED ON ALUMINIUM HYDROXIDE, ALGELDRATE, HEPATITIS A VIRUS GBM STRAIN (INACTIVATED) PRODUCED ON MRC-5 HUMAN DIPLOID CELLS ADSORBED ON ALUMINIUM HYDROXIDE, ALUMINIUM HYDROXIDE] (S - Influenza immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842465&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842466,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Cardiac flutter (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[BUDESONIDE, BUDESONIDE, MICRONISED] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRADIOL] (C - Vulvovaginal dryness - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842466&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842467,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Colitis ulcerative (n/a - Unknown - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[MESALAZINE] (C - Colitis ulcerative - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842467&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842468,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Asthenopia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Cerebral congestion (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling drunk (n/a - Unknown - Other Medically Important Condition),<BR><BR>Head discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Influenza (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[SIMVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[WARFARIN, WARFARIN SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842468&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842470,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Deep vein thrombosis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842470&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842471,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Pruritus (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pruritus genital (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842471&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842472,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842472&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842473,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Circulatory collapse (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Sleep disorder (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[BECLOMETASONE DIPROPIONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - Depression - n/a - [n/a - n/a - n/a]),<BR><BR>[FLUTICASONE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[HYDROXYZINE, HYDROXYZINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL SULFATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ZOLMITRIPTAN] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842473&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842474,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Cold sweat (n/a - Unknown - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dizziness postural (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Head discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hunger (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypertension (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pallor (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Syncope (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","DULOXETINE [DULOXETINE, DULOXETINE HYDROCHLORIDE] (C - Depression - n/a - [n/a - n/a - n/a]),<BR><BR>[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[HYDROXYCHLOROQUINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[MIRTAZAPINE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842474&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842475,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Deafness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tinnitus (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842475&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842476,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Agitation (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Impaired work ability (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842476&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842477,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Fatigue (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Somnolence (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","IBUPROFEN [IBUPROFEN, IBUPROFEN SODIUM] (C - Oropharyngeal pain - n/a - [13d - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Oropharyngeal pain - n/a - [13d - n/a - n/a]),<BR><BR>[PSEUDOEPHEDRINE HYDROCHLORIDE] (C - Headache - n/a - [10d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842477&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842478,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Gastrointestinal pain (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rectal haemorrhage (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842478&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842479,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Heart rate increased (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842479&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842480,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abnormal dreams (2d - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Colitis ulcerative (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Pyrexia (4d - Recovered/Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","TECFIDERA [DIMETHYL FUMARATE] (C - Multiple sclerosis - n/a - [n/a - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[BUDESONIDE] (C - Colitis ulcerative - n/a - [56d - n/a - n/a]),<BR><BR>[DESOGESTREL] (C - Contraception - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a]),<BR><BR>[MESALAZINE] (C - Colitis ulcerative - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842480&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842481,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842481&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842482,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Giant cell arteritis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Mass (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vomiting (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FAMOTIDINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842482&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842483,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Pain of skin (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","AZATHIOPRINE [AZATHIOPRINE] (C - Colitis ulcerative - n/a - [n/a - n/a - n/a]),<BR><BR>[PROPRANOLOL, PROPRANOLOL HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842483&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842484,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dyspnoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Heart rate increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Swollen tongue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842484&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842485,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Disabling),<BR><BR>Fatigue (n/a - Unknown - Disabling),<BR><BR>Hyperhidrosis (n/a - Unknown - Disabling),<BR><BR>Hypersomnia (n/a - Unknown - Disabling),<BR><BR>Lymphadenopathy (n/a - Unknown - Disabling),<BR><BR>Migraine (n/a - Unknown - Disabling),<BR><BR>Nausea (n/a - Unknown - Disabling),<BR><BR>Oropharyngeal pain (n/a - Unknown - Disabling),<BR><BR>Pain (n/a - Unknown - Disabling),<BR><BR>Photosensitivity reaction (n/a - Unknown - Disabling),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Disabling),<BR><BR>Rhinorrhoea (n/a - Unknown - Disabling),<BR><BR>Swelling (n/a - Unknown - Disabling),<BR><BR>Tremor (n/a - Unknown - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842485&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842486,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Feeling cold (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842486&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842487,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Unknown - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vomiting (2d - Recovered/Resolved With Sequelae - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842487&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842488,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Costochondritis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Off label use (n/a - Unknown - ),<BR><BR>Product use issue (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (S - Immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842488&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842491,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Anxiety (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Asthenia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hot flush (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Illness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nervousness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Respiratory disorder (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842491&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842492,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chest discomfort (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Chest pain (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Eye pruritus (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842492&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842770,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal pain (n/a - Unknown - ),<BR><BR>Blood pressure decreased (n/a - Unknown - ),<BR><BR>Cyanosis (n/a - Unknown - ),<BR><BR>Decreased appetite (n/a - Unknown - ),<BR><BR>Depressed level of consciousness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - ),<BR><BR>Fall (n/a - Unknown - ),<BR><BR>Feeling abnormal (n/a - Unknown - ),<BR><BR>Headache (n/a - Unknown - ),<BR><BR>Heart rate decreased (n/a - Unknown - ),<BR><BR>Lip disorder (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Unknown - ),<BR><BR>Shock (n/a - Unknown - Other Medically Important Condition),<BR><BR>Therapeutic response unexpected (n/a - Unknown - ),<BR><BR>Tinnitus (n/a - Unknown - ),<BR><BR>Vaginal haemorrhage (n/a - Unknown - ),<BR><BR>Vomiting (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842770&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842776,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Sleep disorder (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842776&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842778,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Pneumonia (n/a - Unknown - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842778&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842781,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal pain upper (n/a - Recovered/Resolved - ),<BR><BR>Depressed level of consciousness (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Recovered/Resolved - ),<BR><BR>Fall (n/a - Recovered/Resolved - ),<BR><BR>Heart rate decreased (n/a - Recovered/Resolved - ),<BR><BR>Nausea (n/a - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842781&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842786,Spontaneous,2023-03-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Cough (12d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Dyspnoea (9d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Interstitial lung disease (6d - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Physical deconditioning (8d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (12d - Recovered/Resolved - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])",[PEMAFIBRATE] (C - Hyperlipidaemia - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842786&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842795,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Ear pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Sciatica (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Sinus pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Swelling (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Toothache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination site erythema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ESTRADIOL] (C - Oral contraception - n/a - [n/a - n/a - n/a]),<BR><BR>[MEDROXYPROGESTERONE] (C - Oral contraception - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842795&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842799,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Back pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling cold (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Influenza (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Productive cough (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842799&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842806,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842806&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014842816,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Crying (n/a - Unknown - ),<BR><BR>Fear (n/a - Unknown - ),<BR><BR>Feeling jittery (n/a - Unknown - ),<BR><BR>Hallucination (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Illness (n/a - Recovered/Resolved - ),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Joint stiffness (n/a - Unknown - ),<BR><BR>Loss of personal independence in daily activities (n/a - Unknown - ),<BR><BR>Malaise (n/a - Unknown - ),<BR><BR>Muscle rigidity (n/a - Unknown - ),<BR><BR>Musculoskeletal stiffness (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014842816&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014843418,Spontaneous,2023-03-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014843418&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014832697,Spontaneous,2023-03-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Headache (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014832697&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014825997,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dysstasia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Gait disturbance (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Muscular weakness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014825997&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014826342,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Lymph node pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nasopharyngitis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - Hiatus hernia - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014826342&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014826343,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nasopharyngitis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Off label use (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Rhinorrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - Bipolar disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[LAMOTRIGINE] (C - Bipolar disorder - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014826343&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014826352,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Arthralgia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014826352&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014826353,Spontaneous,2023-03-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,Rash (n/a - Unknown - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])","LIXIANA [EDOXABAN, EDOXABAN TOSYLATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014826353&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014826362,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal distension (n/a - Unknown - Other Medically Important Condition),<BR><BR>Abdominal pain lower (n/a - Unknown - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Herpes zoster (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rash pruritic (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash vesicular (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tension headache (3d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[ESTROGENS CONJUGATED, ESTRONE SODIUM SULFATE, EQUILIN SULFATE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[GABAPENTIN] (C - Neck pain - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014826362&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014826375,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dizziness (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CODEINE PHOSPHATE HEMIHYDRATE PHEUR, CAFFEINE PH. EUR., PARACETAMOL PH. EUR., PARACETAMOL, CAFFEINE, CODEINE PHOSPHATE HEMIHYDRATE, PARACETAMOL, CODEINE PHOSPHATE HEMIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FLUCLOXACILLIN, FLUCLOXACILLIN SODIUM, FLUCLOXACILLIN SODIUM MONOHYDRATE] (C - Cellulitis - n/a - [17d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014826375&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014826376,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Asthenia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Night sweats (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014826376&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014826379,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Immunisation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Off label use (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vomiting (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014826379&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014826383,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014826383&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014826397,Spontaneous,2023-03-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Breast pain (n/a - Recovering/Resolving - ),<BR><BR>Cardiac flutter (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - ),<BR><BR>Dyspnoea (n/a - Unknown - ),<BR><BR>Fatigue (n/a - Unknown - ),<BR><BR>Neck pain (n/a - Unknown - ),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - ),<BR><BR>Pain in jaw (3d - Recovered/Resolved - ),<BR><BR>Palpitations (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014826397&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014826401,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","IBUPROFEN [IBUPROFEN, IBUPROFEN SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014826401&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014826402,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Allodynia (n/a - Unknown - ),<BR><BR>Contusion (n/a - Unknown - ),<BR><BR>Headache (n/a - Unknown - ),<BR><BR>Hemiparesis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Maternal exposure during breast feeding (n/a - Unknown - ),<BR><BR>Muscle tightness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Neck pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain (n/a - Unknown - ),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain in extremity (n/a - Unknown - ),<BR><BR>Paraesthesia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Paraesthesia (n/a - Unknown - ),<BR><BR>Vaccination site pain (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[FLUOXETINE, FLUOXETINE HYDROCHLORIDE] (C - Depression - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014826402&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014826405,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Ear pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Sensation of foreign body (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014826405&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014826406,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myocarditis (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014826406&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014826408,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal pain upper (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination site pain (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[DIENOGEST, ESTRADIOL VALERATE, ESTRADIOL VALERATE, LACTOSE, LACTOSE MONOHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014826408&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014826409,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling cold (n/a - Unknown - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Neuralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014826409&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014826773,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Convulsions local (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014826773&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014826781,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014826781&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014826784,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Ocular hyperaemia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[FEXOFENADINE, FEXOFENADINE HYDROCHLORIDE] (C - Hypersensitivity - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014826784&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014826789,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Diarrhoea (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (7d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Illness (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain (7d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014826789&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014826792,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (6d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014826792&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014826793,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Blister (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Paraesthesia oral (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Throat irritation (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014826793&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014826799,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Ageusia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014826799&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014828264,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Ischaemic stroke (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014828264&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014828547,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014828547&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014828559,Spontaneous,2023-03-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Gingival swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - ),<BR><BR>Toothache (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014828559&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014828581,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Cerebral infarction (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014828581&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014828593,Spontaneous,2023-03-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Pyrexia (4d - Recovered/Resolved - ),<BR><BR>Seizure (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014828593&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014828595,Spontaneous,2023-03-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Ataxia (n/a - Unknown - ),<BR><BR>Guillain-Barre syndrome (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypoaesthesia (n/a - Unknown - ),<BR><BR>Mastication disorder (n/a - Unknown - ),<BR><BR>Muscular weakness (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014828595&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014828609,Spontaneous,2023-03-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (3d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Drug ineffective (3d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),<BR><BR>SPIKEVAX [ELASOMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","ODEFSEY [EMTRICITABINE, TENOFOVIR ALAFENAMIDE, RILPIVIRINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METOPROLOL TARTRATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014828609&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014828652,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Abdominal pain (n/a - Unknown - ),<BR><BR>Blood pressure increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Unknown - ),<BR><BR>Heart rate increased (n/a - Unknown - ),<BR><BR>Palpitations (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMLODIPINE, AMLODIPINE BESILATE] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014828652&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829770,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Asthenia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Dyspnoea exertional (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hypoaesthesia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 4{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829770&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829841,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829841&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829843,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Joint range of motion decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Muscular weakness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Musculoskeletal stiffness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in jaw (n/a - Unknown - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829843&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829846,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Body temperature abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Intermenstrual bleeding (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Lymph node pain (7d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (7d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Menstruation irregular (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (5d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ESTRADIOL, ESTRADIOL HEMIHYDRATE, ESTRADIOL, NORETHISTERONE, NORETHISTERONE ACETATE, NORETHISTERONE ACETATE, ESTRADIOL, NORETHISTERONE ACETATE, ESTRADIOL HEMIHYDRATE] (C - Hormone replacement therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829846&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829848,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Decreased appetite (n/a - Unknown - Disabling),<BR><BR>Dysphagia (n/a - Unknown - Disabling),<BR><BR>Fatigue (n/a - Unknown - Disabling),<BR><BR>Haematemesis (n/a - Recovering/Resolving - Disabling),<BR><BR>Headache (n/a - Unknown - Disabling),<BR><BR>Hypersomnia (n/a - Unknown - Disabling),<BR><BR>Nausea (4d - Recovered/Resolved - Disabling),<BR><BR>Pruritus (4d - Recovered/Resolved - Disabling),<BR><BR>Retching (n/a - Unknown - Disabling),<BR><BR>Vomiting (n/a - Unknown - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829848&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829850,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Balance disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dysstasia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Heart rate increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tremor (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ATORVASTATIN] (C - Arrhythmia - n/a - [n/a - 20mg - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Arrhythmia - n/a - [n/a - 2.5mg - n/a]),<BR><BR>[LANSOPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - 15mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829850&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829851,Spontaneous,2023-03-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Guillain-Barre syndrome (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),<BR><BR>Maternal exposure during pregnancy (n/a - Unknown - ),<BR><BR>Medication error (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Product use issue (n/a - Unknown - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [1d - n/a - n/a])","[FOLIC ACID] (C - Vitamin supplementation - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829851&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829852,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Abdominal pain upper (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Cognitive disorder (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fibromyalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lethargy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Loss of personal independence in daily activities (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - Arthritis - n/a - [n/a - n/a - n/a]),<BR><BR>[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - Depression - n/a - [n/a - n/a - n/a]),<BR><BR>[CODEINE PHOSPHATE] (C - Arthritis - n/a - [n/a - n/a - n/a]),<BR><BR>[NAPROXEN, NAPROXEN SODIUM] (C - Arthritis - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Arthritis - n/a - [n/a - n/a - n/a]),<BR><BR>[TAPENTADOL] (C - Arthritis - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829852&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829854,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Axillary pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Migraine with aura (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - Menopause - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRADIOL] (C - Menopause - n/a - [n/a - n/a - n/a]),<BR><BR>[PROGESTERONE, PROGESTERONE, MICRONISED] (C - Menopause - n/a - [n/a - n/a - n/a]),<BR><BR>[QUININE] (C - Muscle spasms - n/a - [n/a - n/a - n/a]),<BR><BR>[RIZATRIPTAN, RIZATRIPTAN BENZOATE] (C - Migraine - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829854&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829855,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Facial paralysis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypersensitivity (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hypertension (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lip swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Paraesthesia oral (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829855&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829857,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","APIXABAN [APIXABAN] (C - Pulmonary embolism - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Blood pH increased - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - Blood pH increased - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829857&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829858,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Cardiac flutter (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Heart rate increased (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Unknown - ),<BR><BR>Nasopharyngitis (n/a - Not Recovered/Not Resolved - ),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[BECLOMETASONE DIPROPIONATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - Depression - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - Type 2 diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[NADOLOL] (C - Long QT syndrome congenital - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL MICRONIZED, SALBUTAMOL SULFATE] (C - Asthma - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829858&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829859,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Vaccination site erythema (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site induration (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination site pruritus (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination site swelling (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829859&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829862,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Pleurisy (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829862&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829865,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Contusion (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Syncope (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829865&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829866,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Anxiety (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Asthenia (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Heart rate abnormal (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829866&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829867,Spontaneous,2023-03-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Lymph node pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","SILDENAFIL [SILDENAFIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[TAMSULOSIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829867&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829868,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Insomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Loss of personal independence in daily activities (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rash macular (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Blood pressure increased - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829868&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829869,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hypersomnia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829869&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829872,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Bone pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Joint range of motion decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Limb discomfort (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vision blurred (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[CODEINE] (C - Dysmenorrhoea - n/a - [n/a - n/a - n/a]),<BR><BR>[MEBEVERINE] (C - Abdominal pain upper - n/a - [n/a - n/a - n/a]),<BR><BR>[PLANTAGO INDICA] (C - Abdominal pain upper - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829872&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829874,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829874&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829875,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Blindness transient (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypoacusis (n/a - Unknown - ),<BR><BR>Presyncope (1d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829875&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829876,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Somnolence (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829876&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829878,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Hypoaesthesia (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pulmonary embolism (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Middle aged - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829878&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829879,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Bone pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829879&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829882,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lethargy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rash pruritic (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829882&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829884,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Hot flush (n/a - Unknown - Other Medically Important Condition),<BR><BR>Libido increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Migraine (n/a - Unknown - Other Medically Important Condition),<BR><BR>Oestradiol increased (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - n/a])","ABEMACICLIB [ABEMACICLIB] (C - Breast cancer female - n/a - [n/a - n/a - n/a]),<BR><BR>ZOLEDRONIC ACID [ZOLEDRONIC ACID] (C - Breast cancer female - n/a - [n/a - n/a - n/a]),<BR><BR>[ANASTROZOLE] (C - Breast cancer female - n/a - [955d - n/a - n/a]),<BR><BR>[GOSERELIN] (C - Breast cancer female - n/a - [1122d - n/a - n/a]),<BR><BR>[LOPERAMIDE, LOPERAMIDE HYDROCHLORIDE] (C - Diarrhoea - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829884&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829885,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Musculoskeletal stiffness (n/a - Unknown - Life Threatening, Other Medically Important Condition),<BR><BR>Thrombosis (n/a - Recovering/Resolving - Life Threatening, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829885&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829886,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Asthenia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Diarrhoea (8d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Somnolence (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vomiting (8d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829886&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829887,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Burning sensation (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Rash (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829887&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829888,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Body temperature increased (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Heart rate increased (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Respiratory rate increased (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829888&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829900,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Axillary pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hypoaesthesia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Sleep disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tremor (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - Cardiomegaly - n/a - [n/a - n/a - n/a]),<BR><BR>[PRAVASTATIN, PRAVASTATIN SODIUM] (C - Cardiomegaly - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829900&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829902,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Back pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Erythema (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Muscular weakness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Skin reaction (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829902&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829903,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Cerebrovascular accident (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Thrombosis (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","INSULIN HUMAN [INSULIN HUMAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[GLICLAZIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INSULIN, INSULIN HUMAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829903&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829906,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chills (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Decreased appetite (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Insomnia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Myalgia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Restlessness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829906&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829907,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Loss of personal independence in daily activities (n/a - Unknown - Other Medically Important Condition),<BR><BR>Periarthritis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Poor quality sleep (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829907&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829910,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Lymphadenopathy (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829910&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829912,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal pain upper (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pruritus (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","ESOMEPRAZOLE [ESOMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CANDESARTAN, CANDESARTAN CILEXETIL] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829912&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829913,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Not Specified,Musculoskeletal stiffness (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829913&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829914,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Abnormal dreams (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Anxiety (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Asthenia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chills (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Derealisation (1d - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Dyspnoea (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Night sweats (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Panic attack (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Panic disorder (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Sleep disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tremor (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[CARBAMAZEPINE, CARBAMAZEPINE (PH. EUR.)] (C - Bipolar II disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[MOMETASONE FUROATE, MOMETASONE FUROATE MONOHYDRATE] (C - Rhinitis - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829914&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829915,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Headache (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[PERINDOPRIL, PERINDOPRIL TERT-BUTYLAMINE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - Blood cholesterol increased - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829915&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829917,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site erythema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site mass (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829917&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829922,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"Angina pectoris (6d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Migraine (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829922&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829924,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Tinnitus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[DESOGESTREL] (C - Contraception - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a]),<BR><BR>[SODIUM VALPROATE] (C - Generalised tonic-clonic seizure - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829924&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829925,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Axillary pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Breast pain (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypoaesthesia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hypokinesia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Neuralgia (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","NOVORAPID [INSULIN ASPART] (C - Type 1 diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>TOUJEO [INSULIN GLARGINE] (C - Type 1 diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - Type IIa hyperlipidaemia - n/a - [n/a - n/a - n/a]),<BR><BR>[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE, BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[PHENYLEPHRINE HYDROCHLORIDE, GUAIFENESIN, PARACETAMOL] (C - Nasopharyngitis - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829925&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829926,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Anxiety (5h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Delusion (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Thinking abnormal (5h - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829926&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829927,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Body temperature increased (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Crying (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dry throat (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - Major depression - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829927&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829928,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fluid retention (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Limb discomfort (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Muscular weakness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Somnolence (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Swelling of eyelid (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829928&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829931,Spontaneous,2023-03-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Alopecia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Extrasystoles (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829931&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829933,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Arthritis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Gait disturbance (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Limb discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Mobility decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829933&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829935,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Haemorrhage (9d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Rash pruritic (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site haemorrhage (n/a - Recovered/Resolved - ),<BR><BR>Vaccination site rash (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (S - Immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829935&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829938,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Parametritis (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[ETORICOXIB] (C - Inflammation - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829938&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829956,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site urticaria (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829956&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829961,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chest discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspepsia (3d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829961&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829962,Spontaneous,2023-03-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Bradycardia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypotension (n/a - Unknown - ),<BR><BR>Pallor (n/a - Unknown - ),<BR><BR>Syncope (1min - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829962&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829963,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Rash (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rash pruritic (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829963&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829965,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Apathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Eye pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Feeling of body temperature change (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Migraine (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Sleep disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Visual impairment (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829965&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829967,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Erythema (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829967&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829969,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Eye haemorrhage (n/a - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829969&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829970,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Palpitations (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",OCRELIZUMAB [OCRELIZUMAB] (C - Multiple sclerosis - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829970&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829972,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829972&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829973,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Insomnia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Night sweats (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Thyroid disorder - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829973&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829975,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829975&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829976,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Anxiety (n/a - Unknown - Other Medically Important Condition),<BR><BR>Cardiac discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chest discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Heart rate irregular (n/a - Unknown - Other Medically Important Condition),<BR><BR>Maternal exposure during pregnancy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[CEFALEXIN] (C - Urinary tract infection - n/a - [6d - n/a - n/a]),<BR><BR>[FOLIC ACID] (C - Vitamin supplementation - n/a - [n/a - 400ug - n/a]),<BR><BR>[NITROFURANTOIN] (C - Urinary tract infection - n/a - [6d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829976&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829977,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Diarrhoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Photophobia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829977&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829979,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Immunisation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Incorrect dose administered (n/a - Unknown - ),<BR><BR>Myalgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Off label use (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Sensitive skin (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829979&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829980,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Cough (n/a - Unknown - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829980&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829981,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Allergy to vaccine (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829981&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829982,Spontaneous,2023-03-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Transient ischaemic attack (1d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - Transient ischaemic attack - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - Cardiovascular disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[GLICLAZIDE] (C - Type 2 diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - Type 2 diabetes mellitus - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829982&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829984,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Cold sweat (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Syncope (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vomiting (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[CYTARABINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[DESOGESTREL] (C - Contraception - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829984&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829985,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829985&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829991,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dizziness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Heart rate abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Heart rate increased (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Paralysis (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829991&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829993,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vertigo (5d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829993&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829996,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Herpes zoster (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Autoimmune hypothyroidism - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829996&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014829999,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Heavy menstrual bleeding (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (S - Adrenal disorder, Immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014829999&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830000,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830000&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830007,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Decreased appetite (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","IBUPROFEN [IBUPROFEN, IBUPROFEN SODIUM] (C - Arthralgia - n/a - [n/a - n/a - n/a]),<BR><BR>[CINNARIZINE] (C - Motion sickness - n/a - [n/a - n/a - n/a]),<BR><BR>[METOCLOPRAMIDE] (C - Motion sickness - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Arthralgia - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830007&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830008,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Heart rate increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypertension (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Illness (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",MYCOPHENOLATE MOFETIL [MYCOPHENOLATE MOFETIL] (C - Infection in an immunocompromised host - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830008&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830009,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest discomfort (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Malaise (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830009&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830013,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Agitation (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chills (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - Depression - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830013&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830014,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830014&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830019,Spontaneous,2023-03-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Erythema (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site bruising (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site discolouration (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","MELATONIN [MELATONIN] (C - Somnolence - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Cardiac failure - n/a - [n/a - n/a - n/a]),<BR><BR>[CARVEDILOL] (C - Cardiac failure - n/a - [n/a - n/a - n/a]),<BR><BR>[HYPROMELLOSE] (C - Dry eye - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - Blood pressure abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[SPIRONOLACTONE] (C - Cardiac failure - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830019&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830020,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830020&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830022,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Headache (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Syncope (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830022&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830023,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Aphonia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dysphonia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Odynophagia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Rhinorrhoea (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830023&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830024,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Burning sensation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830024&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830027,Spontaneous,2023-03-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Postmenopausal haemorrhage (6d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830027&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830029,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal discomfort (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Abdominal pain (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Back pain (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Functional gastrointestinal disorder (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Gastrointestinal disorder (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Night sweats (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Rash (2d - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Rash pruritic (2d - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Tremor (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830029&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830030,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Cluster headache (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Cluster headache (n/a - Recovered/Resolved With Sequelae - Disabling),<BR><BR>Head discomfort (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Illness (n/a - Recovered/Resolved - Disabling),<BR><BR>Joint range of motion decreased (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Product use issue (n/a - Unknown - Disabling),<BR><BR>Vomiting (n/a - Not Recovered/Not Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Immunisation - Not applicable - [1d - n/a - n/a])",[PARACETAMOL] (C - Limb discomfort - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830030&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830031,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal discomfort (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Abdominal discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fall (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Head injury (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Syncope (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830031&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830032,Spontaneous,2023-03-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Back pain (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Body temperature increased (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Thirst (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[FERROUS SULFATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LIOTHYRONINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[VITAMIN D] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830032&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830034,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Migraine (n/a - Unknown - Disabling),<BR><BR>Pain (n/a - Unknown - Disabling),<BR><BR>Shoulder injury related to vaccine administration (n/a - Unknown - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830034&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830036,Spontaneous,2023-03-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Anaphylactic reaction (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chest discomfort (n/a - Unknown - ),<BR><BR>Dysphagia (n/a - Unknown - ),<BR><BR>Dyspnoea (n/a - Unknown - ),<BR><BR>Malaise (n/a - Unknown - ),<BR><BR>Throat tightness (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","HYDROCORTISONE [HYDROCORTISONE, HYDROCORTISONE SODIUM SUCCINATE] (C - Addison's disease - n/a - [n/a - n/a - n/a]),<BR><BR>[FLUDROCORTISONE] (C - Addison's disease - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830036&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830039,Spontaneous,2023-03-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Immune thrombocytopenia (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",BUDESONIDE [BUDESONIDE] (C - Asthma - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830039&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830043,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Erythema (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Feeling hot (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Heart rate increased (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Localised infection (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CANDESARTAN, CANDESARTAN CILEXETIL] (C - Migraine - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[SUMATRIPTAN, SUMATRIPTAN SUCCINATE] (C - Migraine - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830043&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830045,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Blood pressure increased (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chills (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (4d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830045&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830046,Spontaneous,2023-03-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Pulmonary embolism (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","BUPRENORPHINE [BUPRENORPHINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>DAPAGLIFLOZIN [DAPAGLIFLOZIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>EXENATIDE [EXENATIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>METHOTREXATE [METHOTREXATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ETORICOXIB] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FOLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MIRTAZAPINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PRAMIPEXOLE, PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830046&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830049,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Weight decreased (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830049&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830051,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Lymphoedema (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Swelling (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[PERINDOPRIL, PERINDOPRIL TERT-BUTYLAMINE] (C - Hypertension - n/a - [n/a - 4mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830051&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830052,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830052&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830054,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Axillary pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Back pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Body temperature increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Spinal pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (S - Immunisation - Unknown - [1d - n/a - n/a])","[LEVONORGESTREL, LEVONORGESTREL MICRONISED] (C - Contraception - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830054&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830056,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,Erectile dysfunction (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830056&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830057,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chills (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nasopharyngitis (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830057&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830064,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830064&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830066,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Abdominal pain upper (n/a - Unknown - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830066&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830067,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Joint range of motion decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830067&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830070,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Loss of personal independence in daily activities (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830070&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830072,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dizziness postural (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Sensation of blood flow (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vertigo (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","RIVAROXABAN [RIVAROXABAN] (C - Atrial fibrillation - n/a - [n/a - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE, BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Atrial fibrillation - n/a - [n/a - n/a - n/a]),<BR><BR>[DIGOXIN] (C - Atrial fibrillation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830072&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830078,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Chest pain (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Heart rate increased (n/a - Unknown - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830078&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830082,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Disabling),<BR><BR>Depressed mood (n/a - Unknown - Disabling),<BR><BR>Dyspnoea (n/a - Unknown - Disabling),<BR><BR>Fatigue (n/a - Unknown - Disabling),<BR><BR>Headache (n/a - Unknown - Disabling),<BR><BR>Inflammation (n/a - Recovering/Resolving - Disabling),<BR><BR>Palpitations (n/a - Unknown - Disabling),<BR><BR>Tachycardia (n/a - Unknown - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[RIZATRIPTAN, RIZATRIPTAN BENZOATE] (C - Migraine - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830082&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830083,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Anxiety (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Transient global amnesia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","ESOMEPRAZOLE [ESOMEPRAZOLE] (C - Reflux gastritis - n/a - [n/a - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830083&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830085,Spontaneous,2023-03-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",[BALSALAZIDE] (C - Colitis ulcerative - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830085&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830088,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830088&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830090,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Immunisation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Incorrect dose administered (n/a - Unknown - ),<BR><BR>Off label use (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830090&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830091,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Unknown - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nasopharyngitis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Photophobia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Sinus headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[INFLUENZA VIRUS] (C - Immunisation, Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[TERBINAFINE, TERBINAFINE HYDROCHLORIDE] (C - Fungal infection - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830091&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830094,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Axillary mass (n/a - Unknown - Other Medically Important Condition),<BR><BR>Axillary pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hypokinesia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830094&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830097,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hypersomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830097&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830098,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Back pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Peripheral coldness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tremor (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","LEVETIRACETAM [LEVETIRACETAM] (C - Epilepsy - n/a - [n/a - n/a - n/a]),<BR><BR>[LABETALOL, LABETALOL HYDROCHLORIDE] (C - Blood pressure measurement - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830098&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830101,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Influenza (3d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830101&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830102,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash erythematous (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE, BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[FLUOXETINE, FLUOXETINE HYDROCHLORIDE] (C - Depression - n/a - [n/a - n/a - n/a]),<BR><BR>[GABAPENTIN] (C - Epilepsy - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVONORGESTREL, LEVONORGESTREL MICRONISED] (C - Endometriosis - n/a - [n/a - n/a - n/a]),<BR><BR>[MOMETASONE] (C - Asthma - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830102&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830103,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Hyperhidrosis (n/a - Unknown - Disabling),<BR><BR>Hypoaesthesia (n/a - Unknown - Disabling),<BR><BR>Influenza like illness (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Insomnia (n/a - Unknown - Disabling),<BR><BR>Interchange of vaccine products (n/a - Unknown - Disabling),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Malaise (n/a - Recovering/Resolving - Disabling),<BR><BR>Nasopharyngitis (n/a - Unknown - Disabling),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Disabling),<BR><BR>Tachyphrenia (1d - Recovered/Resolved - Disabling),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830103&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830104,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Axillary mass (n/a - Unknown - Other Medically Important Condition),<BR><BR>Axillary pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Joint range of motion decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Limb discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination site mass (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site warmth (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Cardiomyopathy - n/a - [n/a - n/a - n/a]),<BR><BR>[FUROSEMIDE] (C - Cardiomyopathy - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Decreased activity - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Analgesic therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[PERINDOPRIL, PERINDOPRIL TERT-BUTYLAMINE] (C - Cardiomyopathy - n/a - [n/a - n/a - n/a]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - Anxiety - n/a - [n/a - n/a - n/a]),<BR><BR>[SPIRONOLACTONE] (C - Cardiomyopathy - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830104&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830105,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abnormal loss of weight (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Bone pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dehydration (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","IBUPROFEN [IBUPROFEN, IBUPROFEN SODIUM] (C - Bone pain - n/a - [n/a - n/a - n/a]),<BR><BR>[ALENDRONATE SODIUM, ALENDRONIC ACID] (C - Bone loss - n/a - [n/a - n/a - n/a]),<BR><BR>[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - Restless legs syndrome - n/a - [n/a - n/a - n/a]),<BR><BR>[CARBOCISTEINE] (C - Bronchiectasis - n/a - [n/a - n/a - n/a]),<BR><BR>[CODEINE] (C - Bone pain - n/a - [n/a - n/a - n/a]),<BR><BR>[DIHYDROCODEINE TARTRATE, PARACETAMOL, PARACETAMOL] (C - Bone pain - n/a - [n/a - n/a - n/a]),<BR><BR>[IPRATROPIUM, IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE ANHYDROUS, IPRATROPIUM BROMIDE MONOHYDRATE] (C - Bronchiectasis - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - Dysphagia - n/a - [n/a - n/a - n/a]),<BR><BR>[PREDNISOLONE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[THEOPHYLLINE, THEOPHYLLINE PH. EUR.] (C - Bronchiectasis - n/a - [n/a - n/a - n/a]),<BR><BR>[VITAMIN D, CALCIUM] (C - Osteopenia - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830105&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830122,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Gait spastic (n/a - Not Recovered/Not Resolved - Life Threatening, Disabling, Other Medically Important Condition),<BR><BR>Musculoskeletal stiffness (n/a - Not Recovered/Not Resolved - Life Threatening, Disabling, Other Medically Important Condition),<BR><BR>Myelitis transverse (n/a - Not Recovered/Not Resolved - Life Threatening, Disabling, Other Medically Important Condition),<BR><BR>Neuralgia (n/a - Not Recovered/Not Resolved - Life Threatening, Disabling, Other Medically Important Condition),<BR><BR>Peripheral coldness (n/a - Unknown - Life Threatening, Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830122&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830475,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - ),<BR><BR>COVID-19 (n/a - Unknown - ),<BR><BR>Headache (n/a - Unknown - ),<BR><BR>Menstruation delayed (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Unknown - ),<BR><BR>Respiratory disorder (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[BILASTINE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[DROSPIRENONE, ETHINYLESTRADIOL, LACTOSE, LACTOSE HYDROUS, LACTOSE MONOHYDRATE] (C - n/a - Unknown - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830475&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830572,Spontaneous,2023-03-17 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Deafness unilateral (25d - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830572&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830592,Spontaneous,2023-03-17 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Polyneuropathy (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830592&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830598,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Migraine (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830598&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830603,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Dyspnoea (21d - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Gait disturbance (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATENOLOL, ATENOLOL BP] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[NYSTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830603&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830609,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Insomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Menstruation delayed (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Restless legs syndrome (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830609&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830617,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dizziness (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),<BR><BR>Fall (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Hip fracture (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Pain (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Syncope (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Vomiting (n/a - Unknown - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830617&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830679,Spontaneous,2023-03-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Anaphylactic reaction (1d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mg - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830679&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830682,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Angina pectoris (n/a - Unknown - Other Medically Important Condition),<BR><BR>Cardiac disorder (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Inappropriate schedule of product administration (n/a - Unknown - ),<BR><BR>Peripheral swelling (17d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pruritus (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site swelling (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - Hormone replacement therapy - n/a - [41d - n/a - n/a]),<BR><BR>[FLURAZEPAM, FLURAZEPAM HYDROCHLORIDE, FLURAZEPAM MONOHYDROCHLORIDE] (C - Insomnia - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830682&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830685,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Anaphylactic reaction (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830685&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830686,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Extrasystoles (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Ventricular extrasystoles (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[PARACETAMOL, CODEINE PHOSPHATE] (C - Back pain - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830686&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830694,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Facial pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Paraesthesia oral (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","MYCOPHENOLATE MOFETIL [MYCOPHENOLATE MOFETIL] (C - Autoimmune hepatitis - n/a - [n/a - n/a - n/a]),<BR><BR>PREGABALIN [PREGABALIN] (C - Analgesic therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[BUDESONIDE] (C - Autoimmune hepatitis - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830694&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830695,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (6d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830695&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830698,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Blood pressure increased (1d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Unknown - ),<BR><BR>Palpitations (1d - Recovered/Resolved - ),<BR><BR>Syncope (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Syncope (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (1d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830698&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830705,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Cheilitis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[AZELASTINE HYDROCHLORIDE, FLUTICASONE PROPIONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL, CALCIUM CARBONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FLUTICASONE PROPIONATE, SALMETEROL, FLUTICASONE PROPIONATE, SALMETEROL XINAFOATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - n/a - n/a - [1d - n/a - n/a]),<BR><BR>[LEVOCETIRIZINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MONTELUKAST, MONTELUKAST SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL MICRONIZED, SALBUTAMOL SULFATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830705&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830709,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Pain in extremity (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830709&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830710,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Angioedema (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830710&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830711,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Eye swelling (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Skin exfoliation (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Swelling face (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Swollen tongue (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[FEXOFENADINE, FEXOFENADINE HYDROCHLORIDE] (C - Adverse drug reaction - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830711&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830713,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Eye pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Herpes zoster reactivation (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Photopsia (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - Insomnia - n/a - [n/a - n/a - n/a]),<BR><BR>[FLUOXETINE, FLUOXETINE HYDROCHLORIDE] (C - Depression - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830713&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830783,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a - More in ICSR]),<BR><BR>COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[GLUCOSAMINE, GLUCOSAMINE SULFATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PROCHLORPERAZINE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830783&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830784,Spontaneous,2023-03-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Disease recurrence (n/a - Unknown - Other Medically Important Condition),<BR><BR>Seizure (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Temporal lobe epilepsy (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830784&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830785,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Feeling hot (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hallucination (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830785&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830786,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Cardiac arrest (n/a - Unknown - Life Threatening),<BR><BR>Chest pain (n/a - Unknown - Life Threatening),<BR><BR>Diarrhoea (n/a - Unknown - Life Threatening),<BR><BR>Dyspnoea (n/a - Unknown - Life Threatening),<BR><BR>Fatigue (n/a - Unknown - Life Threatening),<BR><BR>Pericarditis (n/a - Not Recovered/Not Resolved - Life Threatening),<BR><BR>SARS-CoV-2 test positive (n/a - Unknown - Life Threatening),<BR><BR>Urticaria (1d - Recovered/Resolved - Life Threatening)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - Type 2 diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - Blood pressure measurement - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830786&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830787,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (6d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (6d - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830787&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830789,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Decreased appetite (n/a - Unknown - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Oral pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830789&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830790,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Limb discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site swelling (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830790&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830791,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830791&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830792,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Axillary pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site erythema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pruritus (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site rash (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830792&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830794,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Head discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vision blurred (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830794&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830796,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830796&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830797,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Haemorrhage (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Postmenopausal haemorrhage (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830797&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830798,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Expired product administered (n/a - Unknown - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830798&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830799,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Pyrexia (2d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Vomiting (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[CODEINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTROGENS CONJUGATED, ESTRONE SODIUM SULFATE, EQUILIN SULFATE SODIUM] (C - Hormone replacement therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Congenital hypothyroidism - n/a - [n/a - n/a - n/a]),<BR><BR>[LORATADINE] (C - Hypersensitivity - n/a - [n/a - n/a - n/a]),<BR><BR>[PREDNISOLONE] (C - Myalgia - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830799&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830800,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest pain (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pericarditis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","PREGABALIN [PREGABALIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INSULIN, INSULIN HUMAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830800&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830802,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Anxiety (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Heart rate irregular (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lethargy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830802&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830803,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - Cerebrovascular accident - n/a - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - Cerebrovascular accident - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830803&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830804,Spontaneous,2023-03-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Recovered/Resolved - ),<BR><BR>Dizziness (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Hyperpyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Pain (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Unknown - ),<BR><BR>Syncope (n/a - Unknown - Other Medically Important Condition),<BR><BR>Visual impairment (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830804&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830805,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Heavy menstrual bleeding (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Illness (4h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Joint range of motion decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymph node pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Menstruation irregular (n/a - Unknown - Other Medically Important Condition),<BR><BR>Mobility decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Somnolence (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830805&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830806,Spontaneous,2023-03-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arrhythmia (n/a - Recovering/Resolving - Disabling),<BR><BR>Body temperature decreased (n/a - Unknown - Disabling),<BR><BR>Chills (n/a - Unknown - Disabling),<BR><BR>Fatigue (2d - Recovered/Resolved - Disabling),<BR><BR>Hypersomnia (n/a - Unknown - Disabling),<BR><BR>Nausea (2d - Recovered/Resolved - Disabling),<BR><BR>Sinus headache (3d - Recovered/Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830806&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830807,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Throat tightness (3d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830807&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830808,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chronic fatigue syndrome (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Gait inability (n/a - Unknown - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830808&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830809,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Axillary pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nasopharyngitis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Palpitations (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Swelling (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830809&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830810,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (5d - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Axillary mass (n/a - Unknown - Other Medically Important Condition),<BR><BR>Axillary pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Back pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Gastrooesophageal reflux disease (n/a - Unknown - Other Medically Important Condition),<BR><BR>Migraine (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[FLUOXETINE, FLUOXETINE HYDROCHLORIDE] (C - Depression - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - n/a]),<BR><BR>[RIZATRIPTAN, RIZATRIPTAN BENZOATE] (C - Migraine - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830810&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830811,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"Dysphagia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Postural orthostatic tachycardia syndrome (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Tremor (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Vocal cord paresis (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830811&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830812,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,12-17 Years,Not Specified,No,Female,"Chest discomfort (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Feeling of body temperature change (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rash (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830812&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830813,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Body temperature increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Muscle spasms (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830813&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830814,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dizziness (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Dysstasia (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Gait disturbance (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Illness (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Vertigo (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[LORAZEPAM] (C - Atrial fibrillation - n/a - [n/a - n/a - n/a]),<BR><BR>[PREDNISOLONE] (C - Polymyalgia rheumatica - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830814&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830815,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Feeding disorder (24h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[DESOGESTREL, ETHINYLESTRADIOL, ETHINYLESTRADIOL PH. EUR., DESOGESTREL B.P.] (C - Heavy menstrual bleeding - n/a - [n/a - n/a - n/a]),<BR><BR>[MONTELUKAST, MONTELUKAST SODIUM] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830815&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830816,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pulmonary thrombosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Thrombosis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830816&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830817,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Appetite disorder (1d - Recovered/Resolved - Disabling),<BR><BR>Arthralgia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Chest pain (n/a - Recovering/Resolving - Disabling),<BR><BR>Chills (2d - Recovered/Resolved - Disabling),<BR><BR>Decreased appetite (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Dizziness postural (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Hyperhidrosis (2d - Recovered/Resolved - Disabling),<BR><BR>Lethargy (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Migraine (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Vomiting (2d - Recovered/Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","PREGABALIN [PREGABALIN] (C - Fibromyalgia - n/a - [n/a - n/a - n/a]),<BR><BR>[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - Depression - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRADIOL] (C - Menopause - n/a - [n/a - n/a - n/a]),<BR><BR>[FEXOFENADINE, FEXOFENADINE HYDROCHLORIDE] (C - Hypersensitivity - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830817&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830818,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830818&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830819,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830819&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830820,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Cerebral disorder (n/a - Unknown - Disabling),<BR><BR>Gingival swelling (n/a - Unknown - Disabling),<BR><BR>Limb discomfort (n/a - Unknown - Disabling),<BR><BR>Medication error (n/a - Unknown - Disabling),<BR><BR>Mouth ulceration (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Oral pain (n/a - Unknown - Disabling),<BR><BR>Tongue discomfort (n/a - Unknown - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830820&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830821,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Decreased appetite (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vomiting (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (S - Immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830821&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830822,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Anxiety (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Head discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nervousness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830822&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830823,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Abdominal pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Abdominal pain upper (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830823&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830824,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Muscle strain (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[ATORVASTATIN] (C - Blood pressure abnormal - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830824&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830826,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site mass (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ESTRADIOL, NORETHISTERONE, NORETHISTERONE ACETATE, ESTRADIOL, NORETHISTERONE ACETATE, ESTRADIOL HEMIHYDRATE] (C - Premature menopause - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830826&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014830827,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal pain upper (n/a - Unknown - Other Medically Important Condition),<BR><BR>Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Biliary colic (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Diarrhoea (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Eye pain (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Eye swelling (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pancreatic disorder (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Somnolence (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vomiting (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014830827&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014831672,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014831672&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014831673,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Feeling hot (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014831673&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014831676,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (5d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (6d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Myalgia (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (3d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014831676&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014831677,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Herpes zoster (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014831677&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014831678,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Balance disorder (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Feeling cold (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lethargy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Tremor (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014831678&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014831679,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Immunisation reaction (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014831679&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014831681,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal pain upper (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Asthenia (4d - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Dizziness (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Dyspnoea exertional (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Insomnia (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Malaise (4d - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Migraine (6d - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Night sweats (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - n/a])","[FROVATRIPTAN] (C - Migraine - n/a - [n/a - n/a - n/a]),<BR><BR>[PROPRANOLOL, PROPRANOLOL HYDROCHLORIDE] (C - Migraine - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014831681&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014831683,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Male,Prostate cancer (n/a - Unknown - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014831683&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014831685,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Neuralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Sleep disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tendon pain (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014831685&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014831688,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Dermatomyositis (n/a - Unknown - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014831688&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014831689,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Blood pressure decreased (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014831689&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014831692,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Back pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Cough (10d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ATORVASTATIN] (C - Blood cholesterol increased - n/a - [n/a - n/a - n/a]),<BR><BR>[FINASTERIDE] (C - Prostatomegaly - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - Depression - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014831692&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014831694,Spontaneous,2023-03-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Fibrin D dimer increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pulmonary embolism (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","RIVAROXABAN [RIVAROXABAN] (C - Pulmonary embolism - n/a - [n/a - n/a - n/a]),<BR><BR>SILDENAFIL [SILDENAFIL] (C - Erectile dysfunction - n/a - [n/a - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[ALUMINIUM HYDROXIDE GEL, DRIED, MAGNESIUM CARBONATE, SODIUM CARBONATE, ALGINIC ACID, ALUMINIUM HYDROXIDE, SODIUM CARBONATE, CALCIUM CARBONATE, SODIUM ALGINATE, ALUMINIUM HYDROXIDE, SODIUM HYDROGEN CARBONATE, ALGINIC ACID, ALUMINIUM HYDROXIDE, SODIUM HYDROGEN CARBONATE, ALGINIC ACID, ALUMINIUM HYDROXIDE GEL, DRIED USP, SODIUM HYDROGEN CARBONATE, ALGINIC ACID, SODIUM ALGINATE, ALUMINIUM HYDROXIDE, SODIUM HYDROGEN CARBONATE, ALUMINIUM HYDROXIDE GEL, CALCIUM CARBONATE, SODIUM ALGINATE, SODIUM HYDROGEN CARBONATE, CALCIUM CARBONATE, SODIUM ALGINATE, SODIUM HYDROGEN CARBONATE, CALCIUM CARBONATE, SODIUM ALGINATE, ALUMINIUM HYDROXIDE, SODIUM HYDROGEN CARBONATE, SODIUM ALGINATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[LORATADINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[SUMATRIPTAN, SUMATRIPTAN SUCCINATE] (C - Migraine - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014831694&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014831697,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Herpes zoster (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014831697&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014831698,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Insomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - Cerebrovascular accident - n/a - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - Cerebrovascular accident - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014831698&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014831699,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014831699&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014831707,Spontaneous,2023-03-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Encephalitis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Encephalopathy (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Eye pain (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Headache (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Meningitis viral (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Neck pain (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Tremor (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014831707&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014831711,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Herpes zoster (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[ATORVASTATIN] (C - Blood cholesterol abnormal - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014831711&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014831715,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Fatigue (n/a - Unknown - Disabling),<BR><BR>Hypoaesthesia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Myocarditis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - ),<BR><BR>Palpitations (n/a - Unknown - Disabling),<BR><BR>Pericarditis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Disabling),<BR><BR>Somnolence (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014831715&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014831716,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Delirium (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014831716&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014831721,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Confusional state (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vision blurred (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Visual impairment (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[GLUCOSAMINE, GLUCOSAMINE SULFATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PROCHLORPERAZINE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014831721&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014831722,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Cardiac flutter (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chills (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Lethargy (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Maternal exposure during pregnancy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Movement disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Palpitations (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ACETYLSALICYLIC ACID] (C - Pregnancy - n/a - [n/a - n/a - n/a]),<BR><BR>[FOLIC ACID] (C - Vitamin supplementation - n/a - [n/a - 400ug - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014831722&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014831723,Spontaneous,2023-03-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,Syncope (1d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","FLUCELVAX TETRA [B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/DELAWARE/55/2019 CVR-45), B/AUSTRIA/1359417/2021-LIKE STRAIN (B/SINGAPORE/WUH4618/2021), A/DARWIN/6/2021(H3N2)-LIKE STRAIN (A/DARWIN/11/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), B/WASHINGTON/02/2019-LIKE VIRUS (B/DARWIN/7/2019, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/WASHINGTON/19/2020, WILD TYPE), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/TASMANIA/503/2020, WILD TYPE)] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014831723&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014831724,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Back pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Limb discomfort (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014831724&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014831725,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Interchange of vaccine products (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Joint range of motion decreased (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Neck pain (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Neuralgia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014831725&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014831727,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014831727&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014831730,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Headache (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Viral rash (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014831730&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014831731,Spontaneous,2023-03-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Cardiac ventricular thrombosis (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Cerebral infarction (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Cerebrovascular accident (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Deep vein thrombosis (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Erythema (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),<BR><BR>Feeling hot (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),<BR><BR>Headache (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),<BR><BR>Hypereosinophilic syndrome (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Mental impairment (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Oedema (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),<BR><BR>Peripheral coldness (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),<BR><BR>Psychiatric symptom (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),<BR><BR>Skin discolouration (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),<BR><BR>Thrombosis (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Thrombosis with thrombocytopenia syndrome (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Venous thrombosis limb (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014831731&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014831732,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Breast pain (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chills (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Extrasystoles (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (5d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - Hormone replacement therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014831732&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014831735,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dysstasia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fall (n/a - Unknown - Other Medically Important Condition),<BR><BR>Gait disturbance (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Limb discomfort (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Loss of consciousness (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Movement disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Muscular weakness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014831735&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014831738,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Pruritus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - Blood pressure measurement - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014831738&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014831740,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Deafness unilateral (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Ear canal erythema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Noninfective myringitis (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014831740&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014831741,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Urticaria (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - Anxiety - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014831741&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014831745,Spontaneous,2023-03-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"Chest pain (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Myocarditis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Myopericarditis (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pericarditis (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Troponin increased (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[HALOPERIDOL] (C - n/a - n/a - [n/a - 2{DF} - n/a]),<BR><BR>[LAMOTRIGINE] (C - n/a - n/a - [n/a - 350mg - n/a]),<BR><BR>[PROCYCLIDINE] (C - n/a - n/a - [n/a - 3{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014831745&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014831747,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Abdominal pain lower (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hypoaesthesia (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014831747&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014831748,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Delusion (n/a - Recovering/Resolving - Life Threatening),<BR><BR>Fall (n/a - Unknown - Life Threatening)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","IBUPROFEN [IBUPROFEN, IBUPROFEN SODIUM] (C - Arthralgia - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Arthralgia - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014831748&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014831750,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Body temperature increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Injection related reaction (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014831750&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014831753,Spontaneous,2023-03-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Anaphylactic reaction (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Anaphylactic shock (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Blood pressure increased (n/a - Unknown - ),<BR><BR>Blood pressure systolic increased (n/a - Unknown - ),<BR><BR>Depressed level of consciousness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Seizure (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - n/a])","HUMALOG [INSULIN LISPRO] (C - Diabetes mellitus, Type 2 diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>LANTUS [INSULIN GLARGINE] (C - Type 2 diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[ALISMA PLANTAGO-AQUATICA SUBSP. ORIENTALE ROOT] (C - Dizziness - n/a - [n/a - n/a - Oral use]),<BR><BR>[ATRACTYLODES LANCEA ROOT] (C - Dizziness - n/a - [n/a - n/a - Oral use]),<BR><BR>[CALCIUM POLYSTYRENE SULFONATE] (C - Hyperkalaemia - n/a - [n/a - n/a - Oral use]),<BR><BR>[CHLORPHENAMINE MALEATE, DIHYDROCODEINE PHOSPHATE, METHYLEPHEDRINE HYDROCHLORIDE-DL] (C - Laryngitis - n/a - [n/a - n/a - Oral use]),<BR><BR>[CINNAMOMUM CASSIA BARK] (C - Dizziness - n/a - [n/a - n/a - Oral use]),<BR><BR>[FEXOFENADINE HYDROCHLORIDE] (C - Hypersensitivity - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN HYDROCHLORIDE] (C - Type 2 diabetes mellitus - n/a - [n/a - n/a - Oral use]),<BR><BR>[POLYPORUS UMBELLATUS] (C - Dizziness - n/a - [n/a - n/a - Oral use]),<BR><BR>[PORIAE COCOS SCLEROTIUM] (C - Dizziness - n/a - [n/a - n/a - Oral use]),<BR><BR>[SITAGLIPTIN PHOSPHATE, SITAGLIPTIN PHOSPHATE MONOHYDRATE] (C - Type 2 diabetes mellitus - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014831753&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014831778,Spontaneous,2023-03-17 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Heart rate increased (n/a - Recovering/Resolving - ),<BR><BR>Liver injury (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014831778&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014832297,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Decreased appetite (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014832297&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014832301,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Joint range of motion decreased (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014832301&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014832304,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Anosmia (n/a - Unknown - Disabling),<BR><BR>Arthralgia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Cough (n/a - Unknown - Disabling),<BR><BR>Decreased appetite (n/a - Unknown - Disabling),<BR><BR>Fatigue (n/a - Unknown - Disabling),<BR><BR>Illness (n/a - Unknown - Disabling),<BR><BR>Migraine (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Oropharyngeal pain (n/a - Unknown - Disabling),<BR><BR>Pain (n/a - Unknown - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014832304&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014832312,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014832312&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014832315,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Injected limb mobility decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014832315&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014832316,Spontaneous,2023-03-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Stillbirth (n/a - Unknown - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[FOLIC ACID] (C - Vitamin supplementation - n/a - [n/a - 400ug - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014832316&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014832318,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[DESOGESTREL] (C - Heavy menstrual bleeding - n/a - [n/a - n/a - n/a]),<BR><BR>[HYDROXYCHLOROQUINE] (C - Arthritis - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014832318&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014832319,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,12-17 Years,Not Specified,No,Female,"Abdominal pain (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Eye pain (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Gait disturbance (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Illness (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Lethargy (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Musculoskeletal stiffness (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Rash (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014832319&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014832328,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Chills (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014832328&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014832331,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Abdominal pain upper (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Angina pectoris (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Back pain (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Cardiac flutter (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chest discomfort (2d - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Scrotal pain (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Suicidal ideation (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tremor (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014832331&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014832333,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Not Specified,"Head discomfort (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Heart rate increased (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Hot flush (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pruritus (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Visual impairment (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","BUMETANIDE [BUMETANIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>EDOXABAN [EDOXABAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL, CALCIUM CARBONATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014832333&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014832335,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Feeling abnormal (n/a - Unknown - Disabling),<BR><BR>Gait disturbance (n/a - Unknown - Disabling),<BR><BR>Influenza like illness (n/a - Unknown - Disabling),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Pain (n/a - Unknown - Disabling),<BR><BR>Pyrexia (n/a - Unknown - Disabling),<BR><BR>Suspected COVID-19 (n/a - Unknown - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014832335&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014832345,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Axillary pain (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Discomfort (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Vaccination site swelling (n/a - Not Recovered/Not Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","DULOXETINE [DULOXETINE, DULOXETINE HYDROCHLORIDE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[CASSIA] (C - Constipation - n/a - [n/a - n/a - n/a]),<BR><BR>[DOCUSATE SODIUM] (C - Constipation - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Thyroid disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[MORPHINE, MORPHINE HYDROCHLORIDE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[NAPROXEN, NAPROXEN SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PERINDOPRIL, PERINDOPRIL TERT-BUTYLAMINE] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014832345&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014832418,Spontaneous,2023-03-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,12-17 Years,Not Specified,No,Male,"Blood pressure decreased (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fall (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pallor (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Presyncope (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014832418&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014832427,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Atrial fibrillation (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Pulmonary hypertension (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[CANDESARTAN, CANDESARTAN CILEXETIL] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014832427&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014832435,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lethargy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pollakiuria (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014832435&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014832518,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Dizziness (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Fatigue (n/a - Unknown - Disabling),<BR><BR>Headache (n/a - Unknown - Disabling),<BR><BR>Interchange of vaccine products (n/a - Unknown - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - Transient ischaemic attack - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - Blood cholesterol increased - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL, CALCIUM CARBONATE] (C - Osteoporosis prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - Pain - n/a - [n/a - n/a - n/a]),<BR><BR>[PROPRANOLOL, PROPRANOLOL HYDROCHLORIDE] (C - Cluster headache - n/a - [n/a - n/a - n/a]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - Depression - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014832518&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014832597,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Intracranial pressure increased (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/BRISBANE/59/2007 (H1N1)-LIKE STRAIN, A/BRISBANE/10/2007 (H3N2)-LIKE STRAIN, B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1) V REASS. X - 179 A, A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/NANCHANG 933/95 (H3N2), A/BAYERN/7/95 (H1N1) - LIKE STRAIN (A/JOHANNESBURG/82/96), B/BEIJING/184/93-LIKE STRAIN (B/HARBIN/7/94), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN (A/NEW CALEDONIA/20/99 REASS. IVR-116), A/CALIFORNIA/7/2004 (H3N2) - LIKE STRAIN (A/NEW YORK/55/2004 REASS. NYMC X-157), B/SHANGHAI/361/2002 - LIKE STRAIN (B/JIANGSU/10/2003), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN (A/NEW CALEDONIA/20/99 REASS. IVR-116), A/MOSCOW/10/99 (H3N2) - LIKE STRAIN (A/PANAMA/2007/99 REASS. RESVIR-17), B/SICHUAN/379/99-LIKE STRAIN (B/JOHANNESBURG/5/99), A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), A/CALIFORNIA/7/2009 (H1N1)-DERIVED STRAIN USED NYMC X-181, B/BRISBANE/60/2008, A/SWITZERLAND/9715293/2013 (H3N2)-LIKE STRAIN (A/SWITZERLAND/9715293/2013, NIB-88), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN B, A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1), A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1)V-LIKE VIRUS, A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/MASSACHUSETTS/2/2012 -DERIVED STRAIN USED (NYMC BX-51B), A/TEXAS/50/2012 (H3N2) – DERIVED STRAIN USED (NYMC X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/MASSACHUSETTS/2/2012 -DERIVED STRAIN USED (NYMC BX-51B), A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN A (H1N1), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN A (H3N2), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN B] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014832597&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014832601,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"COVID-19 (3d - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Drug ineffective (3d - Recovered/Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014832601&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014832607,Spontaneous,2023-03-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Diarrhoea (1d - Recovered/Resolved - Disabling),<BR><BR>Lethargy (1d - Recovered/Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[BUDESONIDE, FORMOTEROL FUMARATE DIHYDRATE, FORMOTEROL FUMARATE, BUDESONIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CARBOMER, CARBOMER 980] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CARBOMER] (C - n/a - n/a - [n/a - 1[drp] - n/a]),<BR><BR>[POTASSIUM HYDROGEN CARBONATE, SODIUM ALGINATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SODIUM HYALURONATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014832607&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014832633,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dysgeusia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Rhinalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Sinus headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Thirst (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014832633&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014832660,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Balance disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Bell's palsy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Gait inability (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Impaired driving ability (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014832660&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014832664,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Back pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Contusion (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Gait inability (n/a - Unknown - Other Medically Important Condition),<BR><BR>Joint swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Muscle strain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Musculoskeletal stiffness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Swelling (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014832664&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014832665,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Eye laser surgery (n/a - Unknown - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014832665&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014832682,Spontaneous,2023-03-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Disease recurrence (n/a - Unknown - Other Medically Important Condition),<BR><BR>Retinal haemorrhage (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014832682&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014832684,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Bone pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Feeling cold (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hot flush (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Illness (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Oversensing (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Photophobia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014832684&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014832691,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Condition aggravated (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myelopathy (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014832691&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014832698,Spontaneous,2023-03-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Blood creatine phosphokinase increased (n/a - Unknown - ),<BR><BR>Myalgia (n/a - Unknown - ),<BR><BR>Rhabdomyolysis (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014832698&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014832700,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal pain upper (n/a - Unknown - Other Medically Important Condition),<BR><BR>Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Feeling hot (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Illness (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014832700&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014832702,Spontaneous,2023-03-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Blood creatine phosphokinase increased (n/a - Unknown - ),<BR><BR>Blood pressure decreased (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>C-reactive protein increased (n/a - Unknown - ),<BR><BR>Chills (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Cough (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Ejection fraction decreased (n/a - Unknown - ),<BR><BR>Electrocardiogram ST segment elevation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fibrin D dimer increased (n/a - Unknown - ),<BR><BR>Hypoxia (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>N-terminal prohormone brain natriuretic peptide increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Oxygen saturation decreased (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>White blood cell count increased (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","DARBEPOETIN ALFA [DARBEPOETIN ALFA] (C - Haemodialysis - n/a - [n/a - n/a - n/a]),<BR><BR>RENAGEL [SEVELAMER, SEVELAMER HYDROCHLORIDE] (C - Hyperphosphataemia - n/a - [n/a - n/a - n/a]),<BR><BR>SEVELAMER CARBONATE [SEVELAMER CARBONATE] (C - Hyperphosphataemia - n/a - [n/a - n/a - n/a]),<BR><BR>[ALOGLIPTIN BENZOATE] (C - Diabetes mellitus - n/a - [n/a - 6.25mg - n/a]),<BR><BR>[AZELNIDIPINE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[AZILSARTAN] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[CELECOXIB] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[DRIED FERROUS SULFATE, FERROUS SULFATE] (C - Iron deficiency anaemia - n/a - [n/a - n/a - n/a]),<BR><BR>[ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM TRIHYDRATE, ESOMEPRAZOLE SODIUM] (C - Gastric ulcer - n/a - [n/a - n/a - n/a]),<BR><BR>[EZETIMIBE] (C - Hyperlipidaemia - n/a - [n/a - n/a - n/a]),<BR><BR>[LOXOPROFEN SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PREGABALIN] (C - Spinal osteoarthritis - n/a - [n/a - n/a - n/a]),<BR><BR>[SENNOSIDE A] (C - Constipation - n/a - [n/a - n/a - Oral use]),<BR><BR>[TRIAZOLAM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014832702&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014832705,Spontaneous,2023-03-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Pericarditis (n/a - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014832705&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014832711,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal pain upper (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dehydration (n/a - Unknown - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Feeding disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling of body temperature change (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Motion sickness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Weight decreased (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE, BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - n/a]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - Blood cholesterol abnormal - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014832711&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014832717,Spontaneous,2023-03-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Urticaria (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014832717&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014832719,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Headache (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Paralysis (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (3d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014832719&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014832721,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Pruritus (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - Cardiac disorder - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014832721&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014832727,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lethargy (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Malaise (3d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014832727&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014832728,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Stomatitis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014832728&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014832856,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Hand fracture (n/a - Unknown - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014832856&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014832864,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,White blood cell count decreased (n/a - Unknown - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014832864&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014832870,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dizziness postural (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014832870&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014832882,Spontaneous,2023-03-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Arthritis (n/a - Unknown - ),<BR><BR>Chills (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Dyspnoea (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Eye disorder (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Hepatic function abnormal (n/a - Unknown - ),<BR><BR>Hepatosplenomegaly (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Infectious mononucleosis (n/a - Unknown - ),<BR><BR>Lymphadenopathy (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Oropharyngeal pain (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Swelling (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Swelling face (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Swelling of eyelid (n/a - Unknown - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014832882&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014832885,Spontaneous,2023-03-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Areflexia (n/a - Unknown - ),<BR><BR>Diabetic complication neurological (n/a - Recovering/Resolving - ),<BR><BR>Gait inability (n/a - Recovering/Resolving - ),<BR><BR>Hyporeflexia (n/a - Recovering/Resolving - ),<BR><BR>Mobility decreased (n/a - Recovering/Resolving - ),<BR><BR>Neuropathy peripheral (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014832885&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014832887,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Gait disturbance (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (24h - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014832887&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014833231,Spontaneous,2023-03-17 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Diplegia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Dysphonia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Fall (n/a - Unknown - Disabling),<BR><BR>Pyrexia (n/a - Unknown - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","FORXIGA [DAPAGLIFLOZIN] (C - Type 2 diabetes mellitus - n/a - [n/a - 5mg - Oral use]),<BR><BR>OZEMPIC [SEMAGLUTIDE] (C - Type 2 diabetes mellitus - n/a - [n/a - n/a - Subcutaneous use]),<BR><BR>TOUJEO DOUBLESTAR [INSULIN GLARGINE] (C - Type 2 diabetes mellitus - n/a - [n/a - n/a - Subcutaneous use]),<BR><BR>[AMISULPRIDE] (C - Mental disorder - n/a - [n/a - 50mg - Oral use]),<BR><BR>[ATORVASTATIN] (C - Hypercholesterolaemia - n/a - [n/a - 40mg - Oral use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[BENDROFLUMETHIAZIDE, POTASSIUM CHLORIDE] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[CLOBETASOL PROPIONATE] (C - Skin disorder - n/a - [n/a - n/a - Cutaneous use]),<BR><BR>[ESCITALOPRAM, ESCITALOPRAM OXALATE] (C - Anxiety - n/a - [n/a - 20mg - Oral use]),<BR><BR>[FLUORIDE, SODIUM FLUORIDE] (C - Dental cleaning - n/a - [n/a - n/a - n/a]),<BR><BR>[HYDROXOCOBALAMIN] (C - Vitamin B12 deficiency - n/a - [n/a - n/a - Intramuscular use]),<BR><BR>[METFORMIN HYDROCHLORIDE] (C - Diabetes mellitus - n/a - [n/a - 500mg - Oral use]),<BR><BR>[METOPROLOL, METOPROLOL SUCCINATE, METOPROLOL TARTRATE] (C - Hypertension - n/a - [n/a - 100mg - Oral use]),<BR><BR>[RAMIPRIL] (C - Hypertension - n/a - [n/a - 5mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014833231&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014833287,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (7d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (7d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - Transient ischaemic attack - n/a - [n/a - n/a - n/a]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - Transient ischaemic attack - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014833287&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014833549,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014833549&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014833572,Spontaneous,2023-03-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Loss of consciousness (12h - Recovered/Resolved - Disabling),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Muscular weakness (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Syncope (n/a - Recovering/Resolving - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BECLOMETASONE DIPROPIONATE] (C - n/a - n/a - [n/a - n/a - Inhalation use]),<BR><BR>[COLECALCIFEROL, CALCIUM CARBONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INDAPAMIDE, INDAPAMIDE HEMIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[QUETIAPINE, QUETIAPINE FUMARATE] (C - Bipolar disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014833572&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014833736,Spontaneous,2023-03-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Subarachnoid haemorrhage (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - Prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[INDAPAMIDE, INDAPAMIDE HEMIHYDRATE] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014833736&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014816531,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Amenorrhoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Heavy menstrual bleeding (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014816531&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014819034,Spontaneous,2023-03-16 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Altered state of consciousness (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Dysarthria (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Gait disturbance (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Lymphadenopathy (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Lymphoma (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Mobility decreased (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Respiratory failure (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014819034&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014820072,Spontaneous,2023-03-16 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Anaphylactic reaction (n/a - Unknown - Life Threatening, Other Medically Important Condition),<BR><BR>Condition aggravated (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash (n/a - Unknown - Other Medically Important Condition),<BR><BR>Wheezing (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014820072&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014820092,Spontaneous,2023-03-16 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Urticaria (0d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014820092&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014820383,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014820383&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014820384,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (99d - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Impaired work ability (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pericarditis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014820384&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014820453,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014820453&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014820455,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest pain (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Illness (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014820455&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014820456,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Axillary pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Body temperature abnormal (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Oral pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pharyngeal inflammation (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Stomatitis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Swelling (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014820456&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014820458,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Back pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dizziness (6d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (6d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Night sweats (9d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Sinus headache (5d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014820458&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014820459,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Abdominal pain upper (n/a - Unknown - Other Medically Important Condition),<BR><BR>Axillary pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Cold sweat (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness postural (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fear (n/a - Unknown - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Restlessness (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Somnolence (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014820459&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014820460,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Balance disorder (n/a - Recovering/Resolving - ),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dizziness (n/a - Recovering/Resolving - ),<BR><BR>Immunisation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Incorrect dose administered (n/a - Unknown - ),<BR><BR>Loss of consciousness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Off label use (n/a - Unknown - Other Medically Important Condition),<BR><BR>Syncope (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014820460&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014820461,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","LUMIGAN [BIMATOPROST] (C - Glaucoma - n/a - [n/a - n/a - n/a]),<BR><BR>SIMBRINZA [BRINZOLAMIDE, BRIMONIDINE TARTRATE] (C - Developmental glaucoma - n/a - [n/a - n/a - n/a]),<BR><BR>[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - Muscle spasms - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BENDROFLUAZIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CODEINE] (C - Arthralgia - n/a - [n/a - n/a - n/a]),<BR><BR>[FLUTICASONE] (C - Antiallergic therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[GLICLAZIDE] (C - Type 2 diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a]),<BR><BR>[LORATADINE] (C - Antiallergic therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[MEBEVERINE] (C - Irritable bowel syndrome - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - Type 2 diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Arthralgia - n/a - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - Blood cholesterol increased - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014820461&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014820462,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Pulmonary embolism (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014820462&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014820464,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Sleep disorder due to a general medical condition (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Tremor (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014820464&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014820465,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Axillary pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Breast pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Breast swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","ESOMEPRAZOLE [ESOMEPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - n/a]),<BR><BR>IBUPROFEN [IBUPROFEN, IBUPROFEN SODIUM] (C - Sinus pain - n/a - [n/a - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[CLARITHROMYCIN] (C - Sinusitis - n/a - [15d - n/a - n/a]),<BR><BR>[DESOGESTREL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRADIOL] (C - Hormone replacement therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRADIOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Sinus pain - n/a - [n/a - n/a - n/a]),<BR><BR>[PROGESTERONE, PROGESTERONE, MICRONISED] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PSEUDOEPHEDRINE HYDROCHLORIDE] (C - Sinusitis bacterial - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014820465&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014820466,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Decreased appetite (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Peripheral swelling (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014820466&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014820468,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"Erythema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Muscle fatigue (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Myalgia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Rash erythematous (5d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014820468&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014820469,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Periarthritis (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014820469&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014820470,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Herpes zoster (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014820470&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014820471,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Dizziness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hypothermia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pallor (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014820471&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014820475,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Cluster headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dizziness postural (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Motion sickness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Tremor (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[EZETIMIBE] (C - Blood cholesterol increased - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PERINDOPRIL, PERINDOPRIL TERT-BUTYLAMINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - Blood cholesterol increased - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014820475&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014820477,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Apathy (n/a - Unknown - Disabling),<BR><BR>Cough (n/a - Unknown - Disabling),<BR><BR>Decreased interest (n/a - Unknown - Disabling),<BR><BR>Fatigue (n/a - Recovering/Resolving - Disabling),<BR><BR>Nasopharyngitis (n/a - Unknown - Disabling),<BR><BR>Pain (n/a - Unknown - Disabling),<BR><BR>Vaccination site pain (n/a - Unknown - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014820477&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014820481,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Disturbance in attention (n/a - Unknown - Other Medically Important Condition),<BR><BR>Ear pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Infectious mononucleosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[MEDROXYPROGESTERONE ACETATE] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014820481&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014820483,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Bone pain (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Dysgeusia (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Dysstasia (3d - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Emotional disorder (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Muscle spasms (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Musculoskeletal stiffness (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Myalgia (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Sitting disability (3d - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014820483&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014820485,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Abdominal pain upper (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Angina pectoris (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Bone pain (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Cardiac discomfort (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Chest pain (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Costochondritis (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Dyspnoea (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Fatigue (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Headache (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Impaired work ability (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Loss of personal independence in daily activities (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Malaise (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Myocardial infarction (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Neck pain (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Pain in extremity (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Palpitations (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Pericarditis (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pneumonitis (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Tachycardia (n/a - Unknown - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[FLUOXETINE HYDROCHLORIDE] (C - Anxiety - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014820485&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014820486,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dysgeusia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Gingival bleeding (n/a - Unknown - Other Medically Important Condition),<BR><BR>Gingival pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Oral pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Paraesthesia oral (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tongue coated (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[FLUOXETINE, FLUOXETINE HYDROCHLORIDE] (C - Anxiety - n/a - [n/a - n/a - n/a]),<BR><BR>[LATANOPROST] (C - Intraocular pressure increased - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014820486&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014820494,Spontaneous,2023-03-16 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Anaphylactic reaction (11min - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (11min - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Throat tightness (11min - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014820494&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014820643,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Lymphadenopathy (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014820643&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014820733,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Hypersensitivity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tremor (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site hypersensitivity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site mass (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014820733&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014820735,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Lymph node pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014820735&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014820736,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014820736&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014820738,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Axillary pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphoedema (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014820738&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014820739,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Aphonia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vocal cord inflammation (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - Menopause - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014820739&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014820747,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Sinus pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","DAPAGLIFLOZIN [DAPAGLIFLOZIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014820747&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014820749,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Back pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Migraine (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (S - Immunisation - Unknown - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014820749&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014820784,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Lower respiratory tract infection (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Sinus headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014820784&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014820787,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (9d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (8d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Visual impairment (5d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014820787&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014820788,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Thirst (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[CICLESONIDE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[HYDROXYCHLOROQUINE] (C - Undifferentiated connective tissue disease - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[MONTELUKAST, MONTELUKAST SODIUM] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - Abdominal pain upper - n/a - [n/a - n/a - n/a]),<BR><BR>[PROPRANOLOL, PROPRANOLOL HYDROCHLORIDE] (C - Migraine - n/a - [n/a - n/a - n/a]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - Menopause - n/a - [n/a - n/a - n/a]),<BR><BR>[SUMATRIPTAN, SUMATRIPTAN SUCCINATE] (C - Migraine - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014820788&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014820789,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014820789&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014820791,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Rash (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Swelling face (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BENDROFLUAZIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CANDESARTAN, CANDESARTAN CILEXETIL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014820791&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014820795,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Abdominal pain upper (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Liver function test increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Retching (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014820795&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014820803,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014820803&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821205,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Cardiac flutter (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Extrasystoles (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[OXCARBAZEPINE] (C - Trigeminal neuralgia - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821205&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821209,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Pyrexia (3d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821209&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821216,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Ear pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nasopharyngitis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in jaw (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","METHOTREXATE [METHOTREXATE] (C - Rheumatoid arthritis - n/a - [n/a - n/a - n/a]),<BR><BR>[HYDROXYCHLOROQUINE SULFATE] (C - Systemic lupus erythematosus - n/a - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - Reynold's syndrome - n/a - [n/a - n/a - n/a]),<BR><BR>[TIBOLONE] (C - Hormone replacement therapy - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821216&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821217,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Muscular weakness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821217&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821223,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Loss of personal independence in daily activities (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pruritus (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Urticaria (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821223&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821239,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Angina pectoris (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Disease recurrence (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Night sweats (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821239&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821240,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal pain upper (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vomiting (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821240&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821241,Spontaneous,2023-03-16 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Blindness (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Retinal artery occlusion (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821241&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821245,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Seizure (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","KEPPRA [LEVETIRACETAM] (C - Epilepsy - n/a - [n/a - n/a - n/a]),<BR><BR>[TOPIRAMATE] (C - Temporal lobe epilepsy - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821245&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821248,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821248&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821249,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Body temperature increased (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Electric shock sensation (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Influenza (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Sinus headache (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821249&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821251,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Loss of personal independence in daily activities (n/a - Unknown - Other Medically Important Condition),<BR><BR>Medication error (n/a - Unknown - Other Medically Important Condition),<BR><BR>Musculoskeletal discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Shoulder injury related to vaccine administration (n/a - Unknown - Other Medically Important Condition),<BR><BR>Sleep disorder due to a general medical condition (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821251&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821252,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Feeling abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Heart rate increased (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[RISEDRONATE SODIUM] (C - Osteoporosis postmenopausal - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821252&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821253,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Drug ineffective (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821253&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821254,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Dizziness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","ARANESP [DARBEPOETIN ALFA] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>TRAJENTA [LINAGLIPTIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ALLOPURINOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[GLICLAZIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821254&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821255,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Immune system disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Immunisation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Incorrect dose administered (n/a - Unknown - ),<BR><BR>Kidney infection (n/a - Unknown - Other Medically Important Condition),<BR><BR>Off label use (n/a - Unknown - Other Medically Important Condition),<BR><BR>Renal impairment (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rosacea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Urinary retention (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821255&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821259,Spontaneous,2023-03-16 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Pulmonary embolism (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821259&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821260,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Dyspnoea (2d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821260&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821261,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Vertigo (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821261&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821269,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,Vomiting (2d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821269&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821272,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Eye irritation (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PROGESTERONE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821272&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821276,Spontaneous,2023-03-16 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Atrial fibrillation (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821276&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821277,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,Deafness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","PREGABALIN [PREGABALIN] (C - Nerve injury - n/a - [n/a - n/a - n/a]),<BR><BR>[CALCIUM CARBONATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821277&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821278,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Asthenia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Balance disorder (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chills (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CANDESARTAN, CANDESARTAN CILEXETIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FINASTERIDE] (C - Prostatomegaly - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PROPRANOLOL, PROPRANOLOL HYDROCHLORIDE] (C - Essential tremor - n/a - [n/a - n/a - n/a]),<BR><BR>[TAMSULOSIN, TAMSULOSIN HYDROCHLORIDE] (C - Prostatomegaly - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821278&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821280,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arrhythmia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypertension (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821280&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821799,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Back pain (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Erythema (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Feeling hot (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rhinorrhoea (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Skin burning sensation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Swelling face (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821799&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821803,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Formication (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","PREGABALIN [PREGABALIN] (C - Anxiety - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - Type 2 diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[MIRTAZAPINE] (C - Anxiety, Depression - n/a - [n/a - n/a - n/a]),<BR><BR>[TRAZODONE, TRAZODONE HYDROCHLORIDE] (C - Depression - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821803&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821816,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Dizziness (n/a - Unknown - ),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Eye movement disorder (n/a - Unknown - ),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>SPIKEVAX [ELASOMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821816&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821835,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Lymphadenopathy (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821835&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821841,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Cardiac flutter (1d - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","IBUPROFEN [IBUPROFEN, IBUPROFEN SODIUM] (C - Pain - n/a - [n/a - n/a - n/a]),<BR><BR>[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - Fibromyalgia - n/a - [n/a - n/a - n/a]),<BR><BR>[BETAHISTINE, BETAHISTINE DIHYDROCHLORIDE, BETAHISTINE MESILATE] (C - Meniere's disease - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[CODEINE PHOSPHATE] (C - Pain - n/a - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[METHOCARBAMOL] (C - Fibromyalgia - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - n/a]),<BR><BR>[VITAMIN D] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821841&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821871,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dry mouth (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Feeling cold (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Feeling drunk (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CANDESARTAN, CANDESARTAN CILEXETIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL, CALCIUM CARBONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FOLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821871&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821873,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Cold sweat (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dyspepsia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypersomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Somnolence (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - Depression - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821873&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821880,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Anaphylactic reaction (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Haemorrhage (n/a - Unknown - Other Medically Important Condition),<BR><BR>Menopause (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821880&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821890,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Migraine (13d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821890&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821906,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Heavy menstrual bleeding (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821906&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821909,Spontaneous,2023-03-16 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Anaemia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Arthralgia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Groin pain (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Joint swelling (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Lethargy (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Musculoskeletal stiffness (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Polymyalgia rheumatica (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Product use issue (n/a - Unknown - ),<BR><BR>Shoulder girdle pain (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Immunisation - Not applicable - [1d - n/a - n/a])","BRINZOLAMIDE [BRINZOLAMIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>UMECLIDINIUM BROMIDE, FLUTICASONE FUROATE, VILANTEROL [UMECLIDINIUM BROMIDE, FLUTICASONE FUROATE, VILANTEROL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CARBOCISTEINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LATANOPROST] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEUPRORELIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821909&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821911,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821911&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821916,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821916&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821917,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Bone pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hypokinesia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tendonitis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821917&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821922,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Dysstasia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Gait disturbance (n/a - Unknown - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Muscular weakness (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vision blurred (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BECLOMETASONE DIPROPIONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821922&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821924,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821924&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821928,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Cardiovascular somatic symptom disorder (n/a - Unknown - ),<BR><BR>Chest discomfort (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Chest pain (2d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Dyspnoea (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Fatigue (n/a - Unknown - ),<BR><BR>Immunisation (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Off label use (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Somnolence (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Left ventricular failure - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821928&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821929,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Abdominal pain upper (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Arthritis (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Back pain (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Coeliac disease (n/a - Unknown - Disabling),<BR><BR>Condition aggravated (n/a - Unknown - Disabling),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Headache (n/a - Unknown - Disabling),<BR><BR>Malaise (n/a - Unknown - Disabling),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Post-acute COVID-19 syndrome (n/a - Unknown - Disabling),<BR><BR>Psoriasis (n/a - Unknown - Disabling),<BR><BR>Psoriatic arthropathy (n/a - Unknown - Disabling),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821929&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821932,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Erythema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling hot (n/a - Unknown - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Joint swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Skin infection (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Weight bearing difficulty (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821932&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821934,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymph node pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821934&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821938,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Abdominal pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Body temperature abnormal (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chills (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Diarrhoea (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (8d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Somnolence (24h - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821938&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821940,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821940&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821941,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Back pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Haematuria (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Proteinuria (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyuria (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[CEFALEXIN] (C - Urinary tract infection - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821941&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821944,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",[COLECALCIFEROL] (C - n/a - n/a - [n/a - 12.5ug - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821944&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821952,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Sudden hearing loss (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821952&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014821955,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Septic rash (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Stomatitis (n/a - Unknown - ),<BR><BR>Swelling face (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014821955&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014822043,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, OMEPRAZOLE SODIUM] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014822043&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014822054,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014822054&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014822090,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dysmenorrhoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Heavy menstrual bleeding (n/a - Unknown - Other Medically Important Condition),<BR><BR>Menstrual disorder (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014822090&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014822111,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Migraine with aura (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (4d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014822111&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014822126,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Abdominal discomfort (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014822126&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014822137,Spontaneous,2023-03-16 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Hepatic function abnormal (n/a - Not Recovered/Not Resolved - Disabling),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014822137&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014822192,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dizziness (n/a - Unknown - ),<BR><BR>Eye swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Feeling hot (n/a - Unknown - ),<BR><BR>Formication (n/a - Not Recovered/Not Resolved - ),<BR><BR>Loss of consciousness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Swelling face (n/a - Unknown - ),<BR><BR>Syncope (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014822192&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014822194,Spontaneous,2023-03-16 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Chest pain (n/a - Unknown - Caused/Prolonged Hospitalisation),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014822194&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014822279,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Abdominal pain upper (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Maternal exposure during pregnancy (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014822279&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014822308,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Superficial vein thrombosis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Varicophlebitis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","PANTOPRAZOLE [PANTOPRAZOLE, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Duodenogastric reflux - n/a - [n/a - n/a - n/a]),<BR><BR>RIVAROXABAN [RIVAROXABAN] (C - n/a - n/a - [76d - n/a - n/a]),<BR><BR>[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - Vaginal prolapse - n/a - [n/a - 2{DF} - n/a]),<BR><BR>[PRAVASTATIN, PRAVASTATIN SODIUM] (C - Blood cholesterol increased - n/a - [n/a - 20mg - n/a]),<BR><BR>[SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (C - Constipation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014822308&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014822309,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chest pain (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Diarrhoea (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Dyspnoea (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Fatigue (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Myocarditis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Vomiting (n/a - Unknown - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014822309&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014822313,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Night sweats (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014822313&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014822317,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Fatigue (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hyperhidrosis (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hypersomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypoacusis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Impaired work ability (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nervousness (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Sensory disturbance (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014822317&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014822319,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,12-17 Years,Not Specified,No,Male,Diarrhoea (3d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014822319&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014822328,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeding disorder (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Gait inability (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014822328&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014822331,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014822331&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014822332,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Catarrh (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Condition aggravated (n/a - Unknown - Other Medically Important Condition),<BR><BR>Disorientation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Ear discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Ear disorder (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Increased upper airway secretion (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Otitis externa (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vertigo positional (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014822332&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014822333,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal pain upper (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Anosmia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Back pain (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Chest discomfort (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Decreased appetite (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Diplopia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Hypersomnia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Hypoaesthesia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Intraocular pressure increased (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Muscular weakness (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Paraesthesia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Somnolence (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ALENDRONATE SODIUM, ALENDRONIC ACID] (C - Breast cancer - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL, CALCIUM CARBONATE] (C - Breast cancer - n/a - [n/a - n/a - n/a]),<BR><BR>[LETROZOLE] (C - Breast cancer - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014822333&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014822336,Spontaneous,2023-03-16 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Collagen disorder (n/a - Unknown - ),<BR><BR>Condition aggravated (n/a - Unknown - ),<BR><BR>Joint swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Limb mass (n/a - Unknown - ),<BR><BR>Rheumatoid arthritis (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014822336&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014822337,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Angina pectoris (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chest discomfort (n/a - Unknown - ),<BR><BR>Chest pain (n/a - Unknown - ),<BR><BR>Dyspnoea (n/a - Unknown - ),<BR><BR>Fatigue (n/a - Unknown - ),<BR><BR>Immunisation (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myocarditis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Off label use (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014822337&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014822339,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Myocarditis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Pericarditis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014822339&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014822340,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Disease recurrence (n/a - Unknown - Other Medically Important Condition),<BR><BR>Leukaemia (n/a - Unknown - Other Medically Important Condition),<BR><BR>White blood cell count increased (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014822340&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014822341,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal pain upper (n/a - Unknown - Other Medically Important Condition),<BR><BR>Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Burning sensation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Musculoskeletal chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nasal congestion (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Parosmia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Rhinalgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rhinorrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[QUETIAPINE, QUETIAPINE FUMARATE] (C - Schizophrenia - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014822341&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014822353,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Generalised tonic-clonic seizure (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014822353&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014822372,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Erythema multiforme (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014822372&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014822386,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Axillary pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chills (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ACETYLSALICYLIC ACID] (C - Cardiac failure - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Cardiac failure - n/a - [n/a - n/a - n/a]),<BR><BR>[CALCIUM CARBONATE, COLECALCIFEROL CONCENTRATE (POWDER FORM) (SDS), COLECALCIFEROL, CALCIUM CARBONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRADIOL] (C - Menopause - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - Heart rate abnormal - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014822386&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014822387,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Atrial fibrillation (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Disease recurrence (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","APIXABAN [APIXABAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>DRONEDARONE [DRONEDARONE] (C - Atrial fibrillation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014822387&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014822395,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Back pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Condition aggravated (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Respiration abnormal (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","OXYBUTYNIN [OXYBUTYNIN, OXYBUTYNIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METHADONE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PROPRANOLOL, PROPRANOLOL HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014822395&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014822409,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chest pain (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Vaccination site inflammation (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014822409&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014822537,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Blister (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Burning sensation (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Eye pruritus (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Neuralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rash (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014822537&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014822546,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Incontinence (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Loss of personal independence in daily activities (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014822546&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014822565,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Breast pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Breast swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (12d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Formication (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Lymph node pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (8d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain of skin (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Blood pressure abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - Gastritis, Hyperchlorhydria - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Osteoarthritis - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014822565&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014822586,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Erythema (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Pain of skin (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Pruritus (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Skin haemorrhage (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Skin warm (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Urticaria (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014822586&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014822693,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Condition aggravated (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Injection site swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Injection site urticaria (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Thyroidectomy - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014822693&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014822695,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Unknown - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014822695&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014822697,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rhinorrhoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Throat irritation (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014822697&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014822720,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[ATORVASTATIN] (C - Blood cholesterol increased - n/a - [n/a - n/a - n/a]),<BR><BR>[CETIRIZINE, CETIRIZINE DIHYDROCHLORIDE] (C - Upper-airway cough syndrome - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Antiviral prophylaxis - n/a - [1d - n/a - n/a]),<BR><BR>[NORETHISTERONE ACETATE, ESTRADIOL, NORETHISTERONE, ESTRADIOL HEMIHYDRATE] (C - Hormone replacement therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - Dyspepsia - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014822720&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014822722,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Body temperature increased (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rhinorrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Throat irritation (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[NAPROXEN, NAPROXEN SODIUM] (C - Arthralgia, Inflammation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014822722&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014822872,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Confusional state (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",METHOTREXATE [METHOTREXATE] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014822872&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014823328,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Heart rate increased (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Syncope (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tremor (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","VORTIOXETINE [VORTIOXETINE] (C - Depression - n/a - [n/a - n/a - n/a]),<BR><BR>[LORAZEPAM] (C - Panic disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[METHYLPHENIDATE] (C - Attention deficit hyperactivity disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[QUETIAPINE, QUETIAPINE FUMARATE] (C - Depression suicidal - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014823328&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014823339,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Loss of consciousness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nystagmus (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Seizure (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014823339&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014823568,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Asthenia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","PANTOPRAZOLE [PANTOPRAZOLE, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>PREGABALIN [PREGABALIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[DIAZEPAM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FLUOXETINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MEBEVERINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MONTELUKAST, MONTELUKAST SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[NAPROXEN, NAPROXEN SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PROCHLORPERAZINE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014823568&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014823993,Spontaneous,2023-03-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chronic fatigue syndrome (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Condition aggravated (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014823993&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014808388,Spontaneous,2023-03-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Myocardial infarction (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014808388&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014809167,Spontaneous,2023-03-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Vertigo (n/a - Not Recovered/Not Resolved - Disabling),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014809167&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014810065,Spontaneous,2023-03-15 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Malaise (10min - Recovered/Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [1d - .3mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014810065&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014810825,Spontaneous,2023-03-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Hot flush (n/a - Not Recovered/Not Resolved - ),<BR><BR>Oligomenorrhoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Oligomenorrhoea (n/a - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014810825&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014811453,Spontaneous,2023-03-15 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Myocardial infarction (163d - Recovered/Resolved - Life Threatening),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014811453&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014798967,Spontaneous,2023-03-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Deep vein thrombosis (n/a - Unknown - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])","[ACETYLCYSTEINE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[AMLODIPINE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[BUDESONIDE, BUDESONIDE, MICRONISED] (C - n/a - n/a - [n/a - n/a - Inhalation use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014798967&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014799181,Spontaneous,2023-03-14 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Acute kidney injury (n/a - Recovered/Resolved With Sequelae - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Cardiac arrest (n/a - Recovered/Resolved With Sequelae - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Cardiovascular disorder (n/a - Recovered/Resolved With Sequelae - Life Threatening, Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Cerebral haemorrhage (n/a - Recovered/Resolved With Sequelae - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Coagulopathy (n/a - Recovered/Resolved With Sequelae - Life Threatening, Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Disseminated intravascular coagulation (n/a - Recovered/Resolved With Sequelae - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Multiple organ dysfunction syndrome (n/a - Recovered/Resolved With Sequelae - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Muscle twitching (n/a - Recovered/Resolved With Sequelae - Life Threatening, Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Pulmonary haemorrhage (n/a - Recovered/Resolved With Sequelae - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014799181&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014799559,Spontaneous,2023-03-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest discomfort (n/a - Not Recovered/Not Resolved - Life Threatening, Other Medically Important Condition),<BR><BR>Chest pain (n/a - Not Recovered/Not Resolved - Life Threatening, Other Medically Important Condition),<BR><BR>Contusion (n/a - Unknown - Life Threatening, Other Medically Important Condition),<BR><BR>Cytokine storm (n/a - Not Recovered/Not Resolved - Life Threatening, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Life Threatening, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Life Threatening, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Life Threatening, Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Not Recovered/Not Resolved - Life Threatening, Other Medically Important Condition),<BR><BR>Inflammation (n/a - Not Recovered/Not Resolved - Life Threatening, Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Life Threatening, Other Medically Important Condition),<BR><BR>Muscle spasms (n/a - Not Recovered/Not Resolved - Life Threatening, Other Medically Important Condition),<BR><BR>Muscle tightness (n/a - Not Recovered/Not Resolved - Life Threatening, Other Medically Important Condition),<BR><BR>Musculoskeletal discomfort (n/a - Not Recovered/Not Resolved - Life Threatening, Other Medically Important Condition),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - Life Threatening, Other Medically Important Condition),<BR><BR>Varicose vein (n/a - Unknown - Life Threatening, Other Medically Important Condition),<BR><BR>Vasospasm (n/a - Not Recovered/Not Resolved - Life Threatening, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[BIFONAZOLE, CLOTRIMAZOLE] (C - Genital candidiasis - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRADIOL] (C - Genital candidiasis - n/a - [n/a - n/a - n/a]),<BR><BR>[NITROFURANTOIN] (C - Urinary tract infection - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014799559&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014799784,Spontaneous,2023-03-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Ankylosing spondylitis (n/a - Not Recovered/Not Resolved - Life Threatening, Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014799784&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014800096,Spontaneous,2023-03-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Hypoaesthesia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Mobility decreased (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Pain of skin (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Taste disorder (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014800096&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014800431,Spontaneous,2023-03-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Burning sensation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling hot (n/a - Unknown - Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rotator cuff syndrome (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Shoulder injury related to vaccine administration (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site discomfort (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE, BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[DESOGESTREL] (C - Heavy menstrual bleeding - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 4, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6B, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9V, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 14, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 18C, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 33F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 22F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 20, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19A, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 17F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 15B, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 12F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 11A, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9N, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 7F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 5, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 3, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 2, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 1, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 10A, PNEUMOCOCCAL POLYSACCHARIDE VACCINE (23 VALENT), PNEUMOCOCCAL VACCINE] (C - Pneumococcal immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014800431&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014800466,Spontaneous,2023-03-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Coagulopathy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Peripheral coldness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Thrombosis (26d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014800466&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014800590,Spontaneous,2023-03-14 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014800590&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014801705,Spontaneous,2023-03-14 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Rosacea (n/a - Unknown - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014801705&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014801769,Spontaneous,2023-03-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest pain (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Dyspnoea (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Myocarditis (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Palpitations (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Syncope (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Tachycardia (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014801769&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014804010,Spontaneous,2023-03-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Dyspnoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Eczema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Rash (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014804010&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014790291,Spontaneous,2023-03-13 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Pulmonary venous thrombosis (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014790291&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014790327,Spontaneous,2023-03-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Eye injury (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014790327&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014790711,Spontaneous,2023-03-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Bell's palsy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Ocular hyperaemia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014790711&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014791366,Spontaneous,2023-03-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Immunisation reaction (n/a - Recovered/Resolved - ),<BR><BR>Palpitations (n/a - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014791366&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014794101,Spontaneous,2023-03-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chest pain (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Dyspnoea (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Fatigue (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Palpitations (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Pericarditis (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Pyrexia (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Tachycardia (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014794101&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014783996,Spontaneous,2023-03-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (2wk - Recovered/Resolved - ),<BR><BR>Injection site pain (3d - Recovered/Resolved - ),<BR><BR>Malaise (2d - Recovered/Resolved - ),<BR><BR>Menstruation delayed (n/a - Not Recovered/Not Resolved - ),<BR><BR>Polymenorrhoea (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014783996&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014777301,Spontaneous,2023-03-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abnormal menstrual clots (n/a - Recovered/Resolved - ),<BR><BR>Arthralgia (n/a - Unknown - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Groin pain (n/a - Unknown - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Unknown - ),<BR><BR>Menometrorrhagia (n/a - Recovered/Resolved - ),<BR><BR>Myalgia (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014777301&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014777973,Spontaneous,2023-03-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Cardiac flutter (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Disease recurrence (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014777973&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014783669,Spontaneous,2023-03-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,Death (n/a - Fatal - Results in Death),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014783669&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014783705,Spontaneous,2023-03-10 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Orthostatic hypotension (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014783705&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014783717,Spontaneous,2023-03-10 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Aphasia (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Apraxia (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Cognitive disorder (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Disturbance in attention (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Gait disturbance (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Gaze palsy (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Haemorrhage intracranial (n/a - Recovered/Resolved With Sequelae - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Headache (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Hemiplegia (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Malaise (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Memory impairment (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Neurologic neglect syndrome (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Visual impairment (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014783717&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014767597,Spontaneous,2023-03-09 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Adult,No,Female,"Drug ineffective (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",[INFLUENZA VIRUS] (C - n/a - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014767597&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014770350,Spontaneous,2023-03-09 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Rash (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [1d - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014770350&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014773960,Spontaneous,2023-03-09 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (3d - Recovered/Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014773960&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014759296,Spontaneous,2023-03-08 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Angina pectoris (n/a - Recovering/Resolving - ),<BR><BR>Disturbance in attention (n/a - Recovered/Resolved - ),<BR><BR>Dyspnoea (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovered/Resolved - ),<BR><BR>Headache (n/a - Recovered/Resolved - ),<BR><BR>Muscle twitching (n/a - Recovering/Resolving - ),<BR><BR>Neuralgia (n/a - Recovering/Resolving - ),<BR><BR>Sensory disturbance (12d - Recovered/Resolved - ),<BR><BR>Tachycardia (n/a - Recovering/Resolving - ),<BR><BR>Vision blurred (n/a - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014759296&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014760171,Spontaneous,2023-03-08 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Headache (6d - Recovered/Resolved - ),<BR><BR>Myalgia (1d - Recovered/Resolved - ),<BR><BR>Nausea (6d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use])","[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[ANASTROZOLE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[CALCIUM CARBONATE, CALCIUM LACTATE GLUCONATE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[COLECALCIFEROL, IBANDRONIC ACID] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014760171&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014761735,Spontaneous,2023-03-08 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Dizziness (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])","[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[DEXAMETHASONE PHOSPHATE] (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[DORZOLAMIDE, TIMOLOL] (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN POTASSIUM] (C - Hypertension - Dose not changed - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014761735&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014761766,Spontaneous,2023-03-08 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Palpitations (2d - Recovered/Resolved - ),<BR><BR>Sense of oppression (2d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014761766&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014761770,Spontaneous,2023-03-08 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Palpitations (3d - Recovered/Resolved - ),<BR><BR>Sense of oppression (3d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014761770&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014761830,Spontaneous,2023-03-08 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Hypoacusis (n/a - Not Recovered/Not Resolved - ),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - .3mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014761830&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014761877,Spontaneous,2023-03-08 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Vaccination site pain (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014761877&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014750527,Spontaneous,2023-03-07 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (6d - Recovered/Resolved - Disabling),<BR><BR>Chills (6d - Recovered/Resolved - Disabling),<BR><BR>Extensive swelling of vaccinated limb (6d - Recovered/Resolved - Disabling),<BR><BR>Fatigue (6d - Recovered/Resolved - Disabling),<BR><BR>Headache (6d - Recovered/Resolved - Disabling),<BR><BR>Heavy menstrual bleeding (6d - Recovered/Resolved - Disabling),<BR><BR>Injection site reaction (6d - Recovered/Resolved - Disabling),<BR><BR>Intermenstrual bleeding (6d - Recovered/Resolved - Disabling),<BR><BR>Malaise (6d - Recovered/Resolved - Disabling),<BR><BR>Menstruation irregular (6d - Recovered/Resolved - Disabling),<BR><BR>Myalgia (6d - Recovered/Resolved - Disabling),<BR><BR>Nausea (6d - Recovered/Resolved - Disabling),<BR><BR>Pyrexia (6d - Recovered/Resolved - Disabling),<BR><BR>Rest regimen (6d - Recovered/Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","NOT AVAILABLE (C - n/a - Unknown - ),<BR><BR>[PARACETAMOL] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[TOPIRAMATE] (C - Migraine - Unknown - [n/a - 2{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014750527&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014753863,Spontaneous,2023-03-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - ),<BR><BR>Musculoskeletal stiffness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[CETIRIZINE DIHYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014753863&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014753869,Spontaneous,2023-03-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site haematoma (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014753869&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014754208,Spontaneous,2023-03-07 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Chillblains (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014754208&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014756640,Spontaneous,2023-03-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Male,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - )","CERVARIX SUSPENSION FOR INJECTION [HUMAN PAPILLOMAVIRUS TYPE 16 L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18 L1 PROTEIN, MONOPHOSPHORYL LIPID A, HUMAN PAPILLOMAVIRUS TYPE 16 L1 PROTEIN ADJUVANTED BY AS04 ADSORBED ON ALUMINIUM HYDROXIDE, HYDRATED PRODUCED ON BACULOVIRUS HI-5 RIX4446 CELLS, TRICHOPLUSIA NI. DERIVED, HUMAN PAPILLOMAVIRUS TYPE 18 L1 PROTEIN ADJUVANTED BY AS04 ADSORBED ON ALUMINIUM HYDROXIDE, HYDRATED PRODUCED ON BACULOVIRUS HI-5 RIX4446 CELLS, TRICHOPLUSIA NI. DERIVED, ALGELDRATE] (S - Immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014756640&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014741722,Spontaneous,2023-03-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Asthenia (n/a - Recovered/Resolved - Disabling),<BR><BR>COVID-19 immunisation (n/a - Recovered/Resolved - Disabling),<BR><BR>Dizziness (n/a - Recovered/Resolved - Disabling),<BR><BR>Fatigue (n/a - Recovered/Resolved - Disabling),<BR><BR>Headache (n/a - Recovered/Resolved - Disabling),<BR><BR>Myalgia (n/a - Recovered/Resolved - Disabling),<BR><BR>Nasopharyngitis (n/a - Recovered/Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [1d - n/a - n/a])","[ATORVASTATIN] (C - Hypercholesterolaemia - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRIOL] (C - Vulvovaginal dryness - n/a - [n/a - n/a - n/a]),<BR><BR>[MIRTAZAPINE] (C - Depression - n/a - [n/a - n/a - n/a]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - n/a]),<BR><BR>[PERINDOPRIL, PERINDOPRIL TERT-BUTYLAMINE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - Depression - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014741722&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014743090,Spontaneous,2023-03-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Arthralgia (2d - Recovered/Resolved - ),<BR><BR>Fatigue (12h - Recovered/Resolved - ),<BR><BR>Injection site erythema (2d - Recovered/Resolved - ),<BR><BR>Injection site inflammation (2d - Recovered/Resolved - ),<BR><BR>Injection site swelling (2d - Recovered/Resolved - ),<BR><BR>Injection site warmth (2d - Recovered/Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014743090&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014743091,Spontaneous,2023-03-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014743091&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014743633,Spontaneous,2023-03-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,Pain in extremity (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014743633&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014744984,Spontaneous,2023-03-06 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Transient ischaemic attack (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014744984&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014745035,Spontaneous,2023-03-06 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,Urticaria (n/a - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])",SPIKEVAX [ELASOMERAN] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014745035&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014740264,Spontaneous,2023-03-05 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Injection site pain (1d - Recovered/Resolved - ),<BR><BR>Postmenopausal haemorrhage (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014740264&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014737451,Spontaneous,2023-03-04 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Hypersensitivity (1d - Recovering/Resolving - Caused/Prolonged Hospitalisation),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014737451&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014738548,Spontaneous,2023-03-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Hypoacusis (n/a - Not Recovered/Not Resolved - ),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014738548&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014731002,Spontaneous,2023-03-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014731002&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014731417,Spontaneous,2023-03-03 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Heavy menstrual bleeding (n/a - Not Recovered/Not Resolved - ),<BR><BR>Premenstrual dysphoric disorder (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014731417&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014732342,Spontaneous,2023-03-03 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Rash (n/a - Recovered/Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])","[ATORVASTATIN, ATORVASTATIN CALCIUM] (C - n/a - Dose not changed - [n/a - n/a - Oral use]),<BR><BR>[RAMIPRIL] (C - n/a - Dose not changed - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014732342&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014734589,Spontaneous,2023-03-03 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,Pain in extremity (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014734589&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014736879,Spontaneous,2023-03-03 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Cardiac ventricular thrombosis (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Ischaemic stroke (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Off label use (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014736879&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014737158,Spontaneous,2023-03-03 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Heavy menstrual bleeding (n/a - Not Recovered/Not Resolved - ),<BR><BR>Polymenorrhoea (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014737158&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014725516,Spontaneous,2023-03-02 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Neuralgia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pain (n/a - Unknown - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014725516&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014725711,Spontaneous,2023-03-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Male,Pericarditis (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014725711&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014725719,Spontaneous,2023-03-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Female,"Dyspnoea (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[IPRATROPIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014725719&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014712147,Spontaneous,2023-03-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Blindness (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),<BR><BR>Retinal vein occlusion (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [1d - n/a - Intramuscular use])","AVAMYS [FLUTICASONE FUROATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (C - n/a - n/a - [1d - n/a - n/a]),<BR><BR>[CANDESARTAN, CANDESARTAN CILEXETIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CICLESONIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014712147&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014713400,Spontaneous,2023-03-01 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Diarrhoea (n/a - Unknown - Disabling),<BR><BR>Gastrooesophageal reflux disease (n/a - Unknown - Disabling),<BR><BR>Heart rate increased (n/a - Unknown - Disabling),<BR><BR>Herpes zoster (n/a - Unknown - Disabling),<BR><BR>Micturition urgency (n/a - Unknown - Disabling),<BR><BR>Nausea (n/a - Unknown - Disabling),<BR><BR>Neuralgia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Palpitations (n/a - Unknown - Disabling),<BR><BR>Vision blurred (n/a - Unknown - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014713400&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014715515,Spontaneous,2023-03-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Female,"Arthralgia (3wk - Recovered/Resolved - ),<BR><BR>Fatigue (2mo - Recovered/Resolved - ),<BR><BR>Headache (n/a - Recovered/Resolved - ),<BR><BR>Injection site pain (2mo - Recovered/Resolved - ),<BR><BR>Jaw disorder (3mo - Recovered/Resolved - ),<BR><BR>Malaise (2mo - Recovered/Resolved - ),<BR><BR>Myalgia (3wk - Recovered/Resolved - ),<BR><BR>Paraesthesia (3mo - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>REPATHA 140 MG SOLUTION FOR INJECTION IN PRE-FILLED PEN [EVOLOCUMAB] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014715515&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014716307,Spontaneous,2023-03-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Breast pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014716307&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014717301,Spontaneous,2023-03-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Lichen sclerosus (n/a - Not Recovered/Not Resolved - Disabling),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014717301&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014718922,Spontaneous,2023-03-01 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Paraesthesia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Tenderness (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])","[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - Influenza - n/a - [n/a - n/a - n/a]),<BR><BR>[PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 4, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6B, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9V, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 14, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 18C, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 33F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 22F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 20, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19A, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 17F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 15B, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 12F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 11A, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9N, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 7F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 5, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 3, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 2, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 1, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 10A, PNEUMOCOCCAL POLYSACCHARIDE VACCINE (23 VALENT)] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014718922&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014703363,Spontaneous,2023-02-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Atrial fibrillation (n/a - Recovered/Resolved - ),<BR><BR>COVID-19 immunisation (n/a - Unknown - ),<BR><BR>Heart rate increased (n/a - Recovered/Resolved - ),<BR><BR>Heart rate irregular (n/a - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","ESOMEPRAZOLE [ESOMEPRAZOLE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN, ATORVASTATIN CALCIUM] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[EMEDASTINE, ENALAPRIL, ENALAPRIL MALEATE] (C - n/a - Unknown - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014703363&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014705784,Spontaneous,2023-02-28 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Ear discomfort (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014705784&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014706101,Spontaneous,2023-02-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Chills (1d - Recovered/Resolved - ),<BR><BR>Fatigue (3d - Recovered/Resolved - ),<BR><BR>Graves' disease (n/a - Not Recovered/Not Resolved - ),<BR><BR>Heavy menstrual bleeding (n/a - Recovered/Resolved - ),<BR><BR>Injection site pain (7d - Recovered/Resolved - ),<BR><BR>Malaise (1d - Recovered/Resolved - ),<BR><BR>Myalgia (1d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",[THIAMAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014706101&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014706823,Spontaneous,2023-02-28 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Eye pruritus (n/a - Unknown - ),<BR><BR>Paraesthesia oral (n/a - Unknown - ),<BR><BR>Throat irritation (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [1d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014706823&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014707129,Spontaneous,2023-02-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hot flush (n/a - Not Recovered/Not Resolved - ),<BR><BR>Migraine (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Somnolence (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014707129&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014707139,Spontaneous,2023-02-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Chills (1d - Recovered/Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - ),<BR><BR>Swelling (n/a - Recovering/Resolving - ),<BR><BR>Vomiting (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRADIOL VALERATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014707139&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014694705,Spontaneous,2023-02-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Balance disorder (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014694705&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014695120,Spontaneous,2023-02-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Condition aggravated (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Facial paresis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - Immunisation - n/a - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014695120&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014695448,Spontaneous,2023-02-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Chills (1d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Lymph node pain (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014695448&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014695452,Spontaneous,2023-02-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,Myocardial infarction (5h - Recovered/Resolved - Caused/Prolonged Hospitalisation),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014695452&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014697066,Spontaneous,2023-02-27 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Injection site reaction (5wk - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014697066&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014697098,Spontaneous,2023-02-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Eye haemorrhage (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014697098&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014697132,Spontaneous,2023-02-27 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Thrombocytopenia (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - 1{DF} - Intramuscular use]),<BR><BR>DIMETHYL FUMARATE MYLAN [DIMETHYL FUMARATE] (S - Multiple sclerosis - Drug withdrawn - [n/a - n/a - Oral use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014697132&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014698172,Spontaneous,2023-02-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Brain fog (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chest discomfort (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hypersensitivity (n/a - Not Recovered/Not Resolved - ),<BR><BR>Post-acute COVID-19 syndrome (n/a - Not Recovered/Not Resolved - ),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014698172&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014698460,Spontaneous,2023-02-27 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Aggression (4d - Recovered/Resolved - ),<BR><BR>Agitation (4d - Recovered/Resolved - ),<BR><BR>Behaviour disorder (4d - Recovered/Resolved - ),<BR><BR>Condition aggravated (4d - Recovered/Resolved - ),<BR><BR>Mental disorder (4d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014698460&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014701215,Spontaneous,2023-02-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Peripheral swelling (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 4, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6B, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9V, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 14, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 18C, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 33F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 22F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 20, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19A, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 17F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 15B, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 12F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 11A, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9N, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 7F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 5, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 3, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 2, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 1, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 10A, PNEUMOCOCCAL POLYSACCHARIDE VACCINE (23 VALENT)] (S - Pneumococcal immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014701215&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014692734,Spontaneous,2023-02-26 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Heavy menstrual bleeding (n/a - Not Recovered/Not Resolved - ),<BR><BR>Intermenstrual bleeding (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Polymenorrhoea (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014692734&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014692260,Spontaneous,2023-02-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Amenorrhoea (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014692260&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014683551,Spontaneous,2023-02-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Myocarditis (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pericardial effusion (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])","[HEPATITIS B SURFACE ANTIGEN (RDNA) ADSORBED ON ALUMINIUM HYDROXIDE [PRODUCED IN S. CEREVISIAE (STRAIN 2150-2-3) BY RDNA], ALGELDRATE] (C - Immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014683551&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014685149,Spontaneous,2023-02-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Dizziness (n/a - Recovering/Resolving - ),<BR><BR>Hypopnoea (n/a - Recovering/Resolving - ),<BR><BR>Muscular weakness (n/a - Recovering/Resolving - ),<BR><BR>Syncope (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014685149&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014685221,Spontaneous,2023-02-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Back pain (n/a - Recovering/Resolving - ),<BR><BR>Immunisation reaction (n/a - Recovering/Resolving - ),<BR><BR>Neck pain (n/a - Recovering/Resolving - ),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - .3mL - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014685221&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014685407,Spontaneous,2023-02-24 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Anaphylactic reaction (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Chest pain (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [1d - n/a - Intramuscular use]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (S - n/a - n/a - [1d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014685407&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014685505,Spontaneous,2023-02-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Epilepsy (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Seizure (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014685505&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014685523,Spontaneous,2023-02-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chest pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Respiratory distress (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014685523&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014686392,Spontaneous,2023-02-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Abdominal pain (n/a - Recovered/Resolved - ),<BR><BR>Immunisation reaction (n/a - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014686392&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014690410,Spontaneous,2023-02-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Asthenia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>COVID-19 immunisation (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Memory impairment (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Mobility decreased (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Visual impairment (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),<BR><BR>[ELASOMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014690410&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014676519,Spontaneous,2023-02-23 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Asthenia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Body temperature increased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site reaction (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 15ug - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014676519&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014676551,Spontaneous,2023-02-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Intermenstrual bleeding (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014676551&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014677090,Spontaneous,2023-02-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Cough variant asthma (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (4d - Recovered/Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Sinus congestion (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014677090&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014677094,Spontaneous,2023-02-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Female,Photopsia (1h - Recovered/Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014677094&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014677308,Spontaneous,2023-02-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Fatigue (383d - Recovered/Resolved With Sequelae - ),<BR><BR>Influenza like illness (383d - Recovered/Resolved With Sequelae - ),<BR><BR>Palpitations (383d - Recovered/Resolved With Sequelae - ),<BR><BR>Restlessness (383d - Recovered/Resolved With Sequelae - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014677308&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014677309,Spontaneous,2023-02-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Mobility decreased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014677309&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014677549,Spontaneous,2023-02-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Male,Eczema nummular (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","EXFORGE 5 MG/80 MG FILM-COATED TABLETS [VALSARTAN, AMLODIPINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014677549&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014677985,Spontaneous,2023-02-23 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,Periarthritis (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014677985&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014678039,Spontaneous,2023-02-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Epistaxis (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014678039&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014678078,Spontaneous,2023-02-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dizziness (n/a - Recovered/Resolved - ),<BR><BR>Hypertension (n/a - Recovered/Resolved - ),<BR><BR>Influenza like illness (n/a - Recovered/Resolved - ),<BR><BR>Injection site pain (3d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])","[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014678078&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014678934,Spontaneous,2023-02-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Cardiac failure (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014678934&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014679046,Spontaneous,2023-02-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Angina pectoris (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Ataxia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Diplopia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Epilepsy (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Hypotonia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014679046&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014679048,Spontaneous,2023-02-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Thrombocytopenia (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014679048&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014668701,Spontaneous,2023-02-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,Herpes zoster oticus (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014668701&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014668852,Spontaneous,2023-02-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Bladder cancer (n/a - Recovered/Resolved With Sequelae - Life Threatening),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014668852&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014668908,Spontaneous,2023-02-22 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Immunisation reaction (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Status epilepticus (4d - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014668908&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014669160,Spontaneous,2023-02-22 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Cardiac failure (n/a - Not Recovered/Not Resolved - Disabling),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014669160&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014669254,Spontaneous,2023-02-22 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Pruritus (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (3d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014669254&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014669265,Spontaneous,2023-02-22 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Neck pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014669265&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014669595,Spontaneous,2023-02-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Dyspnoea (n/a - Unknown - ),<BR><BR>Fatigue (n/a - Unknown - ),<BR><BR>Illness (n/a - Unknown - ),<BR><BR>Pain in extremity (n/a - Unknown - ),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014669595&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014670743,Spontaneous,2023-02-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Male,Atrial fibrillation (n/a - Unknown - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014670743&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014670746,Spontaneous,2023-02-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,Periarthritis (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014670746&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014670750,Spontaneous,2023-02-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Headache (n/a - Recovering/Resolving - ),<BR><BR>Heavy menstrual bleeding (n/a - Recovering/Resolving - ),<BR><BR>Migraine (n/a - Recovering/Resolving - ),<BR><BR>Ophthalmic migraine (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014670750&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014670755,Spontaneous,2023-02-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Injection site erythema (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (n/a - Recovering/Resolving - ),<BR><BR>Injection site pruritus (n/a - Recovering/Resolving - ),<BR><BR>Injection site swelling (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",[MELATONIN] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014670755&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014670879,Spontaneous,2023-02-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dermatitis atopic (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Disease recurrence (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[FLUOXETINE, FLUOXETINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014670879&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014671941,Spontaneous,2023-02-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Lymph node pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Swelling (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014671941&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014673143,Spontaneous,2023-02-22 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Injection site pain (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014673143&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014673689,Spontaneous,2023-02-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (72h - Recovered/Resolved - ),<BR><BR>Chills (n/a - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (96h - Recovered/Resolved - ),<BR><BR>Nausea (24h - Recovered/Resolved - ),<BR><BR>Polymenorrhoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (36h - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014673689&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014658419,Spontaneous,2023-02-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Chills (n/a - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014658419&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014658975,Spontaneous,2023-02-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,Mechanical urticaria (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014658975&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014660028,Spontaneous,2023-02-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Menstruation delayed (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014660028&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014660231,Spontaneous,2023-02-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Recovering/Resolving - Life Threatening, Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Life Threatening, Other Medically Important Condition),<BR><BR>Hypoaesthesia (n/a - Recovering/Resolving - Life Threatening, Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Life Threatening, Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Recovering/Resolving - Life Threatening, Other Medically Important Condition),<BR><BR>Venous thrombosis limb (n/a - Recovering/Resolving - Life Threatening, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[LEVONORGESTREL, LEVONORGESTREL MICRONISED] (C - n/a - n/a - )","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014660231&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014661377,Spontaneous,2023-02-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Female,Neurological symptom (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014661377&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014648134,Spontaneous,2023-02-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Periarthritis (n/a - Unknown - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014648134&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014648621,Spontaneous,2023-02-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Polymyalgia rheumatica (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014648621&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014650196,Spontaneous,2023-02-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Female,"COVID-19 (10d - Recovered/Resolved - ),<BR><BR>Headache (n/a - Recovered/Resolved - ),<BR><BR>Myalgia (10d - Recovered/Resolved - ),<BR><BR>Nausea (10d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014650196&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014651367,Spontaneous,2023-02-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (2h - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Hyperpyrexia (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Injection site warmth (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (1d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014651367&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014651369,Spontaneous,2023-02-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Female,Herpes zoster (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014651369&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014651371,Spontaneous,2023-02-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (2d - Recovered/Resolved - ),<BR><BR>Chills (2d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Unknown - ),<BR><BR>Malaise (2d - Recovered/Resolved - ),<BR><BR>Myalgia (2d - Recovered/Resolved - ),<BR><BR>Nausea (2d - Recovered/Resolved - ),<BR><BR>Pyrexia (2d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014651371&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014653006,Spontaneous,2023-02-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Dysmenorrhoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Heavy menstrual bleeding (n/a - Not Recovered/Not Resolved - ),<BR><BR>Heavy menstrual bleeding (n/a - Recovered/Resolved - ),<BR><BR>Polymenorrhoea (n/a - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 (15/15 MICROGRAMS)/DOSE [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>SPIKEVAX 0.1 MG/ML DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [ELASOMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A] (C - Immunisation - Not applicable - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014653006&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014653981,Spontaneous,2023-02-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>COVID-19 immunisation (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Decreased appetite (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014653981&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014653983,Spontaneous,2023-02-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (1d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Dizziness (1d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Fatigue (2d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Headache (1d - Recovered/Resolved - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014653983&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014653984,Spontaneous,2023-02-20 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 immunisation (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Superficial vein prominence (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014653984&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014653990,Spontaneous,2023-02-20 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,Vaccination site paraesthesia (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",[PHENOXYMETHYLPENICILLIN POTASSIUM] (C - n/a - n/a - [n/a - n/a - Oral use]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014653990&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014654013,Spontaneous,2023-02-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Pulmonary embolism (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Venous thrombosis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])","[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[ENALAPRIL MALEATE] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014654013&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014654496,Spontaneous,2023-02-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Malaise (3d - Recovered/Resolved - ),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014654496&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014643519,Spontaneous,2023-02-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site haematoma (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014643519&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014644913,Spontaneous,2023-02-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (2d - Recovered/Resolved - ),<BR><BR>Fatigue (2d - Recovered/Resolved - ),<BR><BR>Headache (n/a - Recovered/Resolved - ),<BR><BR>Malaise (2d - Recovered/Resolved - ),<BR><BR>Myalgia (2d - Recovered/Resolved - ),<BR><BR>Nausea (1d - Recovered/Resolved - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014644913&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014644940,Spontaneous,2023-02-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Heavy menstrual bleeding (n/a - Recovering/Resolving - ),<BR><BR>Intermenstrual bleeding (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014644940&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014644966,Spontaneous,2023-02-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Heavy menstrual bleeding (2mo - Recovered/Resolved - ),<BR><BR>Menstruation delayed (2mo - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014644966&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014645109,Spontaneous,2023-02-18 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,Sudden death (0d - Fatal - Results in Death),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - Intramuscular use])","ENTRESTO [SACUBITRIL VALSARTAN SODIUM HYDRATE, VALSARTAN, SACUBITRIL] (C - n/a - n/a - ),<BR><BR>FORXIGA [DAPAGLIFLOZIN] (C - n/a - n/a - ),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - ),<BR><BR>[FUROSEMIDE, FUROSEMIDE SODIUM] (C - n/a - n/a - ),<BR><BR>[METFORMIN HYDROCHLORIDE] (C - n/a - n/a - )","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014645109&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014646270,Spontaneous,2023-02-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Injection site swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014646270&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014637766,Spontaneous,2023-02-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014637766&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014638022,Spontaneous,2023-02-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Blood pressure increased (1d - Recovered/Resolved - ),<BR><BR>Body temperature increased (2d - Recovered/Resolved - ),<BR><BR>Headache (2d - Recovered/Resolved - ),<BR><BR>Heart rate decreased (1d - Recovered/Resolved - ),<BR><BR>Palpitations (1d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014638022&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014638540,Spontaneous,2023-02-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 immunisation (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Postmenopausal haemorrhage (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[DYDROGESTERONE, ESTRADIOL, DYDROGESTERONE, ESTRADIOL HEMIHYDRATE] (C - n/a - Unknown - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014638540&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014640284,Spontaneous,2023-02-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"COVID-19 (n/a - Unknown - ),<BR><BR>Injection site reaction (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014640284&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014640703,Spontaneous,2023-02-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dizziness postural (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Thrombocytosis (n/a - Recovered/Resolved With Sequelae - Disabling, Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014640703&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014641236,Spontaneous,2023-02-17 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Localised oedema (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014641236&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014641587,Spontaneous,2023-02-17 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Cerebrovascular accident (1d - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>SHINGRIX [RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E, RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E, STIMULON, MONOPHOSPHORYL LIPID A] (S - Immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014641587&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014626574,Spontaneous,2023-02-16 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"Carpal tunnel syndrome (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Musculoskeletal disorder (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Unknown]),<BR><BR>COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014626574&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014629436,Spontaneous,2023-02-16 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Drug eruption (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014629436&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014630354,Spontaneous,2023-02-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Eczema (n/a - Unknown - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014630354&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014631784,Spontaneous,2023-02-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (2d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Injection site swelling (n/a - Recovering/Resolving - ),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (2d - Recovered/Resolved - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014631784&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014631787,Spontaneous,2023-02-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (1d - Recovered/Resolved - ),<BR><BR>Chills (1d - Recovered/Resolved - ),<BR><BR>Fatigue (1d - Recovered/Resolved - ),<BR><BR>Headache (1d - Recovered/Resolved - ),<BR><BR>Heavy menstrual bleeding (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (1d - Recovered/Resolved - ),<BR><BR>Myalgia (1d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014631787&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014632980,Spontaneous,2023-02-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,Palpitations (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014632980&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014632981,Spontaneous,2023-02-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Nipple pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Uterine pain (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014632981&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014632993,Spontaneous,2023-02-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Chest pain (14d - Recovered/Resolved - ),<BR><BR>Chills (5d - Recovered/Resolved - ),<BR><BR>Dyspnoea (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (7d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[FLUTICASONE PROPIONATE, SALMETEROL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014632993&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014633255,Spontaneous,2023-02-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014633255&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014633302,Spontaneous,2023-02-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Arthralgia (3d - Recovered/Resolved - ),<BR><BR>Chills (3d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovered/Resolved - ),<BR><BR>Headache (3d - Recovered/Resolved - ),<BR><BR>Malaise (5d - Recovered/Resolved - ),<BR><BR>Myalgia (3d - Recovered/Resolved - ),<BR><BR>Nausea (2d - Recovered/Resolved - ),<BR><BR>Pyrexia (4d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",ADALIMUMAB - SOLUTION FOR INJECTION  (C - n/a - Dose not changed - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014633302&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014633472,Spontaneous,2023-02-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal pain upper (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Asthenia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Depression suicidal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Feeding disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Heart rate increased (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Major depression (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Middle insomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Migraine (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Sinus headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Tremor (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>IRON [IRON] (C - Vomiting, Weight decreased - n/a - [n/a - n/a - n/a]),<BR><BR>[ANHYDROUS LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a]),<BR><BR>[ASCORBIC ACID, BETACAROTENE, BIOTIN, ERGOCALCIFEROL, CYANOCOBALAMIN, FOLIC ACID, NICOTINAMIDE, PYRIDOXINE, RIBOFLAVIN, THIAMINE, ZINC, CALCIUM, CHROMIUM, COPPER, IODINE, IRON, MAGNESIUM, MANGANESE, PANTOTHENIC ACID, PHOSPHORUS, POTASSIUM, SELENIUM, TOCOPHERYL ACETATE, MOLYBDENUM, ASCORBIC ACID, BETACAROTENE, ERGOCALCIFEROL, CYANOCOBALAMIN, FOLIC ACID, NICOTINAMIDE, PYRIDOXINE, RIBOFLAVIN, THIAMINE, ZINC, CALCIUM, CHROMIUM, COPPER, IODINE, IRON, MAGNESIUM, MANGANESE, PANTOTHENIC ACID, PHOSPHORUS, POTASSIUM, SELENIUM, MOLYBDENUM, DL-ALPHA TOCOPHEROL ACETATE, D-BIOTIN, ERGOCALCIFEROL, RETINOL] (C - Vomiting, Weight decreased - n/a - [n/a - n/a - n/a]),<BR><BR>[CYANOCOBALAMIN] (C - Vomiting, Weight decreased - n/a - [n/a - n/a - n/a]),<BR><BR>[CYCLIZINE] (C - Nausea, Vomiting - n/a - [n/a - n/a - n/a]),<BR><BR>[DIHYDROCODEINE, DIHYDROCODEINE TARTRATE BP] (C - Back pain, Pain in extremity, Pelvic pain - n/a - [n/a - n/a - n/a]),<BR><BR>[HYOSCINE] (C - Back pain, Pain in extremity, Pelvic pain - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - n/a]),<BR><BR>[METOCLOPRAMIDE] (C - Nausea, Vomiting - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Back pain, Pain in extremity, Pelvic pain - n/a - [n/a - n/a - n/a]),<BR><BR>[PROCHLORPERAZINE] (C - Nausea, Vomiting - n/a - [n/a - n/a - n/a]),<BR><BR>[THIAMINE] (C - Vomiting, Weight decreased - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014633472&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014635254,Spontaneous,2023-02-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (12h - Recovered/Resolved - ),<BR><BR>Headache (1d - Recovered/Resolved - ),<BR><BR>Malaise (12h - Recovered/Resolved - ),<BR><BR>Nausea (12h - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014635254&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014620657,Spontaneous,2023-02-15 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dizziness (n/a - Unknown - ),<BR><BR>Nasopharyngitis (n/a - Unknown - ),<BR><BR>Paraesthesia (n/a - Unknown - ),<BR><BR>Respiratory disorder (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Sleep apnoea syndrome (n/a - Unknown - ),<BR><BR>Tremor (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a])","[ESCITALOPRAM, ESCITALOPRAM OXALATE] (C - Post-traumatic stress disorder - n/a - [n/a - 5mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014620657&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014620854,Spontaneous,2023-02-15 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,Sudden death (n/a - Fatal - Results in Death),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, IVR-186), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021 HAEMAGGLUTININ ANTIGEN, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (S - Immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014620854&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014621153,Spontaneous,2023-02-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Diarrhoea (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014621153&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014621154,Spontaneous,2023-02-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chest pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014621154&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014621884,Spontaneous,2023-02-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Atrial fibrillation (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chest discomfort (4h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014621884&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014621974,Spontaneous,2023-02-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Lymph node pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE, BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LISINOPRIL, LISINOPRIL DIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MONTELUKAST, MONTELUKAST SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[TIOTROPIUM, TIOTROPIUM BROMIDE, TIOTROPIUM BROMIDE MONOHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014621974&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014622053,Spontaneous,2023-02-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Tinnitus (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014622053&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014622478,Spontaneous,2023-02-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Contusion (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Cough (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[TRAMADOL, TRAMADOL HYDROCHLORIDE] (C - Neuralgia - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014622478&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014624789,Spontaneous,2023-02-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014624789&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014625392,Spontaneous,2023-02-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Heavy menstrual bleeding (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (4d - Recovered/Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Polymenorrhoea (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014625392&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014611514,Spontaneous,2023-02-14 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Herpes zoster (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014611514&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014612702,Spontaneous,2023-02-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Atrial flutter (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Chest discomfort (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Heart rate increased (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Musculoskeletal stiffness (4d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014612702&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014612854,Spontaneous,2023-02-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Dizziness (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Muscle spasms (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vertigo (n/a - Unknown - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014612854&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014613373,Spontaneous,2023-02-14 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Angioedema (3d - Recovered/Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014613373&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014616484,Spontaneous,2023-02-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Influenza (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nasopharyngitis (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014616484&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014617029,Spontaneous,2023-02-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014617029&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014601156,Spontaneous,2023-02-13 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Feeling cold (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Rash erythematous (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Syncope (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Unknown])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Antiviral prophylaxis - n/a - [1d - n/a - Unknown])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014601156&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014602201,Spontaneous,2023-02-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Male,Arthritis (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Dose not changed - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014602201&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014603213,Spontaneous,2023-02-13 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Back pain (n/a - Recovered/Resolved - Life Threatening, Other Medically Important Condition),<BR><BR>Bone pain (n/a - Recovered/Resolved - Life Threatening, Other Medically Important Condition),<BR><BR>Hepatic lesion (n/a - Unknown - Life Threatening, Other Medically Important Condition),<BR><BR>Inflammation (n/a - Unknown - Life Threatening, Other Medically Important Condition),<BR><BR>Pelvic bone injury (n/a - Unknown - Life Threatening, Other Medically Important Condition),<BR><BR>Sarcoma (n/a - Not Recovered/Not Resolved - Life Threatening, Other Medically Important Condition),<BR><BR>Spinal column injury (n/a - Unknown - Life Threatening, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014603213&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014604341,Spontaneous,2023-02-13 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Dyspnoea exertional (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Mast cell activation syndrome (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Oedema peripheral (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Pleural effusion (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014604341&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014600688,Spontaneous,2023-02-12 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Myalgia (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014600688&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014597907,Spontaneous,2023-02-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Eczema eyelids (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Postmenopausal haemorrhage (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014597907&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014600474,Spontaneous,2023-02-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Heavy menstrual bleeding (n/a - Not Recovered/Not Resolved - ),<BR><BR>Polymenorrhoea (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014600474&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014600600,Spontaneous,2023-02-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (4d - Recovered/Resolved - ),<BR><BR>Chills (24h - Recovered/Resolved - ),<BR><BR>Headache (24h - Recovered/Resolved - ),<BR><BR>Malaise (1d - Recovered/Resolved - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014600600&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014590684,Spontaneous,2023-02-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Asthenia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Back pain (n/a - Recovered/Resolved - ),<BR><BR>Blindness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Disorientation (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Exophthalmos (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Muscular weakness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Skin burning sensation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Transient ischaemic attack (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - Intramuscular use]),<BR><BR>PREVENAR 13 [ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 1 CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 5 CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 3 CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6A CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 18C CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19A CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 7F CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 4 CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 14 CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9V CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6B CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23F CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19F CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 1 CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 5 CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 3 CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6A CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 18C CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 7F CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 4 CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 14 CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9V CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6B CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23F CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19F CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19A CONJUGATED TO CRM197, ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 4 CONJUGATED TO CRM197, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19F CONJUGATED TO CRM197, PNEUMOCOCCAL OLIGOSACCHARIDE SEROTYPE 18C CONJUGATED TO CRM197, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 14 CONJUGATED TO CRM197, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9V CONJUGATED TO CRM197, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6B CONJUGATED TO CRM197, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23F CONJUGATED TO CRM197, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 1 CONJUGATED TO CRM197, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 3 CONJUGATED TO CRM197, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 5 CONJUGATED TO CRM197, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6A CONJUGATED TO CRM197, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 7F CONJUGATED TO CRM197, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19A CONJUGATED TO CRM197] (S - Pneumococcal immunisation - n/a - [n/a - 1{DF} - Intramuscular use]),<BR><BR>SHINGRIX [RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E, RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E, STIMULON, MONOPHOSPHORYL LIPID A] (S - Herpes zoster immunisation - n/a - [n/a - 1{DF} - Intramuscular use])",[ACETYLSALICYLIC ACID] (C - Platelet aggregation inhibition - n/a - [n/a - 1{DF} - Oral use]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014590684&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014590859,Spontaneous,2023-02-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Diarrhoea (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Interchange of vaccine products (n/a - Unknown - Disabling),<BR><BR>Local reaction (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Vomiting (n/a - Recovered/Resolved With Sequelae - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Unknown]),<BR><BR>[INFLUENZA VIRUS] (S - Influenza immunisation - Not applicable - [1d - n/a - Unknown])",[PROGESTERONE] (C - n/a - n/a - [n/a - n/a - Unknown]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014590859&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014593058,Spontaneous,2023-02-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Thyroid disorder (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014593058&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014593379,Spontaneous,2023-02-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Abdominal discomfort (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Unknown])","[PARACETAMOL, CODEINE PHOSPHATE] (C - Back pain - n/a - [n/a - n/a - Unknown]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014593379&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014581183,Spontaneous,2023-02-09 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Trigeminal neuralgia (6d - Recovered/Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])",[LEVOTHYROXINE SODIUM] (C - n/a - n/a - ),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014581183&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014581487,Spontaneous,2023-02-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Hyperhidrosis (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Illness (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Nasopharyngitis (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pyrexia (13d - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Respiratory disorder (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014581487&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014583486,Spontaneous,2023-02-09 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Female,"Aphonia (n/a - Recovering/Resolving - ),<BR><BR>Eye pain (n/a - Recovering/Resolving - ),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - ),<BR><BR>Nasopharyngitis (n/a - Recovering/Resolving - ),<BR><BR>Oropharyngeal pain (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014583486&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014583747,Spontaneous,2023-02-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"Dyspnoea (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Myocarditis (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Pericarditis (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014583747&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014583999,Spontaneous,2023-02-09 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Back pain (n/a - Recovered/Resolved - ),<BR><BR>Disturbance in attention (1d - Recovered/Resolved - ),<BR><BR>Fatigue (1d - Recovered/Resolved - ),<BR><BR>Mobility decreased (n/a - Recovered/Resolved - ),<BR><BR>Nightmare (n/a - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014583999&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014584565,Spontaneous,2023-02-09 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014584565&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014584872,Spontaneous,2023-02-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Myalgia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014584872&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014584995,Spontaneous,2023-02-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014584995&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014585055,Spontaneous,2023-02-09 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Atrial fibrillation (24d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Chest discomfort (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Dyspnoea (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),<BR><BR>Heart failure with reduced ejection fraction (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Inappropriate schedule of product administration (n/a - Unknown - ),<BR><BR>Malaise (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Palpitations (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>IBUPROFEN [IBUPROFEN, IBUPROFEN SODIUM] (C - Analgesic therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[DIHYDROCODEINE, DIHYDROCODEINE TARTRATE BP] (C - Osteoarthritis - n/a - [n/a - n/a - n/a]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - Depression - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014585055&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014585699,Spontaneous,2023-02-09 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"C-reactive protein increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Cutaneous vasculitis (7d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Purpura (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Rash erythematous (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - n/a - n/a - [1d - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014585699&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014585733,Spontaneous,2023-02-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myocarditis (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014585733&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014586034,Spontaneous,2023-02-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypotension (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Migraine (6d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Syncope (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Urticaria (7d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vision blurred (6d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[BECLOMETASONE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BETAHISTINE, BETAHISTINE DIHYDROCHLORIDE, BETAHISTINE MESILATE] (C - n/a - n/a - [n/a - 8mg - n/a]),<BR><BR>[SALMETEROL, SALMETEROL XINAFOATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014586034&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014586226,Spontaneous,2023-02-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dizziness (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Eye pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Loss of personal independence in daily activities (n/a - Unknown - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Presyncope (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tinnitus (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014586226&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014586790,Spontaneous,2023-02-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[TOZINAMERAN NOS] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014586790&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014587241,Spontaneous,2023-02-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Axillary pain (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Mobility decreased (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Musculoskeletal disorder (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Neck pain (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Off label use (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014587241&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014587961,Spontaneous,2023-02-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"Fatigue (n/a - Unknown - ),<BR><BR>Feeling hot (n/a - Unknown - ),<BR><BR>Joint swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Skin discolouration (n/a - Unknown - ),<BR><BR>Thrombosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - ),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014587961&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014574141,Spontaneous,2023-02-08 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Haematoma (n/a - Recovering/Resolving - ),<BR><BR>Immune thrombocytopenia (n/a - Recovering/Resolving - Life Threatening)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224)] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",[COLECALCIFEROL] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014574141&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014574705,Spontaneous,2023-02-08 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Heavy menstrual bleeding (n/a - Not Recovered/Not Resolved - ),<BR><BR>Menstruation delayed (34d - Recovered/Resolved - ),<BR><BR>Menstruation irregular (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014574705&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014576001,Spontaneous,2023-02-08 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Carotid artery stenosis (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Retinal artery occlusion (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [1d - n/a - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (S - n/a - n/a - [1d - n/a - n/a])",[EZETIMIBE] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014576001&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014576805,Spontaneous,2023-02-08 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Chest discomfort (n/a - Recovering/Resolving - ),<BR><BR>Dyspnoea (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (7d - Recovered/Resolved - ),<BR><BR>Injection site erythema (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (n/a - Recovering/Resolving - ),<BR><BR>Injection site swelling (n/a - Recovering/Resolving - ),<BR><BR>Injection site warmth (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Palpitations (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014576805&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014577430,Spontaneous,2023-02-08 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Dizziness (1d - Recovered/Resolved - ),<BR><BR>Headache (1d - Recovered/Resolved - ),<BR><BR>Injection site erythema (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Injection site swelling (n/a - Recovering/Resolving - ),<BR><BR>Injection site warmth (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (1d - Recovered/Resolved - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014577430&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014578077,Spontaneous,2023-02-08 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Asthenia (n/a - Recovering/Resolving - ),<BR><BR>Dizziness (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Rash (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014578077&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014578177,Spontaneous,2023-02-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Contusion (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Mobility decreased (24h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (24h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014578177&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014578329,Spontaneous,2023-02-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (10d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014578329&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014578795,Spontaneous,2023-02-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal pain upper (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Night sweats (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BUDESONIDE, FORMOTEROL FUMARATE DIHYDRATE, FORMOTEROL FUMARATE, BUDESONIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[VENLAFAXINE, VENLAFAXINE HYDROCHLORIDE] (C - Hot flush - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014578795&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014579994,Spontaneous,2023-02-08 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014579994&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014580582,Spontaneous,2023-02-08 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014580582&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014564211,Spontaneous,2023-02-07 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Head discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hypoaesthesia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Impaired work ability (n/a - Unknown - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014564211&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014564554,Spontaneous,2023-02-07 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Generalised tonic-clonic seizure (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Seizure (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Unknown]),<BR><BR>SPIKEVAX [ELASOMERAN] (S - COVID-19 prophylaxis - Unknown - [n/a - 1{DF} - Unknown])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014564554&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014566356,Spontaneous,2023-02-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Herpes zoster (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014566356&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014566645,Spontaneous,2023-02-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Heavy menstrual bleeding (n/a - Recovering/Resolving - ),<BR><BR>Menstruation irregular (n/a - Recovering/Resolving - ),<BR><BR>Ovulation pain (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014566645&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014567768,Spontaneous,2023-02-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Anosmia (1mo - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[SALBUTAMOL, SALBUTAMOL SULFATE] (C - Asthma, Wheezing - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014567768&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014568558,Spontaneous,2023-02-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Diplopia (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Gait inability (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Loss of consciousness (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])","HARTMEDICATIE [NOT AVAILABLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>NIET GESPECIFICEERD GENEESMIDDEL [NOT AVAILABLE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014568558&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014571421,Spontaneous,2023-02-07 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Dermatitis (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014571421&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014571446,Spontaneous,2023-02-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Urticaria chronic (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014571446&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014556521,Spontaneous,2023-02-06 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Nasopharyngitis (n/a - Recovering/Resolving - ),<BR><BR>Respiratory disorder (n/a - Recovering/Resolving - ),<BR><BR>Sinusitis (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[INDAPAMIDE] (C - n/a - Unknown - [n/a - 1{DF} - n/a]),<BR><BR>[ZOPICLONE] (C - n/a - Unknown - [n/a - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014556521&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014557117,Spontaneous,2023-02-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Brain fog (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chest discomfort (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Lethargy (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Rhinorrhoea (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Unknown]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [1d - n/a - Unknown])","[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Blood pressure abnormal - n/a - [n/a - n/a - Unknown]),<BR><BR>[ATORVASTATIN, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM TRIHYDRATE] (C - Blood cholesterol abnormal - Dose not changed - [n/a - n/a - Unknown]),<BR><BR>[ISPAGHULA HUSK BP, MEBEVERINE HYDROCHLORIDE, ISPAGHULA HUSK] (C - Diverticulitis - Dose not changed - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014557117&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014557133,Spontaneous,2023-02-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,Herpes zoster (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014557133&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014557145,Spontaneous,2023-02-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Arthralgia (1d - Recovered/Resolved - ),<BR><BR>Chills (1d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Haemoglobin decreased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Unknown - ),<BR><BR>Injection site inflammation (1d - Recovered/Resolved - ),<BR><BR>Injection site pain (1d - Recovered/Resolved - ),<BR><BR>Injection site swelling (1d - Recovered/Resolved - ),<BR><BR>Lymphadenopathy (3d - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - ),<BR><BR>White blood cell count decreased (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014557145&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014557859,Spontaneous,2023-02-06 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Myocarditis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a])","[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (C - Immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014557859&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014558204,Spontaneous,2023-02-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Appendicitis (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Breast milk discolouration (n/a - Recovered/Resolved - ),<BR><BR>Headache (24h - Recovered/Resolved - ),<BR><BR>Injection site inflammation (4d - Recovered/Resolved - ),<BR><BR>Injection site pain (4d - Recovered/Resolved - ),<BR><BR>Injection site swelling (4d - Recovered/Resolved - ),<BR><BR>Insomnia (n/a - Unknown - ),<BR><BR>Lactation insufficiency (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014558204&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014559121,Spontaneous,2023-02-06 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Male,"COVID-19 (n/a - Recovering/Resolving - Life Threatening),<BR><BR>Cough (n/a - Recovering/Resolving - Life Threatening),<BR><BR>General physical health deterioration (n/a - Recovering/Resolving - Life Threatening),<BR><BR>Headache (n/a - Recovering/Resolving - Life Threatening),<BR><BR>Oropharyngeal pain (n/a - Recovering/Resolving - Life Threatening),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Life Threatening)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[AMLODIPINE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[HYDROCHLOROTHIAZIDE, NEBIVOLOL] (C - n/a - Unknown - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014559121&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014560077,Spontaneous,2023-02-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Gait disturbance (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Musculoskeletal stiffness (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014560077&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014560741,Spontaneous,2023-02-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Dyspnoea exertional (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014560741&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014561345,Spontaneous,2023-02-06 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (5d - Recovered/Resolved - ),<BR><BR>Headache (5d - Recovered/Resolved - ),<BR><BR>Malaise (5d - Recovered/Resolved - ),<BR><BR>Nasopharyngitis (5d - Recovered/Resolved - ),<BR><BR>Vertigo (5d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","AERIUS 5 MG [DESLORATADINE] (C - n/a - Unknown - [n/a - 1{DF} - n/a]),<BR><BR>[ACETYLSALICYLIC ACID] (C - n/a - Unknown - [n/a - 1{DF} - n/a]),<BR><BR>[AMLODIPINE BESILATE, PERINDOPRIL ARGININE, AMLODIPINE, PERINDOPRIL] (C - n/a - Unknown - [n/a - 1{DF} - n/a]),<BR><BR>[AZELASTINE HYDROCHLORIDE] (C - n/a - Unknown - [n/a - 2[drp] - n/a]),<BR><BR>[BILASTINE] (C - n/a - Unknown - [n/a - 1{DF} - n/a]),<BR><BR>[HYDROCHLOROTHIAZIDE, LISINOPRIL] (C - n/a - Unknown - [n/a - .5{DF} - n/a]),<BR><BR>[METFORMIN HYDROCHLORIDE] (C - n/a - Unknown - [n/a - 1.5{DF} - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - Unknown - [n/a - 1{DF} - n/a]),<BR><BR>[PASSIFLORA INCARNATA DRY EXTRACT] (C - n/a - Unknown - [n/a - 2{DF} - n/a]),<BR><BR>[SIMVASTATIN] (C - n/a - Unknown - [n/a - 1{DF} - n/a]),<BR><BR>[SULPIRIDE] (C - n/a - Unknown - [n/a - .5{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014561345&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014562513,Spontaneous,2023-02-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Heavy menstrual bleeding (n/a - Not Recovered/Not Resolved - ),<BR><BR>Polymenorrhoea (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014562513&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014562916,Spontaneous,2023-02-06 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Eczema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Eczema nummular (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])","[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MESILATE MONOHYDRATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[BENDROFLUMETHIAZIDE, POTASSIUM CHLORIDE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[BUDESONIDE, FORMOTEROL FUMARATE DIHYDRATE, FORMOTEROL FUMARATE, BUDESONIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[GABAPENTIN] (C - Neuralgia - n/a - [n/a - n/a - n/a]),<BR><BR>[TIOTROPIUM, TIOTROPIUM BROMIDE, TIOTROPIUM BROMIDE MONOHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014562916&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014554689,Spontaneous,2023-02-05 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Hypoaesthesia oral (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014554689&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014554694,Spontaneous,2023-02-05 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Haematoma (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])","[TAMOXIFEN, TAMOXIFEN CITRATE] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014554694&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014554743,Spontaneous,2023-02-05 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Headache (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014554743&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014551839,Spontaneous,2023-02-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Injection site pain (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014551839&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014551854,Spontaneous,2023-02-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Body temperature increased (12h - Recovered/Resolved - ),<BR><BR>Headache (12h - Recovered/Resolved - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Malaise (12h - Recovered/Resolved - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014551854&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014551872,Spontaneous,2023-02-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014551872&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014553445,Spontaneous,2023-02-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Dyspnoea (n/a - Recovering/Resolving - ),<BR><BR>Heart rate increased (n/a - Recovering/Resolving - ),<BR><BR>Palpitations (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014553445&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014553453,Spontaneous,2023-02-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Polymenorrhoea (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014553453&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014544631,Spontaneous,2023-02-03 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dizziness (39d - Recovered/Resolved - ),<BR><BR>Vertigo (39d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use])","[LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[SIMVASTATIN] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014544631&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014548931,Spontaneous,2023-02-03 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Headache (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [1d - .3mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014548931&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014549003,Spontaneous,2023-02-03 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Influenza like illness (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014549003&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014549211,Spontaneous,2023-02-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vomiting (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014549211&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014549230,Spontaneous,2023-02-03 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Male,"Cerebral infarction (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014549230&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014549403,Spontaneous,2023-02-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014549403&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014549431,Spontaneous,2023-02-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Herpes zoster (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014549431&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014549461,Spontaneous,2023-02-03 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Heavy menstrual bleeding (n/a - Not Recovered/Not Resolved - ),<BR><BR>Menstruation irregular (n/a - Not Recovered/Not Resolved - ),<BR><BR>Polymenorrhoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Rash (n/a - Not Recovered/Not Resolved - )","COMIRNATY 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>COMIRNATY ORIGINAL/OMICRON BA.1 (15/15 MICROGRAMS)/DOSE DISPERSION FOR INJECTION [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014549461&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014549542,Spontaneous,2023-02-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014549542&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014549814,Spontaneous,2023-02-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Peripheral coldness (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014549814&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014550021,Spontaneous,2023-02-03 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Dizziness (20d - Recovered/Resolved - ),<BR><BR>Ear pain (20d - Recovered/Resolved - ),<BR><BR>Gait disturbance (20d - Recovered/Resolved - ),<BR><BR>Nausea (20d - Recovered/Resolved - ),<BR><BR>Vomiting (20d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014550021&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014550085,Spontaneous,2023-02-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Decreased appetite (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>IVABRADINE [IVABRADINE, IVABRADINE HYDROCHLORIDE] (C - Heart rate abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - Conversion disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014550085&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014550821,Spontaneous,2023-02-03 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Male,Epilepsy (n/a - Recovered/Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014550821&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014552986,Spontaneous,2023-02-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>IBUPROFEN [IBUPROFEN, IBUPROFEN SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 4, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6B, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9V, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 14, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 18C, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 33F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 22F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 20, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19A, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 17F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 15B, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 12F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 11A, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9N, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 7F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 5, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 3, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 2, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 1, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 10A, PNEUMOCOCCAL POLYSACCHARIDE VACCINE (23 VALENT), PNEUMOCOCCAL VACCINE] (C - n/a - n/a - [1d - n/a - n/a]),<BR><BR>[PSEUDOEPHEDRINE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014552986&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014537137,Spontaneous,2023-02-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Female,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fear of death (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hypertension (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014537137&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014539676,Spontaneous,2023-02-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chills (1d - Recovered/Resolved - ),<BR><BR>Fatigue (3d - Recovered/Resolved - ),<BR><BR>Headache (2d - Recovered/Resolved - ),<BR><BR>Malaise (2d - Recovered/Resolved - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - ),<BR><BR>Vaccination site lymphadenopathy (2d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014539676&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014540247,Spontaneous,2023-02-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Axillary pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Back pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypokinesia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Sciatica (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014540247&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014540255,Spontaneous,2023-02-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,Arthralgia (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014540255&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014540885,Spontaneous,2023-02-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Heart rate increased (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Night sweats (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Somnolence (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pruritus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site warmth (n/a - Unknown - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014540885&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014541010,Spontaneous,2023-02-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Back pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014541010&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014541063,Spontaneous,2023-02-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,12-17 Years,Not Specified,No,Not Specified,"Dizziness (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Syncope (n/a - Unknown - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014541063&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014541128,Spontaneous,2023-02-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Ocular discomfort (n/a - Not Recovered/Not Resolved - ),<BR><BR>Photopsia (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014541128&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014541413,Spontaneous,2023-02-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Influenza (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014541413&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014541431,Spontaneous,2023-02-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Musculoskeletal pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pericarditis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>ESOMEPRAZOLE [ESOMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>OZEMPIC [SEMAGLUTIDE] (C - Type 2 diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[GLICLAZIDE] (C - Type 2 diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - Type 2 diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[QUININE SULPHATE BP] (C - Restless legs syndrome - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014541431&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014541824,Spontaneous,2023-02-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Dizziness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hypertension (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Migraine (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Unknown - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014541824&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014541826,Spontaneous,2023-02-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Peripheral swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014541826&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014541963,Spontaneous,2023-02-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Eye pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Mouth ulceration (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Oral herpes (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Oral pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014541963&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014526985,Spontaneous,2023-02-01 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Pericarditis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .5mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014526985&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014526986,Spontaneous,2023-02-01 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,Cardiac arrest (0d - Fatal - Results in Death),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - .3mL - Subcutaneous use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014526986&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014529806,Spontaneous,2023-02-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014529806&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014529808,Spontaneous,2023-02-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adolescent,No,Female,"Dizziness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014529808&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014530526,Spontaneous,2023-02-01 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Diarrhoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeding disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Immune system disorder (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nasopharyngitis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Unknown - Other Medically Important Condition),<BR><BR>Weight decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014530526&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014531078,Spontaneous,2023-02-01 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Loss of personal independence in daily activities (n/a - Unknown - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014531078&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014531773,Spontaneous,2023-02-01 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Hypotension (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014531773&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014531824,Spontaneous,2023-02-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Herpes zoster (24d - Recovered/Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014531824&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014532961,Spontaneous,2023-02-01 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Back pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[ESTRADIOL, NORETHISTERONE, NORETHISTERONE ACETATE, ESTRADIOL, NORETHISTERONE ACETATE, ESTRADIOL HEMIHYDRATE] (C - Menopause - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Lung disorder - n/a - [1d - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - Blood pressure abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - Anxiety - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014532961&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014533559,Spontaneous,2023-02-01 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Rash macular (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash pruritic (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014533559&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014535013,Spontaneous,2023-02-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Headache (n/a - Recovering/Resolving - ),<BR><BR>Myositis (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014535013&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014535208,Spontaneous,2023-02-01 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Pulmonary embolism (n/a - Unknown - Life Threatening),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (C - Influenza immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014535208&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014518005,Spontaneous,2023-01-31 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Pyrexia (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014518005&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014520260,Spontaneous,2023-01-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Female,"Hypertension (n/a - Recovering/Resolving - ),<BR><BR>Tachycardia (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014520260&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014520739,Spontaneous,2023-01-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Female,"Fatigue (1h - Recovered/Resolved - ),<BR><BR>Vertigo (2d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014520739&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014520878,Spontaneous,2023-01-31 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Periarthritis (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014520878&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014521418,Spontaneous,2023-01-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Pain (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014521418&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014522285,Spontaneous,2023-01-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Angina pectoris (n/a - Not Recovered/Not Resolved - ),<BR><BR>Cardiac failure (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dyspnoea exertional (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014522285&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014522305,Spontaneous,2023-01-31 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Infertility (n/a - Unknown - Other Medically Important Condition),<BR><BR>Menstrual disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Menstruation delayed (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014522305&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014522759,Spontaneous,2023-01-31 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Axillary pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Bone contusion (n/a - Unknown - Other Medically Important Condition),<BR><BR>Breast pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Burning sensation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypoaesthesia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Musculoskeletal chest pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tenderness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014522759&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014523270,Spontaneous,2023-01-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Female,Vertigo (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014523270&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014523574,Spontaneous,2023-01-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arrhythmia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Disturbance in attention (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Limb discomfort (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Memory impairment (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Movement disorder (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Respiratory distress (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Restlessness (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Sleep disorder (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Syncope (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Weight bearing difficulty (n/a - Unknown - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014523574&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014523986,Spontaneous,2023-01-31 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Asthenia (n/a - Unknown - Life Threatening),<BR><BR>Dizziness (2d - Recovered/Resolved - Life Threatening),<BR><BR>Dyspnoea (n/a - Unknown - Life Threatening),<BR><BR>Fatigue (2d - Recovered/Resolved - Life Threatening),<BR><BR>Feeling abnormal (n/a - Unknown - Life Threatening),<BR><BR>Loss of consciousness (n/a - Unknown - Life Threatening),<BR><BR>Malaise (n/a - Unknown - Life Threatening),<BR><BR>Nausea (1d - Recovered/Resolved - Life Threatening),<BR><BR>Near death experience (n/a - Unknown - Life Threatening),<BR><BR>Palpitations (2d - Recovered/Resolved - Life Threatening),<BR><BR>Vertigo (n/a - Unknown - Life Threatening),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - Blood cholesterol increased, Type 2 diabetes mellitus - n/a - [n/a - 40mg - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Thyroid disorder - n/a - [n/a - 150ug - n/a]),<BR><BR>[MIRTAZAPINE] (C - Depression - n/a - [n/a - 15mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014523986&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014524029,Spontaneous,2023-01-31 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Hypertension (n/a - Not Recovered/Not Resolved - Disabling),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014524029&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014524035,Spontaneous,2023-01-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Thrombosis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014524035&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014524200,Spontaneous,2023-01-31 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Urticaria (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014524200&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014524595,Spontaneous,2023-01-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Neck pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Photophobia (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014524595&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014525546,Spontaneous,2023-01-31 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Dyspnoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Muscular weakness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[AZELASTINE HYDROCHLORIDE, FLUTICASONE PROPIONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE, BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FEXOFENADINE, FEXOFENADINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014525546&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014525718,Spontaneous,2023-01-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Gait disturbance (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014525718&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014526189,Spontaneous,2023-01-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Rash (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014526189&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014526221,Spontaneous,2023-01-31 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Urticaria chronic (n/a - Not Recovered/Not Resolved - Disabling),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])","[ATORVASTATIN] (C - Hypercholesterolaemia - n/a - [n/a - n/a - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (C - Influenza immunisation - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[LERCANIDIPINE, LERCANIDIPINE HYDROCHLORIDE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[METOPROLOL SUCCINATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[WARFARIN, WARFARIN SODIUM, WARFARIN SODIUM BP] (C - Anticoagulant therapy - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014526221&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014526231,Spontaneous,2023-01-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Ageusia (90d - Recovered/Resolved - ),<BR><BR>Asthma (19d - Recovered/Resolved - ),<BR><BR>Diarrhoea (93d - Recovered/Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014526231&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014526289,Spontaneous,2023-01-31 00:00:00,Healthcare Professional,European Economic Area,Not available,12-17 Years,Adolescent,No,Female,Urticaria chronic (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014526289&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014509752,Spontaneous,2023-01-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chest pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myocarditis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pericarditis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014509752&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014510370,Spontaneous,2023-01-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,Heavy menstrual bleeding (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>VOEDINGSSUPPLEMENT [NOT AVAILABLE] (S - Post-acute COVID-19 syndrome - Drug withdrawn - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014510370&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014510947,Spontaneous,2023-01-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,Herpes zoster (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014510947&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014512253,Spontaneous,2023-01-30 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Blepharospasm (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Condition aggravated (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Eye pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hypoaesthesia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Inflammation (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Intervertebral disc degeneration (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Muscle spasms (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Muscular weakness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Musculoskeletal pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Radiculopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Sensory disturbance (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Spinal pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vertebral foraminal stenosis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM TRIHYDRATE, ESOMEPRAZOLE SODIUM] (C - n/a - n/a - [4y - n/a - n/a]),<BR><BR>[ESTRADIOL] (C - Menopause - n/a - [3y - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014512253&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014512521,Spontaneous,2023-01-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Heavy menstrual bleeding (n/a - Not Recovered/Not Resolved - ),<BR><BR>Intermenstrual bleeding (n/a - Not Recovered/Not Resolved - ),<BR><BR>Polymenorrhoea (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224)] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014512521&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014513164,Spontaneous,2023-01-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Gingivitis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>IBUPROFEN [IBUPROFEN, IBUPROFEN SODIUM] (C - Endodontic procedure - n/a - [4d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Endodontic procedure - n/a - [4d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014513164&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014513709,Spontaneous,2023-01-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Axillary pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014513709&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014513965,Spontaneous,2023-01-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Heavy menstrual bleeding (n/a - Recovering/Resolving - ),<BR><BR>Polymenorrhoea (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014513965&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014514818,Spontaneous,2023-01-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Dyspnoea (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014514818&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014514844,Spontaneous,2023-01-30 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Myalgia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Skin texture abnormal (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Vaccination site discolouration (n/a - Not Recovered/Not Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014514844&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014514846,Spontaneous,2023-01-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Muscular weakness (n/a - Recovered/Resolved With Sequelae - Disabling),<BR><BR>Myalgia (94d - Recovered/Resolved With Sequelae - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014514846&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014516235,Spontaneous,2023-01-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Ageusia (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Balance disorder (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Ear discomfort (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Inappropriate schedule of product administration (n/a - Unknown - ),<BR><BR>Loss of personal independence in daily activities (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Nasal congestion (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Nasopharyngitis (8d - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Vision blurred (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014516235&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014516971,Spontaneous,2023-01-30 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Burning sensation (n/a - Unknown - ),<BR><BR>Herpes zoster (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - Influenza immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014516971&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014516993,Spontaneous,2023-01-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Influenza (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pneumonia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014516993&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014506536,Spontaneous,2023-01-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash erythematous (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site erythema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site induration (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[ATENOLOL, ATENOLOL BP] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014506536&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014508807,Spontaneous,2023-01-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Rash (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rash pruritic (n/a - Unknown - Other Medically Important Condition),<BR><BR>Skin reaction (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014508807&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014508847,Spontaneous,2023-01-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Autonomic nervous system imbalance (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Condition aggravated (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>PREGABALIN [PREGABALIN] (C - Neuralgia - n/a - [n/a - n/a - n/a]),<BR><BR>[CODEINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MIDODRINE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014508847&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014508937,Spontaneous,2023-01-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Abdominal pain upper (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID] (C - Cerebrovascular accident - n/a - [n/a - n/a - n/a]),<BR><BR>[ANHYDROUS LEVOTHYROXINE SODIUM] (C - Thyroid disorder - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014508937&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014508952,Spontaneous,2023-01-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Asthenia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Decreased appetite (4d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Dyspnoea (1d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Fatigue (5d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Headache (2d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Myalgia (6d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Nausea (4d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Palpitations (1d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pyrexia (2d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID] (C - Cardiac disorder - n/a - [n/a - 75mg - n/a]),<BR><BR>[BISOPROLOL FUMARATE] (C - Cardiac disorder - n/a - [n/a - 1.25mg - n/a]),<BR><BR>[RAMIPRIL] (C - Cardiac disorder - n/a - [n/a - 1.25mg - n/a]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - Cardiac disorder - n/a - [n/a - 20mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014508952&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014508959,Spontaneous,2023-01-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myocardial infarction (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014508959&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014508961,Spontaneous,2023-01-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pharyngeal swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Skin sensitisation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[FEXOFENADINE, FEXOFENADINE HYDROCHLORIDE] (C - Mast cell activation syndrome - n/a - [n/a - n/a - n/a]),<BR><BR>[KETOTIFEN, KETOTIFEN HYDROGEN FUMARATE] (C - Mast cell activation syndrome - n/a - [n/a - n/a - n/a]),<BR><BR>[MONTELUKAST, MONTELUKAST SODIUM] (C - Mast cell activation syndrome - n/a - [n/a - n/a - n/a]),<BR><BR>[SODIUM CROMOGLICATE] (C - Mast cell activation syndrome - n/a - [n/a - n/a - n/a]),<BR><BR>[VALACICLOVIR] (C - Herpes simplex - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014508961&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014508964,Spontaneous,2023-01-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Facial pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Swelling face (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Toothache (5d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (S - Immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014508964&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014509431,Spontaneous,2023-01-29 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Hepatocellular injury (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - .3mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014509431&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014506159,Spontaneous,2023-01-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Foetal death (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Maternal exposure during pregnancy (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014506159&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014506183,Spontaneous,2023-01-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,Menstruation delayed (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014506183&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014507530,Spontaneous,2023-01-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Vaccination site lymphadenopathy (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014507530&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014507537,Spontaneous,2023-01-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014507537&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014508060,Spontaneous,2023-01-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Joint range of motion decreased (n/a - Unknown - Disabling),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014508060&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014499250,Spontaneous,2023-01-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Bone pain (n/a - Unknown - ),<BR><BR>Cough (n/a - Unknown - ),<BR><BR>Decreased appetite (n/a - Unknown - ),<BR><BR>Dizziness (n/a - Unknown - ),<BR><BR>Headache (n/a - Unknown - ),<BR><BR>Interchange of vaccine products (n/a - Unknown - ),<BR><BR>Ligament pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Micturition urgency (n/a - Unknown - ),<BR><BR>Mobility decreased (n/a - Unknown - ),<BR><BR>Nasal discharge discolouration (n/a - Unknown - ),<BR><BR>Oedema peripheral (n/a - Unknown - ),<BR><BR>Off label use (n/a - Unknown - ),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Peripheral swelling (n/a - Unknown - ),<BR><BR>Rhinorrhoea (n/a - Unknown - ),<BR><BR>Skin burning sensation (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224)] (S - Immunisation - Not applicable - [1d - .5mL - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014499250&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014502770,Spontaneous,2023-01-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Thrombosis (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014502770&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014503018,Spontaneous,2023-01-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Hypertensive crisis (n/a - Not Recovered/Not Resolved - Life Threatening),<BR><BR>Pallor (n/a - Not Recovered/Not Resolved - ),<BR><BR>Tremor (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014503018&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014504018,Spontaneous,2023-01-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Influenza like illness (2d - Recovered/Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])","[D,L-LYSINE ACETYLSALICYLATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[POTASSIUM, SODIUM, MACROGOL 3350, CHLORIDE ION, HYDROGEN CARBONATE, SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014504018&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014505499,Spontaneous,2023-01-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Polymyalgia rheumatica (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014505499&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014506398,Spontaneous,2023-01-27 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Myalgia (2wk - Unknown - Disabling),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014506398&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014492878,Spontaneous,2023-01-26 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,Laryngeal oedema (0d - Recovered/Resolved - Life Threatening),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014492878&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014492975,Spontaneous,2023-01-26 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Blister (76d - Recovered/Resolved - ),<BR><BR>Pruritus (76d - Recovered/Resolved - ),<BR><BR>Rash (76d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014492975&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014493356,Spontaneous,2023-01-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Pallor (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash macular (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash pruritic (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Urticaria (n/a - Unknown - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014493356&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014494568,Spontaneous,2023-01-26 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Male,Myalgia (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",[BACLOFEN] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014494568&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014494578,Spontaneous,2023-01-26 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Abdominal discomfort (n/a - Not Recovered/Not Resolved - ),<BR><BR>Polyuria (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014494578&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014494957,Spontaneous,2023-01-26 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Groin pain (20h - Recovered/Resolved - ),<BR><BR>Headache (5h - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Recovered/Resolved - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014494957&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014495344,Spontaneous,2023-01-26 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,Bacterial vaginosis (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[SELENIUM SULFIDE] (S - Tinea versicolour - Not applicable - [1wk - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014495344&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014496530,Spontaneous,2023-01-26 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Arthralgia (3d - Recovered/Resolved - ),<BR><BR>Breast inflammation (n/a - Recovering/Resolving - ),<BR><BR>Injection site erythema (4d - Recovered/Resolved - ),<BR><BR>Injection site inflammation (4d - Recovered/Resolved - ),<BR><BR>Injection site swelling (4d - Recovered/Resolved - ),<BR><BR>Lactation insufficiency (4d - Recovered/Resolved - ),<BR><BR>Malaise (3wk - Recovered/Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (1d - Recovered/Resolved - ),<BR><BR>Pyrexia (3d - Recovered/Resolved - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014496530&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014498149,Spontaneous,2023-01-26 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Pain in extremity (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])","[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CITALOPRAM HYDROBROMIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014498149&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014498173,Spontaneous,2023-01-26 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Paraesthesia (n/a - Recovered/Resolved - ),<BR><BR>Sinus congestion (n/a - Recovered/Resolved - ),<BR><BR>Sinusitis (n/a - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014498173&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014485930,Spontaneous,2023-01-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Male,Lip swelling (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014485930&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014485933,Spontaneous,2023-01-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Headache (1d - Recovered/Resolved - ),<BR><BR>Malaise (1d - Recovered/Resolved - ),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",[LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014485933&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014486355,Spontaneous,2023-01-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Contusion (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Hypertension (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Limb discomfort (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Unknown]),<BR><BR>SPIKEVAX [ELASOMERAN] (S - COVID-19 prophylaxis - Unknown - [n/a - 1{DF} - Unknown])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014486355&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014489216,Spontaneous,2023-01-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Heavy menstrual bleeding (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014489216&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014489332,Spontaneous,2023-01-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Cerebral venous thrombosis (n/a - Unknown - Life Threatening, Disabling, Other Medically Important Condition),<BR><BR>Dysarthria (n/a - Unknown - Life Threatening, Disabling, Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Life Threatening, Disabling, Other Medically Important Condition),<BR><BR>Muscular weakness (n/a - Unknown - Life Threatening, Disabling, Other Medically Important Condition),<BR><BR>Neck pain (n/a - Unknown - Life Threatening, Disabling, Other Medically Important Condition),<BR><BR>Presyncope (n/a - Unknown - Life Threatening, Disabling, Other Medically Important Condition),<BR><BR>Sensation of blood flow (n/a - Unknown - Life Threatening, Disabling, Other Medically Important Condition),<BR><BR>Sensory loss (n/a - Not Recovered/Not Resolved - Life Threatening, Disabling, Other Medically Important Condition),<BR><BR>Thrombosis (n/a - Recovering/Resolving - Life Threatening, Disabling, Other Medically Important Condition),<BR><BR>Transient ischaemic attack (n/a - Unknown - Life Threatening, Disabling, Other Medically Important Condition),<BR><BR>Vascular pain (n/a - Unknown - Life Threatening, Disabling, Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Headache - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014489332&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014490526,Spontaneous,2023-01-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Cerebral thrombosis (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - Influenza immunisation - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[PREDNISOLONE] (C - Polymyalgia rheumatica - n/a - [n/a - 12.5mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014490526&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014490539,Spontaneous,2023-01-25 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Paraesthesia (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014490539&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014490562,Spontaneous,2023-01-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Rash (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014490562&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014490587,Spontaneous,2023-01-25 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Rash (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])","INFLIXIMAB [INFLIXIMAB] (C - Rheumatoid arthritis - n/a - [n/a - n/a - n/a]),<BR><BR>NOVORAPID [INSULIN ASPART] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>SEMGLEE [INSULIN GLARGINE] (C - Diabetes mellitus - n/a - [n/a - n/a - Subcutaneous use]),<BR><BR>ZESSLY [INFLIXIMAB] (C - Rheumatoid arthritis - n/a - [n/a - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID, ACETYLSALICYLIC ACID, MAGNESIUM OXIDE] (C - Thrombosis prophylaxis - n/a - [n/a - n/a - Oral use]),<BR><BR>[ANHYDROUS LEVOTHYROXINE SODIUM, LEVOTHYROXINE, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS EP] (C - Hypometabolism - n/a - [n/a - n/a - Oral use]),<BR><BR>[CHLORAMPHENICOL] (C - Eye infection - n/a - [n/a - n/a - Subconjunctival use]),<BR><BR>[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - Hormone therapy - n/a - [n/a - n/a - Vaginal use]),<BR><BR>[FUROSEMIDE, FUROSEMIDE SODIUM] (C - Diuretic therapy - n/a - [n/a - n/a - Oral use]),<BR><BR>[GABAPENTIN] (C - Pain - n/a - [n/a - n/a - Oral use]),<BR><BR>[IBUPROFEN] (C - Pain - n/a - [n/a - n/a - Oral use]),<BR><BR>[LOSARTAN POTASSIUM] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[METFORMIN HYDROCHLORIDE] (C - Diabetes mellitus - n/a - [n/a - n/a - Oral use]),<BR><BR>[METOPROLOL, METOPROLOL SUCCINATE, METOPROLOL TARTRATE] (C - Heart rate irregular - n/a - [n/a - n/a - Oral use]),<BR><BR>[PANTOPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - Oral use]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - Oral use]),<BR><BR>[POTASSIUM CHLORIDE] (C - Mineral supplementation - n/a - [n/a - n/a - Oral use]),<BR><BR>[SIMVASTATIN] (C - Thrombosis prophylaxis - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014490587&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014475650,Spontaneous,2023-01-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Headache (n/a - Recovering/Resolving - ),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - .3mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014475650&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014476667,Spontaneous,2023-01-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Deep vein thrombosis (n/a - Unknown - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014476667&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014477025,Spontaneous,2023-01-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Male,Vitreous floaters (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014477025&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014477026,Spontaneous,2023-01-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Chills (8h - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (12h - Recovered/Resolved - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Vomiting (12h - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014477026&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014477215,Spontaneous,2023-01-24 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Eating disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Unknown])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014477215&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014477597,Spontaneous,2023-01-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Male,"Cough (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (1d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014477597&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014477599,Spontaneous,2023-01-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Decreased appetite (n/a - Recovering/Resolving - ),<BR><BR>Palpitations (n/a - Recovering/Resolving - ),<BR><BR>Restlessness (n/a - Recovering/Resolving - ),<BR><BR>Stress (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014477599&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014477609,Spontaneous,2023-01-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Female,Chronic obstructive pulmonary disease (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014477609&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014480355,Spontaneous,2023-01-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Menstruation delayed (40d - Recovered/Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014480355&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014480447,Spontaneous,2023-01-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Asthenia (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Balance disorder (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Delirium (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Eructation (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Feeding disorder (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Muscular weakness (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Retching (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Tinnitus (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Unknown])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014480447&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014481305,Spontaneous,2023-01-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Syncope (n/a - Recovered/Resolved - Life Threatening),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - Life Threatening)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014481305&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014482441,Spontaneous,2023-01-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chest pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Food aversion (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Insomnia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site pain (2d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014482441&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014482472,Spontaneous,2023-01-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Hypoacusis (n/a - Not Recovered/Not Resolved - ),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014482472&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014482524,Spontaneous,2023-01-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Arthritis reactive (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014482524&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014482541,Spontaneous,2023-01-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Urticaria (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014482541&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014482578,Spontaneous,2023-01-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Tinnitus (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014482578&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014482586,Spontaneous,2023-01-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Dizziness (n/a - Recovering/Resolving - ),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - ),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - ),<BR><BR>Presyncope (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014482586&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014482589,Spontaneous,2023-01-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Abdominal pain upper (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Syncope (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014482589&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014482591,Spontaneous,2023-01-24 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Rash pruritic (n/a - Not Recovered/Not Resolved - ),<BR><BR>Salivary hypersecretion (n/a - Not Recovered/Not Resolved - ),<BR><BR>Sneezing (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","XARELTO [RIVAROXABAN] (C - Thrombosis prophylaxis - n/a - [n/a - n/a - Oral use]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BENDROFLUMETHIAZIDE, POTASSIUM CHLORIDE] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[BUDESONIDE] (C - Asthma - n/a - [133d - n/a - Inhalation use]),<BR><BR>[CETIRIZINE, CETIRIZINE DIHYDROCHLORIDE] (C - Urticaria - n/a - [n/a - n/a - Oral use]),<BR><BR>[KETOCONAZOLE, KETOCONAZOLE PH. EUR.] (C - Dandruff - n/a - [890d - n/a - Cutaneous use]),<BR><BR>[KETOTIFEN, KETOTIFEN HYDROGEN FUMARATE] (C - Rhinitis allergic - n/a - [n/a - n/a - Ocular use]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[MECILLINAM, PIVMECILLINAM, PIVMECILLINAM HYDROCHLORIDE] (C - Prophylaxis urinary tract infection - n/a - [337d - n/a - Oral use]),<BR><BR>[METOPROLOL TARTRATE] (C - Heart rate irregular - n/a - [n/a - n/a - Oral use]),<BR><BR>[METRONIDAZOLE] (C - Rosacea - n/a - [n/a - n/a - Cutaneous use]),<BR><BR>[MICONAZOLE NITRATE, HYDROCORTISONE] (C - n/a - n/a - [n/a - n/a - Cutaneous use]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - Oral use]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - Bronchospasm - n/a - [147d - n/a - Subcutaneous use]),<BR><BR>[TERBINAFINE, TERBINAFINE HYDROCHLORIDE] (C - Fungal infection - n/a - [n/a - n/a - Cutaneous use]),<BR><BR>[VITAMIN D, CALCIUM] (C - Calcium deficiency - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014482591&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014482611,Spontaneous,2023-01-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - ),<BR><BR>Vomiting (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014482611&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014482922,Spontaneous,2023-01-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fear (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Illness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Sinus disorder (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vomiting (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (S - Immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014482922&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014483201,Spontaneous,2023-01-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Heavy menstrual bleeding (n/a - Not Recovered/Not Resolved - ),<BR><BR>Polymenorrhoea (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014483201&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014468650,Spontaneous,2023-01-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Urinary retention (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (8d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Unknown]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [1d - n/a - Unknown])","[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - Dose not changed - [n/a - n/a - Unknown]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - Dose not changed - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014468650&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014469085,Spontaneous,2023-01-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"Constipation (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Injection related reaction (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (S - Immunisation - Not applicable - [1d - n/a - n/a])","LEFLUNOMIDE [LEFLUNOMIDE] (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[DIHYDROCODEINE TARTRATE, PARACETAMOL, PARACETAMOL BP, DIHYDROCODEINE TARTRATE BP, PARACETAMOL, DIHYDROCODEINE TARTRATE BP] (C - n/a - Dose not changed - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014469085&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014470862,Spontaneous,2023-01-23 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Pain in extremity (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014470862&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014471601,Spontaneous,2023-01-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Immune system disorder (n/a - Not Recovered/Not Resolved - ),<BR><BR>Sciatica (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014471601&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014472776,Spontaneous,2023-01-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Somnolence (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014472776&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014472939,Spontaneous,2023-01-23 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Death (0d - Fatal - Results in Death),<BR><BR>Dysphagia (0d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Epilepsy (0d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Hypotonia (0d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Postictal state (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Sopor (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Tremor (0d - Recovered/Resolved - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - Immunisation - Not applicable - [n/a - .3mL - Intramuscular use])","[BISACODYL] (C - Constipation - Not applicable - [n/a - 10mg - Oral use]),<BR><BR>[DROTAVERINE HYDROCHLORIDE] (C - Urine output decreased - Unknown - [n/a - 80mg - Oral use]),<BR><BR>[FUROSEMIDE] (C - n/a - Unknown - [n/a - 40mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014472939&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014473682,Spontaneous,2023-01-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,"Erythema (n/a - Recovered/Resolved With Sequelae - ),<BR><BR>Eye inflammation (n/a - Recovered/Resolved With Sequelae - ),<BR><BR>Vision blurred (n/a - Recovered/Resolved With Sequelae - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014473682&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014474719,Spontaneous,2023-01-23 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Urticaria (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014474719&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014474723,Spontaneous,2023-01-23 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Urticaria (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[ALGELDRATE, ALGELDRATE, TICK-BORNE ENCEPHALITIS VIRUS (INACTIVATED), NEUDOERFL STRAIN, ALUMINIUM, TICK-BORNE ENCEPHALITIS VIRUS (INACTIVATED), NEUDOERFL STRAIN, ALUMINIUM, TICK-BORNE ENCEPHALITIS VIRUS NEUDOERFL STRAIN ADSORBED ON ALUMINIUM HYDROXIDE, HYDRATED PRODUCED IN CHICK EMBRYO CELLS, TICK-BORNE ENCEPHALITIS VIRUS (INACTIVATED), TICK-BORNE ENCEPHALITIS VIRUS (INACTIVATED), NEUDOERFL STRAIN, TICK-BORNE ENCEPHALITIS VIRUS NEUDOERFL STRAIN ADSORBED ON ALUMINIUM HYDROXIDE, HYDRATED PRODUCED IN CHICK EMBRYO CELLS, ALGELDRATE, TICK-BORNE ENCEPHALITIS VIRUS, ALGELDRATE] (C - Immunisation - n/a - [n/a - n/a - Intramuscular use]),<BR><BR>[CHLORAMPHENICOL] (C - Eye infection - n/a - [n/a - n/a - Subconjunctival use]),<BR><BR>[DOCUSATE SODIUM, SORBITOL (E420)] (C - n/a - n/a - [n/a - n/a - Rectal use]),<BR><BR>[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - Hormone therapy - n/a - [n/a - n/a - Vaginal use]),<BR><BR>[MOMETASONE FUROATE] (C - Nasal polyps - n/a - [n/a - n/a - Nasal use]),<BR><BR>[VITAMIN D, CALCIUM] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014474723&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014474748,Spontaneous,2023-01-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Groin pain (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - ),<BR><BR>Musculoskeletal discomfort (n/a - Recovering/Resolving - ),<BR><BR>Musculoskeletal stiffness (n/a - Recovering/Resolving - ),<BR><BR>Neck pain (n/a - Recovering/Resolving - ),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - ),<BR><BR>Restlessness (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014474748&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014474803,Spontaneous,2023-01-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Recovered/Resolved - ),<BR><BR>Blister (n/a - Not Recovered/Not Resolved - ),<BR><BR>Rash (n/a - Not Recovered/Not Resolved - ),<BR><BR>Skin fissures (n/a - Not Recovered/Not Resolved - ),<BR><BR>Swelling of eyelid (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - Influenza immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014474803&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014467382,Spontaneous,2023-01-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chills (2d - Recovered/Resolved - ),<BR><BR>Fatigue (3d - Recovered/Resolved - ),<BR><BR>Headache (3d - Recovered/Resolved - ),<BR><BR>Malaise (3d - Recovered/Resolved - ),<BR><BR>Myalgia (2d - Recovered/Resolved - ),<BR><BR>Nausea (1d - Recovered/Resolved - ),<BR><BR>Pyrexia (2d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014467382&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014464844,Spontaneous,2023-01-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Male,Feeling cold (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014464844&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014464878,Spontaneous,2023-01-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Intermenstrual bleeding (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014464878&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014466000,Spontaneous,2023-01-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adolescent,No,Male,Syncope (75min - Recovered/Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014466000&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014466237,Spontaneous,2023-01-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (3d - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (3d - Recovered/Resolved With Sequelae - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - .3mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014466237&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014457852,Spontaneous,2023-01-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Cheilitis (n/a - Not Recovered/Not Resolved - ),<BR><BR>Eye irritation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Lip swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Skin exfoliation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Stomatitis (n/a - Not Recovered/Not Resolved - ),<BR><BR>Tachycardia (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [n/a - n/a - Intramuscular use])","ESOMEPRAZOLE [ESOMEPRAZOLE] (C - n/a - n/a - ),<BR><BR>[BUDESONIDE, FORMOTEROL FUMARATE DIHYDRATE, FORMOTEROL FUMARATE, BUDESONIDE] (C - n/a - n/a - )","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014457852&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014457907,Spontaneous,2023-01-20 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Bell's palsy (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - Intramuscular use])","APROVEL [IRBESARTAN] (C - n/a - n/a - ),<BR><BR>COAPROVEL [HYDROCHLOROTHIAZIDE, IRBESARTAN] (C - n/a - n/a - ),<BR><BR>LYRICA [PREGABALIN] (C - n/a - n/a - ),<BR><BR>[ACETYLSALICYLIC ACID, ACETYLSALICYLIC ACID, ALUMINIUM HYDROXIDE GEL, MAGNESIUM HYDROXIDE, ACETYLSALICYLIC ACID, MAGNESIUM HYDROXIDE, ALGELDRATE, ALUMINIUM OXIDE, HYDRATED, ACETYLSALICYLIC ACID, MAGNESIUM HYDROXIDE] (C - n/a - n/a - ),<BR><BR>[ALPRAZOLAM] (C - n/a - n/a - ),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE] (C - n/a - n/a - ),<BR><BR>[ATENOLOL, ATENOLOL HYDROCHLORIDE, ATENOLOL PH. EUR.] (C - n/a - n/a - ),<BR><BR>[ATORVASTATIN, EZETIMIBE] (C - n/a - n/a - ),<BR><BR>[DOXAZOSIN, DOXAZOSIN MESILATE] (C - n/a - n/a - ),<BR><BR>[LEVOTHYROXINE SODIUM] (C - n/a - n/a - )","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014457907&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014458085,Spontaneous,2023-01-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[TOZINAMERAN NOS] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014458085&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014458183,Spontaneous,2023-01-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Arthritis (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - Hypercholesterolaemia - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014458183&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014460265,Spontaneous,2023-01-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Injection site haematoma (5d - Recovered/Resolved - ),<BR><BR>Vaccination site lymphadenopathy (5d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014460265&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014462722,Spontaneous,2023-01-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Intermenstrual bleeding (n/a - Recovered/Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014462722&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014462725,Spontaneous,2023-01-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Female,Urticaria (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014462725&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014462947,Spontaneous,2023-01-20 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Vaccination failure (n/a - Unknown - ),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 DISPERSION FOR INJECTION (15/15 MICROGRAMS)/DOSE [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014462947&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014463008,Spontaneous,2023-01-20 00:00:00,Healthcare Professional,European Economic Area,Not available,12-17 Years,Child,No,Male,Wrong product administered (n/a - Recovered/Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014463008&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014463219,Spontaneous,2023-01-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Myalgia (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>IBUPROFEN [IBUPROFEN, IBUPROFEN SODIUM] (C - Headache - n/a - [n/a - n/a - n/a]),<BR><BR>[DYDROGESTERONE, ESTRADIOL, DYDROGESTERONE, ESTRADIOL HEMIHYDRATE] (C - Hormone replacement therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation, Prophylaxis - n/a - [1d - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Analgesic therapy - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014463219&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014464921,Spontaneous,2023-01-20 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Heavy menstrual bleeding (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014464921&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014465101,Spontaneous,2023-01-20 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Malaise (n/a - Unknown - ),<BR><BR>Myalgia (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - n/a - n/a - [n/a - n/a - n/a])",[FLUVOXAMINE] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014465101&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014465455,Spontaneous,2023-01-20 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,Herpes zoster (8d - Recovered/Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","TRAJENTA [LINAGLIPTIN] (C - Type 2 diabetes mellitus - n/a - [n/a - n/a - Oral use]),<BR><BR>[BUDESONIDE, FORMOTEROL FUMARATE DIHYDRATE, FORMOTEROL FUMARATE, BUDESONIDE] (C - Asthma - n/a - [n/a - n/a - Inhalation use]),<BR><BR>[BUPRENORPHINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FUROSEMIDE, FUROSEMIDE SODIUM] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[OXYCODONE HYDROCHLORIDE] (C - Pain - n/a - [n/a - n/a - Oral use]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - Oral use]),<BR><BR>[POTASSIUM CHLORIDE] (C - Mineral supplementation - n/a - [n/a - n/a - Oral use]),<BR><BR>[POTASSIUM, SODIUM, MACROGOL 3350, CHLORIDE ION, HYDROGEN CARBONATE, SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (C - Constipation - n/a - [n/a - n/a - Oral use]),<BR><BR>[SODIUM PICOSULFATE] (C - Constipation - n/a - [n/a - n/a - Oral use]),<BR><BR>[TERBUTALINE SULFATE] (C - Bronchospasm - n/a - [n/a - n/a - Inhalation use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014465455&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014465458,Spontaneous,2023-01-20 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,Influenza (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","ULTIBRO BREEZHALER [GLYCOPYRRONIUM BROMIDE, INDACATEROL MALEATE] (C - n/a - n/a - [n/a - n/a - Inhalation use]),<BR><BR>XARELTO [RIVAROXABAN] (C - Thrombosis prophylaxis - n/a - [n/a - n/a - Oral use]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[FUROSEMIDE, FUROSEMIDE SODIUM] (C - Diuretic therapy - n/a - [n/a - n/a - Oral use]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - Bronchospasm - n/a - [n/a - n/a - Inhalation use]),<BR><BR>[SPIRONOLACTONE] (C - Diuretic therapy - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014465458&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014465477,Spontaneous,2023-01-20 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Cutaneous vasculitis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Haematuria (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Proteinuria (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - Influenza immunisation - n/a - [n/a - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014465477&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014465517,Spontaneous,2023-01-20 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Immune thrombocytopenia (n/a - Unknown - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014465517&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014465525,Spontaneous,2023-01-20 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,"Abdominal pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[FEXOFENADINE, FEXOFENADINE HYDROCHLORIDE] (C - Urticaria - n/a - [n/a - n/a - Oral use]),<BR><BR>[FORMOTEROL FUMARATE DIHYDRATE] (C - Asthma - n/a - [n/a - n/a - Inhalation use]),<BR><BR>[HYDROCORTISONE BUTYRATE] (C - Skin disorder - n/a - [n/a - n/a - Cutaneous use]),<BR><BR>[MECILLINAM, PIVMECILLINAM, PIVMECILLINAM HYDROCHLORIDE] (C - Cystitis - n/a - [n/a - n/a - Oral use]),<BR><BR>[METOPROLOL TARTRATE] (C - Heart rate irregular - n/a - [n/a - n/a - Oral use]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - Oral use]),<BR><BR>[VITAMIN D, CALCIUM] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[VITAMINS NOS] (C - Vitamin supplementation - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014465525&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014465561,Spontaneous,2023-01-20 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"C-reactive protein increased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - Hormone therapy - n/a - [n/a - n/a - Vaginal use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014465561&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014465641,Spontaneous,2023-01-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (1d - Recovered/Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (1d - Recovered/Resolved - ),<BR><BR>Pyrexia (2d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014465641&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014465748,Spontaneous,2023-01-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Lymphadenopathy (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","OZEMPIC [SEMAGLUTIDE] (C - Overweight - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN HYDROCHLORIDE] (C - Polycystic ovarian syndrome - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014465748&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014465775,Spontaneous,2023-01-20 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Meniere's disease (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])","[ANHYDROUS LEVOTHYROXINE SODIUM, LEVOTHYROXINE, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS EP] (C - Hypometabolism - n/a - [n/a - 200ug - Oral use]),<BR><BR>[BETAHISTINE DIHYDROCHLORIDE, BETAHISTINE HYDROCHLORIDE] (C - Meniere's disease - n/a - [n/a - n/a - Oral use]),<BR><BR>[LERCANIDIPINE HYDROCHLORIDE] (C - Hypertension - n/a - [n/a - 10mg - Oral use]),<BR><BR>[LOSARTAN POTASSIUM] (C - Hypertension - n/a - [n/a - 100mg - Oral use]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - 1000mg - Oral use]),<BR><BR>[TRIMETAZIDINE, TRIMETAZIDINE DIHYDROCHLORIDE] (C - Meniere's disease - n/a - [n/a - 20mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014465775&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014465777,Spontaneous,2023-01-20 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Rash pruritic (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (C - n/a - n/a - [1d - n/a - n/a]),<BR><BR>[PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 4, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6B, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9V, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 14, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 18C, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 33F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 22F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 20, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19A, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 17F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 15B, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 12F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 11A, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9N, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 7F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 5, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 3, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 2, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 1, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 10A, PNEUMOCOCCAL POLYSACCHARIDE VACCINE (23 VALENT)] (C - n/a - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014465777&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014450734,Spontaneous,2023-01-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chest pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Decreased appetite (8d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Ear pain (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Increased viscosity of upper respiratory secretion (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Lower respiratory tract infection (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Photophobia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Rash (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[ENALAPRIL, ENALAPRIL MALEATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[PROPRANOLOL, PROPRANOLOL HYDROCHLORIDE] (C - Anxiety - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014450734&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014451504,Spontaneous,2023-01-19 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Male,"Diarrhoea (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014451504&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014451797,Spontaneous,2023-01-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Headache (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014451797&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014451960,Spontaneous,2023-01-19 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Female,"Alopecia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Sexual dysfunction (n/a - Not Recovered/Not Resolved - ),<BR><BR>Tinnitus (n/a - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014451960&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014451961,Spontaneous,2023-01-19 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Cough (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>General physical health deterioration (n/a - Not Recovered/Not Resolved - ),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014451961&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014452554,Spontaneous,2023-01-19 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Male,"Drug interaction (4h - Unknown - ),<BR><BR>Hypoglycaemia (4h - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>NOVORAPID FLEXPEN 100 U/ML SOLUTION FOR INJECTION IN PRE-FILLED PEN [INSULIN ASPART] (S - Diabetes mellitus - Dose reduced - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014452554&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014453436,Spontaneous,2023-01-19 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Male,"Abdominal pain upper (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (4h - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014453436&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014453788,Spontaneous,2023-01-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Anxiety (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dysphonia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Flushing (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Heart rate increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","IBUPROFEN [IBUPROFEN, IBUPROFEN SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[CETIRIZINE, CETIRIZINE DIHYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CODEINE PHOSPHATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LAMOTRIGINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014453788&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014453905,Spontaneous,2023-01-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Anxiety (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Depression (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Insomnia (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Nightmare (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Panic attack (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Post-traumatic stress disorder (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Sleep terror (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Suicidal ideation (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (S - Influenza immunisation - Not applicable - [1d - n/a - n/a])","ABASAGLAR [INSULIN GLARGINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>DULOXETINE [DULOXETINE, DULOXETINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>DUORESP SPIROMAX [BUDESONIDE, FORMOTEROL FUMARATE DIHYDRATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>NOVORAPID [INSULIN ASPART] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>PIOGLITAZONE [PIOGLITAZONE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MONTELUKAST, MONTELUKAST SODIUM] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[NORTRIPTYLINE, NORTRIPTYLINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PROMETHAZINE, PROMETHAZINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[QUETIAPINE, QUETIAPINE FUMARATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014453905&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014453933,Spontaneous,2023-01-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Insomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymph node pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014453933&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014453935,Spontaneous,2023-01-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>SPIKEVAX [ELASOMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014453935&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014454057,Spontaneous,2023-01-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Urticaria (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[NAPROXEN, NAPROXEN SODIUM] (C - Arthritis - n/a - [76d - n/a - n/a]),<BR><BR>[PARACETAMOL, CODEINE PHOSPHATE] (C - Arthralgia - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014454057&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014454374,Spontaneous,2023-01-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Axillary pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014454374&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014454626,Spontaneous,2023-01-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,12-17 Years,Not Specified,No,Male,"Blindness transient (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Ophthalmic migraine (n/a - Unknown - Other Medically Important Condition),<BR><BR>Sight disability (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014454626&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014454718,Spontaneous,2023-01-19 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"COVID-19 immunisation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Cough (n/a - Unknown - Other Medically Important Condition),<BR><BR>Death (0d - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Pulmonary embolism (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>VAXZEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","ELIQUIS 2.5 MG [APIXABAN] (C - n/a - Unknown - [n/a - 2{DF} - n/a]),<BR><BR>[ALLOPURINOL] (C - n/a - Unknown - [n/a - 1{DF} - n/a]),<BR><BR>[COLCHICINE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL, CALCIUM CARBONATE] (C - n/a - Unknown - [n/a - 1{DF} - n/a]),<BR><BR>[COLECALCIFEROL] (C - n/a - Unknown - [n/a - 1{DF} - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - Unknown - [n/a - 3{DF} - n/a]),<BR><BR>[PERINDOPRIL ARGININE] (C - n/a - Unknown - [n/a - .5{DF} - n/a]),<BR><BR>[PRAVASTATIN SODIUM] (C - Hypercholesterolaemia - Unknown - [n/a - .5{DF} - n/a]),<BR><BR>[TRAZODONE HYDROCHLORIDE] (C - n/a - Unknown - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014454718&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014455333,Spontaneous,2023-01-19 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Facial paralysis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - Oral use]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014455333&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014455376,Spontaneous,2023-01-19 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,Alopecia (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014455376&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014455687,Spontaneous,2023-01-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Heart rate decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypertension (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Tinnitus (19d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014455687&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014455856,Spontaneous,2023-01-19 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014455856&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014455871,Spontaneous,2023-01-19 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Dyspnoea exertional (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","AVAMYS [FLUTICASONE FUROATE] (C - Rhinitis allergic - n/a - [n/a - n/a - Nasal use]),<BR><BR>[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - Hormone therapy - n/a - [n/a - n/a - Vaginal use]),<BR><BR>[HYDROCORTISONE ACETATE, POLYMYXIN B SULFATE, OXYTETRACYCLINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[IBUPROFEN] (C - Inflammation - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014455871&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014455876,Spontaneous,2023-01-19 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Dizziness (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014455876&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014455879,Spontaneous,2023-01-19 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BUDESONIDE, FORMOTEROL FUMARATE DIHYDRATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[MOMETASONE FUROATE] (C - Sinusitis - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014455879&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014455881,Spontaneous,2023-01-19 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Rash (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site irritation (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MESILATE MONOHYDRATE] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[IBUPROFEN] (C - Pain - n/a - [n/a - n/a - Oral use]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - Oral use]),<BR><BR>[SULFAMETHIZOLE] (C - Cystitis - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014455881&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014455882,Spontaneous,2023-01-19 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Skin disorder (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[ALENDRONATE SODIUM, ALENDRONATE SODIUM TRIHYDRATE] (C - Osteoporosis - n/a - [n/a - n/a - Oral use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - Hormone therapy - n/a - [n/a - n/a - Vaginal use]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - Oral use]),<BR><BR>[VITAMIN D, CALCIUM] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014455882&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014455888,Spontaneous,2023-01-19 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Diarrhoea (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Vomiting (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014455888&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014455889,Spontaneous,2023-01-19 00:00:00,Non Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,Vomiting (2d - Recovered/Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","PRADAXA [DABIGATRAN ETEXILATE, DABIGATRAN ETEXILATE MESILATE] (C - Anticoagulant therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[MAGNESIUM HYDROXIDE] (C - Constipation - n/a - [n/a - n/a - n/a]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Gastric pH decreased - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - n/a]),<BR><BR>[SERTRALINE] (C - Depression - n/a - [n/a - n/a - n/a]),<BR><BR>[VITAMIN D, CALCIUM] (C - Mineral supplementation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014455889&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014455894,Spontaneous,2023-01-19 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Vomiting (0d - Recovered/Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014455894&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014455910,Spontaneous,2023-01-19 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Axillary pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014455910&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014455922,Spontaneous,2023-01-19 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Diarrhoea (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","CANNABIDIOL [CANNABIDIOL] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>TRIMBOW [BECLOMETASONE DIPROPIONATE, GLYCOPYRRONIUM BROMIDE, FORMOTEROL FUMARATE DIHYDRATE] (C - Chronic obstructive pulmonary disease - n/a - [n/a - n/a - Inhalation use]),<BR><BR>[ALENDRONATE SODIUM, ALENDRONATE SODIUM TRIHYDRATE, ALENDRONIC ACID] (C - Osteoporosis - n/a - [n/a - n/a - Oral use]),<BR><BR>[ALPRAZOLAM] (C - Sedative therapy - n/a - [n/a - n/a - Oral use]),<BR><BR>[AZITHROMYCIN] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[BIFONAZOLE, CLOTRIMAZOLE] (C - Vulvovaginal candidiasis - n/a - [n/a - n/a - Vaginal use]),<BR><BR>[BISACODYL] (C - Constipation - n/a - [n/a - n/a - Oral use]),<BR><BR>[CODEINE] (C - Pain - n/a - [n/a - n/a - Oral use]),<BR><BR>[DOCUSATE SODIUM, SORBITOL (E420)] (C - Constipation - n/a - [n/a - n/a - Rectal use]),<BR><BR>[FUROSEMIDE, FUROSEMIDE SODIUM] (C - Diuretic therapy - n/a - [n/a - n/a - Oral use]),<BR><BR>[MORPHINE SULFATE] (C - Pain - n/a - [n/a - n/a - Oral use]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - Oral use]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - Oral use]),<BR><BR>[POTASSIUM CHLORIDE] (C - Mineral supplementation - n/a - [n/a - n/a - Oral use]),<BR><BR>[PREDNISOLONE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[TERBUTALINE SULFATE] (C - Asthma - n/a - [n/a - n/a - Inhalation use]),<BR><BR>[VITAMIN D, CALCIUM] (C - Calcium deficiency - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014455922&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014455934,Spontaneous,2023-01-19 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Chills (0d - Recovered/Resolved - ),<BR><BR>Tremor (0d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])","[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - Influenza immunisation - n/a - [n/a - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014455934&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014455935,Spontaneous,2023-01-19 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Abdominal pain (n/a - Recovering/Resolving - ),<BR><BR>Bile output abnormal (n/a - Recovering/Resolving - ),<BR><BR>Faeces discoloured (n/a - Recovering/Resolving - ),<BR><BR>Hepatic function abnormal (n/a - Recovering/Resolving - ),<BR><BR>Pruritus (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])","[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014455935&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014455936,Spontaneous,2023-01-19 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Diarrhoea (n/a - Recovering/Resolving - ),<BR><BR>Flatulence (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014455936&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014455941,Spontaneous,2023-01-19 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chest discomfort (n/a - Not Recovered/Not Resolved - ),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - ),<BR><BR>Menstruation irregular (4d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014455941&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014441453,Spontaneous,2023-01-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Erythema (1d - Recovered/Resolved - ),<BR><BR>Injection site erythema (2d - Recovered/Resolved - ),<BR><BR>Injection site pain (2d - Recovered/Resolved - ),<BR><BR>Injection site swelling (2d - Recovered/Resolved - ),<BR><BR>Injection site warmth (2d - Recovered/Resolved - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - .3mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014441453&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014441707,Spontaneous,2023-01-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Product use issue (n/a - Unknown - ),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014441707&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014443471,Spontaneous,2023-01-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,Illness (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014443471&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014444273,Spontaneous,2023-01-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","[PARACETAMOL, CODEINE PHOSPHATE] (C - Back pain - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014444273&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014444874,Spontaneous,2023-01-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site discomfort (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site haematoma (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014444874&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014445030,Spontaneous,2023-01-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014445030&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014445365,Spontaneous,2023-01-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,Injected limb mobility decreased (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014445365&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014445686,Spontaneous,2023-01-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Headache (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014445686&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014446517,Spontaneous,2023-01-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Abdominal pain upper (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Asthenia (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>COVID-19 (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Coeliac disease (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014446517&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014446788,Spontaneous,2023-01-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Axillary mass (n/a - Unknown - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014446788&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014446930,Spontaneous,2023-01-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Bone pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Bone swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymph node pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014446930&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014447243,Spontaneous,2023-01-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Lymphadenopathy (55d - Recovered/Resolved With Sequelae - Life Threatening, Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014447243&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014448444,Spontaneous,2023-01-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Pain in extremity (3d - Recovered/Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014448444&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014448619,Spontaneous,2023-01-18 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Vaccination site mass (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])","[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - Hypercholesterolaemia - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014448619&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014448620,Spontaneous,2023-01-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Dizziness (19d - Recovered/Resolved - ),<BR><BR>Hot flush (n/a - Recovering/Resolving - ),<BR><BR>Nasopharyngitis (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014448620&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014448623,Spontaneous,2023-01-18 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Vaccination site infection (n/a - Recovered/Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014448623&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014448631,Spontaneous,2023-01-18 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Migraine (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","OPATANOL [OLOPATADINE, OLOPATADINE HYDROCHLORIDE] (C - Rhinitis allergic - n/a - [n/a - n/a - Ocular use]),<BR><BR>[ACETYLSALICYLIC ACID, CODEINE PHOSPHATE HEMIHYDRATE, MAGNESIUM OXIDE] (C - Pain - n/a - [n/a - n/a - Oral use]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ELETRIPTAN, ELETRIPTAN HYDROBROMIDE] (C - Migraine - n/a - [n/a - n/a - Oral use]),<BR><BR>[FELODIPINE] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[MOMETASONE FUROATE] (C - Eczema - n/a - [n/a - n/a - Cutaneous use]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Prophylaxis against gastrointestinal ulcer - n/a - [n/a - n/a - Oral use]),<BR><BR>[PNEUMOCOCCAL POLYSACCHARIDE VACCINE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014448631&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014448641,Spontaneous,2023-01-18 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,Facial paresis (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014448641&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014448643,Spontaneous,2023-01-18 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Vaccination site haematoma (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site pain (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])","[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014448643&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014448650,Spontaneous,2023-01-18 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,Wound infection (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","PROLIA [DENOSUMAB] (C - n/a - n/a - [n/a - n/a - Subcutaneous use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CLOBETASOL PROPIONATE] (C - Skin disorder - n/a - [n/a - n/a - Cutaneous use]),<BR><BR>[MAGNESIUM HYDROXIDE, MAGNESIUM OXIDE, MAGNESIUM OXIDE, LIGHT] (C - Constipation - n/a - [n/a - n/a - Oral use]),<BR><BR>[MELATONIN] (C - Insomnia - n/a - [n/a - n/a - Oral use]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - Oral use]),<BR><BR>[TRAMADOL HYDROCHLORIDE] (C - Pain - n/a - [n/a - n/a - Oral use]),<BR><BR>[VITAMIN D, CALCIUM] (C - Calcium deficiency - n/a - [n/a - n/a - Oral use]),<BR><BR>[ZOPICLONE] (C - Insomnia - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014448650&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014448657,Spontaneous,2023-01-18 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Lymphadenopathy (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[ACETYLSALICYLIC ACID, ACETYLSALICYLIC ACID, MAGNESIUM OXIDE] (C - Anticoagulant therapy - n/a - [n/a - n/a - Oral use]),<BR><BR>[ATORVASTATIN] (C - Hypercholesterolaemia - n/a - [n/a - n/a - Oral use]),<BR><BR>[OMEPRAZOLE] (C - Prophylaxis against gastrointestinal ulcer - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014448657&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014448659,Spontaneous,2023-01-18 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Myalgia (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014448659&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014448665,Spontaneous,2023-01-18 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Skin infection (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site warmth (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CHLORAMPHENICOL] (C - Eye infection - n/a - [n/a - n/a - Subconjunctival use]),<BR><BR>[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - Hormone therapy - n/a - [n/a - n/a - Vaginal use]),<BR><BR>[IBUPROFEN] (C - Pain - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014448665&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014448666,Spontaneous,2023-01-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014448666&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014448668,Spontaneous,2023-01-18 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Headache (25d - Recovered/Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014448668&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014448679,Spontaneous,2023-01-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Herpes zoster (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","METHOTREXATE [METHOTREXATE] (C - Rheumatoid arthritis - n/a - [n/a - n/a - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[FOLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[IBUPROFEN] (C - Pain - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014448679&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014448684,Spontaneous,2023-01-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Headache (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014448684&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014448693,Spontaneous,2023-01-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Lymph node pain (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014448693&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014448694,Spontaneous,2023-01-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Herpes zoster (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - Influenza immunisation - n/a - [n/a - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014448694&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014448696,Spontaneous,2023-01-18 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hot flush (n/a - Not Recovered/Not Resolved - ),<BR><BR>Impaired work ability (n/a - Unknown - ),<BR><BR>Musculoskeletal stiffness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Rash erythematous (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BENDROFLUMETHIAZIDE, POTASSIUM CHLORIDE] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[CHLORZOXAZONE] (C - Muscle relaxant therapy - n/a - [n/a - n/a - Oral use]),<BR><BR>[CLOBETASOL PROPIONATE] (C - Skin disorder - n/a - [n/a - n/a - Cutaneous use]),<BR><BR>[ENALAPRIL MALEATE] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[EPINEPHRINE, EPINEPHRINE BITARTRATE] (C - n/a - n/a - [n/a - n/a - Intramuscular use]),<BR><BR>[HYDROCORTISONE ACETATE, POLYMYXIN B SULFATE, OXYTETRACYCLINE] (C - Ear infection - n/a - [n/a - n/a - n/a]),<BR><BR>[HYDROCORTISONE BUTYRATE] (C - Eczema - n/a - [n/a - n/a - Cutaneous use]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - Oral use]),<BR><BR>[PHENOXYMETHYLPENICILLIN, PHENOXYMETHYLPENICILLIN POTASSIUM] (C - Pneumonia - n/a - [n/a - n/a - Oral use]),<BR><BR>[SILDENAFIL] (C - Erectile dysfunction - n/a - [n/a - n/a - Oral use]),<BR><BR>[TRIAMCINOLONE HEXACETONIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014448696&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014448700,Spontaneous,2023-01-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Lymph node pain (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014448700&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014448705,Spontaneous,2023-01-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Dyspnoea (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014448705&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014448714,Spontaneous,2023-01-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Abdominal discomfort (n/a - Not Recovered/Not Resolved - ),<BR><BR>Abdominal pain upper (n/a - Not Recovered/Not Resolved - ),<BR><BR>Back pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vulvovaginal pain (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014448714&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014433311,Spontaneous,2023-01-17 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,Facial paresis (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014433311&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014433935,Spontaneous,2023-01-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Vaccination site erythema (n/a - Recovered/Resolved - ),<BR><BR>Vaccination site induration (n/a - Recovered/Resolved - ),<BR><BR>Vaccination site pain (n/a - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014433935&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014435305,Spontaneous,2023-01-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Headache (n/a - Recovering/Resolving - ),<BR><BR>Rash (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014435305&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014435782,Spontaneous,2023-01-17 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Angioedema (3d - Recovered/Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - .3mL - Intramuscular use - More in ICSR])",[LORATADINE] (C - Rhinitis - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014435782&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014437301,Spontaneous,2023-01-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Recovered/Resolved - ),<BR><BR>Heavy menstrual bleeding (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014437301&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014438196,Spontaneous,2023-01-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Male,Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014438196&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014438442,Spontaneous,2023-01-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Abdominal discomfort (n/a - Unknown - ),<BR><BR>Asthenia (n/a - Unknown - ),<BR><BR>Blood pressure abnormal (n/a - Unknown - ),<BR><BR>Chills (n/a - Unknown - ),<BR><BR>Dizziness (n/a - Unknown - ),<BR><BR>Fatigue (n/a - Unknown - ),<BR><BR>Vaccination site pain (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>SPIKEVAX [ELASOMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014438442&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014438470,Spontaneous,2023-01-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal discomfort (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Back pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Neurological symptom (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Paranasal sinus discomfort (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Temporomandibular pain and dysfunction syndrome (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014438470&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014439130,Spontaneous,2023-01-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Injected limb mobility decreased (n/a - Recovering/Resolving - Disabling),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])","[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (C - n/a - n/a - [n/a - n/a - Intramuscular use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014439130&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014439131,Spontaneous,2023-01-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Myalgia (n/a - Not Recovered/Not Resolved - Disabling),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",NO DRUG [NOT AVAILABLE] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014439131&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014439141,Spontaneous,2023-01-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Urticaria (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014439141&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014440339,Spontaneous,2023-01-17 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Herpes zoster (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])","[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014440339&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014440347,Spontaneous,2023-01-17 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Memory impairment (0d - Recovered/Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","PROLIA [DENOSUMAB] (C - Osteoporosis - n/a - [n/a - n/a - Subcutaneous use]),<BR><BR>[ANHYDROUS LEVOTHYROXINE SODIUM, LEVOTHYROXINE, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS EP] (C - Hypometabolism - n/a - [n/a - n/a - Oral use]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (C - Influenza immunisation - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[ENTEROCOCCUS FAECIUM] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[METOPROLOL, METOPROLOL SUCCINATE, METOPROLOL TARTRATE] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - Oral use]),<BR><BR>[PYRIDOXINE, RIBOFLAVIN, THIAMINE HYDROCHLORIDE, CALCIUM PANTOTHENATE, NICOTINAMIDE, RIBOFLAVIN, PYRIDOXINE HYDROCHLORIDE] (C - Vitamin supplementation - n/a - [n/a - n/a - Oral use]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - Lung disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[VENLAFAXINE, VENLAFAXINE HYDROCHLORIDE] (C - Depression - n/a - [n/a - n/a - Oral use]),<BR><BR>[VITAMIN D, CALCIUM] (C - Vitamin supplementation - n/a - [n/a - n/a - Oral use]),<BR><BR>[VITAMINS NOS] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014440347&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014440355,Spontaneous,2023-01-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Cough (n/a - Recovering/Resolving - ),<BR><BR>Lung disorder (n/a - Recovering/Resolving - ),<BR><BR>Oropharyngeal pain (n/a - Recovering/Resolving - ),<BR><BR>Productive cough (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",[PERPHENAZINE] (C - Schizophrenia - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014440355&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014440411,Spontaneous,2023-01-17 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Rash (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BENDROFLUMETHIAZIDE, POTASSIUM CHLORIDE] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[ENALAPRIL MALEATE] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[FLUOCORTOLONE PIVALATE PH. EUR., ANHYDROUS LIDOCAINE HYDROCHLORIDE, FLUOCORTOLONE PIVALATE PH. EUR., LIDOCAINE HYDROCHLORIDE, FLUOCORTOLONE PIVALATE, ANHYDROUS LIDOCAINE HYDROCHLORIDE, FLUOCORTOLONE PIVALATE, LIDOCAINE HYDROCHLORIDE] (C - Haemorrhoids - n/a - [n/a - n/a - Rectal use]),<BR><BR>[MOMETASONE FUROATE] (C - Eczema - n/a - [n/a - n/a - Cutaneous use]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014440411&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014440426,Spontaneous,2023-01-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014440426&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014440433,Spontaneous,2023-01-17 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Herpes zoster (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain in extremity (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[ACETYLSALICYLIC ACID, ACETYLSALICYLIC ACID, MAGNESIUM OXIDE] (C - Anticoagulant therapy - n/a - [n/a - n/a - Oral use]),<BR><BR>[ATORVASTATIN] (C - Hypercholesterolaemia - n/a - [n/a - n/a - Oral use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[HYDROXOCOBALAMIN] (C - Vitamin B12 deficiency - n/a - [n/a - n/a - Intramuscular use]),<BR><BR>[METOPROLOL SUCCINATE, METOPROLOL TARTRATE] (C - Angina pectoris - n/a - [n/a - n/a - Oral use]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014440433&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014440437,Spontaneous,2023-01-17 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Limb discomfort (n/a - Not Recovered/Not Resolved - ),<BR><BR>Paraesthesia (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014440437&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014440447,Spontaneous,2023-01-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Lymphadenopathy (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - Immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014440447&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014440455,Spontaneous,2023-01-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014440455&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014440460,Spontaneous,2023-01-17 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Back pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])","BETMIGA [MIRABEGRON] (C - Hypertonic bladder - n/a - [n/a - n/a - Oral use]),<BR><BR>[ANHYDROUS LEVOTHYROXINE SODIUM, LEVOTHYROXINE, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS EP] (C - Hypometabolism - n/a - [n/a - n/a - Oral use]),<BR><BR>[AZELASTINE HYDROCHLORIDE, FLUTICASONE PROPIONATE] (C - Seasonal allergy - n/a - [n/a - n/a - Nasal use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - Influenza immunisation - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE, BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE, FORMOTEROL FUMARATE DIHYDRATE, BECLOMETASONE DIPROPIONATE ANHYDROUS] (C - Asthma - n/a - [n/a - n/a - Inhalation use]),<BR><BR>[IBUPROFEN, IBUPROFEN BP] (C - Pain - n/a - [n/a - n/a - Oral use]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[NAPROXEN] (C - Pain - n/a - [n/a - n/a - Oral use]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - Oral use]),<BR><BR>[SUMATRIPTAN, SUMATRIPTAN SUCCINATE] (C - Migraine - n/a - [n/a - n/a - Oral use]),<BR><BR>[TERBUTALINE SULFATE] (C - Asthma - n/a - [n/a - n/a - Inhalation use]),<BR><BR>[TRAMADOL HYDROCHLORIDE] (C - Pain - n/a - [n/a - n/a - Oral use]),<BR><BR>[VITAMIN D, CALCIUM] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014440460&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014440492,Spontaneous,2023-01-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Adult,No,Female,Influenza (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014440492&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014440496,Spontaneous,2023-01-17 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Herpes zoster (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])","[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014440496&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014440497,Spontaneous,2023-01-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014440497&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014425601,Spontaneous,2023-01-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Haemolytic anaemia (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Hodgkin's disease (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014425601&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014427739,Spontaneous,2023-01-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Male,"Coordination abnormal (n/a - Recovering/Resolving - ),<BR><BR>Dizziness (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014427739&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014427746,Spontaneous,2023-01-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - ),<BR><BR>Intermenstrual bleeding (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","APIXABAN 5MG TABLET  (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>ELIQUIS 5 MG FILM-COATED TABLETS [APIXABAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014427746&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014428585,Spontaneous,2023-01-16 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,Herpes zoster (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014428585&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014428587,Spontaneous,2023-01-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Male,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Oropharyngeal pain (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - ),<BR><BR>Somnolence (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014428587&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014428588,Spontaneous,2023-01-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Fatigue (2d - Recovered/Resolved - ),<BR><BR>Headache (1d - Recovered/Resolved - ),<BR><BR>Injection site erythema (3d - Recovered/Resolved - ),<BR><BR>Injection site inflammation (3d - Recovered/Resolved - ),<BR><BR>Injection site pruritus (3d - Recovered/Resolved - ),<BR><BR>Injection site warmth (3d - Recovered/Resolved - ),<BR><BR>Vaccination site lymphadenopathy (3d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014428588&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014428590,Spontaneous,2023-01-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Blood glucose increased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovered/Resolved - ),<BR><BR>Injection site erythema (n/a - Recovered/Resolved - ),<BR><BR>Injection site inflammation (n/a - Recovered/Resolved - ),<BR><BR>Injection site pruritus (n/a - Recovered/Resolved - ),<BR><BR>Injection site warmth (n/a - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Recovered/Resolved - ),<BR><BR>Nausea (n/a - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","BETMIGA 50 MG PROLONGED-RELEASE TABLETS [MIRABEGRON] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>VICTOZA 6 MG/ML SOLUTION FOR INJECTION IN PRE-FILLED PEN [LIRAGLUTIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014428590&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014429869,Spontaneous,2023-01-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Male,Vision blurred (1d - Recovered/Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014429869&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014429876,Spontaneous,2023-01-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Dizziness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hypoacusis (n/a - Not Recovered/Not Resolved - ),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014429876&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014432589,Spontaneous,2023-01-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Confusional state (1d - Recovered/Resolved - ),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014432589&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014432590,Spontaneous,2023-01-16 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Pain in extremity (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[BUDESONIDE, FORMOTEROL FUMARATE DIHYDRATE] (C - n/a - n/a - [n/a - n/a - Inhalation use]),<BR><BR>[CODEINE PHOSPHATE HEMIHYDRATE] (C - Antitussive therapy - n/a - [n/a - n/a - Oral use]),<BR><BR>[DESLORATADINE] (C - Urticaria - n/a - [n/a - n/a - Oral use]),<BR><BR>[ESOMEPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - Oral use]),<BR><BR>[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - Hormone therapy - n/a - [n/a - n/a - Vaginal use]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - Oral use]),<BR><BR>[PREDNISOLONE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[ZOPICLONE] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014432590&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014432670,Spontaneous,2023-01-16 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,"Asthenia (2d - Recovered/Resolved - ),<BR><BR>Dizziness (9d - Recovered/Resolved - ),<BR><BR>Fatigue (2d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])","ELIQUIS [APIXABAN] (C - Thrombosis prophylaxis - n/a - [n/a - n/a - Oral use]),<BR><BR>SEMGLEE [INSULIN GLARGINE] (C - n/a - n/a - [n/a - n/a - Subcutaneous use]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MESILATE MONOHYDRATE] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[DIGOXIN] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[FUROSEMIDE] (C - Diuretic therapy - n/a - [n/a - n/a - Oral use]),<BR><BR>[METFORMIN HYDROCHLORIDE] (C - Type 2 diabetes mellitus - n/a - [n/a - n/a - Oral use]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - Oral use]),<BR><BR>[POTASSIUM CHLORIDE] (C - Mineral supplementation - n/a - [n/a - n/a - Oral use]),<BR><BR>[RAMIPRIL] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[VITAMIN D, CALCIUM] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014432670&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014432681,Spontaneous,2023-01-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Papule (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - Influenza immunisation - n/a - [n/a - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014432681&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014432704,Spontaneous,2023-01-16 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Arthralgia (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","GREPID [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - Thrombosis prophylaxis - n/a - [n/a - n/a - Oral use]),<BR><BR>LANTUS SOLOSTAR [INSULIN GLARGINE] (C - n/a - n/a - [n/a - n/a - Subcutaneous use]),<BR><BR>NOVORAPID FLEXPEN [INSULIN ASPART] (C - n/a - n/a - [n/a - n/a - Subcutaneous use]),<BR><BR>VIAGRA [SILDENAFIL, SILDENAFIL CITRATE] (C - Erectile dysfunction - n/a - [n/a - n/a - Oral use]),<BR><BR>[ACETYLSALICYLIC ACID, ACETYLSALICYLIC ACID, MAGNESIUM OXIDE] (C - Anticoagulant therapy - n/a - [n/a - n/a - Oral use]),<BR><BR>[AMLODIPINE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[ATORVASTATIN, ATORVASTATIN CALCIUM] (C - Hypercholesterolaemia - n/a - [n/a - n/a - Oral use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CHLORAMPHENICOL] (C - Eye infection - n/a - [n/a - n/a - Subconjunctival use]),<BR><BR>[ENALAPRIL MALEATE] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[EZETIMIBE] (C - Hypercholesterolaemia - n/a - [n/a - n/a - Oral use]),<BR><BR>[FLUTICASONE PROPIONATE] (C - Nasal congestion - n/a - [n/a - n/a - Nasal use]),<BR><BR>[GLYCERYL TRINITRATE] (C - Angina pectoris - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - Oral use]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - Bronchospasm - n/a - [n/a - n/a - Inhalation use]),<BR><BR>[TAMSULOSIN HYDROCHLORIDE] (C - Dysuria - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014432704&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014432711,Spontaneous,2023-01-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Lacrimation increased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014432711&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014432712,Spontaneous,2023-01-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Discomfort (1d - Recovered/Resolved - ),<BR><BR>Heart rate increased (1d - Recovered/Resolved - ),<BR><BR>Peripheral coldness (1d - Recovered/Resolved - ),<BR><BR>Taste disorder (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014432712&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014432719,Spontaneous,2023-01-16 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Swelling (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","FORXIGA [DAPAGLIFLOZIN] (C - Diabetes mellitus - n/a - [n/a - n/a - Oral use]),<BR><BR>OZEMPIC [SEMAGLUTIDE] (C - Type 2 diabetes mellitus - n/a - [n/a - n/a - Subcutaneous use]),<BR><BR>[ALUMINIUM HYDROXIDE GEL, DRIED, MAGNESIUM CARBONATE, SODIUM CARBONATE, ALGINIC ACID, ALUMINIUM HYDROXIDE, SODIUM CARBONATE, CALCIUM CARBONATE, SODIUM ALGINATE, ALUMINIUM HYDROXIDE, SODIUM HYDROGEN CARBONATE, ALGINIC ACID, ALUMINIUM HYDROXIDE, SODIUM HYDROGEN CARBONATE, ALGINIC ACID, ALUMINIUM HYDROXIDE GEL, DRIED, SODIUM HYDROGEN CARBONATE, ALGINIC ACID, ALUMINIUM HYDROXIDE GEL, DRIED USP, SODIUM HYDROGEN CARBONATE, ALGINIC ACID, SODIUM ALGINATE, ALUMINIUM HYDROXIDE, SODIUM HYDROGEN CARBONATE, ALUMINIUM HYDROXIDE GEL, CALCIUM CARBONATE, SODIUM ALGINATE, SODIUM HYDROGEN CARBONATE, CALCIUM CARBONATE, SODIUM ALGINATE, SODIUM HYDROGEN CARBONATE, CALCIUM CARBONATE, SODIUM ALGINATE, ALUMINIUM HYDROXIDE, SODIUM HYDROGEN CARBONATE, SODIUM ALGINATE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[ATORVASTATIN, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM TRIHYDRATE] (C - Hypercholesterolaemia - n/a - [n/a - n/a - Oral use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BENDROFLUMETHIAZIDE, POTASSIUM CHLORIDE] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[CYANOCOBALAMIN] (C - Vitamin B12 deficiency - n/a - [n/a - n/a - Oral use]),<BR><BR>[EZETIMIBE] (C - Hypercholesterolaemia - n/a - [n/a - n/a - Oral use]),<BR><BR>[IBUPROFEN] (C - Pain - n/a - [n/a - n/a - Oral use]),<BR><BR>[METFORMIN HYDROCHLORIDE] (C - Type 2 diabetes mellitus - n/a - [n/a - n/a - Oral use]),<BR><BR>[MIANSERIN HYDROCHLORIDE] (C - Sedative therapy - n/a - [n/a - n/a - Oral use]),<BR><BR>[MOMETASONE FUROATE, MOMETASONE FUROATE MONOHYDRATE] (C - Seasonal allergy - n/a - [n/a - n/a - Nasal use]),<BR><BR>[OXAZEPAM] (C - Restlessness - n/a - [n/a - n/a - Oral use]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - Oral use]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014432719&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014432728,Spontaneous,2023-01-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Adult,No,Female,"Heart rate increased (n/a - Recovering/Resolving - ),<BR><BR>Hypertension (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014432728&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014432733,Spontaneous,2023-01-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Arthralgia (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014432733&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014432741,Spontaneous,2023-01-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014432741&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014432775,Spontaneous,2023-01-16 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Musculoskeletal pain (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014432775&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014432782,Spontaneous,2023-01-16 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","CLOPIDOGREL ZENTIVA [CLOPIDOGREL, CLOPIDOGREL HYDROGEN SULFATE] (C - Thrombosis prophylaxis - n/a - [n/a - n/a - Oral use]),<BR><BR>INSULIN DEGLUDEC [INSULIN DEGLUDEC] (C - Diabetes mellitus - n/a - [n/a - n/a - Subcutaneous use]),<BR><BR>JARDIANCE [EMPAGLIFLOZIN] (C - Type 2 diabetes mellitus - n/a - [n/a - n/a - Oral use]),<BR><BR>OZEMPIC [SEMAGLUTIDE] (C - Diabetes mellitus - n/a - [n/a - n/a - Subcutaneous use]),<BR><BR>[ALENDRONIC ACID] (C - Osteoporosis - n/a - [n/a - n/a - Oral use]),<BR><BR>[AMLODIPINE BESILATE] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[ATORVASTATIN] (C - Hypercholesterolaemia - n/a - [n/a - n/a - Oral use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FUROSEMIDE] (C - Diuretic therapy - n/a - [n/a - n/a - Oral use]),<BR><BR>[HYDROCHLOROTHIAZIDE, LOSARTAN, LOSARTAN POTASSIUM, HYDROCHLOROTHIAZIDE] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[LANSOPRAZOLE] (C - Prophylaxis against gastrointestinal ulcer - n/a - [n/a - n/a - Oral use]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE] (C - Type 2 diabetes mellitus - n/a - [n/a - n/a - Oral use]),<BR><BR>[METOPROLOL TARTRATE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - Oral use]),<BR><BR>[POTASSIUM CHLORIDE] (C - Mineral supplementation - n/a - [n/a - n/a - Oral use]),<BR><BR>[VITAMIN D, CALCIUM] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[VITAMINS NOS] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014432782&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014423144,Spontaneous,2023-01-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Female,Blepharospasm (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014423144&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014423159,Spontaneous,2023-01-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Amenorrhoea (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014423159&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014423165,Spontaneous,2023-01-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Arthralgia (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014423165&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014423168,Spontaneous,2023-01-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (12h - Recovered/Resolved - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014423168&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014423171,Spontaneous,2023-01-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Body temperature increased (n/a - Recovering/Resolving - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014423171&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014423176,Spontaneous,2023-01-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,Vertigo (12h - Recovered/Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014423176&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014423178,Spontaneous,2023-01-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Injection site pain (36h - Recovered/Resolved - ),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014423178&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014423180,Spontaneous,2023-01-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014423180&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014423191,Spontaneous,2023-01-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (6h - Recovered/Resolved - ),<BR><BR>Nausea (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014423191&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014423204,Spontaneous,2023-01-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014423204&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014423408,Spontaneous,2023-01-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Body temperature increased (n/a - Recovering/Resolving - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Injection site warmth (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014423408&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014423409,Spontaneous,2023-01-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Heavy menstrual bleeding (n/a - Not Recovered/Not Resolved - ),<BR><BR>Postmenopausal haemorrhage (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])","[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014423409&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014423410,Spontaneous,2023-01-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Heavy menstrual bleeding (n/a - Unknown - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",[LEVONORGESTREL] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014423410&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014423411,Spontaneous,2023-01-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Heavy menstrual bleeding (n/a - Unknown - ),<BR><BR>Menstruation delayed (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014423411&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014423416,Spontaneous,2023-01-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Body temperature increased (12h - Recovered/Resolved - ),<BR><BR>Chills (12h - Recovered/Resolved - ),<BR><BR>Malaise (12h - Recovered/Resolved - ),<BR><BR>Myalgia (12h - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014423416&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014423419,Spontaneous,2023-01-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Heavy menstrual bleeding (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",[LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014423419&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014423962,Spontaneous,2023-01-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014423962&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014418857,Spontaneous,2023-01-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chest discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myocardial injury (n/a - Unknown - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014418857&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014418911,Spontaneous,2023-01-13 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Facial paresis (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - Subcutaneous use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014418911&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014419345,Spontaneous,2023-01-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Dystonia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Fatigue (n/a - Recovered/Resolved - ),<BR><BR>Headache (7d - Recovered/Resolved - ),<BR><BR>Influenza like illness (n/a - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Recovered/Resolved - ),<BR><BR>Nausea (n/a - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vomiting (n/a - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","NOT AVAILABLE (C - Depression - n/a - [n/a - n/a - n/a]),<BR><BR>NOT AVAILABLE (C - Migraine - n/a - [n/a - n/a - n/a]),<BR><BR>NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014419345&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014419818,Spontaneous,2023-01-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Heavy menstrual bleeding (2d - Recovered/Resolved - ),<BR><BR>Lymphadenopathy (13d - Recovered/Resolved - ),<BR><BR>Vaccination site lymphadenopathy (13d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014419818&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014420545,Spontaneous,2023-01-13 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Subacute cutaneous lupus erythematosus (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (S - Hiatus hernia - Drug withdrawn - [n/a - 20mg - n/a - More in ICSR])","[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BENDROFLUAZIDE, BENDROFLUMETHIAZIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CYANOCOBALAMIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[DESLORATADINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FOLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METOPROLOL, METOPROLOL TARTRATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014420545&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014420886,Spontaneous,2023-01-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Tinnitus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014420886&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014421537,Spontaneous,2023-01-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Fall (n/a - Unknown - Other Medically Important Condition),<BR><BR>Heart rate decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>PROLIA [DENOSUMAB] (C - Osteoporosis - n/a - [n/a - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL, CALCIUM CARBONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[LISINOPRIL, LISINOPRIL DIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014421537&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014422536,Spontaneous,2023-01-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Dizziness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Presyncope (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014422536&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014422539,Spontaneous,2023-01-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Rash macular (n/a - Recovering/Resolving - ),<BR><BR>Urticaria (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Unknown - [n/a - 1{DF} - n/a])",[CICLESONIDE] (C - Asthma - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014422539&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014422540,Spontaneous,2023-01-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014422540&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014422541,Spontaneous,2023-01-13 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Ecchymosis (n/a - Unknown - ),<BR><BR>Skin haemorrhage (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])","[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - Prophylaxis - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014422541&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014422547,Spontaneous,2023-01-13 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Tremor (360d - Recovered/Resolved - ),<BR><BR>Tremor (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014422547&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014422565,Spontaneous,2023-01-13 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Dizziness (8d - Recovered/Resolved - ),<BR><BR>Hot flush (8d - Recovered/Resolved - ),<BR><BR>Paraesthesia (7d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","NUCALA [MEPOLIZUMAB] (C - Asthma - n/a - [n/a - n/a - Subcutaneous use]),<BR><BR>TRELEGY ELLIPTA [UMECLIDINIUM BROMIDE, FLUTICASONE FUROATE, VILANTEROL] (C - Chronic obstructive pulmonary disease - n/a - [n/a - n/a - Inhalation use]),<BR><BR>[COLECALCIFEROL] (C - Osteoporosis - n/a - [n/a - n/a - Oral use]),<BR><BR>[ESOMEPRAZOLE] (C - Prophylaxis against gastrointestinal ulcer - n/a - [n/a - n/a - Oral use]),<BR><BR>[FEXOFENADINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[FLUTICASONE PROPIONATE] (C - Asthma - n/a - [n/a - n/a - Inhalation use]),<BR><BR>[HYDROCORTISONE] (C - Eczema - n/a - [n/a - n/a - Cutaneous use]),<BR><BR>[MOMETASONE FUROATE, MOMETASONE FUROATE MONOHYDRATE] (C - Seasonal allergy - n/a - [n/a - n/a - Nasal use]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - Oral use]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - Asthma - n/a - [n/a - n/a - Inhalation use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014422565&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014422569,Spontaneous,2023-01-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Vaccination site pain (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014422569&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014422581,Spontaneous,2023-01-13 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Dyspnoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])","[MAGNESIUM HYDROXIDE, MAGNESIUM OXIDE, MAGNESIUM OXIDE, LIGHT] (C - Constipation - n/a - [n/a - 1000mg - Oral use]),<BR><BR>[NORETHISTERONE ACETATE, ANHYDROUS ESTRADIOL, NORETHISTERONE ACETATE, ESTRADIOL, NORETHISTERONE ACETATE, ESTRADIOL HEMIHYDRATE, NORETHISTERONE, ESTRADIOL HEMIHYDRATE] (C - Hormone therapy - n/a - [n/a - n/a - Oral use]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - 1000mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014422581&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014422584,Spontaneous,2023-01-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (5d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014422584&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014422598,Spontaneous,2023-01-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Abdominal pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014422598&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014422599,Spontaneous,2023-01-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Lymph node pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014422599&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014422601,Spontaneous,2023-01-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Abdominal pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Food aversion (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014422601&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014422616,Spontaneous,2023-01-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Dyspnoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[LOSARTAN POTASSIUM, HYDROCHLOROTHIAZIDE] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014422616&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014422622,Spontaneous,2023-01-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Pruritus (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",[MOMETASONE FUROATE] (C - Pruritus - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014422622&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014422627,Spontaneous,2023-01-13 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chest discomfort (n/a - Recovering/Resolving - ),<BR><BR>Dizziness (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014422627&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014405847,Spontaneous,2023-01-12 00:00:00,Non Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Hyperhidrosis (n/a - Recovering/Resolving - ),<BR><BR>Pain (2d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014405847&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014406149,Spontaneous,2023-01-12 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Cardio-respiratory arrest (0d - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Cardiomegaly (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Cold sweat (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Malaise (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Myocardial ischaemia (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Pallor (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Somnolence (n/a - Fatal - Results in Death, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Unknown]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [1d - n/a - Unknown])","NOVORAPID [INSULIN ASPART] (C - n/a - Dose not changed - [n/a - n/a - Unknown]),<BR><BR>[ACETYLSALICYLIC ACID, ACETYLSALICYLIC ACID PH. EUR., ASPIRIN BP] (C - n/a - Dose not changed - [n/a - n/a - Unknown]),<BR><BR>[ATORVASTATIN] (C - n/a - Dose not changed - [n/a - n/a - Unknown]),<BR><BR>[BENDROFLUMETHIAZIDE] (C - n/a - Dose not changed - [n/a - n/a - Unknown]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - Dose not changed - [n/a - n/a - Unknown]),<BR><BR>[DOXAZOSIN, DOXAZOSIN MESILATE] (C - n/a - Dose not changed - [n/a - n/a - Unknown]),<BR><BR>[FELODIPINE] (C - n/a - Dose not changed - [n/a - n/a - Unknown]),<BR><BR>[FEXOFENADINE, FEXOFENADINE HYDROCHLORIDE] (C - n/a - Dose not changed - [n/a - n/a - Unknown]),<BR><BR>[GLYCERYL TRINITRATE] (C - n/a - Dose not changed - [n/a - n/a - Unknown]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - n/a - Dose not changed - [n/a - n/a - Unknown]),<BR><BR>[RAMIPRIL] (C - n/a - Dose not changed - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014406149&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014406926,Spontaneous,2023-01-12 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Muscle twitching (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a])","[ASCORBIC ACID] (C - n/a - n/a - ),<BR><BR>[TURMERIC] (C - n/a - n/a - ),<BR><BR>[VITAMIN D] (C - n/a - n/a - )","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014406926&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014409781,Spontaneous,2023-01-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014409781&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014410951,Spontaneous,2023-01-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chest pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014410951&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014411013,Spontaneous,2023-01-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Hypoaesthesia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Peripheral coldness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014411013&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014411107,Spontaneous,2023-01-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Skin plaque (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014411107&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014411316,Spontaneous,2023-01-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Hyperglycaemia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>HUMALOG [INSULIN LISPRO] (C - Type 1 diabetes mellitus - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014411316&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014411704,Spontaneous,2023-01-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Axillary pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014411704&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014412333,Spontaneous,2023-01-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Illness (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Pulmonary embolism (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Pulmonary thrombosis (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014412333&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014412351,Spontaneous,2023-01-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Migraine (30min - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (30min - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014412351&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014413396,Spontaneous,2023-01-12 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Constipation (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","PLAVIX [CLOPIDOGREL, CLOPIDOGREL HYDROGEN SULFATE] (C - Thrombosis prophylaxis - n/a - [n/a - n/a - Oral use]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MESILATE MONOHYDRATE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[GLYCERYL TRINITRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - Oral use]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - Hypercholesterolaemia - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014413396&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014413403,Spontaneous,2023-01-12 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (2d - Recovered/Resolved - ),<BR><BR>Nausea (3d - Recovered/Resolved - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014413403&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014413404,Spontaneous,2023-01-12 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"General physical health deterioration (n/a - Recovering/Resolving - ),<BR><BR>Influenza (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","ELIQUIS [APIXABAN] (C - Thrombosis prophylaxis - n/a - [n/a - n/a - Oral use]),<BR><BR>[ALGELDRATE, TICK-BORNE ENCEPHALITIS VIRUS (INACTIVATED), NEUDOERFL STRAIN, ALUMINIUM, TICK-BORNE ENCEPHALITIS VIRUS (INACTIVATED), NEUDOERFL STRAIN, ALUMINIUM, TICK-BORNE ENCEPHALITIS VIRUS NEUDOERFL STRAIN ADSORBED ON ALUMINIUM HYDROXIDE, HYDRATED PRODUCED IN CHICK EMBRYO CELLS, TICK-BORNE ENCEPHALITIS VIRUS (INACTIVATED), TICK-BORNE ENCEPHALITIS VIRUS (INACTIVATED), NEUDOERFL STRAIN, TICK-BORNE ENCEPHALITIS VIRUS NEUDOERFL STRAIN ADSORBED ON ALUMINIUM HYDROXIDE, HYDRATED PRODUCED IN CHICK EMBRYO CELLS, ALGELDRATE, TICK-BORNE ENCEPHALITIS VIRUS, ALGELDRATE] (C - n/a - n/a - [124d - n/a - Intramuscular use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BISACODYL] (C - n/a - n/a - [35d - n/a - Oral use]),<BR><BR>[GLYCERYL TRINITRATE] (C - Angina pectoris - n/a - [n/a - n/a - n/a]),<BR><BR>[IRBESARTAN] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[MAGNESIUM OXIDE, LIGHT, CITRIC ACID, SODIUM PICOSULFATE MONOHYDRATE, SODIUM PICOSULFATE, CITRIC ACID ANHYDROUS, MAGNESIUM OXIDE, SODIUM PICOSULFATE, MAGNESIUM OXIDE, LIGHT, CITRIC ACID, SODIUM PICOSULFATE, MAGNESIUM OXIDE, LIGHT, CITRIC ACID ANHYDROUS] (C - n/a - n/a - [35d - n/a - Oral use]),<BR><BR>[METFORMIN HYDROCHLORIDE] (C - Type 2 diabetes mellitus - n/a - [n/a - n/a - Oral use]),<BR><BR>[METOPROLOL, METOPROLOL SUCCINATE, METOPROLOL TARTRATE] (C - Heart rate irregular - n/a - [n/a - n/a - Oral use]),<BR><BR>[MIRTAZAPINE] (C - Depression - n/a - [n/a - n/a - Oral use]),<BR><BR>[OXAZEPAM] (C - Sedative therapy - n/a - [n/a - n/a - Oral use]),<BR><BR>[PANTOPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [7d - n/a - Oral use]),<BR><BR>[ROSUVASTATIN] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014413404&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014413406,Spontaneous,2023-01-12 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Feeling cold (n/a - Not Recovered/Not Resolved - ),<BR><BR>Gait disturbance (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pulmonary pain (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[BENDROFLUMETHIAZIDE, POTASSIUM CHLORIDE] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[BUDESONIDE, FORMOTEROL FUMARATE DIHYDRATE] (C - Lung disorder - n/a - [n/a - n/a - Inhalation use]),<BR><BR>[HYPROMELLOSE] (C - Eye lubrication therapy - n/a - [n/a - n/a - Ocular use]),<BR><BR>[METFORMIN HYDROCHLORIDE] (C - Type 2 diabetes mellitus - n/a - [n/a - n/a - Oral use]),<BR><BR>[MOMETASONE FUROATE, MOMETASONE FUROATE MONOHYDRATE] (C - n/a - n/a - [n/a - n/a - Nasal use]),<BR><BR>[PHENOXYMETHYLPENICILLIN, PHENOXYMETHYLPENICILLIN POTASSIUM] (C - Infection - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014413406&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014413415,Spontaneous,2023-01-12 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,Vertigo (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014413415&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014413423,Spontaneous,2023-01-12 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Palpitations (0d - Recovered/Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014413423&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014413427,Spontaneous,2023-01-12 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014413427&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014413431,Spontaneous,2023-01-12 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Palpitations (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","AVAMYS [FLUTICASONE FUROATE] (C - Rhinorrhoea - n/a - [n/a - n/a - Nasal use]),<BR><BR>EMADINE [EMEDASTINE, EMEDASTINE DIFUMARATE] (C - Rhinitis allergic - n/a - [n/a - n/a - Ocular use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[IPRATROPIUM, IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE ANHYDROUS, IPRATROPIUM BROMIDE MONOHYDRATE] (C - Rhinorrhoea - n/a - [n/a - n/a - Nasal use]),<BR><BR>[LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE HYDROCHLORIDE] (C - Seasonal allergy - n/a - [n/a - n/a - Oral use]),<BR><BR>[MONTELUKAST, MONTELUKAST SODIUM] (C - Asthma - n/a - [n/a - n/a - Oral use]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - Oral use]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - Rectal use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014413431&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014413434,Spontaneous,2023-01-12 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Discomfort (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Peripheral swelling (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014413434&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014413437,Spontaneous,2023-01-12 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Lymphadenopathy (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014413437&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014413440,Spontaneous,2023-01-12 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Cognitive disorder (n/a - Not Recovered/Not Resolved - ),<BR><BR>Muscular weakness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014413440&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014413443,Spontaneous,2023-01-12 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,Haematoma (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[ACETYLSALICYLIC ACID, CODEINE PHOSPHATE HEMIHYDRATE, MAGNESIUM OXIDE] (C - Pain - n/a - [n/a - n/a - Oral use]),<BR><BR>[ANHYDROUS LEVOTHYROXINE SODIUM, LEVOTHYROXINE, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS EP] (C - Hypometabolism - n/a - [n/a - n/a - Oral use]),<BR><BR>[ENALAPRIL MALEATE] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[ERGOTAMINE TARTRATE, CAFFEINE] (C - Migraine - n/a - [n/a - n/a - Oral use]),<BR><BR>[FUROSEMIDE, FUROSEMIDE SODIUM] (C - Diuretic therapy - n/a - [n/a - n/a - Oral use]),<BR><BR>[FUROSEMIDE] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[IBUPROFEN] (C - Pain - n/a - [n/a - n/a - Oral use]),<BR><BR>[METOPROLOL TARTRATE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - Oral use]),<BR><BR>[POTASSIUM CHLORIDE] (C - Mineral supplementation - n/a - [n/a - n/a - Oral use]),<BR><BR>[SIMVASTATIN] (C - Hypercholesterolaemia - n/a - [n/a - n/a - Oral use]),<BR><BR>[TRAMADOL HYDROCHLORIDE] (C - Pain - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014413443&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014413449,Spontaneous,2023-01-12 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Head discomfort (n/a - Recovering/Resolving - ),<BR><BR>Influenza (n/a - Recovering/Resolving - ),<BR><BR>Pruritus (n/a - Recovering/Resolving - ),<BR><BR>Rash macular (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014413449&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014413452,Spontaneous,2023-01-12 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Blister (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - ),<BR><BR>Skin fissures (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>SPIKEVAX [ELASOMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014413452&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014413459,Spontaneous,2023-01-12 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Fatigue (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MAGNESIUM HYDROXIDE, MAGNESIUM OXIDE, MAGNESIUM OXIDE, LIGHT] (C - Constipation - n/a - [n/a - n/a - Oral use]),<BR><BR>[NORETHISTERONE ACETATE, ANHYDROUS ESTRADIOL, NORETHISTERONE ACETATE, ESTRADIOL, NORETHISTERONE ACETATE, ESTRADIOL HEMIHYDRATE, NORETHISTERONE, ESTRADIOL HEMIHYDRATE] (C - Hormone therapy - n/a - [n/a - n/a - Oral use]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014413459&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014413676,Spontaneous,2023-01-12 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (1d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (15d - Recovered/Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (1d - Recovered/Resolved - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014413676&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014413678,Spontaneous,2023-01-12 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014413678&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014397660,Spontaneous,2023-01-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Muscle fatigue (1d - Recovered/Resolved - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - .3mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014397660&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014398783,Spontaneous,2023-01-11 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Asthenia (n/a - Recovered/Resolved - ),<BR><BR>Back pain (n/a - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovered/Resolved - ),<BR><BR>Insomnia (n/a - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Recovered/Resolved - ),<BR><BR>Vaccination site pain (n/a - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014398783&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014399749,Spontaneous,2023-01-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - ),<BR><BR>Paraesthesia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014399749&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014399751,Spontaneous,2023-01-11 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Male,Hyperglycaemia (n/a - Recovering/Resolving - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014399751&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014399754,Spontaneous,2023-01-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Drug interaction (n/a - Unknown - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site erythema (4d - Recovered/Resolved - ),<BR><BR>Injection site inflammation (12d - Recovered/Resolved - ),<BR><BR>Injection site pain (12d - Recovered/Resolved - ),<BR><BR>Injection site swelling (12d - Recovered/Resolved - ),<BR><BR>Injection site warmth (12d - Recovered/Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Premenstrual dysphoric disorder (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[GOSERELIN] (S - Premenstrual dysphoric disorder - Not applicable - [n/a - 1{DF} - n/a])",NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014399754&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014399755,Spontaneous,2023-01-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Male,"Hypertension (n/a - Not Recovered/Not Resolved - ),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014399755&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014399759,Spontaneous,2023-01-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adolescent,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site discomfort (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014399759&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014399760,Spontaneous,2023-01-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Arthralgia (4d - Recovered/Resolved - ),<BR><BR>Chest pain (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (4d - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (3d - Recovered/Resolved - ),<BR><BR>Poor quality sleep (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014399760&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014400160,Spontaneous,2023-01-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014400160&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014400811,Spontaneous,2023-01-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Lymph node pain (n/a - Recovered/Resolved - ),<BR><BR>Lymphadenopathy (n/a - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014400811&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014401140,Spontaneous,2023-01-11 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,Yes,Male,Injection site pain (72h - Recovered/Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014401140&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014403659,Spontaneous,2023-01-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Extensive swelling of vaccinated limb (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014403659&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014404764,Spontaneous,2023-01-11 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Herpes zoster (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","ANORO [UMECLIDINIUM BROMIDE, VILANTEROL] (C - Chronic obstructive pulmonary disease - n/a - [n/a - n/a - n/a]),<BR><BR>ELIQUIS [APIXABAN] (C - Thrombosis prophylaxis - n/a - [n/a - n/a - Oral use]),<BR><BR>[ASCORBIC ACID, MAGNESIUM OXIDE, HEAVY, MAGNESIUM] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL] (C - Vitamin D deficiency - n/a - [n/a - n/a - Oral use]),<BR><BR>[FUROSEMIDE] (C - Diuretic therapy - n/a - [n/a - n/a - Oral use]),<BR><BR>[MESALAZINE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - Oral use]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - Anxiety - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014404764&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014404766,Spontaneous,2023-01-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Pruritus (n/a - Not Recovered/Not Resolved - ),<BR><BR>Rash (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014404766&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014404794,Spontaneous,2023-01-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Tearfulness (3d - Recovered/Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [n/a - 1{DF} - n/a])","[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014404794&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014404809,Spontaneous,2023-01-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Asthenopia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Cold sweat (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Feeling abnormal (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",[METHOTREXATE] (C - Psoriasis - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014404809&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014404810,Spontaneous,2023-01-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Tinnitus (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014404810&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014404824,Spontaneous,2023-01-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hypogeusia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014404824&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014404833,Spontaneous,2023-01-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Migraine (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014404833&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014404834,Spontaneous,2023-01-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Muscle spasms (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014404834&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014404839,Spontaneous,2023-01-11 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Urticaria (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[ATORVASTATIN, ATORVASTATIN CALCIUM] (C - Hypercholesterolaemia - n/a - [n/a - n/a - Oral use]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CLOPIDOGREL, CLOPIDOGREL BESILATE, CLOPIDOGREL HYDROGEN SULFATE] (C - Thrombosis prophylaxis - n/a - [n/a - n/a - Oral use]),<BR><BR>[LOSARTAN POTASSIUM] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - Oral use]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - Bronchospasm - n/a - [n/a - n/a - Inhalation use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014404839&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014405176,Spontaneous,2023-01-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Injection site haematoma (7d - Recovered/Resolved - ),<BR><BR>Injection site pain (7d - Recovered/Resolved - ),<BR><BR>Postmenopausal haemorrhage (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014405176&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014405335,Spontaneous,2023-01-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Heavy menstrual bleeding (n/a - Not Recovered/Not Resolved - ),<BR><BR>Intermenstrual bleeding (n/a - Not Recovered/Not Resolved - ),<BR><BR>Polymenorrhoea (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014405335&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014389513,Spontaneous,2023-01-10 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Asthenia (n/a - Recovering/Resolving - ),<BR><BR>Transient ischaemic attack (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - .3mL - Intramuscular use])","[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - 100mg - n/a]),<BR><BR>[ATENOLOL] (C - n/a - n/a - [n/a - 50mg - n/a]),<BR><BR>[ATORVASTATIN, ATORVASTATIN CALCIUM] (C - n/a - n/a - [n/a - 40mg - n/a]),<BR><BR>[FUROSEMIDE, FUROSEMIDE SODIUM] (C - n/a - n/a - [n/a - 25mg - n/a]),<BR><BR>[LERCANIDIPINE, LERCANIDIPINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - 20mg - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - 10mg - n/a]),<BR><BR>[TAPENTADOL, TAPENTADOL HYDROCHLORIDE] (C - n/a - n/a - [n/a - 100mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014389513&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014389598,Spontaneous,2023-01-10 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Lymphangitis (n/a - Unknown - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014389598&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014390280,Spontaneous,2023-01-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Pneumonitis (n/a - Not Recovered/Not Resolved - Life Threatening, Other Medically Important Condition),<BR><BR>Rheumatic disorder (n/a - Not Recovered/Not Resolved - Life Threatening, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014390280&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014390701,Spontaneous,2023-01-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Pemphigoid (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Skin disorder (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014390701&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014391132,Spontaneous,2023-01-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Male,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014391132&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014392216,Spontaneous,2023-01-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Abdominal distension (6h - Recovered/Resolved - ),<BR><BR>Decreased appetite (6h - Recovered/Resolved - ),<BR><BR>Injection site inflammation (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Injection site swelling (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014392216&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014392229,Spontaneous,2023-01-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Male,"Dizziness (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",[HYDROCORTISONE] (C - n/a - Dose increased - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014392229&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014392235,Spontaneous,2023-01-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Condition aggravated (n/a - Recovering/Resolving - ),<BR><BR>Endometriosis (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014392235&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014393144,Spontaneous,2023-01-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014393144&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014393627,Spontaneous,2023-01-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Abortion spontaneous (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Maternal exposure during pregnancy (n/a - Unknown - )","CIMZIA 200 MG SOLUTION FOR INJECTION [CERTOLIZUMAB PEGOL] (S - Rheumatoid arthritis - Dose not changed - [n/a - 1{DF} - n/a]),<BR><BR>COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014393627&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014393774,Spontaneous,2023-01-10 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Blood pressure increased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Head discomfort (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [1d - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - n/a - n/a - [253d - n/a - n/a])","TRAVATAN [TRAVOPROST] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BRIMONIDINE, BRIMONIDINE TARTRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BUDESONIDE, FORMOTEROL FUMARATE DIHYDRATE, FORMOTEROL FUMARATE, BUDESONIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014393774&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014394286,Spontaneous,2023-01-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Headache (n/a - Not Recovered/Not Resolved - Disabling),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a])","BETMIGA 50 MG PROLONGED-RELEASE TABLETS [MIRABEGRON] (C - Micturition urgency - n/a - [n/a - 50mg - n/a]),<BR><BR>CYMBALTA [DULOXETINE, DULOXETINE HYDROCHLORIDE] (C - Neuralgia - n/a - [n/a - 60mg - n/a]),<BR><BR>[ASCORBIC ACID, MAGNESIUM OXIDE, HEAVY, MAGNESIUM] (C - n/a - n/a - ),<BR><BR>[CETIRIZINE DIHYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL] (C - n/a - n/a - ),<BR><BR>[CYANOCOBALAMIN, VITAMIN B12] (C - Gastric bypass - n/a - [n/a - n/a - n/a]),<BR><BR>[DOCONEXENT, ICOSAPENT, FISH OIL, ICOSAPENT ETHYL, DOCOSAHEXAENOIC ACID ETHYL ESTER, OMEGA-3-ACID ETHYL ESTERS 90, OMEGA-3-ACID ETHYL ESTERS 90, DOCOSAHEXAENOIC ACID ETHYL ESTER] (C - n/a - n/a - ),<BR><BR>[ESCITALOPRAM, ESCITALOPRAM OXALATE] (C - Depression - n/a - [n/a - n/a - n/a]),<BR><BR>[ESOMEPRAZOLE, NAPROXEN, NAPROXEN, ESOMEPRAZOLE MAGNESIUM] (C - Arthralgia - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Arthralgia - n/a - [n/a - n/a - n/a]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - Depression - n/a - [n/a - 100mg - n/a]),<BR><BR>[VITAMINS NOS] (C - n/a - n/a - ),<BR><BR>[ZINC] (C - n/a - n/a - )","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014394286&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014394817,Spontaneous,2023-01-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014394817&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014395229,Spontaneous,2023-01-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Vocal cord paralysis (3h - Recovered/Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - .3mL - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014395229&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014395485,Spontaneous,2023-01-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Diarrhoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014395485&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014396832,Spontaneous,2023-01-10 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Urticaria (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","NOVORAPID [INSULIN ASPART] (C - n/a - n/a - [n/a - n/a - Subcutaneous use]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MESILATE MONOHYDRATE] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[DULOXETINE] (C - Depression - n/a - [n/a - n/a - Oral use]),<BR><BR>[FEXOFENADINE, FEXOFENADINE HYDROCHLORIDE] (C - Urticaria - n/a - [n/a - n/a - Oral use]),<BR><BR>[GLUCAGON, GLUCAGON HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - Intramuscular use]),<BR><BR>[HYDROXOCOBALAMIN] (C - Pernicious anaemia - n/a - [n/a - n/a - Intramuscular use]),<BR><BR>[LOSARTAN POTASSIUM, HYDROCHLOROTHIAZIDE] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[POTASSIUM CHLORIDE] (C - Mineral supplementation - n/a - [n/a - n/a - Oral use]),<BR><BR>[SIMVASTATIN] (C - Hypercholesterolaemia - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014396832&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014396899,Spontaneous,2023-01-10 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Dermatitis (n/a - Recovering/Resolving - ),<BR><BR>Pruritus (n/a - Recovering/Resolving - ),<BR><BR>Urticaria (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014396899&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014383799,Spontaneous,2023-01-09 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Menstrual disorder (n/a - Not Recovered/Not Resolved - ),<BR><BR>Menstruation delayed (n/a - Unknown - ),<BR><BR>Menstruation irregular (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a])","MYSIMBA [BUPROPION HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE] (C - Overweight - n/a - [n/a - n/a - n/a]),<BR><BR>[ASCORBIC ACID, CALCIUM GLUBIONATE, CALCIUM CARBONATE, CALCIUM, CALCIUM GLUBIONATE, CALCIUM CARBONATE, COLECALCIFEROL, CALCIUM] (C - n/a - n/a - ),<BR><BR>[CYANOCOBALAMIN, FOLIC ACID, PYRIDOXINE HYDROCHLORIDE] (C - n/a - n/a - ),<BR><BR>[LISDEXAMFETAMINE DIMESYLATE] (C - Attention deficit hyperactivity disorder - n/a - [n/a - 70mg - n/a]),<BR><BR>[SACCHAROMYCES CEREVISIAE] (C - n/a - n/a - ),<BR><BR>[THIAMINE HYDROCHLORIDE, RETINOL] (C - n/a - n/a - )","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014383799&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014385050,Spontaneous,2023-01-09 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Blister (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Blood glucose increased (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Dehydration (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Interchange of vaccine products (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Neurodermatitis (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Pemphigoid (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Rash pruritic (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Unknown])","DULOXETINE [DULOXETINE, DULOXETINE HYDROCHLORIDE] (C - n/a - Unknown - [n/a - n/a - Unknown]),<BR><BR>IRBESARTAN [IRBESARTAN] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[CYANOCOBALAMIN, VITAMIN B12] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[INSULIN HUMAN, INSULIN HUMAN (RDNA)] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[PRAVASTATIN, PRAVASTATIN SODIUM] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[TAMSULOSIN, TAMSULOSIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014385050&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014385126,Spontaneous,2023-01-09 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Haemoptysis (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pharyngeal swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",ANTIBIOTICA [NOT AVAILABLE] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014385126&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014385129,Spontaneous,2023-01-09 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Female,"Axillary pain (n/a - Recovering/Resolving - ),<BR><BR>Breast pain (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014385129&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014385130,Spontaneous,2023-01-09 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Body temperature increased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Herpes zoster (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014385130&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014385134,Spontaneous,2023-01-09 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Arrhythmia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Back pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Cardiac flutter (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chest discomfort (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chest pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Heart rate increased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014385134&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014385138,Spontaneous,2023-01-09 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (1d - Recovered/Resolved - ),<BR><BR>Chills (2d - Recovered/Resolved - ),<BR><BR>Malaise (1d - Recovered/Resolved - ),<BR><BR>Polymenorrhoea (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014385138&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014385140,Spontaneous,2023-01-09 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Amenorrhoea (n/a - Unknown - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014385140&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014385145,Spontaneous,2023-01-09 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014385145&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014385151,Spontaneous,2023-01-09 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site erythema (n/a - Recovering/Resolving - ),<BR><BR>Injection site haematoma (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Injection site warmth (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014385151&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014385153,Spontaneous,2023-01-09 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,Menstruation delayed (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014385153&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014385155,Spontaneous,2023-01-09 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Heavy menstrual bleeding (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site erythema (7d - Recovered/Resolved - ),<BR><BR>Injection site inflammation (7d - Recovered/Resolved - ),<BR><BR>Injection site swelling (7d - Recovered/Resolved - ),<BR><BR>Injection site warmth (7d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014385155&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014385158,Spontaneous,2023-01-09 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Body temperature increased (3h - Recovered/Resolved - ),<BR><BR>Fatigue (1d - Recovered/Resolved - ),<BR><BR>Malaise (8h - Recovered/Resolved - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014385158&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014385612,Spontaneous,2023-01-09 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Headache (7d - Recovered/Resolved - ),<BR><BR>Heavy menstrual bleeding (n/a - Not Recovered/Not Resolved - ),<BR><BR>Intermenstrual bleeding (n/a - Not Recovered/Not Resolved - ),<BR><BR>Menstruation delayed (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (7d - Recovered/Resolved - ),<BR><BR>Polymenorrhoea (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014385612&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014386173,Spontaneous,2023-01-09 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Haematoma (n/a - Not Recovered/Not Resolved - ),<BR><BR>Heavy menstrual bleeding (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site erythema (2d - Recovered/Resolved - ),<BR><BR>Injection site inflammation (2d - Recovered/Resolved - ),<BR><BR>Injection site pain (2d - Recovered/Resolved - ),<BR><BR>Intermenstrual bleeding (n/a - Not Recovered/Not Resolved - ),<BR><BR>Polymenorrhoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Throat tightness (2h - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014386173&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014387443,Spontaneous,2023-01-09 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Headache (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",AJOVY [FREMANEZUMAB] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014387443&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014387916,Spontaneous,2023-01-09 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,Yes,Female,Pulmonary embolism (2d - Fatal - Results in Death),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])","[ACETYLSALICYLIC ACID] (C - Product used for unknown indication - n/a - [n/a - 100mg - Oral use]),<BR><BR>[ATORVASTATIN] (C - Product used for unknown indication - n/a - [n/a - 20mg - Oral use]),<BR><BR>[BETAHISTINE, BETAHISTINE DIHYDROCHLORIDE, BETAHISTINE MESILATE] (C - Product used for unknown indication - n/a - [n/a - 48mg - Oral use]),<BR><BR>[CYANOCOBALAMIN] (C - Product used for unknown indication - n/a - [n/a - 2mg - Oral use]),<BR><BR>[DIAZEPAM] (C - Product used for unknown indication - n/a - [n/a - 5mg - Oral use]),<BR><BR>[FOLIC ACID] (C - Product used for unknown indication - n/a - [n/a - 10mg - Oral use]),<BR><BR>[GLYCERYL TRINITRATE] (C - Product used for unknown indication - n/a - [n/a - 10mg - Transdermal use]),<BR><BR>[IRON PROTEIN SUCCINYLATE, IRON(III) ION] (C - Product used for unknown indication - n/a - [n/a - 1{DF} - Oral use]),<BR><BR>[PARACETAMOL] (C - Product used for unknown indication - n/a - [n/a - 3g - Oral use]),<BR><BR>[TRAZODONE HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - 150mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014387916&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014388380,Spontaneous,2023-01-09 00:00:00,Healthcare Professional,European Economic Area,Not available,12-17 Years,Not Specified,No,Female,Skin discolouration (n/a - Unknown - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014388380&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014389057,Spontaneous,2023-01-09 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Diarrhoea (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014389057&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014382416,Spontaneous,2023-01-08 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014382416&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014382183,Spontaneous,2023-01-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014382183&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014375597,Spontaneous,2023-01-06 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Anaphylactic shock (0d - Fatal - Results in Death),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - Infection prophylaxis - Not applicable - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014375597&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014378119,Spontaneous,2023-01-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Neuralgia (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014378119&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014378204,Spontaneous,2023-01-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014378204&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014378841,Spontaneous,2023-01-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dyspnoea (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Oropharyngeal discomfort (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014378841&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014379222,Spontaneous,2023-01-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (36h - Recovered/Resolved - ),<BR><BR>Malaise (36h - Recovered/Resolved - ),<BR><BR>Myalgia (36h - Recovered/Resolved - ),<BR><BR>Pyrexia (36h - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014379222&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014379223,Spontaneous,2023-01-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Dose not changed - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014379223&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014379224,Spontaneous,2023-01-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Headache (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014379224&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014379225,Spontaneous,2023-01-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Axillary pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Swelling (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014379225&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014379226,Spontaneous,2023-01-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adolescent,No,Female,Dizziness (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014379226&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014379227,Spontaneous,2023-01-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[PNEUMOCOCCAL POLYSACCHARIDE VACCINE (23 VALENT)] (S - Pneumococcal immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014379227&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014379228,Spontaneous,2023-01-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Maternal exposure during pregnancy (n/a - Unknown - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014379228&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014379231,Spontaneous,2023-01-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","FORXIGA 10 MG FILM-COATED TABLETS [DAPAGLIFLOZIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PANTOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014379231&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014379232,Spontaneous,2023-01-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Heavy menstrual bleeding (n/a - Unknown - ),<BR><BR>Intermenstrual bleeding (n/a - Unknown - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014379232&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014379233,Spontaneous,2023-01-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Body temperature increased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (1d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014379233&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014379733,Spontaneous,2023-01-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Heavy menstrual bleeding (n/a - Not Recovered/Not Resolved - ),<BR><BR>Polymenorrhoea (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014379733&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014380790,Spontaneous,2023-01-06 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Deep vein thrombosis (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Pulmonary embolism (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - .3mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014380790&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014381460,Spontaneous,2023-01-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014381460&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014381621,Spontaneous,2023-01-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014381621&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014368060,Spontaneous,2023-01-05 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Muscle spasms (4d - Recovered/Resolved - ),<BR><BR>Pyrexia (4d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])","CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - n/a - n/a - ),<BR><BR>[ACETYLSALICYLIC ACID] (C - n/a - n/a - ),<BR><BR>[ATENOLOL] (C - n/a - n/a - ),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - ),<BR><BR>[FLUTICASONE PROPIONATE, SALMETEROL, FLUTICASONE PROPIONATE, SALMETEROL XINAFOATE] (C - n/a - n/a - )","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014368060&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014368069,Spontaneous,2023-01-05 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Discoloured vomit (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - ),<BR><BR>Somnolence (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - .3mL - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014368069&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014369965,Spontaneous,2023-01-05 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (6d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (6d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014369965&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014370222,Spontaneous,2023-01-05 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Deep vein thrombosis (n/a - Not Recovered/Not Resolved - Life Threatening, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Recovering/Resolving - Life Threatening, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Life Threatening, Other Medically Important Condition),<BR><BR>Exercise tolerance decreased (n/a - Recovering/Resolving - Life Threatening, Other Medically Important Condition),<BR><BR>Fibrin D dimer increased (n/a - Unknown - Life Threatening, Other Medically Important Condition),<BR><BR>Mass (n/a - Unknown - Life Threatening, Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Life Threatening, Other Medically Important Condition),<BR><BR>Product use issue (n/a - Unknown - ),<BR><BR>Pulmonary embolism (n/a - Not Recovered/Not Resolved - Life Threatening, Other Medically Important Condition),<BR><BR>Superficial vein thrombosis (n/a - Unknown - Life Threatening, Other Medically Important Condition),<BR><BR>Thrombosed varicose vein (n/a - Unknown - Life Threatening, Other Medically Important Condition),<BR><BR>Varicose vein (n/a - Unknown - Life Threatening, Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Unknown]),<BR><BR>[INFLUENZA VIRUS] (S - n/a - Not applicable - [1d - n/a - Unknown])",[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - 75mg - Unknown]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014370222&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014370339,Spontaneous,2023-01-05 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Brain fog (n/a - Not Recovered/Not Resolved - ),<BR><BR>Breakthrough COVID-19 (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Recovered/Resolved - ),<BR><BR>Cystitis (n/a - Not Recovered/Not Resolved - ),<BR><BR>Disturbance in attention (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Limb discomfort (n/a - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Memory impairment (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nasopharyngitis (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014370339&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014371220,Spontaneous,2023-01-05 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Confusional state (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hallucination (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014371220&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014371331,Spontaneous,2023-01-05 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Feeling abnormal (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Lower respiratory tract infection (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Tonsillitis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Upper respiratory tract infection (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014371331&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014371493,Spontaneous,2023-01-05 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Dyspnoea (n/a - Fatal - Results in Death),<BR><BR>Myocardial infarction (n/a - Fatal - Results in Death),<BR><BR>Vomiting (n/a - Fatal - Results in Death)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224)] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])","LEVETIRACETAM TEVA 500 MG FILM-COATED TABLETS [LEVETIRACETAM] (C - Epilepsy - n/a - [n/a - n/a - n/a]),<BR><BR>[CLONAZEPAM] (C - Epilepsy - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL] (C - Osteoporosis - n/a - [n/a - n/a - n/a]),<BR><BR>[DOCUSATE SODIUM, SORBITOL (E420)] (C - Constipation - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - n/a]),<BR><BR>[PHENOBARBITAL] (C - Epilepsy - n/a - [n/a - n/a - n/a]),<BR><BR>[PHENYTOIN] (C - Epilepsy - n/a - [n/a - n/a - n/a]),<BR><BR>[SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (C - Constipation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014371493&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014371585,Spontaneous,2023-01-05 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Aphonia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014371585&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014371745,Spontaneous,2023-01-05 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Oral herpes (10d - Recovered/Resolved - Disabling),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use])","[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224)] (C - Immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014371745&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014371821,Spontaneous,2023-01-05 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Abdominal tenderness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Back pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Blister (n/a - Unknown - Other Medically Important Condition),<BR><BR>COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Herpes zoster (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain of skin (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pelvic pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash erythematous (n/a - Unknown - Other Medically Important Condition),<BR><BR>Urticaria (n/a - Unknown - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014371821&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014372429,Spontaneous,2023-01-05 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Male,"Herpes zoster (n/a - Recovering/Resolving - ),<BR><BR>Injection site haematoma (2d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014372429&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014372441,Spontaneous,2023-01-05 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Fatigue (3d - Recovered/Resolved - ),<BR><BR>Heavy menstrual bleeding (n/a - Not Recovered/Not Resolved - ),<BR><BR>Intermenstrual bleeding (n/a - Not Recovered/Not Resolved - ),<BR><BR>Polymenorrhoea (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])","[CETIRIZINE DIHYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ETHINYLESTRADIOL, ETONOGESTREL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METHYLPHENIDATE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014372441&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014372442,Spontaneous,2023-01-05 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Nausea (n/a - Unknown - ),<BR><BR>Nystagmus (n/a - Unknown - ),<BR><BR>Vertigo positional (n/a - Recovering/Resolving - ),<BR><BR>Vomiting (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014372442&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014372451,Spontaneous,2023-01-05 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Amenorrhoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Illness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014372451&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014373127,Spontaneous,2023-01-05 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Asthma (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chest discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypersensitivity (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Swelling face (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE, BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FEXOFENADINE, FEXOFENADINE HYDROCHLORIDE] (C - Hypersensitivity - n/a - [n/a - 120mg - n/a - More in ICSR]),<BR><BR>[MONTELUKAST, MONTELUKAST SODIUM] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[THEOPHYLLINE, THEOPHYLLINE PH. EUR.] (C - Asthma - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014373127&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014373143,Spontaneous,2023-01-05 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Male,Lymphadenopathy (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014373143&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014373146,Spontaneous,2023-01-05 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Female,"Chest pain (2d - Recovered/Resolved - ),<BR><BR>Hypertension (2d - Recovered/Resolved - ),<BR><BR>Malaise (2d - Recovered/Resolved - ),<BR><BR>Musculoskeletal pain (2d - Recovered/Resolved - ),<BR><BR>Tachycardia (2d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014373146&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014374136,Spontaneous,2023-01-05 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Ageusia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Unknown - Other Medically Important Condition),<BR><BR>Facial discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Taste disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014374136&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014374247,Spontaneous,2023-01-05 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Lymphadenopathy (n/a - Unknown - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014374247&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014374420,Spontaneous,2023-01-05 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Cellulitis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Joint swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lip swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Off label use (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Paraesthesia oral (n/a - Unknown - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Piloerection (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rash (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site mass (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL, CODEINE PHOSPHATE] (C - Back pain - n/a - [n/a - n/a - n/a]),<BR><BR>[TRAZODONE, TRAZODONE HYDROCHLORIDE] (C - Depressed mood - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014374420&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014360358,Spontaneous,2023-01-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014360358&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014360529,Spontaneous,2023-01-04 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Paraesthesia (n/a - Unknown - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - .3mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014360529&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014361291,Spontaneous,2023-01-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal discomfort (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Abdominal pain (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Abnormal dreams (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Affective disorder (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Agitation (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Anosmia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Anxiety (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Asthenia (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Blepharospasm (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Chills (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Chronic fatigue syndrome (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Crying (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Depersonalisation/derealisation disorder (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Diaphragm muscle weakness (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Dizziness postural (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Dry eye (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Eye pain (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Fear (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Feeling jittery (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Gait disturbance (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Gastrooesophageal reflux disease (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Heart rate increased (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Hypervigilance (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Insomnia (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Muscular weakness (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Pain (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Photophobia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Postural orthostatic tachycardia syndrome (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Restless legs syndrome (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Sneezing (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Speech disorder (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Unknown - Disabling, Other Medically Important Condition)...","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Unknown])","CIRCADIN [MELATONIN] (C - Insomnia - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACETYLSALICYLIC ACID] (C - Anxiety - n/a - [n/a - n/a - Unknown]),<BR><BR>[ACETYLSALICYLIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Unknown]),<BR><BR>[AMITRIPTYLINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[FAMOTIDINE] (C - Reflux gastritis - n/a - [n/a - n/a - Unknown]),<BR><BR>[LANSOPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - Unknown]),<BR><BR>[VENLAFAXINE HYDROCHLORIDE] (C - Anxiety - n/a - [n/a - n/a - Unknown]),<BR><BR>[VENLAFAXINE, VENLAFAXINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - Unknown]),<BR><BR>[ZOLPIDEM, ZOLPIDEM TARTRATE] (C - Insomnia - n/a - [n/a - n/a - Unknown])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014361291&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014361713,Spontaneous,2023-01-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Gait inability (n/a - Unknown - Other Medically Important Condition),<BR><BR>Musculoskeletal stiffness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014361713&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014361843,Spontaneous,2023-01-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Hypertension (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])","COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID] (C - Myocardial infarction - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Myocardial infarction - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - Myocardial infarction - n/a - [n/a - n/a - n/a]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - Blood cholesterol abnormal - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014361843&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014362462,Spontaneous,2023-01-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Hallucination, auditory (n/a - Not Recovered/Not Resolved - ),<BR><BR>Menstruation delayed (1mo - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014362462&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014362469,Spontaneous,2023-01-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,Dizziness (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014362469&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014363368,Spontaneous,2023-01-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Male,Cerebral infarction (n/a - Recovering/Resolving - Life Threatening),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014363368&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014365999,Spontaneous,2023-01-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site swelling (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014365999&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014366198,Spontaneous,2023-01-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Eye pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Eye swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Off label use (n/a - Unknown - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014366198&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014366234,Spontaneous,2023-01-04 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Hypoaesthesia (n/a - Recovered/Resolved - ),<BR><BR>Hypoaesthesia oral (n/a - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])","[DESOGESTREL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014366234&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014366237,Spontaneous,2023-01-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Epistaxis (n/a - Unknown - ),<BR><BR>Formication (n/a - Unknown - ),<BR><BR>Oedema peripheral (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])","[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - n/a - n/a - [n/a - n/a - Vaginal use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014366237&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014366275,Spontaneous,2023-01-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Atrial fibrillation (n/a - Not Recovered/Not Resolved - Life Threatening, Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014366275&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014366511,Spontaneous,2023-01-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Angina pectoris (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myocarditis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014366511&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014366541,Spontaneous,2023-01-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Rash erythematous (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014366541&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014366745,Spontaneous,2023-01-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Blood pressure increased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Cardiac discomfort (n/a - Not Recovered/Not Resolved - ),<BR><BR>Cardiovascular disorder (n/a - Unknown - ),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014366745&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014366904,Spontaneous,2023-01-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Bell's palsy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Facial paralysis (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hypoaesthesia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL] (C - Bone densitometry - n/a - [n/a - n/a - n/a]),<BR><BR>[GLICLAZIDE] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[MORPHINE SULFATE] (C - Back pain - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - Blood pressure abnormal - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014366904&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014366988,Spontaneous,2023-01-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dizziness postural (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Presyncope (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vertigo (n/a - Unknown - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - Other Medically Important Condition)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014366988&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014352754,Spontaneous,2023-01-03 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Tinnitus (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014352754&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014353198,Spontaneous,2023-01-03 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal pain upper (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Unknown - ),<BR><BR>Uveitis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","BRAFTOVI [ENCORAFENIB] (S - Product used for unknown indication - Drug withdrawn - [n/a - n/a - Oral use]),<BR><BR>COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Unknown]),<BR><BR>MEKTOVI [BINIMETINIB] (S - Product used for unknown indication - Drug withdrawn - [n/a - n/a - Oral use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014353198&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014354245,Spontaneous,2023-01-03 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Feeling hot (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site erythema (n/a - Recovered/Resolved - ),<BR><BR>Vaccination site pruritus (n/a - Recovered/Resolved - ),<BR><BR>Wound (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use])","[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - n/a - n/a - [n/a - 20mg - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - 75mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014354245&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014354913,Spontaneous,2023-01-03 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Spondyloarthropathy (n/a - Not Recovered/Not Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[MOMETASONE FUROATE, MOMETASONE FUROATE MONOHYDRATE] (C - n/a - Unknown - )","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014354913&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014356235,Spontaneous,2023-01-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Palpitations (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Sleep disorder due to a general medical condition (n/a - Unknown - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014356235&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014356343,Spontaneous,2023-01-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Angioedema (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>COVID-19 (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Syncope (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014356343&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014356471,Spontaneous,2023-01-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Vomiting projectile (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",COMIRNATY [TOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014356471&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014356777,Spontaneous,2023-01-03 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Back pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Burning sensation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hyperaesthesia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Neck pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain of skin (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - ),<BR><BR>Rash (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [1d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014356777&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014358740,Spontaneous,2023-01-03 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Rash pruritic (n/a - Recovering/Resolving - ),<BR><BR>Skin oedema (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014358740&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014358743,Spontaneous,2023-01-03 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Pericarditis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014358743&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014358744,Spontaneous,2023-01-03 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Bursitis (n/a - Not Recovered/Not Resolved - ),<BR><BR>Shoulder injury related to vaccine administration (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])","[COLECALCIFEROL, CALCIUM, COLECALCIFEROL, CALCIUM CARBONATE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[MAGNESIUM] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[METOPROLOL, METOPROLOL TARTRATE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[SERTRALINE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[SIMVASTATIN] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[STERCULIA, STERCULIA GUM] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014358744&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014358753,Spontaneous,2023-01-03 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Pulmonary embolism (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014358753&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014358756,Spontaneous,2023-01-03 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Fatigue (107d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Inflammation (107d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (107d - Recovered/Resolved - Caused/Prolonged Hospitalisation)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])","NOVORAPID FLEXPEN 100 E/ML INJEKTIONSVÄTSKA, LÖSNING, I FÖRFYLLD INJEKTIONSPENNA [INSULIN ASPART] (C - n/a - n/a - [n/a - 12[iU] - Subcutaneous use]),<BR><BR>TRESIBA [INSULIN DEGLUDEC] (C - n/a - n/a - [n/a - 25[iU] - Subcutaneous use]),<BR><BR>[ENALAPRIL MALEATE, HYDROCHLOROTHIAZIDE] (C - n/a - n/a - [n/a - 1{DF} - Oral use]),<BR><BR>[METFORMIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - 500mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014358756&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014358800,Spontaneous,2023-01-03 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Male,"Acute kidney injury (n/a - Unknown - ),<BR><BR>Cold sweat (n/a - Unknown - ),<BR><BR>Dyspnoea (n/a - Fatal - Results in Death),<BR><BR>Hypoxia (n/a - Fatal - Results in Death),<BR><BR>Malaise (n/a - Unknown - ),<BR><BR>Pleural effusion (n/a - Unknown - ),<BR><BR>Pneumonia (n/a - Fatal - Results in Death)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224)] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])","[CETOMACROGOL 100] (C - Dry skin prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL, CALCIUM] (C - Osteoporosis - n/a - [n/a - n/a - n/a]),<BR><BR>[DENOSUMAB] (C - Osteoporosis - n/a - [n/a - n/a - n/a]),<BR><BR>[DICLOFENAC SODIUM] (C - Pain - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - Gastric haemorrhage - n/a - [n/a - n/a - n/a]),<BR><BR>[OXAZEPAM] (C - Agitation - n/a - [n/a - n/a - n/a]),<BR><BR>[OXYCODONE HYDROCHLORIDE] (C - Pain - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - n/a]),<BR><BR>[SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (C - Constipation - n/a - [n/a - n/a - n/a]),<BR><BR>[THIAMINE HYDROCHLORIDE, RETINOL] (C - Deficiency anaemia - n/a - [n/a - n/a - n/a]),<BR><BR>[VASELINE] (C - Dry skin prophylaxis - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014358800&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014359481,Spontaneous,2023-01-03 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,Urticaria (n/a - Recovered/Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014359481&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014359884,Spontaneous,2023-01-03 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Menstruation delayed (9d - Recovered/Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014359884&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014360278,Spontaneous,2023-01-03 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014360278&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014348315,Spontaneous,2023-01-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"COVID-19 immunisation (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Condition aggravated (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Insomnia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Muscle twitching (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Paraesthesia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Restless arm syndrome (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Restless legs syndrome (n/a - Not Recovered/Not Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [1d - n/a - Intramuscular use]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (S - n/a - n/a - [1d - n/a - n/a])","[BECLOMETASONE, BECLOMETASONE DIPROPIONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CLOPIDOGREL] (C - Coronary artery disease - n/a - [n/a - n/a - n/a]),<BR><BR>[FLUTICASONE PROPIONATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[FLUTICASONE PROPIONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ISOSORBIDE DINITRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PSEUDOEPHEDRINE HYDROCHLORIDE, ACRIVASTINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ROSUVASTATIN] (C - Coronary artery disease - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014348315&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014348596,Spontaneous,2023-01-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Injection site swelling (5d - Recovered/Resolved - ),<BR><BR>Vaccination site lymphadenopathy (5d - Recovered/Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014348596&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014348728,Spontaneous,2023-01-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Chest pain (n/a - Recovered/Resolved With Sequelae - ),<BR><BR>Palpitations (n/a - Recovered/Resolved With Sequelae - ),<BR><BR>White blood cell count decreased (n/a - Recovered/Resolved With Sequelae - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014348728&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014349305,Spontaneous,2023-01-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Malaise (3d - Recovered/Resolved - Disabling),<BR><BR>Myalgia (3d - Recovered/Resolved - Disabling),<BR><BR>Skin disorder (3d - Recovered/Resolved - Disabling),<BR><BR>Urticaria (3d - Recovered/Resolved - Disabling)","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",[LEVOCETIRIZINE] (C - n/a - Unknown - ),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014349305&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014349925,Spontaneous,2023-01-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Hypoaesthesia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Movement disorder (n/a - Not Recovered/Not Resolved - ),<BR><BR>Paraesthesia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014349925&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014351510,Spontaneous,2023-01-02 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Palmar-plantar erythrodysaesthesia syndrome (n/a - Not Recovered/Not Resolved - ),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014351510&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014351578,Spontaneous,2023-01-02 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Cerebrovascular accident (n/a - Unknown - Caused/Prolonged Hospitalisation),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014351578&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10014347429,Spontaneous,2023-01-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Body temperature increased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )","COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10014347429&_xpt=1&_xf=pdf"">ICSR</a>"